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Clinical and serological associations of insulin- dependent 
(Type 1) diabetes mellitus (ID1M) with the classical organ- 
specific autoimmune diseases are reviewed. The significance of the 
insulitis lesion for the concept of autoimmune diabetes mellitus in 
man and in experimental animal models is discussed. The results 
of the following original in vitro studies of human diabetes mellitus 
are presented: 
1. Humoral autoimmunity was studied with the indirect immuno- 
fluorescence technique, using fresh human pancreas as tissue substrate. 
An autoantibody directed against the endocrine cells of the islets of 
Langerhans was detected in sera from 51 of 353 diabetics tested. All 
but 3 antibody- positive patients had insulin -dependent diabetes. 
Islet -cell antibody prevalence was 30% in a group of 46 diabetics 
with coexistent overt autoimmune disease; 1:'. in a group of 107 
diabetics with circulating thyrogastric autoantibodies; and 9% in 
a group of 200 diabetics with no clinical or serological evidence of 
autoimmune disease. The antibody was found in only 2 of 200 non - 
diabetics with thyrogastric or adrenal autoimmunity (one of whom 
subsequently developed IDDM) and in none of 350 normal subjects. 
Islet -cell antibody was shown to be a complement -fixing immuno- 
globulin of IgG class while the antigen against which it is directed 
(common to all cell types in the pancreatic islets) is probably 
microsomal in nature. 
Subsequent extensive studies which have examined the signifi- 
cance of this pancreatic islet -cell antibody, now termed pancreatic 
cytoplasmic islet -cell antibody (ICA), are reviewed, with particular 
reference/ 
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reference to its relationship to the duration of clinical IDIOM, 
its prevalence in IDDM with coexistent autoimmune disease, and its 
value as a marker for the eventual development of IDIE in patients 
with non -insulin -dependent (Type 2) diabetes (NIDDM) and in 
noñdiabetic subjects. The detection and possible significance of 
other antipancreatic autoantibodies is briefly described. 
2a. Cell- mediated autoimmune mechanisms were investigated with 
the leucocyte migration inhibition test (LMT) and antigen- induced 
lymphocyte transformation tests. Using the EMT, cellular hyper- 
sensitivity was found to antigen of human pancreas homogenate in 
29 of 101 diabetics and to an antigen of human islet -cell tumour 
(insulinoma) in 14 of 28 diabetics. The difference in response 
between diabetics and controls was confined to insulin- dependent 
patients, whether untreated (newly diagnosed) or insulin- treated 
at the time of study; there was no distinction between normal 
subjects and non -insulin- dependent diabetics treated by diet or 
oral hypoglycaemics. The use of liver mitochondria, insulin and 
glucagon as antigens in the LMT did not induce inhibition of leuco- 
cyte migration in diabetics or controls. 
When considered in conjunction with other studies, these 
results suggest that cell -mediated autoimmunity to antigens which 
are organ -specific (pancreatic) and species- non -specific is 
demonstrable in a proportion of insulin- dependent diabetics, 
including newly diagnosed patients who have never received insulin. 
2b. The ability of bovine and porcine insulin antigens to induce 
lymphocyte. transformation was tested with cells from 30 normal 
controls, 50 established insulin- dependent diabetics with no 
clinical 
clinical evidence of insulin allergy, and 15 newly -diagnosed 
diabetics. Lymphocytes from 27 diabetics showed significant blasto- 
genesis to insulin, as compared to 2 controls: the phenomenon was 
found in both established and newly -diagnosed patients, including 
4 who had never taken insulin. The separate chains of insulin were 
further used to demonstrate that isolated B chain was a potent 
stimulator of blastogenesis but that isolated A chain was without 
significant effect. 
These results indicate that cellular hypersensitivity to insulin 
is relatively common in insulin -treated patients without in vivo 
evidence of allergy (i.e. no immediate or delayed type cutaneous 
reaction to injected insulin, daily insulin requirement of less than 
200 units); they further suggest that trueautoimmunity to insulin 
may also be present in untreated diabetics. The insulin chain 
experiments might suggest that B chain is the major antigenic site 
determining cellular hypersensitivity to insulin: alternatively the 
negative response to A chain might merely reflect the damage sus- 
tained by this chain during the splitting of insulin. 
3. The correlation of humoral and cellular autoimmunity was assessed 
by testing insulin -dependent diabetics (including newly -diagnosed 
patients), with and without circulating ICA, for their response to 
the LMT using an antigen of human islet -cell tumour (insulinoma). 
Migration inhibition was found in 50% of antibody- positive diabetics 
and in an equal number of antibody- negative patients. The signifi- 
cance of the weak correlation between humoral and cellular anti - 
pancreatic autoimmunity in these patients is discussed. 
4. General immune function was assessed by mitogen- induced lympho- 
cyte/ 
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lymphocyte transformation tests and measurement of circulating 
lymphocyte subpopulations. The lymphocyte transformation response 
to phytohaemagglutinin (PHA) was found to be identical in a group 
of 40 well -controlled insulin- dependent diabetics and matched 
normal subjects: however transformation was grossly depressed in 
14 poorly -controlled insulin- dependent diabetics. Subpopulations 
of T and B lymphocytes were measured in the same subjects: the 
results were identical in normals, well -controlled and poorly - 
controlled diabetics, each group showing an average of 63% T and 
20% B cells in peripheral blood. The depressed PHA response in 
poorly -controlled diabetes seemed to reflect transient metabolic 
disturbance, rather than inherent immunologic abnormality, and 
returned to normal as the metabolic abnormalities were corrected. 
Serum samples from poorly -controlled diabetics were further shown 
to inhibit the PHA- induced transformation of lymphocytes from normal 
subjects, while serum removed from the same patients after correction 
of their metabolic abnormalities had no such inhibitory effects. 
Additional experiments indicated that hyperglycaemia and high levels 
of free (unsaturated) fatty acids both contributed to the inhibitory 
effects of sera from poorly -controlled diabetics. 
These studies suggest that metabolic decompensation in diabetes 
is causally associated with depression of cell -mediated immune 
function, the depression being reversed by correction of the 
metabolic disturbance. 
5. Immune abnormality in relation to the complications of diabetes 
was examined by a serological study of the prevalence of antibodies 
to non -pancreatic antigens in 400 diabetics and matched normal 
controls 
lU 
controls. Antibodies to thyroid cell and gastric parietal -cell 
occurred more than twice as commonly in diabetics as in non - 
diabetics, the excess frequency being found almost entirely in 
insulin- dependent patients. Thyrogastric antibody prevalence in 
insulin -dependent diabetes was not influenced by the age of onset 
or duration of disease, nor by the presence or absence of clinical 
microangiopathy. 
All the above studies have indicated that insulin- dependent 
diabetics are immunologically distinct from non -insulin- dependent 
patients. Antipanoreatic humoral and cellular autoimmune phenomena 
are both demonstrable in a proportion of insulin- dependent diabetics 
and autoimmunity may be of aetiological importance in this type of 
diabetes mellitus. The possible significance of autoimmunity in 
the aetiology of Type 1 diabetes, with particular reference to the 
role of viral infections and genetic factors, is briefly considered. 
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CHAPTER ONE 
INTRODUCTION: CLINICAL AND SEROLOGICAL ASSOCIATIONS OF 
DIABETES MELLITUS WITH ORGAN- SPECIFIC AUTOIMMUNITY: 
THE INSULITIS LESION IN MAN AND EXPERIMENTAL ANIMAL MODELS 
OF IMMUNE DIABE`T'ES MELLITUS. 
1/1 The concept of autoimmunity 
An autoimmune disease may be defined as a condition in which 
'self' components (that is, components of the body's own tissues) 
are recognised as antigens by the lymphoid system of the affected 
individual. The consequence of such recognition is the appearance 
of immunologically competent cells, and the production of auto- 
antibodies, directed against body tissues. Implicit in this 
definition is the assumption that sensitised cells and autoantibodies 
have a pathogenic role in the development of the disease, as opposed 
to the circumstances in which transient and ostensibly harmless anti- 
bodies appear as the sequel to tissue damage. An example of the 
latter phenomenon would be the formation of heart antibodies after 
myocardial infarction. The role of autoimmunity in many disorders 
is often not sufficiently clearcut to permit the above assumption; 
nonetheless in the present state of knowledge, it is acceptable to 
apply certain criteria that allow a disease to be considered as 
being of autoimmune aetiology. These criteria are summarised in 
table 101, while a broad outline of the interactions of various 
immune mechanisms implicated in the production of autoimmune disease 
is given in figure 1 /1. 
As Roitt (1980) has indicated, autoimmune disorders are conven- 




Criteria for a disease of autoimmune aetiology 
1. Presence of circulating autoantibodies in the serum (humoral 
- autoimmunity). 
2. Presence of circulating lymphoid cells sensitised to tissue 
autoantigens (cell- mediated autoimmunity). 
3. Identification of the autoantigen(s). 
4. Presence of tissue lesion(s) with lymphocytic or plasma cell 
infiltration. 
5. Aggregation of the disease in the relatives of affected persons. 
6. Aggregation of other autoimmune phenomena (subclinical or overt) 
in affected persons and/or their families. 




Loss of tolerance to self-antigens 
(? triggered by virus infection 

























Inducing inflammation Antigen-antibody 
non-specific damage in tissue containing 
to tissue in the vicility target cell 
The interactions of immune responses Types II-VI in 
the production of autoimmune disease. Cell-mediated 
immune mechanisms lie broadly on the left of the figure, 
humoral mechanisms on the right; but co-operation between 
T and B lymphocytes is also displayed. 
From Irvine (1979) 
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TABLE 1/2 

















Primary biliary Systemic lupus 
cirrhosis erythematosus 
Active chronic Dermatomyositis 
hepatitis 
Rheumatoid 
Ulcerative colitis arthritis 
Scleroderma 
Modified from Roitt (1980) 
15 
one end of the spectrum are the organ- specific diseases, 
characterised by infiltration of the affected organ with mono- 
nuclear cells, destruction of the organ's normal architecture and 
the appearance of circulating serum antibodies directed specifically 
against constituents of the affected organ. It will be noted from 
table 1/2 that hormone -producing organs seem to be peculiarly 
vulnerable to involvement by this type of autoimmune disease process; 
examples of endocrine autoimmunity include not only Hashimoto thyroid- 
itis and primary hypothyroidism ( Doniach and Roitt, 1974) but also 
thyrotoxicosis (Adams et al, 1974; Kendall -Taylor, 1975), pernicious 
anaemia and atrophic gastritis (Irvine, 1965; Roitt et al, 1965), 
idiopathic Addison's disease (Blizzard and Kyle, 1963; Irvine and 
Barnes, 1972, 1975), premature ovarian failure (Irvine and Barnes, 
1974, 1975) and idiopathic hypoparathyroidism (Blizzard et al, 1966; 
Irvine and Scarth, 1969). The centre of the spectrum contains those 
disorders where the infiltrative lesion tends to be localised to a 
single organ but the autoantibodies are non -organ specific. Primary 
biliary cirrhosis is a typical example of 'mid- spectrum' autoimmune 
disease; the small bile ductule is the main target for mononuclear 
infiltration but the serum antibodies, mainly to mitochondria, are 
not specific for the liver (Doniach et al, 1966). The other end of 
the spectrum consists of autoimmune diseases which are clearly non - 
organ specific, and systemic lupus erythematosus is an example of a 
condition in which both lesions and autoantibodies are not confined 
to a single organ. 
1/2 The criteria for autoimmune diabetes mellitus 
Diabetes mellitus has been defined as 'a state of chronic 
hyperglycaemia/ 
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hyperglycaemia which may result from many environmental and genetic 
factors, often acting jointly' (World Health Organisation, 1980). 
The hyperglycaemia may be due to a lack of insulin or to an excess 
of factors that oppose its action. It is now recognised unequi- 
vocally that there are two main and distinct types of primary diabetes 
which are presently classified by reference to therapy required: 
Type 1 diabetes, otherwise termed insulin- dependent diabetes (IDDM) 
and Type 2 diabetes, otherwise termed non -insulin- dependent diabetes 
(NIDi ). Type 1 diabetics are ketosis -prone individuals who are 
absolutely dependent on daily injections of exogenous insulin for 
preservation of life; this is the common form of diabetes present- 
ing in individuals under the age of 30 years but is not infrequent 
in elderly patients. Type 2 diabetics have a milder syndrome in 
which hyperglycaemia can be contained by dietary carbohydrate 
restriction or oral hypoglycaemic drugs; these patients are not 
prone to ketosis, are usually middle -aged or elderly and are frequently 
obese. The clinical classification of diabetes mellitus has undergone 
several major revisions in the past twenty years, and the terms 
'juvenile -onset diabetes' for Type 1 patients and 'maturity -onset 
diabetes' for Type 2 patients have largely been abandoned. The 
modern classification of diabetes was exhaustively considered at an 
International Workshop organised by the National Diabetes Data Group 
of the National Institutes of Health, Bethesda, U.S.A., which met 
between 1978 and 1979. Its recommendations (NDDG, 1979) were sub- 
sequently adopted as an interim classification by the WHO Expert 
Committee on Diabetes (WHO, 1980), are summarised in table 103 and 





Type 1 - Insulin-dependent type (IDDM) 
Type 2 - Non -insulin- dependent type (NIDDM) 
(a) Non -obese NIDDM 
(b) Obese NIDDM 
Other Types - Including diabetes mellitus associated with 
certain conditions and syndromes: 
(1) pancreatic disease, (2) disease of 
hormonal aetiology, (3) drug- or chemical - 
induced condition, (4) insulin receptor 
abnormalities, (5) certain genetic syndromes, 
(6) miscellaneous. 
The clinical classification of diabetes mellitus (DM). 
Simplified from the classification scheme prepared by 
the National Diabetes Data Group of the National Institutes 
of Health, USA (1979) and adopted by the Second Report of 
the WHO Expert Committee on Diabetes Mellitus (1980). 
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classification, the NDDG took special cognisance of a large corpus 
of information which had become available regarding the aetiology 
of diabetes, in particular of insulin -dependent diabetes, which it 
summarised thus: 'Evidence regarding etiology (of Type 1 diabetes) 
suggests genetic and environmental or acquired factors, association 
with certain HLA types, and abnormal immune responses, including 
autoimmune reactions' (NDDG, 1979). The purpose of this thesis is 
to review some of the evidence for immunologic abnormalities in 
diabetes mellitus and in particular to describe some original studies 
designed to examine the hypothesis that some cases of human diabetes 
mellitus may represent a true organ -specific autoimmune disease. 
By analogy with the known immunopathology of endocrinopathies in 
which autoimmunity is established or postulated as a major aetiologic 
factor, it is possible to apply certain criteria which must be met 
before the concept of an autoimmune form of diabetes could be con- 
sidered viable: these criteria are summarised in table 1/4. 
First, it is necessary to identify a close clinical connection 
between diabetes and established autoimmune disease. The autoimmune 
endocrinopathies are known to be intimately inter -related, they may 
coexist in the same patient, and they may appear in a familial pattern. 
Such diseases should therefore be over -represented, in this fashion, 
in a diabetic population. 
Second, a significant association of diabetes with subclinical 
or preclinical autoimmunity should also exist, i.e. sera from 
diabetics should contain a high prevalence of organ- specific auto- 
. antibodies directed against the thyroid, the stomach and the adrenal 




The criteria for ' autoimmune diabetes mellitus' 
1. Close clinical association with autoimmune endocrinopathies. 
2. High prevalence of serum autoantibodies to nonpancreatic 
antigens. 
3. Mononuclear cellular infiltration of the endocrine pancreas. 
4. Presence of circulating lymphoid cells sensitised to antigens 
of the endocrine pancreas. 
5. Presence of serum autoantibody directed against the endocrine 
pancreas. 
6. Induction of diabetes by autoimmune mechanisms in experimental 
animals. 
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constant feature of accepted autoimmune disease and are independent 
of the increasing antibody prevalence with advancing age in the 
normal population. These first two criteria would provide good 
indirect evidence for an association of diabetes with autoimmunity. 
More direct evidence of an immune lesion in diabetes might 
first be sought by examining the pathology of the endocrine pancreas 
at the onset of clinical diabetes, looking in particular for the 
mononuclear cell infiltrate of lymphocytes or plasma cells that is 
an established feature of thyroid, gastric and adrenal autoimmunity. 
It would further be necessary to demonstrate in diabetics that the 
serum contained an autoantibody directed against the endocrine 
pancreas and that circulating lymphoid cells were sensitised to anti- 
gens derived from the substance or hormones of the endocrine pancreas. 
Finally, it would be equally important to demonstrate that 
clinical carbohydrate intolerance in experimental animals could be 
induced by immunological mechanisms, and that such intolerance was 
accompanied by appropriate evidence of an autoimmune lesion. 
It is now proposed to examine the existing evidence for auto - 
immunity in diabetes using each of these criteria in turn. This 
chapter considers the clinical and serological associations of 
diabetes with autoimmune disease, the pathology of the endocrine 
pancreas in diabetes and the animal models of experimental immune 
diabetes. Subsequent chapters will review the evidence for humoral 
and cell- mediated autoimmunity in diabetes in the context of 
original studies undertaken by the author. 
1/3 The clinical associations of diabetes with autoimmune disease 
Some of the earliest and most compelling indirect evidence for 
abnormal/ 
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abnormal immune mechanisms in diabetes has been provided by the 
clinical observation of an association between diabetes and the 
classical organ- specific autoimmune endocrinopathies. Coexisting 
diabetes and adrenal insufficiency in a single patient was first 
recorded in the mid -nineteenth century (Ogle, 1866), barely eleven 
years after Addison's classical description of the disease that 
bears his name; and numerous subsequent studies have reinforced 
the view that the two disorders - one common, one rare - are linked 
more intimately than can be accounted for by chance (Balfour and 
Sprague, 1949; Faber and Gronbaek, 1956; Beaven et al, 1959; 
Solomon et al, 1965; Irvine and Barnes, 1972; Nerup and Binder, 
1973; Nerup, 1974; Irvine and Barnes, 1975; Irvine et al, 1980a; 
Nerup et al, 1980). From these and other studies the prevalence of 
diabetes in Addison's disease has been reported as between 7 and 23 
per cent, with an approximate average of 18 per cent (Irvine and 
Barnes, 1975), thus representing an excess of at least ten -fold over 
the estimated prevalence (about 1.5 per cent) of diabetes in the 
overall population of Britain or the United States (Marks et al, 
1971). Fewer investigators have attempted to estimate the prevalence 
of Addison's disease in diabetes but Kozak (1971) recorded a figure 
of 0.032 per cent among forty -three thousand newly -diagnosed cases 
of diabetes at the Joslin Clinic and Nerup (1974) reported a very 
similar figure (0.028 per cent) when he examined the prevalence of 
Addison's disease in a population of fifty thousand Danish diabetics. 
The prevalence of Addison's disease in the general population has 
been estimated at between 0.0039 per cent (Stuart Mason et al, 1978) 
and 0.0060 per cent ( Nerup, 1974); thus the excess prevalence of 
Addison' E/ 
22 
Addison's disease in diabetics appears to be in the order of five- 
fold over the general population. The development of more 
sophisticated diagnostic aids, in particular the ability to detect 
organ- specific adrenal antibodies (Anderson et al, 1957; Blizzard 
and - Kyle, 1963), has confirmed that diabetes is usually associated 
with idiopathic ( autoimmune) adrenal failure rather than tuberculous 
adrenal destruction, and this is borne out by pathological studies. 
Oneextensive review of the literature noted idiopathic adrenal 
atrophy in 74 per cent, and tuberculous adrenal involvement in only 
22 per cent of those patients with dual disease who came to autopsy, 
and a similar pattern of adrenal pathology was demonstrated in 
diabetics with combined thyroid and adrenal dysfunction (Solomon et 
al, 1965). The combination of thyroid and adrenal insufficiency, 
which is sometimes referred to as Schmidt's syndrome (Schmidt, 1926), 
is a particularly striking expression of a strong autoimmune diathesis 
and is frequently associated with diabetes mellitus: this triad of 
endocrinopathy was present in twenty -eight of the one hundred and 
thirteen patients with Addison's disease and diabetes reviewed by 
Solomon et al (1965), and others (Blizzard et al, 1967; Frey et al, 
1973) have confirmed the preponderance of idiopathic as opposed to 
tuberculous Addison's disease in these patients. From all the above 
studies, it has become clear that autoimmune adrenal disease is 
associated with insulin -dependent (IDIáM) rather than non- insulin- 
dependent diabetes (NIDD ), sometimes very strikingly so: the 
large series of Irvine et al (1980a) found IDI»I in thirty -two (10 per 
cent) of three hundred and twenty -one patients with Addison's disease 
as opposed to only six (2 per cent) with NIDI and observed that the 
age/ 
23 
age at diagnosis of IDDM was over a very wide range. Only half 
the patients had developed diabetes before the age of thirty -five 
years, which is quite unlike the expected age -related incidence of 
IDI4, and suggests that cases of diabetes with idiopathic Addison's 
disease are much more likely to need insulin irrespective of the age 
at which diabetes appears, even if diabetic control is initially 
achieved by oral hypoglycaemic drugs (Irvine et al, 1980a). It has 
also become clear that adrenal failure precedes pancreatic failure 
and vice versa in approximately equal numbers and that both diseases 
make a simultaneous clinical appearance in the minority of cases. 
The association between diabetes and pernicious anaemia was 
first described in 1910 (Parkinson, 1910) and since then has been 
described by several investigators (Arapkis et al, 1963; Munichoodappa 
and Kozak, 1970; Ungar et al, 1968; Irvine et al, 1970). The pre- 
valence of diabetes in patients with pernicious anaemia is said to be 
7 per cent (Ungar et al, 1967), again well in excess of the figure 
for the general population, and conversely the prevalence of pernicious 
anaemia in selected diabetic populations has been variously estimated 
as 0.39 per cent (Chanarin, 1964), 4.0 per cent (Ungar et al, 1968) 
and 5.0 per cent (Irvine et al, 1970). The lower figures probably 
underestimate the true position as pernicious anaemia is often of 
latent form in diabetics and associated with intrinsic -factor anti- 
bodies, frequently suggested as the 'marker' of latent or frank 
pernicious anaemia, in only 50 - 60 per cent of cases (Ardeman and 
Chanarin, 1963; Irvine, 1965). An accurate estimate of prevalence 
is therefore only achieved when the clinician is prepared to screen 
all diabetics at risk (mainly middle -aged to elderly females, 
irrespective/ 
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irrespective of anti -diabetic treatment) not only for intrinsic- 
factor autoantibodies but also for an adequate serum vitamin B12 
level (Ungar et al, 1968). 
Multiple reports have indicated an association between diabetes 
and thyroid disorders. The diseases in question comprise thyro- 
toxicosis, usually in young IDDM (Hayles et al, 1959; Perlman, 1961; 
Nerup et al, 1977; Nerup et al, 1980; Cudworth and Wolf, 1982); 
chronic or Hashimoto thyroiditis, in both children and middle -aged 
patients (Landing et al, 1963; Crome et all 1967; Masi et al, 1965); 
and primary hypothyroidism (Solomon et al, 1965; Hecht and Gerschberg, 
1968; Andreani, 1974; Ganz and Kozak, 1974). In a prospective 
study of thyroid function in a diabetic population, excluding patients 
known to have thyroid disease, it was found that 9.8 per cent had 
impaired thyroid reserve (as indicated by a raised plasma TSH level) 
and 2.6 per cent had primary hypothyroidism (as indicated by low 
plasma T4 plus raised plasma TSH). The prevalence of this previously 
unrecognised thyroid dysfunction was greatest in IDDM over the age of 
fifty years, in whom impaired thyroid reserve was recorded in 22 per 
cent and hypothyroidism in 6.6 per cent of patients (Gray et al, 1979). 
Both pernicious anaemia and thyroid disorders occur with significant 
frequency (3 and 9 per cent respectively) in the first -degree relatives 
of diabetic patients (Irvine et al, 1970). 
104 Serum autoantibodies to non -pancreatic antigens in diabetes 
mellitus 
The clinical associations of diabetes with overt autoimmunity 
are impressive but perhaps even more striking is the' high prevalence 
of certain organ- specific autoantibodies in diabetic sera. Numerous 
serological studies have been performed in diabetics, directed in 
particular/ 
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particular to the detection of thyroid or gastric autoantibodies, 
and the results of some of the more extensive investigations are 
presented in table 1/5. These studies have been performed in young 
and elderly as well as in unselected (random) populations, patients 
with overt thyroid, adrenal or gastric disease have been excluded, 
and in most instances the results have been compared with those from 
large nondiabetic populations of comparable age and sex distribution. 
The overall prevalence of various autoantibodies in diabetics can 
therefore be calculated with fair accuracy from the pooled data of 
the major series (table 1/6) and more detailed information is given 
in the following explanatory notes: 
Thyroglobulin autoantibodies 
Most investigators agree that the prevalence of antibodies to 
thyroglobulin in diabetes (measured by the tanned cell haemagglutin- 
ation technique) is marginally but hardly significantly increased 
over that in the nondiabetic population. In both groups the overall 
prevalence seems to lie between 7 and 10 per cent (tables 1/5, 1/6), 
and major deviations from this relatively narrow range are found only 
in selected population strata: for example, the high figures recorded 
by Maret and Bethaud (1965) in diabetics and controls were obtained 
from groups whose members were almost exclusively female and all aged 
over seventy years. Only one study (Simkins, 1968) has described a 
major difference between diabetics and controls (prevalence 10 and 4 
per cent respectively) and the results obtained by this investigator 
may be partly explicable by the ethnic differences between the groups; 
Simkins examined mixed Caucasian/Negro populations but half the 
diabetics and only 29 per cent of the control group were Negroes. 
Aut oant ibodies/ 
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TABLE 1/5 (OPPOSITE): 
Prevalence of autoantibodies in sera from diabetic and nondiabetic 
(control) populations, reported by various authors 
T/G = antibody to thyroglobulin 
TIC . antibody to thyroid cytoplasm 
PCA = antibody to gastric parietal -cell cytoplasm 
IF . antibody to gastric intrinsic- factor 
ANF . antibody to cell nuclei 
ADR . antibody to adrenal cortex 
TABLE 1/5 
Prevalence of autoantibodies in sera from diabetic and nondiabetic 
(control) populations, reported by various authors 
NUMBER (PER CENT) POSITIVE IOR: 
REFERENCE 
SUBJECTS 












Moore and Diabetics (65) 
Neilson (1963) Controls (65) 5( 8) - - - 
Diabetics (83 - 14(17) 18(22) - 
Controls (166 - 7(4) 13(8) - 
Maret and Diabetics (82) 27(33) - 
Berthaux Controls (110) 28(26) - 
(1965)b 
Ungar et al Diabetics (400) - - 84(21) 8(2) - 
(1968) Controls 600) 65í 
Controls 1600) - - 11) 5( <l) - 
Simkins (1968) Diabetics (317) 32(10) - 
Controls (424) 17(4) - 
Irvine et al Diabetics (1054) 90(9) 170 16) 176(17) - 11(1 - 
(1970) Controls (871) 56(6) 68(8) 53(6) - 9(1 - 
Diabetics (380) - 13(3) - 
Controls (296) - - - i( <1) - - 
Goldstein et al Diabetics (252) 22(9) 15(6) o(o) 
(1970) c Controls (340) 20(6) 4(1) o(o) 
Whittingham et Diabetics (400) - 56(14) 84( 21) 8( 2) 88( 22) - 










- ó(o 0(0 
MacCuish and Diabetics(250) 23 (9) 43 17) 20(8) 45 18 ) - 3 1 - Irvine (1975)d Controls (250) 18(7) 21 8) 2(1) - 
a All subjects aged under 16 years. 
b All subjects aged over 70 years. 
c No distinction between antibodies to thyroglobulin 
and thyroid cytoplasm. 
d Part of study desoribed in chapter six of this thesis. 
TABLE 1/6 
Overall prevalence of autoantibodies in sera from diabetic and nondiabetic 
populations, calculated from the pooled data in table 1)4 
SUBJECTS 
(NUMBER STUDIED) 
NUMBER (PER CENT) POSITivi: FOR: 









































































Abbreviations as in table 1/5 
c7 
Autoantibodies to thyroid and gastric parietal cytoplasm 
Antibodies to thyroid or gastric parietal cell (detected 
initially by complement fixation, latterly by the Coons indirect 
immunofluorescence technique) are conveniently considered jointly 
as -their distribution is very similar in diabetic populations and 
indeed they may coexist in the same patient. Most investigators 
(table 1/5, figure 1/2) record a two- to four -fold increase in 
diabetics over the expected prevalence of either antibody in the 
general population but in selected groups, for example in juveniles, 
the difference may be even greater (Pettit et alp 1961). The com- 
bined effects of age, sex and anti- diabetic therapy on thyrogastric 
antibody prevalence have been carefully analysed in several studies 
and allow the following conclusions to be drawn: 
a) Thyrogastric antibodies are found most commonly in young (age 
forty or less), female, insulin- dependent diabetics. 
b) The prevalence of thyrogastric antibodies in older diabetics 
(i.e. above age forty) is much closer to that in control populations. 
Again the excess is mainly associated with insulin dependency and 
female sex. 
c) There is no significant difference in thyrogastric antibody 
prevalence between non -insulin -dependent diabetics and matched non - 
diabetic controls. 
d) The joint occurrence of thyroid and gastric antibodies is 
significantly more common in diabetics than nondiabetics. 
Thus the marked difference in thyrogastric antibody prevalence 
between diabetics and ( nondiabetic) controls is attributable to the 
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Percentage incidence of autoantibodies specific for 
thyroglobulin, thyroid cytoplasm and gastric parietal - 
cell cytoplasm in a series of 1032 diabetics and of 
871 controls according to sex and age in decades. 
From Irvine et al (1970) 
have shown that thyroid and gastric antibodies, or overt autoimmune 
diseases, are significantly more frequent among first -degree relatives 
of diabetic children with thyrogastric antibodies than among relatives 
of antibody- negative children (Nissley et al, 1973; Bottazzo et al, 
1978a). The association with autoimmunity is particularly striking 
in families with two or more insulin- dependent diabetic members 
(Bottazzo et al, 1978a). All these observations suggest that it is 
the insulin- dependent type of diabetes that is intimately associated 
with the possession of thyrogastric antibodies and with a familial 
background of autoimmunity. 
Few studies have related thyrogastric antibody prevalence to 
duration of diabetes. Some workers have described increasing 
prevalence of thyrogastric antibodies with lengthening duration of 
disease, but this relationship only appears to be valid for insulin - 
dependent patients, aged under thirty years, who have been diabetic 
for more than ten years (Nerup and Binder, 1973). Conversely the 
most extensive published series found no clearcut relationship between 
antibody prevalence and duration of disease (Irvine et al, 1970. 
Whittingham et al (1971) applied a computer programme to carefully - 
matched populations and claimed to detect an actual decrease in 
thyrogastric antibody prevalence with increasing duration of insulin - 
dependent diabetes, the decrease being especially marked in diabetics 
of more than twenty years' standing. These authors offered the 
explanation that their findings reflected an unexpectedly high death 
rate among long-standing diabetics with thyrogastric antibodies, and 
further demonstrated that antibody prevalence in longterm insulin - 
dependent diabetics aged under forty is equal to that in the nondiabetic 
population/ 
population aged over sixty. Serologically, therefore, there is some 
suggestion that the longterm insulin -dependent diabetic population, 
especially female, has aged prematurely by at least twenty years, but 
how this phenomenon might contribute to an excess mortality amongst 
these patients is not clear. Apart from degenerative disease of the 
large blood vessels, there is no other convincing biological evidence 
of premature ageing in diabetes mellitus. 
Autoantibodies to gastric intrinsic factor 
Antibodies to intrinsic factor (IF), detected by a radio - 
immunoassay method using coated charcoal, are found much less commonly 
than parietal -cell antibodies in diabetes. Nonetheless their presence 
is of especial importance because of the strong association, mentioned 
earlier, with underlying pernicious anaemia; thus Ungar et al (1968) 
found IF antibody in eight of four hundred diabetics studied, three 
of whom had latent pernicious anaemia, while Irvine et al (1970) found 
IF antibody in thirteen of three hundred and eighty patients studied, 
latent pernicious anaemia being present in six of the nine patients who 
underwent additional investigations. The apparently low prevalence 
of IF antibody in the overall diabetic population (table 1/5) appears 
in correct perspective when it is appreciated that all investigators 
who have searched for this antibody are unanimous in indicating that 
IF antibodies are found only in middle -aged to elderly diabetics, 
almost exclusively female and predominantly insulin- dependent. In 
these selected population strata it has been estimated that the 
prevalence of IF antibody is between 4 and 5 per cent (Ungar et al, 
1968; Irvine et al, 1970) and half the patients thus identified will 
have latent pernicious anaemia. These figures represent an increase 
of/ 
s 
of at least four -fold over the expected prevalence of IF antibody in 
matched non -diabetic populations and are sufficiently impressive to 
reinforce the value of screening for IF antibody in the diabetic 
population at particular risk. 
Autoantibodies to adrenal cortex 
Few investigators have examined diabetic populations for adrenal 
antibodies (table 1/4). However it is worth noting that this anti- 
body, which is detectable in 50 to 70 per cent of patients with 
idiopathic Addison's disease and is extremely rare outwith that 
context, was found by Nerup and Binder (1973) in three and by 
Cudworth et al (1980) in four insulin- dependent diabetics with no 
overt evidence of adrenal failure. The strong clinical associations 
of diabetes with Addison's disease have already been commented upon, 
and cell -mediated immunity against adrenal antigen has also been 
demonstrated in vitro in diabetics (Nerup and Bendixen, 1969). 
Other autoantibodies in diabetes 
The prevalence of antibodies which are tissue -specific rather 
than organ -specific, for example mitochondrial antibody and anti- 
nuclear antibody (ANF), does not appear to be increased in diabetic 
populations (table 1/5). 
1/5 Pathology of the endocrine pancreas in diabetes 
A number of studies over the past two decades have described 
the pathological findings in the endocrine pancreas of both major 
types of diabetes mellitus. The major conclusions are summarised 
in table 1/7, which brings together the information from numerous 
histopathological studies using 'classical' staining techniques 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































immunocytochemical techniques which allow reliable identification 
of the various hormone- producing cells within and outwith the islets 
of Langerhans. It is immediately apparent from table 1/7 that there 
are major differences between the changes observed in the pancreas 
in insulin- dependent and non -insulin- dependent diabetes: the 
histology of the gland in NIDDM is essentially normal, apart from a 
moderate reduction in total numbers of islets and B (beta) cell 
population. By contrast, IDDM is distinguished by a severe reduction 
in total islet numbers and the beta cell population is grossly 
reduced, in fact decimated. Many of the remaining islets are so 
small that they readily go undetected by light microscopy: formerly 
referred to as 'atrophic', these small islets are now known to be 
composed almost exclusively of A (alpha: glucagon -producing) and D 
(delta: somatostatin -producing) cells. They are termed 'pseudo- 
atrophic' islets and presumably reflect normal islets after loss of 
the beta cell population. Hyperactive islets are much rarer, found 
only in cases of short clinical duration and comprise mainly of 
hyperactive, degranulated beta cells of low insulin content; their 
significance is self -evident. The PP islets are entirely composed 
of irregular cords of columnar cells, sometimes called F cells, 
which secrete pancreatic polypeptide (PP) hormone; they seem to be 
more common in IDDM of long or short duration. 
In the context of autoimmunity, the finding of insulitis has 
excited particular speculation. The term ' insulitis' was first 
coined by von Meyenburg (1940) to describe the inflammatory lesions 
in the islets of Langerhans of some diabetics, although such lesions 
had in fact been described by the early investigators of diabetic 
pathology/ 
pathology at the beginning of this century, well before the era of 
insulin treatment (Schmidt, 1902; Heiberg, 1911). The lesions of 
insulitis may be heavy, involving the majority of the islets, or 
light, involving only scattered islets. Affected islets are usually 
of the pseudo-atrophic type and infiltrated with lymphocytes, 
commonly round their periphery but sometimes throughout the islet. 
Large mononuclear cells, sometimes polymorphs and very rarely 
eosinophils may also be present in the infiltrate, but plasma cells 
have never been observed. The most common appearance seems to be of 
a 'halo' of lymphocytes just outside the capsule of the islet, extend- 
ing a little way into the periphery of the endocrine tissue and 
probably cuffing capillaries in the islet stroma (Warren et al, 1966); 
more diffuse lymphocytic infiltration, over- running the whole islet, 
is less commonly encountered ( Gepts, 1965). These lesions in human 
diabetes are quite distinct from the insulitis which occurs in some 
infants of diabetic mothers; the latter condition is characterised by 
an infiltrate which is predominantly of polymorphs, includes many 
eosinophils, and is without effect on pancreatic insulin production. 
For many years insulitis was considered to be a very rare 
phenomenon, confined to a few cases of diabetes of recent onset in 
children (Warren and Root, 1925; LeCompte, 1958; Ogilvie, 1964). 
It was only briefly mentioned, or not at all, in many textbooks on 
pathology of diabetes and many pathologists have never seen a case 
(LeCompte and Legg, 1972). The finding by Gepts (1965) of insulitis 
in fifteen out of twenty -two young diabetics, i.e. two- thirds of the 
cases that he examined, was therefore in direct contrast to this 
classical opinion and since then there have been two further reported 
studies/ 
studies of insulitis in diabetes. Doniach and Morgan (1973) were 
unable to find the lesion in any of nine young insulin- dependent 
diabetics who had died within a few weeks of diagnosis, or in four 
further cases who had been diabetic for longer periods but Junker 
et al (1977) found typical insulitis in the pancreas of six of 
eleven young patients that they examined. In all, these three 
papers described the finding of insulitis in twenty -one from a total 
of forty -two cases, i.e. a prevalence of 50 per cent, and this is 
probably as accurate a figure as can be arrived at in the modern 
clinical era of diabetic therapy. 
Why was insulitis considered to be so rare? There are probably 
several reasons. First, very few pathologists now have the opportunity 
to examine by modern techniques the.pancreas in ID14 shortly after the 
onset of clinical disease, and of course this is a direct result of 
the advent of insulin therapy. Even the modern studies from which 
the prevalence of insulitis has been estimated are comprised largely 
of material from pathological archives: all the specimens examined 
by Gepts, Doniach and Morgan were from persons who died between 1913 
and 1930, i.e. before and shortly after insulin became available. 
Second, insulitis is a transient lesion which has never been detected 
in IDDM who have died more than twelve months after the onset of 
disease. Its appearance is confined to IDII of short duration, 
irrespective of the age of onset of the disease (LeCompte and Legg 
(1972) found it in two IDDM aged sixty -six and seventy years), and 
it has never been found in NIDDM. Third, insulitis is a patchy 
lesion even when present; it may be absent from the bulk of the 
pancreas 
pancreas or may affect only scattered pseudo -atrophic islets. It 
has never been observed in the PP islets and is rarely seen in 
hyperactive islets. These correlations of islet morphology with 
insulitis are interesting insofar as they suggest that the mono- 
nuclear infiltrate is heaviest in the islets which have lost the 
highest proportion of beta cells and the inference might be drawn 
that the two phenomena are causally related. 
Several theories have been advanced as to the cause(s) of 
insulitis, and by inference as to the cause of IDDM in cases where 
the lesion has been observed. Early workers considered that 
insulitis represented destruction of the islet cells by over - 
stimulation or by some unidentified chemical cytotoxic agent 
(von Meyenburg, 1940). The former explanation seems improbable, and 
no similar lesions have ever been observed in other endocrine glands 
submitted to overstimulation but the latter suggestion is a possi- 
bility, to judge from the finding of insulitis and diabetes in mice 
treated by repeated injections of streptozotocin (Like et al, 1976, 
1978). The observation that streptozotocin- induced insulitis can 
only be induced in certain strains of mice (Rossini et al, 1976) 
further suggests that specific genetically -determined immunological 
responses must be present before the lesion can develop and this 
may have important implications for human diabetes. The various 
animal models in which insulitis has been induced by immune mechanisms, 
or observed to occur spontaneously, are considered below while direct 
and indirect evidence for viral infection as a cause of insulitis is 
discussed in chapter seven. In passing, it can be said that there 
has been a very natural tendency to compare insulitis with the organ- 
specific/ 
39 
specific chronic inflammatory lesions found in classical thyro- 
gastric and adrenal autoimmune diseases but the analogy does not 
extend to the presence of plasma cells, which have never been 
described in the insulitis lesion in man. 
1/6 Animal models of experimental immune diabetes 
The immunological methods which have been used for the experi- 
mental induction of insulitis (and diabetes mellitus) are detailed 
in table 1/8 while the various animal models in which these methods 
have been applied are summarised in table 1/9. It will be seen 
that both passive (e.g. injection of heterologous anti- insulin serum) 
and active immunisation procedures (e.g. injection of heterologous 
or homologous insulin and endocrine pancreas) have been successful 
.in producing insulitis in a variety of species. Experimentally 
induced lesions of the islets of Langerhans, which to some extent 
deserve the term ' insulitis', were observed first by Lacy and Wright 
(1965). These authors injected guinea -pig antiserum against bovine 
insulin into rats, producing a diabetic state by neutralisation of 
endogenous insulin. Morphological studies in a few animals revealed 
mononuclear and eosinophilic cells with some islets but the main 
histological feature was a diffuse exocrine pancreatitis. Shortly 
afterwards Logothetopoulos and Bell (1968) used the same technique 
to induce very similar lesions of the islets in mice. These experi- 
ments led to an acute form of insulitis but Freytag (1972) later 
demonstrated that heterologous antiserum in mice could also induce 
a chronic form of insulitis, typified by the infiltration of mono- 




Immunological methods used for the induction of insulitis 
in experimental animals 
Principle Method Species 
Intravenous injection of ( Rats 
guinea. -pig anti- bovine- insulin ( 
Passive serum ( Mice 
Immunisation Transfer of lymphoid cells from 
insulin -immunised animals to 
immunosuppressed young animals 
Guinea -pigs 
Subcutaneous injection of Cattle 
homologous or heterologous Sheep 
Active insulin + Freund's adjuvant Rabbits 
Guinea-pigs 
Immlln; sation Subcutaneous injection of ( Rats 
homologous or heterologous ( 
endocrine pancreas + CFA* ( Mice 
*CFA = complete Freund's Adjuvant 
TABLE 119 
The induction of insulitis in experimental animals 
ber passive and active immunisation procedures 







Lacy and Wright 
(1965) 
Logothetopoulos 
and Bell (1968) 
Diffuse exocrine pancreatitis. 
Acute transient insulitis 
(mainly eosinophils). 
Carbohydrate intolerance. 









Titlbach et al 
(1975) 
Insulitis (mononuclear) 








Renold et al 
(1964) 
LeCompte et al 
(1966) 
Federlin et al 
(1968) 
Toreson et al 
(1964) 
Grodsky et al 
(1966) 
Lee et al (1969) 




Fibrosis of some islets. 
Exocrine pancreas normal. 
Humoral anti -insulin 
antibody production 
Diabetes in a few animals 
Injection of 
homologous 
insulin in FA 
Cattle 
Sheep 
Renold et al 
(1964) 
LeCompte et al 
(1966) 
Federlin et al 
(1968) 
Identical to experiments 





pancreas in CFA 
Rat 
a 
Nerup et al 
(1973a) 
Andersen et al 
(1974) 
Insulitis (mononuclear). 
B cell degeneration. 
Exocrine pancreas normal. 
Antipancreatic cellular 
hypersensitivity (by LMT) 
Transient diabetic state. 
In the context of autoimmunity against the endocrine pancreas, 
the experiments by the group of Renold (Renold et al, 1964; LeCompte 
et al, 1966; Federlin et al, 1968) were of particular interest and 
importance. These workers showed that the injection of homologous 
insulin in cattle or sheep, over periods ranging from four months to 
two years, frequently results in pathological changes in the pancreatic 
islets which strongly resembled the lesions of insulitis found by 
Gepts (1965) in human diabetes. In affected animals the lesions were 
confined to islet tissue, the exocrine pancreas being uninvolved. The 
infiltration was typically mononuclear, mainly mature lymphocytes, and 
in some islets there was extensive fibrosis ( LeCompte et al, 1966). 
The appearance of insulitis was consistently accompanied by the develop- 
ment of humoral anti -insulin antibodies, while the presence of coexisting 
cell - mediated immunity to insulin was shown by the appearance of strongly 
positive delayed -type skin hypersensitivity to injected insulin. 
A difficulty in accepting the results of Renold et al as applicable 
to the development of insulitis in man was the relative rarity with 
which insulitis in animals was accompanied by carbohydrate intolerance. 
This objection was overcome in the rodent model of experimental immune 
insulitis described by Nerup and his colleages (Nerup et al, 1973a; 
Andersen et al, 1974). These workers prepared suspensions of homo- 
logous endocrine pancreas by using the collagenase dissection technique 
to isolate the islets of murine pancreas and admixing the tissue in 
complete Freund's adjuvant: they found that the injection of this 
preparation into inbred mice was followed by the appearance of classical 
insulitis, glucose intolerance and cell- mediated antipancreatic hyper- 
sensitivity (by the LMT) within fourteen days of injection. The 
.carbohydrate/ 
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carbohydrate intolerance and morphological changes were transient 
in nature, disappearing within a month of the initial injection; 
nonetheless the findings have relevance to the hypothesis of auto - 
immune diabetes in man. 
The most obvious objection to extrapolating the results of all 
the above studies to man has been the artificial nature of the 
procedures used for immunisation of experimental animals. Perhaps 
more relevant for the aetiology of human IDDM are the recent experi- 
ments in which diabetes has been induced in rodents by common 
viruses or by exposure to noxious chemicals, or the fascinating animal 
model of spontaneous autoimmune diabetes which has been lately des- 
cribed. These models are summarised in table 1/10. It will be seen 
that diabetes mellitus with selective beta cell loss has now been 
induced in mice by three. different viruses (EMC virus, reovirus and 
Coxsackie virus). The relevance of these observations to the aetiology 
of IDDM in man is considered more fully in chapter seven (section 7/2) 
but for the present, it should be noted that susceptibility to the 
effects of viral infection is largely dependent upon the strain of the 
mice under test (Boucher et al, 1975), thus indicating immediately 
that there is a genetic variation in immunologically mediated response 
to a viral infection. The animal model (table 110) in which insulitis 
and severe diabetes was induced by repeated small doses of strepto- 
zotocin might be thought to have little or no relevance to the aetiology 
of human diabetes with insulitis: however streptozotocin is a nitros- 
amine compound with molecular structure similar to a widely -used 
pesticide which was introduced into agricultural use about ten years 
ago/ 
TABLE 110 
Insulitis and diabetes mellitus induced by viral infection. toxic 
chemicals or heredity (spontaneous diabetes) in mice and rats 
Agent Authors Findings 
EMC -virus 
Reovirus type 3 
Coxsackie virus 
type B¢ 
Craighead et al 
(1975, 1981) 
Onodera et al (1978) 
Yoon et al (1978) 
Insulitis (mononuclear). 
Beta cell degeneration. 
Exocrine pancreas normal. 
Prolonged diabetic state. 
Streptozotocin 
(40 mg/kg) in 
repeated dosage 
Rossine and Like (1976) 
Like et al (1977, 1978) 
Rossini et al (1980) 
Insulitis (mononuclear). 
Selective beta cell degeneration. 
Proliferation of type -C virus 
in beta cells. Severe insulin - 
dependent diabetes mellitus. 
i 
Outbred strain 
of Wistar rate 
(BB /W rat) 
- approx. 30f 
of colony 
Nakhooda et al 
(1976' 1978) 
Dyrberg et al (1982) 
Like et al (1982) 
Intense insulitis (mononuclear). 
Gross beta cell loss. Severe 
insulin- dependent diabetes. 





ago and has since been implicated as a causative factor in at least 
two hundred cases of human ID] (Prosser et al, 1978; Karam et al, 
1979). Thus it is not impossible that toxic chemicals might cause 
a proportion of cases of immunologically -mediated beta cell destruction 
in man. As with virus infections, there are marked intra- strain 
variations in murine host susceptibility to :Areptozotocin, correlated 
with the haplotype of the animals, which again indicates a genetically - 
determined immune response to an environmental factor. 
The last and perhaps the most interesting animal model of 
insulitis and diabetes is the syndrome of severe, insulin- dependent 
diabetes which appeared spontaneously in a commercial outbred colony 
of Wistar -derived albino rats (now termed the Bio Breeding/Worcester 
or BB /W rat; table 110). The syndrome has been extensively studied 
(Nakhooda et al, 1977, 1978) and its major characteristics are as 
follows: about 30 per cent of genetically susceptible animals develop 
the syndrome at an early age (two to four months), both sexes are 
equally affected and the animals are lean. There is an abrupt onset 
of diabetes and 99 per cent of affected animals need daily insulin 
injections to sustain life. The histology of the pancreas shows a 
profound insulitis, with rapid beta cell destruction and the appear- 
ance of pseudo- atrophic islets (as in human IDm) composed of A and 
D cells. The evidence for cell- mediated autoimmunity in the BB /W 
rat comprises the presence of insulitis; prevention or modification 
of the diabetes by treatment with antilymphocytic serum (ALS); 
prevention of diabetes by neonatal thymectomy or by bone marrow trans- 
plant from normal rats (Like et al, 1979, 1981, 1982; Naji et al, 
1981). The evidence for humoral autoimmunity comprises the demonstra- 
tion/ 
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demonstration of immunoglobulin bound to the surface of pancreatic 
islet cells (islet cell surface antibody: see chapter two) by a 
protein -A radioligand assay (Dyrberg et al, 1982). Finally, 
affected animals show evidence of extra- pancreatic autoimmunity 
in the form of lymphocytic thyroiditis, closely resembling Hashimoto 
thyroiditis in man, and the presence of circulating autoantibodies 
to thyroglobulin, thyroid follicular cell, gastric parietal cell, 
smooth and skeletal muscle, and cell nuclei (Like et al, 1982). This 
fascinating animal model represents the closest approach at the 
present time to a model of polyendocrine autoimmune disease in which 
IDDM is the leading component and has developed through cell- mediated 
autoimmune mechanism. Studies of the BB /W rat have obvious implica- 
tions for the study and manipulation of immune mechanisms in human 
insulin -dependent diabetes, although it appears that the diabetic 
syndrome in these animals is not dependent upon any recognised 
infectious agents (Rossini et al, 1979). 
117 Summary and conclusions 
The studies reviewed in this chapter may be summarised as 
follows: 
a) Insulin- dependent diabetes is intimately related to the classical 
organ -specific autoimmune diseases, both on an individual and a 
familial basis. 
b) Thyrogastric autoantibodies are significantly more common in 
insulin -dependent diabetics than age- and sex -matched nondiabetics. 
c) There is no obvious connection between non -insulin -dependent 
diabetes and overt or serological evidence of endocrine autoimmune 
disease. 
ar 
d) Insulitis (mononuclear infiltration of the pancreatic islets) 
is not found in non- insulin -dependent diabetics or in any patient 
with disease duration of longer than (about) one year. Its presence 
is confined to recently diagnosed insulin- dependent patients and it 
mai be found in about half of such cases. 
e) In animal models it has proved possible to induce insulitis and 
diabetes by various immunisation procedures, viral infection, exposure 
to toxic chemicals and selective breeding. Genetic factors are of 
demonstrable importance in determining the response of individual 
strains of animals to environmental factors and hence of determining 
susceptibility to the insulitis /diabetes syndrome. 
The above studies have therefore provided good indirect evidence 
to associate insulin- dependent diabetes mellitus with autoimmunity. 
Studies which have searched for more direct evidence of humoral and 




STUDIES OF HUMORAL AUTOIMMUNITY IN DIABETES MELLITUS 
2/1 Introduction and purpose of studies 
At the time when this work commenced, one major difficulty in 
applying the autoimmune hypothesis to diabetes mellitus had been 
the failure to find humoral autoantibodies, directed against the 
endocrine pancreas, in sera from diabetics. Early investigators, 
using haemagglutination, gel- diffusion and precipitin techniques for 
antibody detection, claimed to find antibodies against the pancreas 
in the sera of a significant proportion of the diabetics that they 
tested, as well as in other forms of pancreatic disease (Murray and 
Thai, 1960; Fonkalsrud and Longmire, 1961). For example, Murray 
and Thal reported the presence of such antibodies in the sera of 
seven(12%) of sixty -one diabetics and forty -five (90%) of fifty 
patients with chronic pancreatitis or pancreatic cancer. These 
results were not confirmed subsequently and were probably due to 
methodological artefacts. Villavicencio et al (1965) used the 
same techniques as Murray and Thal and failed to find any anti - 
pancreatic antibodies in the sera of one hundred and forty -two 
diabetics and sixteen patients with pancreatitis. These authors noted 
that Murray and Thal's antigen was prepared at 10000 rpm and that 
Fonkalsrud spun his pancreatic extract at 2000 rpm; at these low 
speeds there exists the possibility of spurious positive gel- diffusion 
tests because of incomplete removal of haemoglobin, and the haemag- 
glutination test cannot be performed because of lysis of the red blood 
cells. Later attempts to detect antipancreatic antibody in diabetes 
by the indirect immunofluorescence technique were equally disappointing 
(Irvine 
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(Irvine et al, 1970; Nerup and Binder, 1973; Doniach, 1974a). 
Since the detection of a humoral autoantibody was central to the 
whole concept of autoimmunopathology in diabetes, it was decided to 
make a further search for antipancreatic antibodies in this disease. 
The time was propitious, since quantities of fresh human pancreas to 
use as tissue substrate were becoming available through the increas- 
ing volume of cadaveric renal transplantation surgery, and the quality 
of technical equipment for immunofluorescence microscopy was steadily 
improving. From the earlier literature it was apparent that previous 
investigators had examined very few diabetics with coexistent auto - 
immune endocrinopathies, i.e. those patients who might be expected to 
show the strongest expression of an autoimmune diathesis, and accord- 
ingly it seemed logical to commence the investigation in this selected 
group of patients. 
2/2 Selection of diabetics for study 
For the initial study, sera from a total of one hundred and five 
diabetics and controls were examined, the subjects being subdivided 
into the following groups: 
Group A: Diabetics with coexistent overt autoimmune disease 
This group comprised twenty insulin- dependent diabetics with 
coexistent idiopathic Addison's disease. All had circulating adrenal 
antibodies and all but two were women. Apart from adrenal failure, 
nine had one or more additional autoimmune disease (thyrotoxicosis, 
Hashimoto thyroiditis, primary hypothyroidism, pernicious anaemia, 
premature ovarian failure), accompanied by the appropriate circulating 
antibodies. 
Group B: Diabetics with thyrogastric autoantibodies 
This. 
50 
This group comprised twenty insulin- dependent diabetics with 
circulating thyroid and/or gastric parietal -cytoplasmic antibodies, 
but no evidence of overt autoimmune disease. These patients were 
matched as closely as possible (but not exactly) with the patients 
in group A for age, sex and duration of diabetes. 
Group C: Diabetics with negative autoantibodies 
This group comprised twenty -five insulin -dependent diabetics, 
with no overt autoimmune disease and no organ- specific antibodies 
in the serum. Patients in this group were closely comparable to 
those in groups A and B in respect of age, sex and duration of 
diabetes. 
Group D: Nondiabetic controls with negative autoantibodies 
This group comprised forty healthy nondiabetic controls with 
no overt autoimmune disease and no organ- specific antibodies in the 
serum. They were obtained from the same sources as the normal subjects 
used in the study of nonpancreatic antibodies in diabetes (chapter 
six) and were broadly comparable, in age and sex, to the subjects in 
the three diabetic groups above. 
2/3 Methods used for detection of autoantibodies 
Detection of islet -cell antibodies 
Fresh human pancreas was used as the tissue substrate for these 
experiments, and was obtained immediately after death from cadaveric 
renal transplant donors of blood group 0. Group 0 pancreas was found 
to be essential since the use of pancreas from group A or B donors 
frequently gave immunofluorescence of acinar cells, thus making the 
detection of any possible islet -cell fluorescence extremely difficult; 
the phenomen occurs because the cells of the exocrine pancreas are 
analogous/ 
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analogous to those of the gastric mucosa in possessing membrane 
antigens of the blood group system and in synthesising blood group 
substances in intracellular microsomes. The specimens were kindly 
supplied by Mr. A.C.B. Dean, Consultant Surgeon, Royal Infirmary, 
and Mr. A. McL. Jenkins, Lecturer in Surgery, University of Edinburgh. 
The tissue was snap- frozen immediately after removal, stored in small 
blocks at -40 °C, and cut as required into thin (5-7 micron) sections 
on a cryostat. All tests were performed on air -dried, unfixed 
sections. Islet -cell antibodies were detected by the Coons indirect 
immunofluorescence technique (Appendix 112), using antihuman IgG 
fluorescein- isothiocyanate (FTC) conjugate (Wellcome Reagents) at a 
1:14 dilution. All sera were initially tested undiluted, but those 
giving positive results were subsequently retested in serial dilutions 
to establish the antibody titres. Positive sera were further tested 
with anti -IgA and anti -IgM conjugates to ascertain the immunoglobulin 
class of the antibodies, and complement- fixing ability was studied with 
an anti -B1C conjugate (Boehringer Corp). Experiments were also under- 
taken to confirm that the fluorescence observed with anti -IgG conjugate 
could be abolished by pretreatment of the pancreatic sections with 
unlabelled anti -human IgG. 
Other autoantibody studies 
Using the techniques described in chapter six and Appendix I, all 
sera were tested for antibodies to thyroglobulin, thyroid cytoplasm, 
gastric parietal -cell cytoplasm, cell nuclei and mitochondria. In 
addition sera from patients in group A with premature ovarian failure 
were examined for antibodies reactive to extra -adrenal steroid -producing 
cells (ovary, testis and placenta); this investigation was kindly 
undertaken/ 
52 
undertaken by Dr. E.W. Barnes using the method of Irvine et al (1969). 
Serum from the single patient with pernicious anaemia was examined 
for intrinsic- factor- antibody 1 by radioimmunoassay using albumin - 
coated charcoal as described by Irvine et al (1968). 
2/4 Detection and eneral .ro.erties of . ancreatic islet -cell 
antibody 
Islet -cell antibodies 
Cytoplasmic immunofluorescence of the pancreatic islets was 
detected in five of the hundred and five sera tested, all from patients 
in group A (table 2/1). In each case the fluorescence seemed to involve 
the islet cells diffusely, being present in A (alpha) and D (delta) 
cells in addition to B (beta) cells (figure 2/1). Immunofluorescence 
was detected using undiluted serum only in one case, the antibody titre 
ranging from 1:4 to 1:128 in the other four sera (table 2/2). Some 
variation in the intensity of fluorescence was observed with the two 
strongest sera, but in all cases the islets stood out brightly from 
surrounding exocrine tissue. Islet -cell antibodies were complement - 
fixing as shown by staining with addition of fresh human serum followed 
by anti -B1C conjugate and in all cases were of IgG class, immuno- 
fluorescence being negative with anti -IgA and anti -IgM conjugates. It 
was also possible to abolish the fluorescence by pretreatment of the 
pancreatic sections with unlabelled anti -IgG. With negative sera the 
pattern of fluorescence was entirely different (figure 2/2): the 
islets either merged with surrounding exocrine tissue or were only 
distinguished with difficulty, and any fluorescence observed was 
either an orange -pink autofluorescence or occasional faint cytoplasmic 





Antibodies to pancreatic islet -cell detected by immunofluorescence 
in 65 diabetic patients and 40 normal controls 
Group Patients tested 
Islet -cell antibody 
Positive Negative 
A Diabetics with Addison's disease 5 15 
B Diabetics with thyrogastric antibodies 0 20 
C Diabetics with negative autoantibodies 0 25 
D Controls with negative autoantibodies 0 40 
Total 5 100 
See text for explanation of groups 
From MacCuish et al (1974a). 
FIGURE 2/1 
Pancreatic islet -cell antibody in diabetes mellitus: cryostat section 
of human pancreas treated with serum of a diabetic patient, followed by 
antihuman IgC -FITC conjugate, showing cytoplasmic fluorescence over the 
islet of Langerhans. Fluorescence is apparent in all cell types in the 
islet; the exocrine pancreas is unaffected. 
(Photographed with Leitz Orthomat equipment: Ektachrome EH135B Film) 
TABLE 2/2 (OPPOSITE: 
Clinical and serological findings in five diabetics with 
autoantibodies to pancreatic islets 
Thg antibody to thyroglobulin 
TC e antibody to thyroid cytoplasm 
GPC . antibody to gastric parietal -cell cytoplasm 
IF . antibody to intrinsic factor 
ANA . antibody to cell nuclei 
Mito = antibody to mitochondria 
Plac . antibody-to placenta 
+ . antibody present, titre not determined 
. antibody not present 





































































































































































































































































































































































































































































































































































































































































































































FIGURE 2 2 
Antibody- negative serum in diabetes mellitus. The pancreatic 
section has been prepared and treated exadty as for figure Jl 
but the test serum does not contain islet -cell antibody. The 
islets of Langerhans and the exocrine pancreas are both clearly 
visible in the photograph: neither type of tissue shows specific 
fluorescence. 
(Photographed as for figure 5 /1) 
5 
Other autoimmune lesions in patients with islet -cell antibodies 
The clinical and serological findings in the five cases with 
islet -cell antibodies are presented in table 2/2. As stated, all 
were diabetics with idiopathic Addison's disease and four had 
additional overt autoimmune disease or diseases. The three patients 
with premature ovarian failure had a multiplicity of steroid -cell 
antibodies reacting with different antigens in ovary, placenta and 
testis, typical of the serological findings in this polyendocrine 
syndrome (Irvine et al, 1969). 
2/5 Properties of the pancreatic islet -cell antigen -antibody system 
Using the above five positive sera as reference standards, some 
initial investigations into the nature of the islet -cell antigen - 
antibody system were undertaken. Air -dried pancreatic sections were 
exposed to a variety of fixatives, reagents, proteolytic enzymes, etc. 
before and after treatment with antibody -containing sera. The results 
(table 2/3) indicate that the activity of pancreatic islet -cell antigen 
is destroyed by reagents that separate lipids as much as by proteolytic 
enzymes; the general properties seem strikingly similar to those of 
the thyroid -cell or gastric parietal -cell autoimmune systems, as 
summarised by Doniach (1974b). These preliminary findings do not 
obviate the need for formal characterisation of pancreatic islet -cell 
antigen(s) by absorption and subcellular fractionation studies, but 
at least suggested by analogy that this antigen too may be microsomal 
in nature. 
2/6 The prevalence of islet -cell antibody in diabetes, autoimmune 
disease and the normal population 




Behaviour of the pancreatic islet -cell antigen- antibody 
system when exposed to various fixatives. etc. 



















diabetes, and having determined some of its characteristics, an 
investigation was undertaken to estimate the prevalence of this 
antibody in a larger diabetic population, as well as in nondiabetics 
with known autoimmune disease. For this purpose the initial series 
of one hundred and five sera described in section 2/2 of this chapter 
was extended to include the examination of serum samples from a total 
of nine hundred and three subjects, subdivided into the following 
groups: 
Diabetic with coexistent autoimmune disease 
This group comprised forty -six diabetics (thirty -five women, 
eleven men), all of whom had one or more coexistent autoimmune disease. 
There were twenty -one patients with idiopathic Addison's disease, 
which included the initial twenty patients described in section 2/2. 
Pernicious anaemia coexisted with diabetes in six patients, all of 
whom were on maintenance treatment with vitamin B12 injections. Thyroid 
autoimmune disease was present in the remaining nineteen patients: ten 
had primary hypothyroidism and were receiving L-thyroxine replacement 
therapy; nine were thyrotoxic, being treated with carbimazole, a 
therapeutic dose of 131lodine or (in one case) by partial thyroidectomy. 
Thirty -eight of the patients in this group were insulin- dependent 
diabetics, the remainder being controlled by dietary carbohydrate 
restriction or oral hypoglycaemics (sulphonylurea or biguanide). 
Diabetic with thyrogastric autoantibodies 
This group comprised one hundred and seven diabetics (seventy 
women, thirty -seven men), all with thyroid cytoplasmic and/or gastric. 
parietal -cell cytoplasmic antibodies in the sera but none with overt 
autoimmune disease. Forty -five of these patients had been identified 
by/ 
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by the study described in chapter six and sixty -two had been 
identified during the extensive survey of Irvine et al (1970). 
Seventy -eight were insulin- dependent diabetics, the remainder being 
controlled by dietary carbohydrate restriction or oral hypoglycaemics. 
Diabetic with negative autoantibodies 
This group comprised two hundred diabetics (one hundred and fifty 
women, fifty men) with no overt autoimmune disease, no personal history 
of autoimmunity and no organ- specific antibodies in the serum. The 
majority of these patients had been identified by the study described 
in chapter six; one hundred and fifty were insulin- dependent diabetics, 
the remainder being controlled by dietary carbohydrate restriction or 
oral hypoglycaemics. 
Nondiabetic with pernicious anaemia/atrophic gastritis 
There were fifty patients (forty -five women, five men) in this 
group. In forty -six the diagnosis of pernicious anaemia had been made 
by the usual criteria (anaemia, low serum vitamin B12, megaloblastic 
bone marrow, achlorhydria, low Schilling test corrected with intrinsic 
factor); all these patients were being treated with regular injections 
of vitamin B12 and all had circulating gastric parietal -cell and /or 
intrinsic factor antibodies. The remaining four patients in this 
group had the autoimmune type of atrophic gastritis as defined by 
Goldstone et al (1973). 
Nondiabetic with Hashimoto thyroiditis 
The fifty patients in this group were all women and all were 
attending the Endocrine Clinic at Edinburgh Royal Infirmary. Histo- 
logical confirmation of the diagnosis was available in eighteen 
patients; in a further thirty the diagnosis was made on the basis of 
a/ 
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a goitre and characteristic serological findings (high titres of 
circulating thyroid cytoplasmic and/or thyroglobulin antibodies). 
The remaining two patients had presented with a goitre and hypo- 
thyroidism in middle age and on clinical grounds were considered to 
have Hashimoto thyroiditis, although the antibody titres were low. 
All but four of the patients in this group were on long -term treatment 
with L- thyroxine. 
Nondiabetic with idiopathic Addison's disease 
The hundred patients (seventy -two women, twenty -eight men) in 
this group with idiopathic (autoimmune) Addison's disease had all 
been identified in the studies of Irvine and Barnes (1974, 1975), and 
all had circulating adrenocortical antibodies. They were receiving 
'conventional steroid replacement therapy and thirty had polyendocrine 
autoimmune disease (premature gonadal failure, thyrogastric auto - 
immunity, idiopathic hypoparathyroidism, or a combination of these 
syndromes) in addition to adrenal failure. 
Control subjects 
This group comprised three hundred and fifty healthy nondiabetic 
subjects (two hundred women, one hundred and fifty men) with no overt 
autoimmune disease, no personal history of autoimmunity and no organ - 
specific antibodies in the serum. The majority of these controls 
had previously been used for the studies described in chapter six and 
were obtained from the sources mentioned in that chapter. 
Detection of islet -cell antibodies 
Islet -cell antibodies were detected as described in section 2/3 
of this chapter. All sera giving positive results were tested using 





The prevalence of islet -cell antibody in the various diabetic 
and nondiabetic subgroups is summarised in table 2/4. The antibody 
was found in a total of fifty -one diabetics. Fourteen (eleven women, 
three men, all insulin -dependent) had one or more major overt auto - 
immune disease in addition to diabetes: seven had idiopathic Addison's 
disease (including the five detailed in table 2/2), two had pernicious 
anaemia, four had primary hypothyroidism and one was thyrotoxic. The 
overall prevalence of islet -cell antibody in this selected group of 
forty -six patients was 30% and nine of the antibody -positive subjects 
were aged forty years or younger. 
Nineteen diabetics with islet -cell antibody (twelve women, seven 
men, all but one insulin -dependent) had circulating thyrogastric 
antibodies but no clinical autoimmune disease. The overall prevalence 
of the antibody in this group of one hundred and seven patients was 
18% and thirteen of the antibody- positive subjects were aged forty 
years or younger. 
Islet -cell antibody was found in the serum of eighteen of two 
hundred diabetics who had no other clinical or serological evidence 
of autoimmune disease. The overall prevalence of antibody in this 
group was 9% and twelve of antibody- positive subjects were aged forty 
years or younger. All but two had insulin -dependent diabetes, the 
exceptions being one woman and one man who were being treated with the 
oral hypoglycaemic drug chlorpropamide. 
With regard to nondiabetics with overt autoimmune disease, the 




The prevalence of pancreatic islet -cell antibody in diabetics with 
and without autoimmunity, in nondiabetics with autoimmune disease 
and in normal subjects 
Group of subjects tested 
Islet -cell antibody 
Negative Positive 
Diabetic with coexistent autoimmune disease 32 14(30%) 
Diabetic with thyrogastric autoantibodies 88 19(18%) 
Diabetic with negative autoantibodies 182 18(9%) 
Nondiabetic with PA/atrophic gastritis 49 1(2ó) 
Nondiabetic with Hashimoto thyroiditis 50 0 
Nondiabetic with Addison's disease ' 99 1(1 %)* 
Normal controls 350 0 
(see text for detailed description of the groups) 
_PA = pernicious anaemia 
*Subsequently developed diabetes (see text) 
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prevalence of 1 %. One was a woman, aged thirty -four years with 
pernicious anaemia; no information on her response to glucose 
tolerance testing was available. The other was a forty -six year old 
woman with idiopathic Addison's disease and thyrotoxicosis. This 
patient presented with typical symptoms of thirst and polyuria six 
months after her serum was tested and subsequently developed insulin - 
dependent diabetes mellitus. 
Islet -cell antibody was not found in any of three hundred and 
fifty normal subjects. 
2/7 Discussion of results 
The five examples of pancreatic islet -cell antibody (ICA) detected 
in the initial study described in this chapter (section 2/4; table 2/2) 
were published in detail at the end of 197. .(MacCuish et al, 1974a). 
Four weeks previously the presence of an islet -cell antibody in sera 
from thirteen patients had been reported by Professor Deborah Doniach's 
group at the Middlesex Hospital (Bottazzo et al, 1974): from a com- 
parison of the two reports it was clear that the findings were identical, 
and that the existence of a new antibody directed against the endocrine 
pancreas had thus been confirmed by two independent centres. The first 
question to ask, therefore, was why this particular antibody had 
remained undetected for so long. Several hundred diabetic sera had 
previously been tested by workers interested in this problem, using the 
same immunofluorescence technique but without success; however these 
studies either specifically excluded patients with clinically coexistent 
diabetes and autoimmune disease (Irvine et al, 1970; Nerup and Binder, 
1973) or tested unselected patients, many of whom were insulin - 
independent (Doniach, 1974a). In retrospect it is now clear that these 
populations/ 
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populations were unlikely to have contained antibody- positive patients 
and were markedly different to the populations investigated by Botta!%o 
et al (1974) and by the author. Moreover, earlier workers did not 
fully appreciate that blood group substances are normally secreted by 
the pancreatic acini, so that group A or B organs give substantial 
fluorescence with many sera (Lendrum and Walker, 1975), while fresh 
human pancreas from group 0 donors was not readily available until 
cadaveric renal transplantation became established in the early 1970's. 
Finally, pancreatic islet -cell antibody is present in only low titres 
in most subjects (the highest titre recorded in the present series 
being 1:256), and produces a comparatively weak immunofluorescence by 
comparison with the strikingly vivid cytoplasmic staining exhibited 
by thyroid or gastric microsomal antibodies. Early UT microscopes, 
with dark -field condensers and light reflected from below by a mirror, 
had a much lower visibility than present -day instruments equipped with 
the Ploem epi- illumination (incident light fluorescent microscopy): 
thus weakly fluorescing antibodies could readily go undetected. In 
short, both the technical equipment and the tissue substrate to detect 
pancreatic ICA became simultaneously available at a time when the 
Immunology Laboratories in Edinburgh had painstakingly collected a 
bank of sera from insulin -dependent diabetics, with coexistent auto - 
immune endocrinopathy, which could be properly examined for evidence 
of pancreatic antibodies. 
The studies presented here have indicated that islet -cell antibody 
is an immunoglobulin of IgG class, detectable by immunofluorescence, 
complement fixing and reacting with all cells in the islets. Later 
studies have confirmed that islet -cell antibodies are entirely of 
IgG/ 
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IgG class but may be produced in much more restricted clonal responses 
(for example, IgG2 subclass alone or IgG2 + IgG4) than the widely 
polyclonal responses seen in gastric and thyroid antibodies; moreover, 
not all islet -cell antibodies are complement -fixing (Bottazzo et al, 
1981). The antigen -antibody system was affected by various fixatives 
(table 2/3) in an identical fashion to the thyroid cytoplasmic and 
gastric parietal -cell cytoplasmic autoimmune systems. By analogy 
with these two systems, whose properties have been fully characterised, 
it seemed likely that the antigen(s) of the pancreatic islet -cell were 
also likely to be microsomal, i.e. comprised of membrane lipoproteins 
from subcellular fractions of smooth endoplasmic reticulum. Subsequent 
studies (Bottazzo et al, 1976; Lendrum et al, 1976; Doniach and 
Bottazzo, 1977) have strengthened this belief and have confirmed the 
organ- specificity of the antibody. By elegant studies with double 
immunofluorescence technique, using FITC- labelled antihuman IgG anti- 
body and rhodamine- labelled anti- hormone antibodies, Bottazzo et al 
(1976) have demonstrated clearly that the antibody is not directed 
against islet hormones. The antibody is directed against cytoplasmic 
antigen, probably the cytoplasmic organelles concerned with hormone 
synthesis or secretion. This antigen is common to all four endocrine 
cell types in the islets of Langerhans (Bottazzo and Doniach, 1978) 
and is widely species- non -specific since human islet -cell antibody 
cross -reacts with islets from rat, guinea -pig and monkey. 
The prevalence and significance of islet -cell antibody in diabetics 
and nondiabetics can now be considered. The initial studies presented 
here suggested that islet -cell antibody would be found in approximately 
one -third of insulin- dependent patients with overt autoimmune disease; 
in/ 
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in about 20% of patients with circulating autoantibodies but without 
overt autoimmune disease; and in under 10% of diabetics who had no 
other clinical or serological expression of autoimmunity. Islet -cell 
antibody appeared to be overwhelmingly associated with insulin- dependent 
diabetes, although comparatively few insulin- independent diabetics had 
been tested. However, the presence of antibody in two insulin - 
independent diabetics, and in two nondiabetics with autoimmune disease, 
seemed to confirm that antibody was not related to prior treatment by 
insulin injections. 
2/8 Results of further studies of pancreatic islet -cell cytoplasmic 
antibodies 
Following the initial demonstration of pancreatic islet -cell cyto- 
plasmic antibodies by Bottazzo et al (1974) and by the author, numerous 
further studies have been undertaken in Edinburgh, the Middlesex 
Hospital and a number of other laboratories. The most important and 
extensive of these studies are summarised in tables 2/5, 2/6 and 2/7, 
and now permit an accurate analysis of the prevalence and significance 
of this antibody. (The abbreviation 'ICA' is now applied to pancreatic 
islet -cell cytoplasmic antibody, to distinguish it from other islet -cell 
antibodies which have been subsequently described - see section 2/9). 
Table 2/5 depicts the broad prevalence of ICA in several large 
studies which examined a total of nearly three thousand diabetics. It 
is immediately apparent that the highest overall prevalence of ICA is 
in insulin- dependent diabetics (IDBM) who suffer-from at least one 
other coexistent autoimmune disease (usually thyrogastric or adrenal). 
In this type of diabetic population, having no regard to the duration 
of clinical diabetes, ICA prevalence is about 38% ( Bottazzo et al, 




The overall .revalence of .ancreatic islet -cell antibo. ICA) 
in patients with insulin- dependent diabetes mellitus (IDDM), 
non -insulin- dependent diabetes (NIDIM), with and without 
associated autoimmune disease 
Authors Patients tested 
Number Per cent 
Tested Positive 
Bottazzo et al IDDM, overt autoimmune disease 120 38 
(1976) 
Lendrum et al IDDM 829 38 
(1976a) 
NIDDM 112 5.3 
Irvine et al IDDM, overt autoimmune disease 60 38 
( 977a) IDIM, thyrogastric autoantibodies 141 34.7 
IDDM, without autoimmune disease 588 22 
NIDI, overt autoimmune disease 19 10 ) 
NIDBM, without autoimmune disease 305 4.6) 
Del Prete et al ID}} (onset aged under 35 years) 191 24.2 
(1977) IDDM (onset after age 35 years) 200 15.5 
NIDDI 373 8.3 
*Seven of these sixteen patients (44%) subsequently developed IDBM 
lo 
TABLE 2/6 
The correlation between the prevalence of ICA in insulin -de endent diabetics 
(IDDM) and the duration of clinically apparent diabetes 
Authors Patients tested 
Number Per cent 
Tested Positive 
Christy et al 
(1976) 
Lendrum et al 
(1976a) 
Muntefering et al 
(1976) 
Buschard et al 
(1976) 
Irvine et al 
(1977a) 
Del Prete et al 
(1977) 
Ginsberg- 
Fenner et al 
(1982) 
IDD (mean duration 3.2 years 
IDDM (duration one week) 
IDDM (duration one month) 
IDDM (duration above one year) 
IDIM (duration less than 3 months) 















under one year) 
1 - 5 years) 
above 5 years) 
less than 6 months) 
6 - 12 months) 
1 - 5 years) 














65 IDDM children (aged under 15 years 74 
mean duration of Iii 3.1 years) 
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TABLE 2/7 
The prevalence of ICA in non- diabetic populations, with and without 
associated autoimmune disease, and in first degree relatives of 
IDDM children 
Authors Patients tested 




Bottazzo et al 
(1976) 
Irvine et al 
(1976, 1977a) 
Del Prete et al 
(1977) 
Ginsberg- 
Fenner et al 
(1982) 
Rodger et al 
(1980) 
'Healthy controls' (non diabetic, 
no autoimmune disease) 








Non diabetic, first degree relatives 
of ICA -positive subjects 
'Healthy controls' (non diabetic, 
no autoimmune disease) 
'Healthy controls' (normal GTT) 
'Non diabetic patients' 
First degree relatives of IDDM 
children 
Non diabetic adults (mean age 54) 













GTT â oral glucose tolerance test 
aEight subjects were found to be diabetic by oral GTT 
bOne subject was found to be diabetic by oral GTT 
cOne subject was found to be diabetic by oral GTT 
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disease, the possession of circulating thyrogastric antibodies to 
IDDM implies that patients who exhibit this phenomenon will carry 
ICA in the same proportion as those with clinically apparent auto - 
immunity (Irvine et al, 1977a). By contrast, large populations of 
IDDM in whom the phenomenon of autoimmunity - clinical or serological - 
is specifically excluded will have an ICA prevalence of only about 20%. 
The exception is the prevalence of 38% in the large series described 
by Lendrum et al (1976a) but this population study included a large 
number of juveniles (57% were aged less than twenty years), a high 
percentage of patients with short duration of IDDM (50% had had 
diabetic symptoms for less than one year) and a significant proportion 
of patients with evidence of subclinical autoimmunity (23% had cir- 
culating thyroid and/or gastric parietal cell antibodies). All these 
factors are now known to increase the prevalence of ICA in an IDDM 
population. 
Non- insulin- dependent diabetics (NIDDM) whether controlled by 
oral hypoglycaemics or by dietary measures alone, are very much less 
likely to possess ICA. The large series examined by Irvine et al 
(1977a) and by Lendrum et al (1976a) indicate an ICA prevalence of 
about 5% in such patients, although this figure doubles to about 10% 
if NIDBM with coexistent autoimmune diseases are considered separately 
(Irvine et al, 1977a). The rarity of ICA in NIDDM treated by diet 
alone is particularly striking: indeed Irvine et al found no ICA - 
positive subjects among one hundred and seven diet -treated patients 
whom they examined and if this subgroup of NIDDM is excluded from the 
analysis in table 2/5, the prevalence of ICA rises to 8% in a 
population of NIDDM treated with oral hypoglycaemic drugs (Irvine et 
al 
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al, 1977a). Furthermore, ICA- positive diabetics treated with oral 
hypoglycaemics show a strong tendency to develop typical IDDM within 
three years from the detection of ICA (table 2/5), and thus it was 
postulated that the presence of ICA in such patients could be used 
as a 'marker' to identify patients with initially 'mild' diabetes 
who will go on to require insulin therapy (Irvine et al, 1977b). 
The figure of an ICA prevalence of in NIDDM by Del Prete et al 
(1977) was obtained from a patient population in which one in five of 
the patients which they studied had a clinically overt, coexistent 
autoimmune disease and many were presumably taking oral hypoglycaemics. 
Del Prete and colleagues also examined a small number of patients with 
inherited insulin -independent diabetes appearing in early life - 
sometimes termed MODY (maturity -onset diabetes in youth, or Mason -type 
diabetes; Tattersall and Fajans, 1975) - and found no ICA -positive 
subject. This is an expected finding since MODY is a rare type of 
mild diabetes, inherited as a Mendelian dominant, not associated with 
autoimmunity or HLA type, and distinctly different from all other forms 
of diabetes (Bell et al, 1983). 
These broad population studies are of considerable interest but 
are much enhanced when ICA prevalence is related to the duration of 
clinical diabetes. Table 2/6 summarises the results of some major 
studies in which duration of IDDM has been related to antibody prevalence. 
A strong correlation of ICA with duration of disease is apparent: up to 
85% of IDDM will possess antibody if tested during the first week of 
clinical diabetes but thereafter the prevalence falls rapidly, and only 
about half of such patients will still be ICA -positive if they are 
tested after six to twelve months of IDDM. After one year of IDDM, 
antibody/ 
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antibody prevalence has fallen to about 30% and after five years, 
ICA will only be detected in 10 - 20% of patients. Again it is 
noteworthy that the persistence of ICA -positivity with increasing 
duration of IDDM is related to the presence of coexistent auto- 
immune disease (AID): thus Irvine et al (1977a) detected ICA in about 
60% of all IDIKI tested within one year of diagnosis of diabetes but 
found after five years or more that ICA persisted in 26% of patients 
with coexistent overt AID and in only 7% of patients without AID. 
The series described by Christy et al (1976) and Ginsberg -Fellner et 
al (1982) are the exceptions to these broad general rules; however 
the latter workers specifically examined a population of IDDM children 
with remarkable personal and family backgrounds of autoimmune disease, 
and it seems probable that the series of Christy et al (where the 
patients' ages are not stated) also included a large number of similar 
juveniles. It is also possible, indeed probable, that differences in 
methodology contribute to the apparent discrepancies in results reported 
from different laboratories. For example, sera from the diabetics 
described by Ginsberg -Feltner et al (1982) were examined for the 
presence of ICA by using paraffin- embedded sections of pancreas from 
blood group 0 donors (Bouin's fixed human pancreas: Dobersen et al, 
1979) rather than the snap- frozen sections of fresh human pancreas 
employed by most other workers. Differences in patient selection and 
methodology should not obscure the clear demonstration that first, 
ICA in IDDM disappear quickly from the sera of most patients without 
coexistent autoimmune disease and second, that ICA may persist for 
long periods in- IDDM with coexistent autoimmune disease. The latter 
group of patients - with persistent ICA - behave like patients with a 
classical/ 
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classical organ -specific autoimmune disease, such as Addison's 
disease (Irvine and Barnes, 1975), while the former - with transient 
ICA - are significantly different from patients with other autoimmune 
endocrinopathies. 
The prevalence of ICA in NIDDM treated with oral hypoglycaemics 
is also influenced by duration of clinical diabetes, in a similar 
but less dramatic fashion to IDDM. Islet -cell antibodies were found 
in 20% of such patients at the time of diagnosis, the prevalence falling 
to about 1 after one to two years of clinical diabetes and to less 
than 10% after disease duration of more than two years (Irvine et al, 
1977a). Again, persistence of ICA was found to correlate with other 
evidence of coexistent autoimmunity, either overt or serological 
(presence of thyrogastric antibodies). The tendency of NIDDM with 
ICA to progress to IDDM has already been noted (table 2/5) and was 
amply confirmed in a later study which demonstrated that 86% of such 
patients will progress from oral hypoglycaemic to insulin therapy 
within five years from diagnosis, as compared to 18% of ICA- negative 
patients (Irvine et al, 1979). Metabolic studies of NIDDM treated with 
oral hypoglycaemics have shown that ICA- positive patients have signi- 
ficantly higher blood glucose levels, and significantly lower insulin 
secretion when their response to a glucose load is compared to that 
of ICA -negative patients who are apparently clinically identical (Gray 
et al, 1980; Irvine et al, 1980b). In NIDDM treated by diet alone, 
the number of ICA -positive patients is vanishingly small and obviously 
is unaffected by duration of disease. 
Table 2V7 describes the prevalence of ICA in several large series 
of nondiabetic individuals, with and without autoimmune disease. It 
can/ 
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can be seen that the prevalence of ICA is exceedingly low in a 
putative normal population: the author found none in any of three 
hundred and fifty individuals and a similar finding was reported by 
Del Prete et al (1977) in a group of two hundred healthy individuals 
in whom oral glucose tolerance (GTT) was known to be normal. The 
large series of Irvine et al (1976) found only two ICA- positive 
subjects out of four hundred and thirty -four controls who were neither 
diabetic nor known to have endocrine disease, most being blood donors 
or healthy friends of hospital outpatients. Similar prevalence figures 
(0.2% in adults, 0.4% in children) were obtained when virtually the 
entire (nondiabetic) population of a small Australian town was tested 
for the presence of ICA (Rodger et al, 1980). However, when non - 
diabetics with autoimmune disease are considered, ICA prevalence in 
this type of population is between 4 - 8f (Irvine et al, 1976; Bottazzo 
et al, 1976), thus confirming and strengthening the association between 
antipancreatic autoimmunity and autoimmune disease affecting other 
organs. Thyroid disease and idiopathic Addison's disease, with or 
without coexistent polyendocrine autoimmune disease, are again the 
diseases most commonly associated with ICA -positivity. Of great 
interest was the observation that one quarter (eight out of thirty -one) 
of such patients identified by Irvine et al (1976) were diagnosed as 
diabetic by formal glucose tolerance testing, although none were 
previously known to be diabetic. This study provided the initial 
suggestion that ICA might be a 'marker' for asymptomatic or latent 
diabetes, or might play some part in the' pathogenesis of beta cell 
failure. The same study searched for ICA among first -degree non - 
diabetic relatives of ICA -positive subjects (almost all of whom were 
diabetic 
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diabetic) and found a prevalence of 2.5 %; again one of those 
individuals was found to be diabetic on glucose tolerance testing 
(Irvine et al, 1976, 1977a). In a later investigation, carbohydrate 
tolerance in forty -two subjects with ICA but without clinical diabetes 
was followed for up to five years: within this time, nine had pro- 
gressed to develop clinical diabetes and four had typical IDDM 
(Irvine, 1980). 
The recent study of Ginsberg- Fellner et al (1982) is of particular 
importance since these authors found that more than one in five (21 %) 
of first -degree (nondiabetic) relatives of diabetic children - i.e. 
the siblings and parents of these children - carried ICA in the sera. 
None of these individuals were frankly diabetic on oral glucose test- 
ing but many had significantly raised blood glucose levels following a 
glucose challenge and two (siblings who were both HLA- identical with 
their diabetic probands and who had been ICA -positive for three years 
and eighteen months respectively) developed typical IDDM during the 
study. This type of study - where an ostensibly normal individual is 
found to be ICA -positive, responds abnormally to a brief glucose 
challenge and then progresses to overt IDDM - can be compared with the 
prolonged challenge to carbohydrate tolerance that is imposed by normal 
pregnancy. Here again ICA is of value in predicting the progression 
to insulin- dependent diabetes: Steel and colleagues studied fifty 
'normal' women with impaired glucose tolerance during pregnancy (defined 
as a capillary blood glucose above 6.6 mmols /l (200 mg /dl) two hours 
after a 50 g glucose load). Five women were found to have cytoplasmic 
ICA during pregnancy and three of these five developed typical IDDM 
within one year post- partum, a progression shown by none of the forty- 
five/ 
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forty -five ICA- negative women (Steel et al, 1980). Further support 
for the belief that the presence of ICA in nondiabetics is a predictor 
for the eventual development of IDDM has come from a long prospective 
study of the pre -diabetic period in first -degree relatives of diabetic 
children. The authors searched for ICA in five hundred and twenty - 
eight first- degree nondiabetic relatives of one hundred and sixty 
children with IDDM: after two years of observation, six persons had 
developed IDDM and all were known to have circulating ICA for between 
four and thirty months before the onset of clinical diabetes (Gorsuch 
et al, 1981). All these studies have indicated the value of ICA in 
predating and predicting the eventual onset of IDDM, often after a 
lengthy period, in persons who have normal carbohydrate metabolism 
or minimal impairment of glucose tolerance when the antibody is first 
detected. 
The studies in which the relationship of ICA to HLA typing has 
been examined can now be considered. The first such study was that 
of Landrum et al (1976b), who found no association between the presence 
of ICA and any particular HLA phenotype. However these authors 
examined only one hundred and thirty -nine patients with IDDM, aged 
thirty years or under at the onset of disease, and detected ICA in 
only thirty -three cases. With such small numbers it is not possible 
to make a correlation between the HLA phenotype and the presence of 
ICA. By contrast Christy et al (1976) did find an association between 
the HLA antigen B8 and ICA in juvenile diabetics, although again only a 
small number of patients (thirty -eight cases) were examined. However 
the large series of Irvine et al (1977a) where HLA typing was performed 
in one hundred and twenty -two diabetics including one hundred ICA - 
positivè/ 
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ICA- positive subjects, found a clear association between HLA -B8, Al 
and Al +B8 and the presence of ICA. This series was also sufficiently 
large for the authors to correlate the presence of these HLA types with 
the presence of coexistent autoimmune disease and with the persistence 
of ICA for more than five years from the diagnosis of IDDM. Later 
studies have confirmed that IDDM with persistent ICA are HLA -B8 positive 
more often than antibody -negative patients (Bottazzo et al, 1978b; 
Cudworth, 1978; Irvine et al, 1978b; Cudworth et al, 1980). The 
importance of establishing an association between HLL B8 and the 
presence and persistence of ICA in diabetes is illustrated by the observ- 
ation of a very high prevalence of B8 in (Caucasian) individuals suffering 
from idiopathic ( autoimmune) Addison's disease (Thomsen et al, 1975; 
Nerup et al, 1980; Irvine et al, 1980a), Grave's disease (Beck et al, 
1977; Irvine et al, 1977c; Nerup et al, 1977; Cudworth et al, 1980), 
Hashimoto thyroiditis and primary hypothyroidism (Irvine et al, 1978a; 
Cudworth et al, 1980) - all regarded as classical organ- specific auto - 
immune diseases. Thus on the basis of islet -cell antibody and HLA 
studies alone, it would be reasonable to add IDDM with persistent ICA 
to the above group of diseases. 
An association between IDDM (without regard to islet -cell antibodies) 
and HLA-B8 or B15 had been reported at about the same time in studies 
from both Denmark (Nerup et al, 1974b) and the U.K. (Cudworth and Woodrow, 
1975, 1976) and the validity of an association between IDI& and certain 
HLA types has now been established beyond doubt (Cudworth et al, 1980; 
Nerup et al, 1980; Cudworth and Wolf, 1982). However it is important 
to note that the early studies of the relationships between HLA, IDDM 
and ICA were concerned only with the detection of HLA -A, -B and -C 
'antigens/ 
antigens. These antigens, which are glycoproteins known to be present 
on virtually all nucleated body cells, are characterised on peripheral 
blood lymphocytes by using a wide range of antisera in a complement - 
dependent microlymphocytotoxicity test. In recent years more attention 
has been focused on the HLA -D and -DR (mean D- related) antigens in IDr4, 
the former being detected by mixed lymphocyte culture (M LC) techniques 
and the latter by serological methods. It is now clear that HLA- DW3 -DR3 
and DW4 -DR4 represent the strongest and therefore the primary associations 
with IDDM; over 80% of young diabetics possess either DR3 or DR4 or 
both antigens. Associations with HLA -B, -C and -A antigens and comple- 
ment factors are secondary, and are due to the phenomenon of linkage 
disequilibrium within the genes of the HLA system (Bodmer and Thompson, 
1977; Schernthaner et al, 1977; Svejgaard et al, 1977; Nerup et al, 
1980; Cudworth and Wolf, 1982). A fuller account of the relationship 
between HLA and diabetes is given in chapter seven. 
In retrospect it can now be appreciated that the HLA -ICA studies 
alluded to above were examining secondary rather than primary associations 
between HLA and IDDM in Caucasian populations. If the HLA antigens 
coded for at all loci (HLA -A, -C, -B, -D and -DR) of chromosome 6 had 
been identified, an association would by now have been established 
between the presence of ICA and HLA- DW3- DR3 -B8-Al in IDDM. This is 
the first axis of HLA alleles which confers susceptibility to the 
development of insulin -dependent diabetes in Orthern European Caucasians, 
probably through linkage with an immune response (Ir) gene (see chapter 
seven; figure 7/2). An analogy can again be drawn with Grave's 
disease and idiopathic Addison's disease, both of which are strongly 
DW3 -B8 associated (Nerup et al, 1980). In fact, comparatively few 
studies 
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studies have performed simultaneous HLA typing for D and DR antigens 
and a search for ICA in the same diabetic patients: the most recent 
is that of Ginsberg -Fellner et al (1982) (see also tables 2/6 and 2/7) 
who found HLA -DR3, -DR4 or both antigens in 81% of seventy -four children 
with IDIM and detected ICA in the sera of 64% of these patients. The 
sixty -four families studied by Ginsberg -Fellner et al were a racially 
heterogeneous group, including twenty -seven Asashkenazi- Jewish and 
fourteen Hispanic families as well as Southern Europeans and American 
Negroes: HLA -B8 has an extremely low prevalence in some of these 
ethnic groups so it is not surprising that an association between 
HLA- DR3 -B8 and ICA was not established. However, it is of interest 
to note that these workers found a significantly reduced prevalence of 
ICA in first- degree relatives who carried the HLA -B7 antigen. The 
remarkably low frequency of HLA-B7 (and DR2, with which it is in 
linkage disequilibrium) in populations of IDDM has already led to the 
concept that the HLA- DR2- DW2 -B7 -A3 axis may itself be in linkage 
disequilibrium with an immune response (Ir) gene which provides a 
'protective' function against beta cell damage (Nerup et al, 1980; 
Cudworth et al, 1980; Cudworth and Wolf, 1982; figure 7/2). If 
this is the case, individuals who possess HLA- DR2 /B7 would indeed be 
expected to show less serological evidence of a disease process which 
could damage the endocrine pancreas. 
In summary, following the mass of data and various studies 
described in this section, the following conclusions can be drawn 
regarding pancreatic cytoplasmic islet -cell antibody in diabetes 
mellitus: 
1) ICA is found very commonly (in about 80% of patients) at the time 
of/ 
tit 
of diagnosis of overt IDDM. In most patients, the antibodies tend to 
disappear after a year.ór so of clinical disease but persistent ICA 
will be found in about 38% of patients who have concomitant endocrine 
autoimmune disease. Both the initial presence and the persistence of 
ICA in IDDM has been associated with the possession of HLA-B8 and Al, 
in Caucasian populations, and very probably with the possession of 
HLA- DR3 -DW3. Absence of ICA is associated with possession of HLA B7 
and probably DR2. 
2) The prevalence of ICA is much lower in patients with NIDI , where 
there is no association with HLA. Antibody prevalence is particularly 
low in NIDDM treated by diet alone, probably no higher than in a 
nondiabetic population. In NIDDM treated with oral hypoglycaemics, 
ICA prevalence is about 10% in patients with coexistent autoimmune 
disease and about 5% in patients with no such associated disease. The 
detection of ICA is of value in NIDDM treated with oral drugs in pre- 
dicting patients who will ultimately require insulin therapy: over 
80% of antibody- positive patients may ultimately develop insulin- 
-- dependent diabetes, compared with only 180 of antibody -negative 
individuals (Irvine et al, 1979). 
3) The prevalence of ICA in nondiabetic first -degree relatives of 
IDIA4 varies between 2.5% (Irvine et al, 1977a) and 21% (Ginsberg -Fellner 
et al, 1982), with much of the observed difference in prevalence being 
related to the methodology employed for antibody detection or the 
testing of nondiabetics with established autoimmune disease. The 
presence of ICA in relatives of an insulin- dependent diabetic may also 
identify individuals who already have impaired beta cell function 
(Irvine et al, 1976; Ginsberg -Feltner et al, 1982) and who may progress 
'to/ 
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to develop IDDM (Irvine, 1980; Bottazzo et al, 1981; Gorsuch et 
al, 1981). 
4) The prevalence of ICA in a background ( nondiabetic) or putative 
'normal' population is very low indeed, probably well below 1 %, in 
persons who have no clinical or serological evidence of autoimmune 
disease. In a population of nondiabetics with autoimmune disease, 
ICA prevalence lies between 4% and 8ó. The presence of ICA in such 
cases may again be of predictive value insofar as diabetes. can be 
demonstrated in about one -quarter of these asymptomatic individuals 
by formal glucose tolerance testing. 
5) Multiple studies have now demonstrated the value of cytoplasmic 
ICA as a marker for the eventual development of clinical diabetes 
mellitus. Moreover, there is a strong tendency for such patients to 
progress, with time, through a clinical spectrum of increasingly 
severe insulin deficiency, such that dietary carbohydrate restriction, 
oral hypoglycaemic drugs and eventually exogenous insulin injections 
will be required. There are many clinical situations - for example, 
predicting diabetes in the sibling of an IDDM proband or forecasting 
a failure of sulphonylurea therapy in a drug- treated NIDDM - where 
such a marker would be a valuable aid to patient care. The detection 
of cytoplasmic ICA in an asymptomatic, normal individual should always 
be treated seriously and the rarity of ICA in a background population 
adds to its value as a marker for diabetes; it is incomparably better 
than HLA typing, where calculation demonstrates that less than 1% of 
DR3- or DR4- positive healthy subjects (in the absence of a strong 
family history) are likely to develop IDDM (Cudworth and Wolf, 1982). 
If a standardised, reproducible assay for ICA could be developed - 
perhaps/ 
perhaps a radioimmunoassay - detection of these antibodies need no 
longer be confined to specialised immunology laboratories. ICA 
assays could then be available in district general hospitals and 
would be used by clinicians responsible for diabetic care. An 
analogy can be drawn with the present status of human glycosylated 
protein assays, which were a research tool until recently but are 
now used on a wide scale to assess diabetic control. 
6) A pathogenic role for ICA in the process of beta cell destruction - 
as opposed to its value as a marker for latent or eventual diabetes - 
has not yet been established. Almost certainly it plays no direct 
role, since the cytoplasmic antigen(s) against which it is directed 
are found in all cell types in the islets of Langerhans (Bottazzo 
and Doniach, 1978) and IDDM is characterised by highly selective 
destruction of insulin- producing beta cells. The other endocrine cell 
populations in the islets - glucagon- producing A cells, somatostatin- 
producing D cells, pancreatic polypeptide- producing PP cells - survive 
apparently unharmed in IDDM, even after long duration of disease (Orci 
et al, 1976; Gepts and De Mey, 1978; Gepts and LeCompte, 1981). 
Furthermore, by classical immunological theory, a model involving 
recognition (and subsequent destruction) of beta cells by the immune 
system would require target molecules or antigens to reside in the 
beta cell membrane, facing the external environment (Roitt, 1980; 
McConnell et al, 1981). Cytoplasmic ICA is directed against an intra- 
cellular antigen, albeit unknown, which should be inaccessible to the 
antibody while the beta cell remains viable. Appreciation of these 
ptactical and theoretical difficulties in assigning a pathogenic role 
for cytoplasmic ICA has provided a stimulus to search for other 
antibodies/ 
antibodies directed against components of the endocrine pancreas; 
the results of these searches will now be briefly described. 
2/9 The detection of other islet -cell antibodies in diabetes 
mellitus 
In recent years, pancreatic islet -cell antibodies have been 
detected in several different assay systems: these antibodies, and 
the methods used for their detection, are summarised in table 2/8. 
Shortly after the initial detection of cytoplasmic antibodies (ICA), 
various workers reported the detection of antibodies which would only 
bind to antigen(s) presented on the cell exterior: these antibodies 
are now collectively referred to as islet -cell surface antibodies 
(ICSA). The first study to describe ICSA was that of MacLaren et al 
(1975), who reported the presence of ICSA in 87% of sera from thirty - 
eight children with recent onset IDDM, using immunofluorescence on an 
insulinoma cell line established in 1959. This study is suspect, as 
the insulinoma cells did not produce insulin (MacLaren, 1977), and 
unfortunately the cell line is now extinct. The results could not 
be reproduced with other insulinomas. In 1978 Lernmark et al used a 
similar technique on dispersed rat islet cells in suspension, and 
found positive results in twenty -two out of eighty -eight (32%) of 
cases of IDDM in children, compared to 4% of sera from healthy controls. 
Not all the islet cells in their preparations showed surface fluores- 
cence with positive sera, but no attempt was made to prove that the 
staining was confined to beta cells ( Lernmark et al, 1978). The use 
of human islet cells in an assay system to detect ICSA was described 
by Pujol- Borrell et al (1982), who cultured pancreases from 11 - 24 




Pancreatic islet cell antibodies detected by various assay sy stems 
Antibody Method of Detection Authors. 
Islet cell cytoplasmic 
antibody (ICA) 
Complement- fixing 
islet cell antibodies 
Islet cell surface 
antibody (ICSA) 
Complement -dependent 






islet cell antibodies 
Immunofluorescence on 
tissue sections 
(group 0 human pancreas) 
Immunofluorescence on 
tissue sections 
(group 0 human pancreas) 
Immunofluorescence of 
islet cell suspensions 
Insulinoma cell line: 
Rodent islet cells: 
Human foetal pancreas: 
51Cr release from damaged 
islet cells or vital 
staining (ethidium bromide) 
51Cr release from lysed 
rodent islet cells 
Polyacrylamide gel 
electrophoresis of 
precipitated islet cell 
antigens 
Bottazzo et al (1974) 
MacCuish et al (1974) 
Dobersen et al (1979) 
Betterle et al (1980) 
Bottazzo et al (1980) 
MacLaren et al (1975) 
Lernmark et al (1978) 
Pujol -Borrell et al 
(1982) 
Soderstrum et al (1979, 
Dobersen et al (1980) 
Idahl et al (1980) 





Baekkeskov et al 
(1981, 1982) 
uf 
in sera from nine out of eleven newly -diagnosed insulin- dependent 
diabetics. By using a four -layer double immunofluorescence technique 
with anti- hormone sera these workers also demonstrated that the surface 
antibody was certainly staining insulin- secreting cells, but owing to 
rarity of A and D cells in the foetal cultures they were not able to 
exclude the possibility that the antibody also reacted with glucagon 
or somatostatin cells (Pujol- Borrell et al, 1982). However, a 
quantitative analysis of cell surface immunofluorescence in a flow 
cytofluorophotometer (a fluorescence- activated cell sorter) has 
disclosed that antibodies in IDD sera with ICSA bind preferentially 
to the pancreatic beta cells (Van de Winkel et al, 1981). Thus it 
seems likely that ICSA are more specifically directed against the beta 
cell than cytoplasmic ICA. 
The rodent islet -cell assay for ICSA described by Lernmark et al 
has now been applied, in similar fashion to the earlier studies of 
cytoplasmic ICA, to examine populations of ID]! patients and to compare 
the prevalence of ICSA with that of ICA. It is now established that 
ICSA is present in about 80% of newly -diagnosed IDD patients and in 2 
to 4% of controls ( Lernmark et al, 1978, 1981a). In one study of one 
hundred and forty -four patients with IDDM, seventy -three (51%) were 
found to have islet -cell antibodies detected by cytoplasmic and /or 
cell surface assays. Cytoplasmic ICA alone were detected in thirty - 
seven patients (25 %) , ICA + ICSA in twenty -three patients (10;) and 
ICA alone in thirteen patients (9%) (Freedman et al, 1979). A later 
prospective study by the same group searched for ICA and ICSA in sera 
obtained from thirty -three children and adolescents immediately after 
the diagnosis of IDDM. On the day of diagnosis, before the institution 
of/ 
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of insulin therapy, thirty out of thirty -three (91 %) were antibody- 
positive, 67% having ICA and 67% having ICSA, although both antibodies 
did not always coexist in the same patient. Antibody prevalence was 
followed prospectively in seventeen patients and fell to 57% within 
nine months of clinical diabetes. These results and others involving 
cytotoxic islet -cell antibodies (Dobersen et al, 1980) have indicated 
that first, the prevalence of ICA and ICSA is roughly parallel in 
IDD M; second, that not all patients with islet -cell antibodies 
necessarily have both cytoplasmic and surface antibodies simultaneously; 
and third, that ICA and ICSA both appear as transient phenomena in the 
majority of newly- diagnosed diabetics and tend to disappear through 
the passage of time. 
As with cytoplasmic ICA, the pathogenetic role of ICSA has still 
to be defined. In one in vitro experiment, ICSA was found to inhibit 
the biosynthesis but not the secretion of insulin by rodent islets when 
incubated with immunoglobulin from IDD serum containing ICSA (Lernnuark 
et al, 1979). It remains to be shown whether the antigen recognised by 
ICSA is a protein, perhaps a membrane receptor for agents regulating 
beta cell function. 
Two other immunological phenomena which involve antibodies bound 
to living cells are of possible importance in destruction of beta cells 
and have been applied to the study of insulin- dependent diabetes. First, 
cell surface -bound antibodies are known to be recognised by components 
of the complement systems. Recognition of IgM or IgG molecules on the 
cell surface, with binding of complement, results in activation of the 
complement cascade reaction which leads to a proteolytic attack on the 
cell/ 
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cell membrane. The complement- induced membrane lesions result in an 
increased plasma membrane permeability and eventually to cell death. 
Fresh serum (Idahl et al, 1980) and serum from IDDM patients (Soderstrum 
et al, 1979; Dobersen et al, 1980, 1981), or immunoglobulins obtained 
from such sera, appear to be capable of mediating a complement - 
dependent cytotoxic reaction against a variety of islet cell preparations. 
The assay reactions for these complement- dependent cytotoxic islet -cell 
antibodies (table 2/8) utilised dispersed islet cells (prepared from 
rodent pancreas or human insulinoma) which are first labelled with 
radioactive chromium and then incubated with serum samples. After 
washing by centrifugation the cells are incubated with animal (guinea - 
pig) serum as a source of complement. The release of radioactive 
chromium is taken as an index of cell viability, while lysed cells are 
identified by their capacity to take up ethidium bromide. Proof that 
the lysed cells are beta cells is obtained by staining the preparation 
with fluorescein- conjugated antibody to insulin. Dobersen et al have 
already used this elegant technique to demonstrate that complement 
dependent islet -cell cytotoxic antibodies correlate with ICSA but not 
ICA in diabetic sera; that about 80J of cells lysed in the reaction 
are beta cells; and that the mere presence of these cytotoxic anti- 
bodies does not seem sufficient to produce diabetZs since the antibodies 
can be demonstrated in about one quarter of sera from (nondiabetic) 
first -degree relatives of IDDM probands (Dobersen et al, 1980, 1981). 
This type of islet -cell antibody assay system is of great potential 
interest and importance since it provides evidence of a capacity for 
islet -cell antibodies to damage beta cells and, since the assay employs 
radioisotope release, it offers the promise of an assay system which is 
both/ 
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both, objective and capable of being standardised. 
Second, cell surface antibodies may be the target of cytotoxic 
lymphocytes, the so- called natural killer cells (K cells). The K 
cell can be found among the circulating monocytes (West et al, 1978) 
and is thought to possess several surface receptors which bind the 
constant portion of the antibody molecule. It appears that the 
major proportion of circulating K cells can be identified by their 
ability to form rosettes when incubated at low temperatures with high 
concentrations of sheep red blood cells (E): thus they are referred 
to as low affinity E- rosette forming cells (E -RFC) (West et al, 1978). 
The K cell acts either as an armed cell, with antibodies attached, or 
attacks cells with an antibody bound to the surface; the resulting 
reaction is known as antibody- dependent cellular cytotoxiciy (table 2/8). 
Already there is evidence that increased levels of low affinity E-RFC 
are found in IDDM (Sensi et al, 1982) and preliminary reports (in an 
animal model, using xenogenic rat islet cell surface antiserum against 
rodent islet cells) have suggested that ICSA have the capacity to 
mediate this type of cytotoxic reaction (Lernmark et al, 1981b; 
Soderstrum and Lernmark, 1982). The role of human ICSA in this type 
of reaction has yet to be established. 
A further recently described assay system has been used to 
demonstrate the presence of immuno.reci.itatin: islet cell antibodies 
in sera from IDI1 (Lernmark and Baekkeskov, 1981; Baekkeskov et al, 
1981, 1982). Human pancreatic islets were isolated from cadaver 
kidney donors, labelled biosynthetically with 35S- methionine and 
solubilised in detergents (NP -40). The solubilised radioactive - 
labelled islet cell proteins were then incubated with sera from newly- 
diagnosed/ 
newly -diagnosed diabetic children and normal controls. Immune 
complexes were isolated and analysed by gel electrophoresis; the 
analysis demonstrated that sera from newly -diagnosed diabetics 
contained antibodies against at least two proteins (molecular weight 
approximately 64,000 and 38,000 daltons) present in normal human 
islets. In contrast, sera from normal controls and from IDDM with 
disease duration of more than one year did not contain antibodies 
against such proteins ( Lernmark and Baekkeskov, 1981; Baekkeskov 
et al, 1982). The proteins identified in these interesting experiments 
might be the antigen(s) involved in studies which demonstrated the 
presence of circulating soluble immune complexes in the sera of forty - 
five out of one hundred and ten newly -diagnosed diabetics (41 %) and 
53% of patients with established IDDM (Irvine et al, 1977d, 1980c) and 
it may be anticipated that further studies with modern techniques will 
lead to more precise localisation and characterisation of the target 
antigens in this antigen- antibody system. 
In conclusion, the numerous and complex studies described and 
reviewed in this chapter have discussed the identification of a variety 
of islet -cell antibodies in human diabetes by several different immuno- 
logical assay systems. The list is not exhaustive: for example, ICSA 
can also be detected by a radioactive immunoglobulin- specific reagent 
such as 1251- protein A in a competition assay (radioligand assay) 
(Lernmark et al, 1980); ICA have been detected by immunocytochemical 
staining with peroxidase- conjugated antibodies; ICA can be detected by 
immunofluorescent.complement- fixation tests (Betterle et al, 1980; 
Bottazzo et al, 1980); and there is a little evidence to suggest that 
hypothetical islet -cell receptor antibodies may also exist ( Lernmark 
et/ 
et al, 1979). A survey of the present status and possible future 
significance of islet -cell antibodies must emphasise the following 
points: 
1) The explosion of interest in the immunology of diabetes mellitus 
over the past twelve years has led to the identification of several 
different antibodies directed against various components of the islets 
of Langerhans. Some antibodies - notably cytoplasmic ICA and (to a 
lesser extent) islet cell surface antibody - have already been 
rigorously studied in diabetic populations. Islet -cell antibodies 
have been found in the majority of insulin -dependent diabetics at the 
time when the clinical disease first appears, have been demonstrated 
to be transient phenomena in a majority of patients and have been 
shown to persist for long periods of time in diabetics with coexistent 
autoimmune disease. The presence of islet -cell antibodies has also 
been demonstrated to predate the onset of insulin- dependent diabetes, 
to predict an eventual need for insulin therapy in mild diabetes and 
to identify asymptomatic individuals who are either normal or have 
trivial impairment of glucose tolerance but eventually progress to 
clinical diabetes. 
2) There is a clamant need to refine the precision and the reproduc- 
ibility of assay systems used to detect islet -cell antibodies. This is 
particularly true of assay systems using immunofluorescence as the 
detection method, since multicentre studies have indicated concordant 
scores of only 50 to 60% for IDD sera examined by four different 
laboratories (brash, 1981). Some of these difficulties can be 
resolved by standardisation of the tissue substrates and the micro- 
scopic equipment used in the assays; the present need to use human 
cadaveric/ 
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cadaveric material is likely to disappear as defined suspensions of 
endocrine islet cells ( Eisenbarth et al, 1981a) and eventually 
continuous, cloned specific endocrine cell lines (Gazdav et al, 1980) 
become available. Those assay systems which employ radioisotope 
release are particularly attractive since the end result is objective, 
and should permit quantitative and reproducible antibody assays to be 
established. Such assays would be a valuable adjunct to the clinical 
management of carbohydrate intolerance. 
3) The mechanism whereby any of the islet -cell antibodies might 
exert a pathogenetic influence on beta cell destruction is presently 
obscure, as is the interrelationship between different antibodies in 
the same individual. Many of these difficulties might be resolved 
if the nature and site of the antigens against which they are directed 
was known. The recent advent of human monoclonal autoantibody 
production - by the fusion of human myeloma cells with antibody -producing 
B cells (Eisenbarth et al, 1981b) - is an exciting development with a 
number of practical implications. For example, a radioimmunoassay for 
islet -cell antibody could be developed by using the labelled monoclonal 
autoantibody as a tracer. Furthermore, it might be possible to produce 
a form of immune intervention with antibodies raised against the variable 
regions of the monoclonal autoantibody (anti- idiotypic antibodies). 
Moreover, passive transfer of monoclonal antibodies ( Eisenbarth et al, 
1981c) to immunosuppressed rodents could be used to test the hypothesis 
that a particular islet -cell antibody was diabetogenic. Finally, since 
diabetic sera have been shown to immunoprecipitate some human islet - 
cell proteins, it should be possible to extract the messenger RNA for 
these proteins and determine their structure by molecular cloning. 
This 
i-r 
This type of approach might eventually allow those islet -cell antigens 
to be made by polypeptide synthesis (Lerner et al, 1981). All these 
new techniques of immunology and molecular biology can be used to 
further the study of abnormal immune mechanisms in the genesis of 
diabetes mellitus. 
4) The detection of islet -cell antibodies has given powerful support 
to the whole concept of an autoimmune form of dietes, especially 
when considered in conjunction for the evidence (chapter three) for 
cell -mediated antipancreatic autoimmunity in this disease. Even with 
the limitations of the present techniques, it is clearly important to 
examine both humoral and cellular autoimmune phenomena in the same 
patients. Some preliminary studies of this nature undertaken by 
the author are considered in chapter four. 




STUDIES OF CELL - MEDIATED AUTOIMMUNITY IN DIABETES 
31 Introduction and purpose of studies 
The leucocyte migration technique (lilT), as developed by Bendixen 
and Soborg (1969) for studies of immune phenomena in human disease, has 
been used by several investigators to provide in vitro evidence of 
cellular (delayed type) hypersensitivity to specific antigens in diabetes 
mellitus. The theoretical basis of the test depends on the ability of 
lymphocytes from a sensitised individual, when cultured in contact with 
specific antigen, to release a variety of soluble factors known 
collectively as lymphokines (Dumonde, 1970): among these substances is 
migration inhibition factor (MIF), which interferes with or inhibits 
the normal in vitro migration of white blood cells in culture medium. 
In the context of autoimmune disease, the I1IT has been widely used to 
provide presumptive evidence of cell- mediated immunity to thyroglobulin 
and thyroid tissue antigens in Hashimoto thyroiditis (Soborg and 
Halberg, 1968; Brostoff, 1970; Calder and Irvine, 1975), intrinsic 
'factor and gastric tissue antigens in pernicious anaemia (Brostoff, 
1970; Finlayson et al, 1971; Goldstone et al, 1973), adrenal antigen 
in Addison's disease (Nerup et al, 1969) and liver antigen in primary 
biliary cirrhosis (Brostoff, 1970; Smith et al, 1972). 
The first successful demonstration of antipancreatic cellular 
hypersensitivity in diabetes by this technique was accomplished by 
Nerup et al (1971), who prepared an antigen of very high islet -cell 
content from porcine pancreas in which atrophy of exocrine tissue had 
been induced by surgical ligation of the pancreatic duct for eight 
weeks before the organ was removed. The antigenic material was 
obtained/ 
96 
obtained by homogenising the atrophic pancreas and separating the 
homogenate by differential centrifugation: the fraction obtained 
with ultracentrifugation (104000 g) was used as the antigen. This 
preparation induced inhibition of leucocyte migration in peripheral - 
blood samples from fifteen of twenty -two diabetics, all but four of 
whom were insulin -dependent and most aged under forty -five years. 
Intracutaneous injection of the same preparation into six diabetics 
with positive in vitro reactions (inhibition) induced typical delayed - 
type hypersensitivity in four, thus strengthening the validity of the 
results as an indicator of in vivo cell- mediated immunity. It is 
particularly important to note that migration inhibition was detected 
by Nerup et al in five patients who had received no antidiabetic 
therapy of any description at the time of study, and in whom there 
was therefore no question of prior sensitisation by exogenous insulin 
injection. Likewise no correlation was found between the presence of 
insulin antibodies and a positive III!' in the insulin -treated diabetics. 
In the light of these findings, it seems reasonable to regard this 
study as demonstrating a phenomenon of true autoimmunity against the 
endocrine pancreas in diabetes. 
The position regarding migration inhibition with antigens from 
other organs is more controversial and has centred round the question 
as to whether liver mitochondria are also capable of inhibiting 
leucocyte migration in diabetes. In the study described above, Nerup 
et al cultured diabetic leucocytes in the presence of antigens prepared 
from porcine liver and kidney, as well as porcine and bovine insulin, 
and found no migration inhibition in diabetics to any of these antigens. 
In contrast Richens et al (1973) used antigens consisting of the 
mitochondrial/ 
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mitochondrial fraction of human and rat liver homogenates, and 
described striking migration inhibition of leucocytes from twenty - 
six of thirty -five insulin -dependent diabetics (mean age 27 years) 
and four of twelve insulin- independent diabetics (mean age 62 years). 
Reactivity to liver mitochondria could of course be considered as a 
general nonspecific *marker' for autoimmune disease, since inhibition 
of leucocyte migration is commonly induced by this antigen in patients 
with Hashimoto thyroiditis (Calder et al, 1972) and pernicious anaemia 
(Goldstone et al, 1973). Thus the findings of Richens et al, if 
confirmed, would provide further evidence for aligning diabetes 
mellitus with this group of diseases but might question the organ- 
specificity of the reaction observed by Nerup et al. 
In the light of these published papers, which were the only 
studies extant when the work described below commenced, it was con- 
sidered that further investigation in this aspect of immunology and 
diabetes should be made to assess the effect of a pancreatic antigen 
derived from human rather than animal source; to examine the response 
of cells from non -insulin- dependent patients in the same assay system; 
and to attempt to clarify the reasons for the differing results of 
Nerup et al and Richens et al. 
The studies described below were therefore undertaken with the 
following specific objectives: 
1. To examine the effects of an antigen prepared from human pancreas 
on the in vitro migration of leucocytes from diabetics. 
2. To test the response to this antigen in each of the major types 
of clinical diabetes (insulin- dependent, non -insulin -dependent) rather 
than confining the tests to insulin- dependent patients. 
3/ 
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3. To observe the effects of liver mitochondrial antigens on leuco- 
cyte migration in diabetes. 
4. To determine whether soluble antigens of pancreatic hormones 
(insulin, glucagon) had any effect on leucocyte migration in diabetes. 
3/2 Migration inhibition studies in diabetes 
Patients used for study 
Samples from one hundred and one diabetics and fifty -six non - 
diabetic controls were examined for their response to various antigens 
in the MT. These subjects were divided into the following groups: 
Youná diabetics. These were thirty -one insulin- dependent diabetics 
(eighteen women and thirteen men), aged from eighteen to forty -two 
years (mean 28.5), and insulin- treated for between one and nineteen 
years (mean 7.4). 
Y controls. These were twenty -seven healthy nondiabetic 
volunteers who were selected to allow statistical comparisons with the 
young diabetics. Fifteen were women and twelve men, aged from eighteen 
to forty -two years (mean 28.6). 
Older diabetics on oral haolxcaemic agents (OHA). These were 
thirty-four diabetics diagnosed at age forty years or more who were 
controlled by dietary carbohydrate restriction plus a sulphonylurea. 
Twelve were women and fourteen men, aged from forty -five to seventy 
years (mean 59.7). 
Older diet -treated diabetics. These thirty -six patients were 
controlled by simple carbohydrate restriction only; twenty -one were 
women and fifteen men, aged from forty -six to sixty -nine years (mean 
60.5). 




were studied, selected by sex (thirteen women and ten men) and age 
(range forty -eight to sixty -nine, mean 57.4 years) to allow valid 
statistical comparison with the previous two groups. 
Positive reactors. This small group, included to check the 
potency of the mitochondrial preparation, consisted of one patient 
with primary biliary cirrhosis and five with Hashimoto thyroiditis, 
known to show inhibition of leucocyte migration when previously 
tested with mitochondria (Calder et al, 1972). 
All the diabetics regularly attended the Diabetic Department 
of Edinburgh Royal Infirmary and when blood was taken for study, 
were well -controlled and free of infection. Control subjects were 
healthy volunteers, with the exception of the 'positive reactors'. 
Antigens used in study 
Human pancreas was obtained immediately after death from a 
previously healthy young man who sustained fatal head injuries in 
a car accident and whose kidneys were used for transplant; this 
organ was made available through the kindness of Mr. J.B. Morton, 
Lecturer in Surgery, University of Edinburgh. The fresh pancreas 
was cut into small pieces, homogenised in sterile phosphate -buffered 
saline (Appendix I /1), filtered through fine gauze and then centri- 
fuged at 700 g for twenty minutes. The supernatant was used as 
antigen, its protein content being adjusted to 10 mg /ml and stored 
at -20 °C in small aliquots. When required these were thawed and 
further diluted with tissue culture fluid consisting of Eagle's 
Basal Medium (EEM, Wellcome Reagents Ltd.: Appendix I /1), supple- 
mented with 10 per cent foetal calf serum. Pilot experiments showed 
the highest nontoxic concentration of antigen to be 200 }zg /ml which 
was/ 
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was used for all experiments. 
Mitochondrial preparations were obtained from the livers of 
young Wistar rats by the differential centrifugation technique of 
Nerup and Bendixen (1969), this antigen being used at a protein 
concentration of 200 pg /ml culture medium. A similar preparation 
was made from human liver using an identical technique and this 
human mitochondrial preparation was used at a concentration of 
50 pg /ml culture,medium. 
Purified bovine insulin was obtained from the Lilly Research 
Laboratories, Indianapolis (lot No. 615- D63 -5), through the kindness 
of Dr. J.A. Galloway. This insulin had been repeatedly recrystallised 
to remove the a component (which consists of high molecular weight 
non -hormonal pancreatic proteins) with which commercial insulin is 
contaminated. The crystalline insulin was diluted in culture medium 
to give a working concentration of 116 jiJml culture medium. 
Purified bovine glucagon was obtained from the same source and 
used at a concentration of 100 ?ig /ml culture medium. 
Leucocyte migration test (LMT) 
The IMT was performed by the method of Bendixen and Soborg 
(1969), with the minor modifications incorporated by Calder et al 
(1972). Fifty ml venous blood was collected from patients and controls, 
heparinised (preservative -free heparin, 10 units /ml) and allowed to 
sediment at 37 °C for one to two hours. The leucocyte -rich plasma was 
removed, centrifuged at 150g for ten minutes and the cell pellet washed 
three times in Eli. Contaminating red cells were lysed with ammonium 
chloride (0.83 per cent) for five minutes, and the resultant leucocyte 
pellet washed a further three times with ICI. The washed cells were 
then/ 
then resuspended in ELI with 10 per cent foetal calf serum. Capillary 
tubes (25p) were filled with the cell suspension, sealed at one end 
and centrifuged at 150g for five minutes. The tubes were then cut 
1 mm below the cell -fluid interface and the cell pellet positioned, 
with a dab of silicone grease, in a leucocyte migration chamber 
(obtained from Sterilin Ltd.). One series of at least three chambers 
was filled with culture medium alone, and a second series with culture 
medium plus antigen. The chambers were sealed with glass coverslips 
and incubated on a flat surface at 37 °C for twenty -four hours. The 
fanlike pattern of migration was then projected (Projectina microscope) 
and the area measured by planimetry. The effect of antigen on cell 
migration (the 'migration index') was expressed as a percentage of 
migration without antigen using the formula: 
Migration index = 
Mean migration with antigen 
X loofa 
Mean migration without antigen 
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A figure of less than 80 per cent was taken to indicate significant 
inhibition of migration and above 120 per cent, significant stimulation; 
this range is identical to that adopted by other investigators (Nerup 
et al, 1971; Richens et al, 1973) and represents two standard deviations 
above and below the mean migration index shown by six normal subjects 
to pancreatic antigen during the pilot experiments. An example of 
inhibition of leucocyte migration in the presence of antigen is shown 
in figure 3/1. 
Results 
The results of leucocyte migration tests in diabetics and controls 




Inhibition of leucocyte migration in the presence of 
pancreatic antigen. On the left, leucocytes have 
migrated normally from the capillary tube into culture 
medium; on the right, migration has been inhibited by 
the addition of pancreatic antigen to the culture medium. 
From MacCuish et al (1974b) 
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1947). All diabetics and normal controls were tested with human 
pancreatic antigen (figures 3/2, 3/3). Seventeen of the thirty - 
one young diabetics showed inhibition as compared with only four of 
the twenty -seven young controls; the mean migration index for the 
former (77.7 -- 2.3 S.E.M.) was significantly lower than in the 
latter (88.3 
± 
2.1). In contrast only six older diabetics on OHA 
and six of those on diet alone showed migration inhibition compared 
with two of the corresponding controls: the respective mean migration 
indices were 93.4 2.8, 91.5 2.4 and 94.4 - 2.5 and do not differ 
significantly. The young insulin- dependent diabetics differed 
significantly from all other groups, both individually and collect- 
ively (p<0.01 by Wilcoxon's test) but there were otherwise no 
significant differences between the groups (table 3/1). 
The results of tests using rat liver mitochondrial antigen are 
shown in figure 3/4. The mean migration indices 
± 
S.E.M. for young 





2.3 and 91.9 
± 
2.3 respectively, these groups not differing 
significantly. In contrast all patients with Hashimoto thyroiditis 
or primary biliary cirrhosis, included as positive reactors, showed 
marked migration inhibition (mean 69.5 ± 2.4), confirming the 
potency of mitochondrial antigen: this group differed significantly 
from all other groups, both collectively and individually (p <0.01 
by Wilcoxon's test, table 3/2). 
Very similar results were obtained using human instead of rat 
liver mitochondria. The mean migration indices with this antigen in 
young diabetics, normal controls and older diabetics were 93.5 
± 
2.9, 
94.8 ± 2.5 and 94.1 
± 


























diabetics n= 31 
Leucocyte migration tests with human pancreatic antigen 
in young controls and insulin -dependent diabetics. 
Inhibition of migration is shown by seventeen (55 %) of 
the diabetics as compared with four (15 %) controls. 





































Leucocyte migration tests with human pancreatic antigen in older 
controls and insulin -independent diabetics. Inhibition of 
migration is shown by six (17%) each of diabetics on OHA and diet 
respectively, compared with two (9%) of the controls. 
From MacCuish et al (1974b) 
TABLE 3/1 
Statistical comparisons of leucocyte migration tests in 





Young diabetics - all other groups p <0.01 
Young controls - older controls p >0.10 NS 
Young controls - older diabetics (diet and OHA) p >0.10 NS 
Older controls - older diabetics (diet and OHA) p >0.10 NS 
Analysis by the Wilcoxon rank sum test. 
NS = not significant. 
From MacCuish et al (1974b) 
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FIGUR1, 3/4 
RAT LIVER MITOCHONDRIA- 200/ug /ml 
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Leucocyte migration tests with rat liver mitochondrial 
antigen in insulin -dependent and independent diabetics, 
normal controls and 'positive reactors' (see text). 
Only the group of positive reactors shows significant 
inhibition of migration. 
From MacCuish et al (1974b) 
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TADLE 3/2 
Statistical comparisons of leucocyte migration tests in 





Young diabetics - controls p >0.10 NS 
Young diabetics - older diabetics (diet and OHA) p >0.10 NS 
Older diabetics - controls (diet and OHA) p >0.10 NS 
Positive reactors - all other groups p 4:0.01 
Analysis by the Wilcoxon rank sum test. 
NS = not significant. 
From MacCuish et al (1974b) 
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significantly. This potency of this human antigen preparation was 
again confirmed by the small group of positive reactors, all of whom 
demonstrated marked migration inhibition (mean 66.2 ± 2.8) and differed 
significantly fróm all other groups (table 3/2). 
Bovine insulin was used as antigen to test leucocyte migration 
in all the young insulin -treated diabetics and corresponding normal 
controls; none showed migration inhibition to insulin at a concentration 
of 116 p.g /mi culture medium (equivalent to 3.2 i.u. /ml culture medium). 
Above?this level a toxic effect was observed. The mean migration index 




Bovine glucagon was likewise without effect on leucocyte migra- 
tion in the young diabetics and corresponding controls. The mean 
migration index to this antigen (at a concentration of 100 »g /ml 
culture medium) in diabetics and controls was 98.1 3.6 and 
100.2 4.0 respectively. 
3/3 Discussion of mi- ration inhibition studies in diabetes 
Two further studies of antigen -induced migration inhibition in 
diabetes were reported while the present work was in progress and the 
results obtained by all the investigators Who have used this test are 
summarised in table 3/3. As stated, Nerup et al (1971) first described 
inhibition of leucocyte migration to a pancreatic antigen in fifteen 
of twenty -two diabetics, all but four of whom were insulin- dependent 
and most aged under forty -five years. The antigen used was derived 
from pooled porcine pancreas in which atrophy of exocrine tissue had 
been induced by prolonged ligation of the pancreatic duct. The same 
investigators (Nerup et al, 1973, 1974; table 3/3) later used an 
antigen/ 
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TABLE 3 ¡3 
Summary of migration inhibition studies in diabetes mellitus, 
using pancreatic and nonpancreatic antigens 
Antigens used in the LMT 








Pig liver mito- 
chondria. 
Porcine kidney. 
Pig and bovine 
insulin. 
Inhibition in 
65% of 22 
diabetics (most 
young, insulin - 
dependent). 



















































Human insulinoma. - Inhibition in 
50% of 28 
diabetics 
(juvenile -onset) 
LMT - Leucocyte migration test. 
* = Studies described in this chapter. 
Modified from MacCuish and Irvine (1975) 
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antigen of homogenated foetal calf pancreas to demonstrate migration 
inhibition in thirty -one (28%) of one hundred and twelve diabetics. 
Inhibition was shown in both juvenile- and maturity -onset diabetics, 
occurring in insulin -dependent and insulin - independent patients; 
however, the phenomenon was most commonly found in young recently - 
diagnosed diabetics, irrespective of therapy. 
The present studies using human pancreas have demonstrated 
migration inhibition in a comparable number of diabetics (29% of one 
hundred and one patients) and confirm that cell- mediated immunity, 
as judged by the ICdT, is found most often in insulin- dependent 
patients with juvenile -onset diabetes. The most obvious deficiencies 
of this investigation - i.e. the use of a relatively crude homogenate 
of whole human pancreas, and the failure to test juvenile -onset 
diabetics who were either untreated or insulin -independent - have 
been remedied by the later studies using an antigen of human islet - 
cell tumour (table 3/3; chapter four of this thesis). The results 
of the present and previous studies would therefore seem to indicate 
the existence in diabetes of a state of cell - mediated immunity to 
antigen(s) which is present in the pancreas and species- non -specific 
(demonstrable with porcine, bovine and human pancreas). The fact 
that migration inhibition is found in untreated and insulin- independent 
subjects provides the main basis for claiming that the reaction reflects 
a state of true antipancreatic cellular autoimmunity, rather than a 
spurious hypersensitivity resulting from exogenous insulin injections. 
The validity of this in vitro test as an indicator of equivalent 
in vivo antipancreatic hypersensitivity would seem to be confirmed by 
the finding by Nerup et al that diabetics with a positive reaction to 
the/ 
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the LMT will also show typical delayed -type hypersensitivity (i.e. 
a type IT reaction) if the same antigen is injected subcutaneously. 
No in vivo tests have been performed in the present investigation, 
in view of the ethical difficulty inherent in injecting healthy 
volunteers with antigens of human tissue. 
The position regarding migration inhibition in diabetics to 
antigens from other organs remains controversial. Richens et al 
(1973) showed inhibition in twenty -six of thirty -five young insulin - 
dependent diabetics and in four of twelve elderly insulin -independent 
diabetics tested with an antigen consisting of liver mitochondria 
from young Sprague- Dawley; subsequent studies by the same investi- 
gators have suggested that the antigenic component is localised to 
the inner mitochondrial membrane (Richens et al, 1974). Richens et 
al described migration inhibition in a small number of insulin - 
dependent patients tested with human liver mitochondria but found no 
inhibition to antigens of mitochondria from rat kidney and adrenal. 
On the other hand, Nerup et al (1971, 1973, 1974) used antigens of 
porcine liver and kidney, foetal calf liver and thymus in their series 
of diabetics and did not demonstrate migration inhibition to any of 
these antigens. The results of the present investigation, which has 
used human and rat liver mitochondrial preparations of proven potency, 
are in agreement with the latter investigators. The reasons for the 
differences between the various studies are not clear but may in part 
reflect different methods of antigen preparation: Richens et al used 
the method of Zamecnik and Keller (1954) while all the other studies 
have used the method of Nerup and Bendixen (1969), in which the tissue 
is centrifuged at different speeds and in different buffers. Until 
this/ 
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this question is resolved, it is not possible to state with certainty 
whether or not the general reactivity to mitochondria that is a 
feature of thyrogastric autoimmune disease is also shown in diabetes. 
Further studies are also needed to define which component of 
pancreatic tissue acts as antigen towards the lymphocyte population 
in diabetic patients. On the one hand the highest number of positive 
results with the IMT has been obtained by using antigens of highest 
islet -cell content (Nerup et al, 1971; this thesis, chapter four), 
suggesting that the antigen is located in the endocrine part of the 
pancreas. On the other hand, the use of purified hormones extracted 
from islet -cell tissue - insulin and glucagon - has failed to inhibit 
migration of leucocytes in the IMT. This observation might therefore 
suggest that the antigenic material is non -hormonal (or at least, not 
the fraction of islet -cell polypeptides that to date has been tested 
for antigenic effects), or might merely reflect the technical limit- 
ations of the IMT, which works well with particulate antigens (i.e. 
fractions of solid tissue) but rarely with soluble antigens. The 
possibility that pancreatic hormones might show some antigenic activity 
in diabetes if used in an alternative in vitro test system for cell - 
mediated hypersensitivity has been explored in the studies described 
below. 
3fit Antigen- induced lymphocyte transformation studies in diabetes 
The transformation of cultured small lymphocytes (presumably T 
cells) to lymphoblasts in the presence of antigen is another widely - 
used in vitro test of cell- mediated immune function (Bloom, 1971; 
Rocklin, 1974). As with studies using a mitogen such as phytohaema- 
gglutinin (PHA), the effect of antigen is assessed by direct examination 
of/ 
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of cultured cell morphology using the light microscope, or more 
conveniently by pulsing the cultures with a radioactive DNA precursor 
(e.g. 3H- thymidine) which will be incorporated into the nuclei of 
transforming cells: the extent of blastogenesis can subsequently be 
measured by beta counting of the extracted nucleoprotein. 
In the context of autoimmune disease, the transformation technique 
has been used to demonstrate the presence of lymphoid cells sensitised 
to intrinsic factor in patients with pernicious anaemia (Tai and 
McGuigan, 1969) and to thyroglobulin in patients with Hashimoto 
thyroiditis (Ehrenfeld et al, 1971). Human diabetes would seem to be 
an equally suitable model for the transformation technique in an 
attempt to demonstrate the existence of lymphoid cell subpopulations 
which 'recognise' components or secretions of the endocrine pancreas. 
However there is little information concerning antigen- induced lympho- 
cyte transformation in this disease except in the context of insulin 
allergy, where various investigators (Halpern et al, 1967; Federlin 
et al, 1968, 1971) have shown that bovine insulin can induce blasto- 
genesis in lymphocytes with both immediate (urticarial) and delayed 
type (cutaneous) insulin allergy. The present investigation was 
therefore undertaken to examine the question of cell- mediated hyper- 
sensitivity to insulin in Type 1 diabetics who had no such in vivo 
evidence of insulin allergy; in addition, a small number of untreated 
diabetics were also tested to determine whether these patients showed 
any evidence of hypersensitivity before treatment with exogenous 
insulin. The latter investigation was considered to be of particular 
importance in the context of autoimmunity and in view of the failure 
of insulin hypersensitivity to be demonstrable by the LMT. When it 
became/ 
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became apparent that lymphocyte transformation in diabetes could 
indeed be induced by insulin, the isolated A and B chains of insulin 
were further examined in an attempt to localise the immunogenic 
portion of the insulin molecule. 
Patients used for study 
Sixty -five diabetics were studied. Forty -five were women and 
twenty were men, aged from sixteen to seventy -one years (mean 42.1). 
Fifty were established diabetics and had been insulin- treated for 
between six months and twenty -four years. Fifteen were newly -diagnosed 
diabetics, five of whom had been insulin- treated for three weeks or 
less and ten of whom were untreated at the time of study. All were 
attending the Diabetic Outpatient Clinic, Edinburgh Royal Infirmary, 
and in all (except for the newly -diagnosed) the disorder was well - 
controlled as judged by the following criteria: steady weight and 
insulin dosage; absence of thirst or polyuria; no heavy glycosuria; 
no ketonuria; mid- morning blood glucose of less than 14 mmol /l 
(250 mg /dl). All were taking insulin of bovine origin, prepared 
either as soluble (Regular) insulin or in a sustained -release form 
(Protamine -Zinc or IZS Lente insulin). None" had evidence of immediate 
or delayed -type insulin allergy. 
The control group comprised thirty healthy nondiabetic volunteers. 
For statistical purposes it was selected to be comparable in terms of 
sex (twenty women, ten men) and age (range fifteen to seventy -two, 
mean 40.8 years) with the diabetic group. Most controls were labor- 
atory or hospital personnel; a few were hospital outpatients who were 




Bovine and porcine insulins, highly purified and of known 
potency and composition (table 3/4), were obtained from the Lilly 
Research Laboratories through the courtesy of Dr. J.A. Galloway. 
Bovine insulin A chain and B chain (aminoethylated), and porcine 
insulin A chain (3- sulphonate) were obtained from the same source. 
All preparations were in crystalline powder form. On the day of 
use they were dissolved in a mixture of 10% sterile phosphate 
bufferéd saline /80% Eagle's Basal Medium /l0% foetal calf serum. 
The optimal concentration of insulin for use in these investi- 
gations was determined by measuring the blastogenic effect of insulin 
on lymphocytes from a diabetic with known insulin allergy; the 
patient was a twenty -two year old man who had a daily insulin require- 
ment in excess of 200 units in addition to cutaneous reactions to 
bovine insulin injections, and who therefore showed evidence of both 
humoral and cell- mediated insulin hypersensitivity. Lymphocytes 
were obtained from this patient on two separate occasions, prepared 
and cultured as described below, and exposed to varying concentrations 
of bovine insulin antigen. The results (table 3/5) show that maximal 
blastogenesis was stimulated with insulin at a concentration of 500 
jig /ml (10 ug /culture), no significant increase in lymphocyte 
3H- thymidine uptake being induced by higher concentrations of insulin. 
Thus on the basis of this preliminary dose -response analysis, all 
experiments were performed with solutions containing 500 jzg /m1 intact 
insulin or insulin fragment. 
Sample collection and lymphocyte culture 
Fifteen ml venous blood was removed from each patient and control 
at/ 
TABLE 3/4 
Lymphocyte transformation in diabetics: composition of 
Lill j ovine and porcine insulins used as antigens 
Content * Bovine Insulin Porcine Insulin 
Proinsulin 0.06 0.15 
Glucagon 0.007 0.002 
Zinc 0.80 0.70 
Monodesamido insulin 13.0 7.0 
'Argininet insulins 1.0 2.0 
Potency (U /mg) 25.4 25.4 
* per cent 




Ability of varying concentrations of bovine insulin to induce 
transformation (judged by 3H- thymidine uptake) of cultured 
lymphocytes from a diabetic with insulin allergy 
Control* Cultures plus Bovine Insulin Antigen* 
Cultures 
50 pg 500 }zg 1000 pg 5000 ug 
/ml /ml /ml /ml 
1pg 10 »g 20pg 100 p 
/culture /culture /culture /culture 
First 
Assay 1,080 8,720 12,480 13,640 10,390 
Second 
Assay 1,769 9,550 14,570 14,210 12,620 
* All results as cpm. 
No significant increase of blastogenesis is obtained by 
adding more than 10 pg insulin per culture 
From MacCuish et al (1975) 
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at mid -morning and anticoagulated with preservative -free heparin. 
Lymphocytes were prepared from whole blood by the methods (density 
centrifugation, repeated washing in EBM) described in chapter five 
of this thesis, and suspended in EBM with 10% foetal calf serum at a 
concentration of 1 x 106 cells /ml. 
A portion of the lymphocytes from each subject was cultured in 
the presence of the mitogen phytohaemagglutinin (PHA) to provide a 
convenient assessment of the adequacy of general cell- mediated immune 
function. The lymphocyte transformation response to PHA was measured 
by exactly the same method as described in chapter five of this thesis: 
a mitogen dose -response curve for each subject could therefore be 
constructed by using PHA at three different concentrations. The 
radioactivity of stimulated cells was determined as before by an 
automatic beta counter and results are expressed as counts per minute 
.(cpm). 
The remaining lymphocytes from each patient and control were 
cultured in the presence of insulin antigen. The technique used was 
'modified from the PHA micromethod and is briefly summarised as follows: 
aliquots of 2 x 105 lymphocytes were pipetted into the wells of plastic 
tissue culture plates (Cooke Microtiter). All experiments were per- 
formed in triplicate and consisted of a control row of cultures without 
antigen, and rows to which 20 111 of the required solution (i.e. 10 pg 
insulin or insulin fragment) was added. The plates were gassed with 
a 95% air /5% 002 atmosphere and incubated at 37 °C in sealed, humidified 
containers. After five days the cultures were labelled with 
3H- thymidine (specific activity 5Ci /mmol, dose 0.5)aci /culture) and 
terminated sixteen hours later by harvesting the cells onto glassfibre 
filter 
1CV 
filter discs and preparing them for scintillation counting. The 
prepared samples were counted in an automatic beta counter. 
Results were expressed as counts per minute (cpm); the effect 
of antigen in stimulating blastogenesis (the 'transformation index') 
was expressed by the formula: 
Transformation Index 
cpm of cultures with antigen 
cpm of cultures without antigen 
The normal range of transformation indices using intact insulin 
antigens was obtained from the mean transformation index 
± 
2 standard 
deviations of the results given by both insulins in the control 
group (i.e. 60 experiments). The range in normals by this method 
was found to be 0.57 - 1.45 (mean 0.01 - 0.44) and a transformation 
index above 1.45 was thus taken to indicate significant antigenic 
stimulation of blastogenesis. Several cultures from controls and 
diabetics were examined by light microscopy to confirm that the 
uptake of radioactive label was paralleled by morphological blast 
transformation. 
All diabetics and controls were tested with intact bovine and 
porcine insulin antigens. Lymphocytes from those patients who showed 
significant transformation were further tested with bovine A and B 
chain and porcine A chain. 
Re sult s 
Mitogenic effects of PHA 
The maximal PHA response of diabetics and controls (i.e. the 
highest lymphocyte incorporation of 3H- thymidine label induced by one 
of the three concentrations of PHA used) is shown in tables 3/6 - 3/8. 




Ability- of bovine insulin, porcine insulin and PHA to 
induce transformation (judged by 3H- thimidine uptake) 
of cultured lymphocytes from thirty normal subjects 











15 /6 939 546 0.58 751 0.80 25,100 
72/f 1,318 806 0.61 1,216 0.92 17,900 
29/f 704 501 0.71 613 0.87 44,400 
19 /6 1,188 893 0.75 1,463 1.23 22,800 
34./f 1,026 784 0.76 1,281 1.24 15,000 
34/f 823 669 0.80 707 0.86 16,300 
66/f 975 792 0.81 800 0.82 8,700 
32/f 1,133 941 0.83 1,497 1.32 22,500 
53/6 1,572 1,322 0.85 1,352 0.86 38,400 
24/f 759 654 0.86 502 0.66 16,800 
58/f 1,033 914 0.88 1,109. 1.07 11,100 
36/6 1,007 899 0.89 1,025 1.02 14,900 
26/f 659 589 0.90 594 0.90 26,100 
68/f 1,583 1,521 0.96 1,456 0.92 21,200 
32/m 1,292 1,250 0.97 1,066 0.83 10,800 
48 /if 875 860 0.98 684 0.78 19,800 
41 /f 958 940 0.98 937 0.98 19,200 
28/f 1,106 1,104 1.00 1,175 1.06 44,700 
36/f 1,136 1,178 1.04 1,264 1.11 14,100 
18 /6 848 891 1.05 903 1.06 29,300 
69/6 710 750 1.05 726 1.02 22,500 
54/f 1,285 1,363 1.06 926 0.72 7,600 
26/f 955 1,042 1.09 1,781 1.86 
mow 
46/f 797 88o 1.10 1,260 1.58 27,400 
48/f 923 1,017 1.10 991 1.07 13,300 
45/m 1,714 1,910 1.11 1,980 1.16 23,500 
32/f 1,073 1,222 1.14 1,300 1.21 38,500 
57/6 1,809 2,583 1.43 1/835 1.01 16,700 
364 1,465 2,109 1.44 1,584 1.08 30,000 
48/f 968 1,457 1.51 1,327 1.37 54,100 
Results are expressed both as counts per minute (cpm) and 
transformation index (T.I. - see text). All figures means 
of triplicate cultures. 
From MacCuish et al (1975) 
Ability of bovine insulin, porcine insulin and PHA to induce 
transformation (judged by 3H- thymidine uptake) of cultured 
lymphocytes from fifty established insulin- dependent diabetics 
Bovine Porcine Maximal PHA 
Study Age /Sex Control Insulin Insulin Response 
No. cpm cpm T.I. cpm T.I. cpm 
1 274 964 705 0.73 1,039 1.08 35,900 
2 50/f 1,541 1,123 0.73 1,326 0.86 17,500 
3 43/f 1,495 1,146 0.85 1,053 0.80 22,400 
4 40/f 809 728 0.90 802 0.98 18,700 
5 31/m 1,475 1,388 0.94 1,400 0.95 26,400 
6 62/f 878 843 0.96 805 0.92 24,100 
7 65/f 1,096 1,071 0.98 956 0.87 30,700 
8 40/f 1,167 1,172 1.00 1,006 0.86 17,600 
9 59/f 1,122 1,120 1.00 1,327 1.10 20,400 
10 66/f 994 1,001 1.01 1,351 1.36 18,500 
il 454 1,226 1,270 1.04 1,164 0.95 26,400 
12 38/f 915 959 1.05 1,049 1.15 25,000 
13 424 1,518 1,597 1.05 2,173 1.43 13,900 
14 25/f 728 760 1.05 881 1.21 17,400 
15 48/f 1,306 1,427 1.09 1,259 0.96 7,800 
16 46/f 811 900 1.11 853 1.05 41,800 
17 55/f 963 1,079 1.12 1,014 1.05 21,400 
18 20/f 870 979 113 1,357 1.56 33,300 
19 37/f 931 1,051 1.13 863 0.93 27,600 
20 694 1,071 1,210 1.13 1,089 1.02 10,600 
21 23/f 1,000 1,140 1.14 1,320 1.32 19,300 
22 46/m 939 1,067 1.14 1,221 1.30 27,400 
23 41/f 1,043 1,210 1.16 1,079 1.03 12,700 
24 45/f 720 848 1.18 794 1.10 15,500 
25 21/f 923 1,155 1.25 1,609 1.74 50,600 
26 70/f 1,320 1,690 1.28 1,990 1.51 20,400 
27 25/f 1,448 11853 1.28 1,445 1.00 
26,600 
28 624 962 1,228 1.28 1,062 1.11 38,200 
29 14/f 634 818 1.29 799 1.26 8,500 
30 27/f 859 1,112 1.30 1,120 1.30 11,900 
31 22/m 951 1,109 1.31 1,561 1.83 21,100 
32 67/f 869 1,169 1.34 927 1.07 21,200 
33 57/m 1,446 1,952 1.35 2,053 1.42 39,500 
34 52/f 1,094 1,557 1.42 1,503 1.37 14,000 
35 464 832 1,192 1.43 1,278 1.53 10,300 
36 42/f 1,391 2,130 1.53 2,465 1.77 18,200 
37 30/f 989 1,533 1.55 1,553 1.57 35,900 
38 41/f 943 1,525 1.62 1,719 1.82 
19,200 
39 37/f 885 1,430 1.62 1,686 1.90 
27,900 
40 48/f 1,000 1,659 1.66 1,809 1.81 26,700 
41 61/f 1,832 3,077 1.68 2,994 1.63 18,900 
42 54/f 1,016 1,802 1.77 1,641 1.61 20,500 
43 59/f 1,547 2,769 1.79 2,614 
1.69 14,100 
44 52/f 843 1,512 1.79 2,366 2.80 
17,600 
45 614 1,042 1,963 1.88 1,777 1.71 26,000 
46 62/f 897 1,790 1.99 1,282 1.42 47,100 
47 26/f 734 1,508 2.06 1,454 1.98 
21,300 
48 71/f 1,458 3,164 2.17 3,762 
2.58 41,000 
49 384 864 2,449 2.83 2,049 2.38 13,900 
50 39/f 1,046 3,797 3.63 4,707 4.50 34,500 
Results as in Table 3/6 From MacCuish et al (1975) 
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TABLE 3/8 
Abilit of bovine insulin orcine insulin and PHA to induce 
transforynation ,judged by 3H- thymidine uptake) of cultured 
lymphocytes from fifteen newly -diagnosed diabetics 
Study 
No. 











51 58/f 1,505 1,472 0.98 1,430 0.95 17,700 
52 37/111 841 832 0.99 699 0.83 7,800 
53 19 4 1,043 1,029 0.99 1,343 1.29 19,400 
54 424 891 972 1.09 881 0.99 9,90o 
55 18 4 619 68o 1.10 930 1.5o 13,800 
56 19 /f 1,473 2,458 1.67 2,591 1.76 38,000 
57 23/f 757 1,493 1.98 1,520 2.00 
25,400 
58 30 /m 802 1,626 2.03 1,729 2.16 16,500 
59 16 4 1,138 2,675 2.35 2,281 2.00 25,400 
6o 19 /f 1,307 5,313 4.07 5,925 4.53 16,600 
61 21 /f 795 1,089 1.37 1,026 1.29 22,400 
62 244 68o 85o 1.25 911 1.34 20, 900 
63 17 /f 1,070 1,947 1.82 11530 1.43 9,90o 
64 294 923 1,228 1.33 1,476 1.60 19,700 
65 37/f 856 813 0.95 899 0.05 23,600 
Results as in Table 3/6 
Modified from MacCuish et al (1975) 
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(expressed as cpm x 103 S.E.M.) while the corresponding figure in 
sixty-five diabetics was 21. + Y  9 - 4.8. The two groups do not differ 
significantly in PHA responsiveness and the results confirm the 
earlier observation (Maccuish et al, 1974c; this thesis, chapter 
five) that mitogen- induced lymphocyte transformation is normal in 
diabetes mellitus, except at times of severe metabolic decompensation. 
The maximal PHA response in five control subjects was further 
measured in lymphocyte cultures to which 10 pg bovine or porcine 
insulin had been added. The results (table 3/9) indicate that neither 
insulin has an appreciable effect on 3H- thymidine uptake in the 
presence of PHA when added to forty- eight -hour cultures in the stated 
concentrations. 
Antigenic effects of intact insulins 
The effects of bovine and porcine insulin antigens in inducing 
blastogenesis of lymphocytes from controls and diabetics are 
presented in tables 3/6 - 3/8 (as absolute cpm) and in figures 3/5 
and 3/6. Only one normal subject showed significant transformation 
using bovine insulin antigen; in contrast fifteen established and 
six newly- diagnosed diabetics (four untreated, two insulin- treated 
for less than three weeks) showed significant transformation, their 
indices ranging from 1.53 to 4.07 (figure 3/5). The groups of both 
established and newly- diagnosed diabetics differed significantly 
(p <0.01 by Wilcoxon's test) from the control group. 
Experiments using porcine insulin as antigen (figure 3/6) gave 
a virtually identical pattern. Two control subjects showed 
significant transformation, as compared with twenty established and 




Effects of bovine and porcine insulin on PHA- induced 
transformation of lymphocytes from five normal subjects 
Age /Sex 
Maximal 3H- thymidíne uptake (cpm) 
With PHA PHA + B.I.* PHA + P.I.* 
36/m 32,000 35,000 31,000 
19 /m 25,000 24,000 22,000 
32/m 9,000 8,000 9,000 
26/f 28,000 26,000 26,000 
36/m 14,000 16,000 14,000 
Neither insulin has a significant effect on the 3H- thymidine 
uptake of PHA- stimulated lymphocytes. 
* B.I. - Bovine insulin 10 Fg/culture 
P.I. - Porcine insulin 10 Fg/culture 
From MacCuish et al (1975) 
FIGURE 3/5 (OPPOSITE): 
Lymphocyte transformation in controls and diabetics by bovine 
insulin antigen. The mean transformation index 
± 
S.E.M. is 
shown to the right of the individual results for each group. 
Dotted lines (- - - -) indicate the normal range (mean 
± 
2 S.D.) 
of transformation indices in control subjects. Significant 
transformation (index 1.45) is shown by fifteen established and 
six newly- diagnosed diabetics as compared to one control. Both 
diabetic groups differ significantly (p <0.01) from the control 
group. 
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BOVINE INSULIN ANTIGEN 
FIGURE 3/6 (OPPOSITE): 
Lymphocyte transformation in controls and diabetics induced 
by porcine insulin antigen. Symbols as in figure 3/5. 
Significant transformation is shown by twenty established 
and seven newly -diagnosed diabetics as compared to two 
controls. Both diabetic groups differ significantly 
(p.(0.01) from the control group. 
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less than three weeks). Both diabetic groups again differed 
significantly (p <0.01) from the controls. Almost all the diabetics 
who showed transformation to bovine insulin also responded to porcine 
insulin (tables 3/7 and 3/8). 
Antigenic effects of A and B chains 
Lymphocytes were available for study from twenty -one of the 
twenty -seven diabetics who showed transformation to intact insulin. 
The effects of bovine A chain, porcine A chain and bovine B chain 
on these lymphocytes are shown in table 3/10 and figure 3/7. The 
A chain of either insulin was almost without effect, inducing 
significant blastogenesis in only one diabetic; in contrast the B 
chain of bovine insulin induced significant lymphocyte transformation 
in fourteen (67 %) of the twenty -one patients tested. In some diabetics 
the isolated B chain appeared to be more potent in stimulating blasto- 
genesis than intact insulin, the transformation index being greater 
than 4.0 in six patients. Statistical analysis confirmed that the 
effects of B chain on lymphocyte transformation differed significantly 
(1340.01) from those of the A chain of either insulin. 
3/5 Discussion of antigen- induced lymphocyte transformation studies 
in diabetes 
Under the stated culture conditions, intact insulin (bovine and 
porcine) was observed to induce transformation of lymphocyte in vitro 
from one third of the diabetics tested. In this contextl'insulin may 
be regarded as showing cellular antigenic activity analogous to the 
effects of PPD on lymphocytes from tuberculin -sensitised patients 
(Pearmain et alp 1963), intrinsic factor on lymphocytes from patients 




Ability of bovine insulin A chain, porcine insulin A chain 
and bovine B chain to induce transformation (judged by 3H- 
thymidine uptake)_ of cultured lymphocytes from twenty -one 














49 f 970 942 0.97 739 0.76 68o 0.70 
47 1,004 1,104 1.10 1,67o 1.69 944 0.94 
38 1,150 1,22o 1.06 781 0.68 1,380 1.20 
*58 902 939 1.04 747 o.83 1,136 1.26 
41 1,623 1,445 0.89 - - 2,173 1.34 
45 1,684 1,161 0.69 - - 21339 1.39 
36 1,092 963 0.88 - - 1,527 1.40 
40 87o 93.8 1.08 523 0. 60 1,313 1.51 
*60 1,422 1,466 1.03 - - 2,415 1.70 
40 759 63.9 0.84 834 1.10 1,364 1.8o 
43 1,670 1,385 0.83 - - 3,173 1.90 
*57 518 682 1.10 - - 1,171 1.90 
42 925 1,833 1.98 906 0.98 1,88o 2.03 
*59 1,062 1,010 0.95 1,094 1.03 2,123 2.10 
26 1,566 1,598 1.02 1,690 1.08 3,445 2.20 
*56 1,241 1,450 1.17 - - 6,452 5.2o 
39 950 1,020 1.07 - - 5,605 5.90 
37 860 1,039 1.20 - - 6,192 7.20 
48 1,287 1,364 1.06 1,094 0.85 11,866 8.70 
25 705 750 1.05 - - 61201 8.8o 
46 964 972 1.01 63o 0.66 9,35o 9.7o 
* newly diagnosed patient. 
'Study numbers' identify patients in Tables 3/7 and 3/8. 
Results as in Table 3/6. 
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IVMPHlfVTF TRANSFf1RMATIHN WITH INSIIIIN FRARMFNTS 
Lymphocyte transformation induced by bovine and porcine A chain 
and bovine B chain in twenty -one diabetics who responded to 
intact insulin. Symbols as in Figure 4/5. 
Closed circles (o) - established diabetics. 
Open circles (o) - newly diagnosed diabetics. 
Significant transformation to either A chain is shown by only 
one diabetic, as compared with fourteen (67ó) who respond to 
B chain. The effects of B chain differ significantly (p<O.O1) 
from those of the A chain of either insulin. 
From MacCuish et al (1975) 
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on lymphocytes from patients with Hashimoto thyroiditis (Ehrenfeld 
et al, 1971). The blastogenic effect of insulin is perhaps not 
surprising in the group of established diabetics that were tested: 
all had been insulin- treated for months or years, virtually all 
would be expected to have humoral antibodies to injected insulin 
(Berson et al, 1956), and it is reasonable to suppose that some 
have developed cellular immunity in the form of an insulin- sensitised 
lymphocyte subpopulation. Similar findings were reported by Halpern 
et al (7967) and Federlin et al (1968, 1971) in diabetics with insulin 
allergy, both of immediate (urticarial) and delayed (cutaneous) type; 
the present study suggests that the phenomenon is not uncommon in 
diabetics who have no such clinical evidence of allergy. In these 
patients the in vitro test of lymphocyte function may be the most 
sensitive measurement of an insulin hypersensitivity which is not of 
clinical significance. 
Of more interest is the finding of insulin- induced lymphocyte 
transformation in seven of fifteen newly- diagnosed patients, four of 
whom had never been given insulin and three of whom had been insulin - 
treated for less than three weeks. Further studies will be needed to 
confirm these observations in larger numbers of untreated diabetics 
but the present results at least suggest that a proportion of such 
patients have an insulin -sensitised lymphocyte population before 
exogenous insulin has been given or before humoral insulin antibodies 
have been developed. Thus the existence of this cell population may 
reflect a state of cell mediated autoimmunity, to insulin or insulin 
precursor, in early (untreated) diabetes; whether the phenomenon is 
analogous to the inhibition of leucocyte migration by pancreatic 
antigens 
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antigens in similar patients, or whether these two in vitro tests 
are identifying different populations of sensitised lymphoid cells, 
is at present entirely speculative. 
The virtually identical findings with bovine and porcine insulin 
prompted an examination of their component chains for antigenic 
effects, and two conclusions are possible from the results obtained. 
In the first place, the striking blastogenic effect of isolated B 
chain (which is metabolically inert) strongly implies that the 
blastogenesis induced by intact insulin is a true immunological 
effect, rather than some metabolic effect brought about by an 
hormonal action of insulin on the insulin receptors of lymphocytes. 
Secondly, there is a clearcut difference between the effects on the 
two major polypeptide chains of insulin. On the one hand, neither 
bovine nor porcine A chain induced significant lymphocyte trans- 
formation, and as the structure of human insulin A chain is identical 
to that of porcine insulin (Smith, 1966; figure 3/8) it might be 
presumed that human A chain would also be without blastogenic effect. 
On the other hand bovine insulin B chain, which is identical to that 
of porcine insulin and differs from the amino -acid sequence of human 
B chain only at position 30 (figure 3/8) had a marked effect in 
inducing blastogenesis of lymphocytes from two -thirds of those 
patients who responded to intact insulin. The results might thus 
suggest that B chain is the major antigenic site producing cellular 
hypersensitivity to insulin. Some support for this hypothesis is 
given by the in vivo animal experiments of Clark and Munoz (1970), 
who injected guinea pigs with bovine insulin, A and B chain in 
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The primary structure of mammalian insulin. The major species 
difference between beef and porcine insulin resides in the A 
chain and in the amino -acid sequence within the intrar -chain 
disulphide bridge. Human insulin is very similar to porcine 
insulin, having an identical A chain and differing only in the 
terminal amino -acid (30) of the B chain. 
From the results of Smith (1966) 
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by intact insulin and by B chain, but A chain had no significant 
effect. 
If the hypothesis is correct, the role of insulin B chain in 
cell -mediated immunity to insulin would be in contrast to the 
humoral immune response to insulin, where various studies (Berson 
and Yalow, 1959; Wilson et al, 1962) have suggested that the A 
chain is the major determinant of antibody production. Thus it is 
possible that differing antigenic activity, whether cellular or 
humoral, resides at different sites on the insulin molecule, although 
the factors governing the expression of such activity are obscure. 
However it must be remembered that an equally plausible explanation 
for the apparent lack of cellular antigenicity of A chain might lie 
in the physical changes undergone by this peptide during the splitting 
of insulin: isolated A chain is 'stretched' by comparison with its 
configuration in the intact insulin molecule, and the intra. -chain 
disulphide bridge between six and eleven is broken with the formation 
of cysteic acid residues which could prevent antigen -antibody reaction 
at this site. 
Further studies-should attempt to define how commonly cell mediated 
autoimmunity to insulin is found in untreated diabetics; to delineate 
more clearly the cellular antigenic portion of insulin; to indicate 
whether related proteins or precursors (e.g. proinsulin, C- peptide) 
have similar properties in early diabetes; and to correlate the 
results with antigen -induced migration inhibition studies in the same 
patients. 




THE CORRELATION OF CELL - MEDIATED AND HUMORAL AUTOIMI4UNITY IN DIABETES 
4/1 Introduction and purpose of study 
The investigations described in this chapter were undertaken in a 
preliminary attempt to correlate the existence of humoral and cellular 
autoimmune phenomena in the same diabetic patients. For this purpose, 
diabetics with identifiable evidence of humoral antipancreatic auto - 
immunity (as judged by the possession of circulating cytoplasmic 
islet -cell antibodies) were tested to see whether they also had evid- 
ence of cellular antipancreatic immunity (as judged in vitro by their 
response to human pancreatic antigen in the leucocyte migration test). 
The results were compared with those given by a matched group of 
diabetics who did not possess islet -cell antibody, and with a control 
group of normal subjects. 
4/2 Selection of diabetics for study 
A total of thirty -eight subjects were studied, subdivided into 
the following groups: 
Insulin -dependent antibo - .ositive diabetics. This group consisted 
of ten patients with circulating pancreatic cytoplasmic islet -cell 
antibodies (chapter two). There were six women and four men, aged 
from twenty -one to fifty -two years (mean 35.6). All were insulin - 
taking patients, the duration of clinical diabetes ranging from four 
months to ten years and the age of onset from fifteen to forty -two 
years. Six had a clinical autoimmune disease in addition to diabetes; 
four had circulating thyrogastric antibodies but no clinical auto - 
immune disease. The relevant details of these patients are summarised 
in 
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in table 4/1. 
Insulin -dependent antibody -negative diabetics. This group comprised 
ten diabetics who did not possess circulating islet -cell antibodies. 
They were matched as closely as possible with the antibody- positive 
group with respect to age, sex and duration of insulin- dependent 
diabetes. 
Normal controls. There were ten healthy nondiabetic volunteers 
(hospital and laboratory personnel) who were selected by sex and age 
to allow valid statistical comparison with the previous two groups. 
All were negative for islet -cell antibody. 
Untreated 'uvenile -onset diabetics. The opportunity was also taken 
to study eight juvenile -onset diabetics who had never taken insulin 
or oral hypoglycaemic agents. Four were women and four men, aged from 
fourteen to thirty -six years (mean 22.3). All were newly -diagnosed 
and untreated at the time of study; three were negative for islet - 
cell antibody. 
All the patients in the above groups were attending the Diabetic 
Department, Edinburgh Royal Infirmary, and (with the exception of the 
newly -diagnosed) all were well- controlled at the time of study. 
Antigen used for study 
The antigen used for these studies consisted of an islet -cell 
adenoma (insulinoma), weight 12.7g, which was removed from the pancreas 
of a twenty -five year old woman who presented with symptoms of spon- 
taneous hypoglycaemia and who was found to have high fasting levels of 
plasma insulin. The tumour was made available by the courtesy of 
Mr. A.C.B. Dean (Consultant Surgeon, Royal Infirmary of Edinburgh), 




Ten insulin- dependent diabetics, with positive islet -cell antibodies, 













TC GPC Adr 
(titre. 
ANA 
21 /f 1.5 yrs - - - + - + 
24/f 9.0 yrs - - - + - - 
26/m 0.3 yrs Addison's disease - - - 32 - 
26/m 2.5 yrs - 25 + - - - 
35/f 3.5 yrs Thyrotoxicosis - + - - - 
37/m 8.5 yrs - 250 + - - - 
38/f 12 yrs Thyrotoxicosis - - - - - 
48/f 6.5 yrs Hashimoto Thyr. 2500 + + - - 
49/m 9.0 yrs Pernicious anaem. - + + - - 
52/f 10 yrs i Hashimoto Thyr. 250 + + - - 
Thg = antibody to thyroglobulin 
TC = antibody to thyroid cytoplasm 
GPC = antibody to gastric parietal -cell cytoplasm 
Adr = antibody to adrenal cortex 
ANA = antibody to cell nuclei 
+ = antibody present, titre not determined 
= antibody not present 
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and "was studied extensively before being considered as a suitable 
antigen. Histological examination was undertaken by Dr. D. Thomson 
(Senior Lecturer in Pathology, University of Edinburgh): this 
confirmed the tissue to be an encapsulated, well -differentiated, 
benign islet -cell tumour, with staining reactions and morphology 
closely approximating to those of normal human islets when examined 
both by light and electron microscopy. Biochemical analysis of the 
tumour, and immunoassay of its hormone content, was kindly undertaken 
by Professor D.F. Steiner (Professor of Biochemistry, University of 
Chicago, to whom a 1.0g fraction of the specimen was sent: these 
studies demonstrated a tumour insulin content approximating to that 
of normal islet tissue; a proinsulin content (11 %) within the high 
normal range; and a normal electrophoretic mobility of the insulin 
separated from the tumour by polyacrylamide gel electrophoresis. All 
these studies provided good evidence for regarding the structure and 
hormone content of this tumour as being virtually identical with that 
of normal islet tissue and the material was felt to be an ideal 
antigen for use in the leucocyte migration test, being an antigen of 
almost pure endocrine pancreas. Accordingly the whole tissue was 
homogenated, and after lyophilisation was stored in small batches at 
-40 °C; each batch was used at a final protein concentration of 
400 }ig /ml culture medium, this being the highest nontoxic concentration 
as determined by pilot experiments with normal controls. 
Leucocyte migration test (111T) 
The LMT was performed exactly as described in the migration 
inhibition studies presented in chapter three of this thesis, i.e. 
by the method of Bendixen and Soborg (1969) with minor modifications. 
The/ 
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The effects of antigen on cell migration (the 'migration index') were 
again expressed as a percentage of migration without antigen using 
the formula: 
Migration index 
Mean migration with antigen 
X 100% 
Mean migration without antigen 
The normal range, of migration indices using human islet -cell antigen 
was derived from the mean migration index 
± 
two standard deviations 
of the results given by the ten control subjects to this antigen at a 
concentration of 400 pg /ml culture medium. The range in normals by 
this method was found to be 76.9% - 122.9% (mean 99.9 ± 23) : thus 
a figure of less than 76% was taken to indicate significant inhibition 
of leucocyte migration and above 123% significant stimulation. 
All patients and controls were tested with the human islet -cell 
antigen. The results in the different subgroups were compared 
.statistically by the Wilcoxon rank sum test ( Wilcoxon, 1947). 
4/3 Results of study 
The results of leucocyte migration tests in diabetics and controls 
are presented in figure 4/1. None of the controls showed significant 
inhibition to human islet -cell antigen, the mean migration index in 
this group being 99. + 9 - 3.6 S.E.M. Five of the antibody -positive 
insulin -dependent diabetics showed significant inhibition, with 
indices ranging from 70% to 450, and one showed significant stimulation 
of migration (index 126%) indicating weak hypersensitivity to islet - 
cell antigen. The mean migration index in these antibody- positive 
patients was 75.7 7.2. Very similar results were given by the 
matched group of antibody -negative insulin -dependent diabetics (mean 




FIGURE 4/1 (OPPOSITE): 
Leucocyte migration tests with human islet -cell antigen (400 ug /m1) 
in normal controls, insulin- dependent diabetics with positive 
islet -cell antibody, insulin -dependent diabetics with negative 
islet -cell antibody, and untreated' insulin- dependent diabetics. 
Significant inhibition (see text) is shown by fourteen (50%) 
of the diabetics and none of the controls. The three diabetic 

































From Irvine et al (1976b) 
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islet -cell antigen with indices ranging from 70% to 48%. Significant 
inhibition was also shown by four of the untreated juvenile -onset 
diabetics (two of whom were antibody- negative), with indices ranging 
from 50% to 70%. The mean migration index in this group of untreated 
patients was 73.5 
± 
4.0. 
Statistical analysis confirmed that each of the three diabetic 
subgroups (antibody -positive; antibody- negative; untreated) differed 
significantly from the control group in their response to islet -cell 
antigen (p <0.01 by Wilcoxon's test in each case), as did the whole 
group of twenty -eight diabetics when considered collectively. When 
the three diabetic subgroups were compared individually with each 
other, there were however no significant differences in their 
responses to islet -cell antigen. 
4/4 Discussion of results 
Several conclusions are possible from this small study. First, 
it is confirmed that cellular hypersensitivity to pancreatic antigen 
by the LMT is demonstrable in a high proportion of juvenile -onset 
diabetics (50% in the present series). The use of an antigen of 
virtually pure islet -cell tissue has given a much sharper distinction 
between diabetics and controls than the earlier studies (chapter three) 
using a homogenate of whole human pancreas, which inevitably contained 
a high proportion of exocrine pancreatic tissue, enzymes and other 
substances that were possibly cytotoxic. The results in the present 
study are very similar indeed to those in the earliest study of 
Nerup et al (1971), in which an antigen of porcine islet -cells was 
used, and have confirmed the finding by these investigators that 
migration inhibition is also shown by juvenile -onset diabetics who 
have/ 
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have never received insulin or indeed any other hypoglycaemic drug 
therapy. The findings in these patients give credence to the belief 
that cellular hypersensitivity to pancreatic antigens in young diabetics 
is a true autoimmune phenomenon, i.e. independent of previous anti - 
diabetic treatment; they are quite different from the responses of 
non -insulin- dependent diabetics, very few of whom show cellular 
hypersensitivity to pancreatic antigens (Nerup et al, 1973, 1974; 
chapter three). 
So far as the author is aware, the present investigation was the 
first study in which the presence of humoral autoimmune phenomena 
(possession of pancreatic islet -cell antibody) and cellular auto - 
immunity (hypersensitivity to islet -cell antigen) were directly com- 
pared in the same diabetic patients. The results (figure 4/1) 
indicate that cellular hypersensitivity is not consistently present 
in antibody -positive diabetics, being found in only half such patients 
studied, and that cellular hypersensitivity may equally be found in a 
similar proportion of diabetics who do not possess this humoral islet - 
cell antibody. These findings would suggest that the correlation 
between humoral and cellular autoimmunity in young diabetics is 
relatively poor and two subsequent studies have supported this con- 
elusion. Christy et al (1976) found no correlation between cyto- 
plasmic ICA and cell- mediated autoimmunity in a group of thirty -eight 
'juvenile diabetics' (presumably insulin -dependent) with a mean 
disease duration of 3.2 years. Richens et al (1979) reported a 
similar finding in a group of forty -nine young diabetics, again with 
disease duration of 3.2 years, where a simultaneous search was made 
for cytoplasmic ICA and evidence of cell -mediated autoimmunity by the 
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IMT. It is clear that both Christy et al and Richens et al employed 
relatively crude antigens in the UNIT - homogenates of whole pancreas 
or liver mitochondrial preparations - and this probably explains the 
low frequency of migration inhibition (about 25% of each group of 
diabetic patients) observed by these workers. Nevertheless, all 
three studies might suggest that cytoplasmic ICA is not an invariable 
'marker' of other autoimmune phenomena in diabetes. 
However it must be remembered that cytoplasmic ICA are only 
detectable (by immunofluorescence) in comparatively low titres and 
that the frequency of positive results varies not only between 
different laboratories but also with the source and fixation of the 
tissue substrate used: for example, it is possible that paraffin - 
embedded sections of human group 0 pancreas as described by Dobersen 
et al (1979) would have yielded a higher number of antibody- positive 
subjects. These kind of difficulties are only likely to be resolved 
when standardised pancreatic endocrine cell lines are generally avail- 
able for use as a substrate in serological testing for antibodies, and 
the other measures suggested in chapter two are taken to standardise 
the equipment used for antibody detection. Alternatively, a different 
objective method might be developed for antibody assay, such as radio- 
immunoassay, or measurement of another of the pancreatic islet -cell 
antibodies (perhaps islet -cell surface antibody) might yield.a better 
correlation. Precisely the same reservations apply to antigens used 
to demonstrate cell- mediated antipancreatic autoimmunity by the IMT: 
the study described here used the purest possible concentration of 
beta cells obtainable from human source but even this was tumour 
material, and the antigens used in the other two studies were relatively 
crude 
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crude homogenates. Again this objection could be answered when pure 
preparations of pancreatic cell lines become available. 
Another consideration is the possibility that the one hundred and 
fifteen insulin- dependent diabetics described here (twenty -eight 
tested by the author, thirty -eight by Christy et alp forty -nine by 
Richens et al) were genetically and aetiologically heterogeneous for 
Type 1 diabetes. HLA typing was not performed in the patients tested 
by the author but was undertaken by both other groups, and Christy et 
al were able to demonstrate a positive association between HLA-B8 and 
antipancreatic autoimmunity, both humoral and cellular. Richens et 
al tested for A and B locus antigens but found only seventeen antibody - 
positive patients and were unable to draw statistical conclusions from 
such a small number. The assocation between'HLA -B8 (and probably 
Dß3) with the persistence of islet -cell antibody and with coexistent 
overt autoimmune disease has already been reviewed (chapter two; see 
also chapter seven) and it is possible that the subgroup of true 
' autoimmune Type 1 diabetes' will be identified by performing HLA 
typing in addition to testing for antipancreatic humoral and cell - 
mediated immunity in these patients. 
In summary, it appears that the question of a correlation between 
in vitro tests for antipancreatic humoral and cell- mediated autoimmune 
phenomena could be accurately examined by the following future studies: 
1. HLA typing of appropriately large number of insulin -dependent 
(Type 1) diabetics at the onset of clinical disease, and separation of 
these patients into those who are HLA -Di.3 positive and HLA -DR4 positive. 
2. Examining both subgroups for the presence of cytoplasmic ICAO 
IOSA or other pancreatic antibodies with standardised assays using 
antigens 
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antigens of known composition, perhaps derived from specific endo- 
crine pancreatic cell lines. 
3. Testing both groups for evidence of antipancreatic cell- mediated 
immunity, again using antigens of known composition (perhaps the same 
antigens used as substrate for the humoral antibody detection). 
4. Comparing the results of these in vitro tests for autoimmunity 
with in vivo evidence of antipancreatic autoimmunity (for example, 
the induction of delayed -type cutaneous hypersensitivity to injections 
of antigens used in the in vitro studies). 
It is possible that a study of this nature would not only extend 
our knowledge of autoimmune phenomena in diabetes mellitus but might 
also define a subgroup of Type 1 diabetics in whom the condition 
could be accepted as a true autoimmune disease. 
Part of this work has already been published (Irvine, MacCuish, 
Campbell and Duncan, 1976b) . 
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CHAPTER FIVE 
STUDIES OF GENERAL CELL- MEDIATED IMMUNE FUNCTION IN DIABETES 
5/1 Introduction and purpose of studies 
The mitogen phytohaemagglutinin (PHA) induces transformation of 
cultured small lymphocytes to blast cells (Nowell, 1960). Under 
appropriate conditions, 60 -70% of lymphocytes are transformed in vitro 
by PHA and the majority of these cells will be T lymphocytes (Roitt et 
all 1969) although some B lymphocytes are also stimulated to transform 
(Phillips and Roitt, 1974). PHA testing is therefore extensively 
employed as a general assessment of cell- mediated immune function in 
a variety of clinical states and may be regarded as a convenient means 
of judging the functional level of the recirculating pool of lympho- 
cytes, especially helper T cells (Roitt, 1980). 
Conflicting results have been reported by investigators who have 
undertaken PHA testing in diabetes. Thus Brody and Merlie (1970) 
reported profound depression of PHA response in six diabetics, five 
of whom were insulin -dependent, and claimed that the direct oxidative 
pathway of glucose metabolism was also abnormal; these results there- 
fore suggested immunological abnormality in diabetes. By contrast 
Ragab et al (1972) tested the PHA response of lymphocytes from twenty - 
three diabetics, seventeen of whom were insulin -dependent, and found 
no difference from the response of cells from twenty -four healthy 
nondiabetic controls in the same assay system. Ragab et al further 
measured the lymphocyte transformation response to a commonly - 
encountered antigen ( Candida albicans) in their diabetic and control 
groups, and again found the response of each group to be identical. 
Thus/ 
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Thus the results of Ragab et al suggested that general cell -mediated 
immune function was normal in diabetes mellitus. 
On reviewing the work of Brody and Merlie and Ragab et al, it 
seemed possible that the differing findings of these two groups 
could perhaps be reconciled by relating PHA response to the degree 
of metabolic control in insulin -dependent diabetes. With this 
possibility in mind, the following studies of general cell- mediated 
immune function in diabetics were therefore undertaken: 
1. The transformation response to PHA was measured using lympho- 
cytes from both well -controlled and poorly -controlled insulin - 
dependent diabetics, the results being compared with those obtained 
from matched nondiabetic controls. 
2. The circulating subpopulations of T lymphocytes (which constitute 
the main bulk of PHA -responsive cells) and B lymphocytes were also 
measured in peripheral blood from the same diabetics and controls. 
When these initial investigations had indicated that the magni- 
tude of PHA response in diabetic lymphocyte cultures was indeed 
related to the adequacy of metabolic control, further studies were 
undertaken in an attempt to define the factor(s) responsible for 
lymphocyte malfunction in poorly -controlled diabetes mellitus. 
5/2 Selection of well- controlled and poorly -controlled diabetics 
for study 
PHA responses were studied in forty well -controlled diabetic and 
forty normal subjects who were carefully matched for age and sex. 
The diabetic subjects (twenty -two women, eighteen men; mean age 
42.4 years) were insulin -dependent, attending the outpatient clinic 
of the Diabetic Department, Edinburgh Royal Infirmary, and were free 
from infection on the day of study. The control subjects were healthy 
volunteers/ 
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volunteers, mainly laboratory personnel or hospital outpatients 
who were not known to have endocrine disease or immunologic abnormal- 
ity. 
PHA responses' were also studied in a group of fourteen poorly- 
. controlled insulin -dependent diabetics. These patients had been 
brought to the outpatient clinic for routine or emergency review and 
their disorder was judged to be poorly controlled by the following 
criteria: midmorning blood glucose exceeding 20 mmol /1 (350 mg /dl); 
recent' increase in insulin requirements; the presence of heavy 
glycosuria and/or ketonuria. Some were subsequently admitted to 
hospital for correction of their metabolic abnormalities but none had 
received antibiotics or drugs other than insulin at the time of study. 
Their clinical details are presented in table 5/1. 
T and B cell subpopulations were measured in fifteen of each of 
the well- controlled diabetic and normal subjects, and in ten of the 
poorly -controlled diabetics. 
5/3 Methods used for collection, culture and identification of 
lymphocytes 
Collection of blood samples and se.aration of 1 hoc es II . 
Venous blood was withdrawn at midmorning and anticoagulated with 
preservative -free heparin (Weddell Pharmaceuticals or Evans Medical). 
A portion of each sample was used for measurement of total and 
differential white blood cell counts. Lymphocytes were separated 
from the remainder by density centrifugation on a Ficoll -Triosil 
gradient (Calder et al, 1973; Appendix I /1b) and washed three times 
in Eagle's Basal Medium (EBM, Appendix I /lc). The cells were then 
resuspended in End with 10. foetal calf serum (Wellcome), counted, 
and/ 
TABLE 5/1 
Clinical details of fourteen poorly -controlled diabetic patients 
in whom lymphocyte transformation and lymphocyte subpopulation 









































Urinary tract infection 
Emotional stress 





Congestive cardiac failure 
I 
Ketoacidosis, cause unknown 
_Skin sepsis, chest infection 




From MacCuish et al (1974c) 
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and the concentration adjusted to 1 x 106 cells per ml. All cell 
suspensions contained more than 95% lymphocytes with a viability 
greater than 98% on trypan blue exclusion. Lymphocytes from the 
same sample were used for the PHA test and for T and B cell esti- 
mations. 
L nhoc e culture with PHA 
The lymphocyte transformation response to PHA was measured by 
a microculture technique using radioisotope labelling of stimulated 
cells. The technique was developed in the MRC Clinical Immunology 
Laboratories, Forrest Road, Edinburgh, under the direction of 
Dr. W.J. Penhale (Senior MRC Research Worker); prior to its use 
the method had been extensively investigated to provide a rapid, 
reproducible and inexpensive technique for PHA -induced lymphocyte 
transformation, using only small quantities of lymphocytes and 
ensuring minimal radiation damage to the cells. The technique 
( Penhale et al, 1974) is described in detail in Appendix II/4 of 
this thesis and is summarised as follows: Stock PHA (PHA -P, Difco) 
was diluted in EBM with 10% foetal calf serum to give three solutions 
containing respectively 0.32, 0.63 and 1.25 pl PHA /ml culture. 
Aliquots of 20 it of each solution were pipetted into the wells of 
Cooke Microtiter trays (Flow Laboratories) and 2 x 105 cells added 
to each well. All determinations were performed in triplicate and 
included control cultures without PHA. The microtrays were gassed 
with an air -5% CO2 mixture and incubated at 37 °C in sealed, humidified 
containers. 
3H- thymidine of specific activity 5 Ci /mmol (Radiochemical Centre, 
Amersham) was diluted with sterile saline to give a working concentra,- 
tion/ 
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concentration of a 2 jiCi /100 ul. Twenty microlitres of this solution 
(i.e. 0.4 jiCi H- thymidine) was added to each culture after forty - 
four hours' incubation. The cultures were regassed and incubated for 
a further four hours. The contents of the wells were then pipetted 
onto glass fibre filter papers (Whatman GF /C) which were air- dried, 
washed successively with cold 5% trichloracetic acid, phosphate 
buffered saline (Appendix I /1) and absolute methanol, and finally 
placed in Packard glass counting vials. Five ml Scintillation fluid 
(NE233, Nuclear Enterprises Ltd.) was added to each vial and the 
samples counted for sixty seconds in an automatic beta counter (Packard 
Tricarb 2425), the results being expressed as counts per minute (cpm). 
Identification of T and B lymphocyte subuopulations 
These investigations were kindly undertaken by Dr. S.J. Urbaniak 
during his tenure of an MRC Junior Research Fellowship in the Clinical 
.Immunology Laboratories under Dr. Irvine's direction. T Lymphocytes 
were identified by their ability to form rosettes with sheep erythro- 
cytes (E- rosettes). The technique used ( Urbaniak et al, 1973) was 
' derived from that of Jondal et al (1972) and incorporated the modifi- 
cations of Stjernsward et al (1972). Results are expressed both as 
absolute numbers and percentages of total lymphocyte counts. 
Blymphocytes were identified by two techniques: a rosette technique 
( Stjernsward et al, 1972), using sheep red cells coated with antibody 
and complement (EAC- rosettes) and indirect immunofluorescence ( Jondal 
et al, 1972), whereby the cells are distinguished by surface immuno- 
globulin marker. 
5/4 Results of lymphocyte transformation with PHA 
The dose -response curves of lymphocytes from well -controlled 
diabetics/ 
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diabetics and normal subjects are shown in figure 5/1. The mean 







cpm x 103 
+ 
15.3 ± 4.3, 
20.8 
± 
4.2 and 21.4 ± 4.3 respectively 
S.E.M.). The corresponding values in the 
19.7 
± 
3.9 and 21.8 ± 3.9. Both curves 
are virtually identical and the lymphocyte transformation response 
to PHA is not therefore abnormal in well -controlled diabetics. 
The dose -response curve of lymphocytes from the fourteen poorly - 
controlled diabetics is compared in figure 5/2 with the curve 
obtained from fourteen of the well -controlled diabetics, matched as 
closely as possible for age, sex and duration of diabetes. The 
mean transformation responses in poorly -controlled diabetics to the 
three doses of PHA were 9.0 
± 
1.33, 9.5 ± 1.4 and 8.2 ± 0.6 respect- 





1.9 and 21.3 ± 2.0. These results show a statis- 
tically significant reduction of PHA response in poorly -controlled 
insulin -dependent diabetics at all three concentrations of PHA 
(p =0.001 by the Student t test). 
5/5 Results of lymphocyte subnopulation studies 
Tables 5/2, 5/3 and 5/4 list the total lymphocyte counts and 
the numbers of circulating T and B cells, expressed both as absolutes 
and percentages of total lymphocyte counts, in samples taken 
respectively from fifteen well -controlled diabetics, fifteen normal 
subjects and ten poorly -controlled diabetics. The results show no 
significance in the mean number and percentage of T cells (assessed 
by E rosettes) or B cells (assessed by EAC rosettes or immuno- 
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PHA CONCENTRATION (pl /ml) 
1.125 
Mean lymphocyte transformation responses in forty well -controlled 
insulin- dependent diabetics ( ) and forty age - and sex -matched 
normal subjects (- - - -) at three concentrations of PHA. The two 
dose -response curves do not differ significantly. S.E.M.'s are 
omitted for clarity but are given in the text. 




PHA concentration -cul /ml 
1.25 
Lymphocyte transformation responses (mean 
± 
S.E.M.) in fourteen 
poorly -controlled insulin -dependent diabetics ( ) and 
fourteen well- controlled insulin -dependent diabetics (- - - -) 
who were matched for age, sex and duration of diabetes. The 
mean response in the poorly -controlled diabetics is significantly 
lower (p <0.001) at all concentrations of PHA. 
From MacCuish et al (1974c) 
TABLE 5/2 
Total lymphocyte counts and subpopulations of T and B lymphocytes 

























22/f 1,403 878 62.6 449 32.0 .111 
28/f 2,350 1,465 62.3 - - 357 15.2 
35/f 1,566 1,038 66.3 188 12.0 227 14.5 
55/f 2,560 1,318 51.5 - - 294 11.5 
56/f 2,211 1,282 58.o 104 4.7 736 33.3 
59/f 1,320 854 64.7 121 9.2 300 22.7 
62/f 671 374 55.8 203 30.3 221 33.0 
62/f 1,360 743 54.6 299 22.0 
68/f 2,132 1,552 72.8 544 25.5 452 21.2 
17/6 2,464 1,627 65.9 315 12.8 490 19.9 
19 /m 3,250 1,570 48.3 504 15.5 523 16.1 
36/m 1,975 1,284 65.o 375 19.0 257 13.0 
42/6 1,682 1,182 70.3 579 34.4 MOD 
63/6 11440 935 64.9 2,321 16.1 
Mean 1,879 1,153 62.0 338 19.5 375 20.4 
± S.E.M. 165 91 1.79 56 3.29 42 1.98 
(E) = T lymphocytes 
(EAC) = B lymphocytes 
rosettes 




sheep erythrocyte rosettes 
erythrocyte -antibody -complement 
indirect immunofluorescence 
From MacCuish et al (1974c) 
TABLE 5/3 
Total phocyte counts and subpopulations of T and B lymphocytes 

























27/f 1,333 857 64.3 216 16.2 - - 
27/f 710 474 66.8 192 27.0 90 12.7 
38/f 1,976 1,320 66.8 174 8.8 326 16.5 
47/f 1,606 896 55.8 527 32.8 390 24.3 
55/f 1,817 950 52.3 136 7.5 - - 
57/f 770 506 65.7 218 28.3 123 16.0 
57/f 2,667 1,560 58.5 494 18.5 416 15.6 
64/f 2.184 1,223 56.0 109 5.0 618 28.3 
69/f 2,054 1,516 73.8 496 24.1 251 12.2 
18/m 3,000 2,223 74.1 1,125 37.5 690 23.0 
25/m 700 513 73.3 86 12.3 123 17.5 
354 2,379 1,421 59.3 43 1.8 816 34.3 
42/m 1,974 1,137 58.4 516 26.5 405 20.8 
,66/m 1,672 1,167 69.8 274 16.4 - - 
Mean 1,855 1,194 64.4 323 19.4 415 20.5 
± 
S.E.M. 194 112 1.64 73 4.02 60 2.56 
Abbreviations as for Table 5/2. 
From MacCuish et al (1974c) 
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TABLE 5/4 
Total lymphocyte counts and subpopulations of T and B lymphocytes 



















24/f 1,035 735 71.0 207 20.0 
37/f 2,700 2,173 80.5 259 9.6 
60 /f 1,936 1,073 55.4 407 21.0 
61 /f 2,430 1,638 67.4 676 27.8 
66/f 2,436 1,571 64.5 470 19.3 
68/f 1,850 1,166 63.0 487 26.3 
19/m 600 303 50.5 102 17.0 
28/m 1,472 883 60.0 202 13.7 
45/m 1,971 1,242 63.0 242 12.3 
46/m 1,950 1,225 62.8 558 28.6 
Mean 1,838 1,201 63.8 361 19.5 
± 
S.E.M. 145 109 1.59 38 3.25 
Abbreviations as for Table 5/2. 
From MacCuish et al (1974c) 
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are therefore normal in diabetics when obtained at times of 'good' 
and 'poor' metabolic control. 
5/6 Serial measurements of lymphocyte transformation during 
recovery from diabetic ketoacidosis 
From the results of the above studies, it appeared likely that 
some (transient) metabolic factor was causing depression of lympho- 
cyte transformation in diabetics at times of poor diabetic control. 
Thus the opportunity was taken to make serial measurements of PHA - 
induced lymphocyte transformation in a diabetic during recovery from 
ketoacidosis. The patient studied was a man aged 36 years, with a 
history of insulin- dependent diabetes for ten years, who was admitted 
to Edinburgh Royal Infirmary in severe diabetic ketoacidosis. The 
cause of his metabolic decompensation was not established but no 
evidence of underlying infection was detected by bacteriological 
examination of the appropriate body fluids. Following admission he 
was treated intensively with intravenous fluids, electrolytes and 
insulin and made an uneventful recovery. Blood for study was with- 
drawn at the time of hospital admission (before treatment commenced) 
and at 12, 24, 48 and 72 hours thereafter, i.e. during the period of 
intensive medical therapy. Lymphocytes from the serial blood 
samples were harvested and cultured in the presence of FHA as 
described in section 5/3. The results are presented in figure 5/3, 
together with biochemical data (serial blood glucose and plasma 
bicarbonate concentrations) obtained at the same times. It will 
be observed that lymphocyte transformation with PHA was grossly 
depressed in severe diabetic metabolic decompensation but slowly 
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Time BG HCO3 
Ohrs 650 <5 
12hrs 270 14 
24hrs 124 21 
48hrs 58 24.5 
72hrs 110 23.5 
BG - blood glucose (m)%o) 
HCO3 a - plasma bicarbonate (mE I) 
Lymphocyte transformation responses to three concentrations of PHA 
in an insulin- dependent diabetic during recovery from ketoacidosis. 
Transformation response is grossly depressed in severe metabolic 
decompensation but returns to normal within 72 hours following 
correction of the ketoacidosis. 
From MacCuish and Irvine (1975) 
the lymphocyte transformation response remained markedly depressed 
at 48 hours, by which time the patient's blood glucose and plasma 
bicarbonate concentrations were both normal. After a further 24 
hours, i.e. 72 hours after admission and treatment, the transformation 
responses to PHA had returned to normal. 
5/7 Effects of diabetic serum on mitogen- induced lymphocyte 
transformation 
A further study was undertaken to establish that some factor 
in serum from poorly -controlled diabetics was responsible for the 
depressed lymphocyte transformation in these patients. Lymphocytes 
were harvested from blood samples withdrawn from a panel of healthy 
volunteers (laboratory personnel) by the techniques described in 
section 5/3 and cultured in EEM enriched with the following serum: 
a) serum from healthy volunteers (14 samples); b) serum from the 
poorly -controlled diabetics described in table 5/1; c) serum with- 
drawn from the same diabetics after their metabolic abnormalities 
were corrected and good control had been established (11 samples). 
In all cases the serum was added to EBM in a concentration of 10% 
and PHA was also added to give a concentration of 0.63 }il PHA/ml. 
All determinations were performed in triplicate. Control cultures 
from all three groups were simultaneously cultured in EBM with 10% 
foetal calf serum, again in the presence of PHA at a concentration of 
0.63 p.l /mi. All results of culture were expressed as counts per 
minute (cpm); the difference between the transformation of lympho- 
cytes cultured in human test serum and lymphocytes cultured in foetal 
calf serum was expressed as the 'Transformation Index' by the follow - 
ing formula: 
cpm of cultures in test serum 
Transformation Index m 




The results of this experiment are shown in figure 5/4. The mean 
transformation index (± S.E.M.) was 1.67 
± 
0.2 for normal lympho- 
cytes cultured in normal serum; using diabetic serum, the mean 
transformation index for normal lymphocytes was 0.81 ± 0.1 when 
cultured with serum from poorly -controlled diabetics and 1.60 
± 
0.23 
when cultured with serum taken from the same patients after good 
diabetic control had been established. Statistical analysis by the 
Wilcoxon rank test confirmed that there was no significant difference 
between the transformation of lymphocytes cultured in normal serum or 
in serum from well -controlled diabetics. However the transformation 
of lymphocytes cultured in serum from poorly -controlled diabetics was 
significantly lower (p 40.01) than both the other groups. These 
results indicate clearly that some factor(s) in the serum of poorly - 
controlled diabetics can inhibit the PHA -induced transformation of 
normal lymphocytes. 
5/8 Effects of varying glucose concentration on mitogen- induced 
lymphocyte transformation 
This experiment was designed to examine the possibility that 
hyperglycaemia per se was responsible for reduced lymphocyte trans- 
formation in poorly -controlled diabetics. Lymphocytes were prepared 
from a panel of eight healthy volunteers and cultured as before in 
ELI with 10% foetal calf serum and PHA at a concentration of 0.63)44111. 
However the final glucose concentration of the culture medium was 
adjusted to give three solutions containing respectively glucose at 
100, 300 and 600 mg /dl culture medium. (Normal EBM contains glucose 
at a concentration of 100 mg /dl). All cultures were performed in 














Normal Diabetic Diabetic Serum 
copoor 
ntrol control 
Effect of serum from fourteen normal subjects and fourteen diabetics 
on the PHA -induced transformation of normal lymphocytes. Serum from 
poorly -controlled diabetics causes significant (p <0.01) depression 
of lymphocyte transformation; repeat serum samples, obtained from 
the same patients when their diabetes was well controlled, have no 
such inhibitory effects of lymphocyte transformation. 
From MacCuish (1976) 
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were expressed as cpm x 103 and are shown in figure 5/5. The mean 
transformation response 
± 
S.E.M. was 14.8 ± 1.8 for lymphocytes 
cultured in a glucose concentration of 100 mg /dl. In contrast, 
lymphocytes cultured in glucose concentrations of 300 mg /dl and 
600 mg /dl yielded transformation responses of 10.5 
± 
1.4 and 11.0 
± 
1.4 respectively. Both groups were significantly different from 
the response of lymphocytes cultured in a glucose solution of 100 
mg /dl but the statistical significance was weak (p <0.05 by Wilcoxon's 
test): There was no significant difference between lymphocyte 
cultures performed in glucose concentrations of 300 mg /dl and 600 
mg /dl. 
5/9 Effects of various free fatt acids FFA on mitoen- induced 
lymphocyte transformation 
Since hyperlipidaemia with high circulating free fatty acids 
(FFA) is common in uncontrolled diabetes, especially in insulin - 
dependent patients, the in vitro effects of various fatty acids (FA) 
on lymphocyte transformation were examined. The FA studied were 
the single unsaturated FA oleic (cis- 9- octadecanoic) (C18:1) and the 
polyunsaturated (PUFA) linoleic (cis -9- cis- l2- octadecadienoic) (C18:2) 
and arachidonic acid (5, 8, 111 14- eicosatetraenoic) (C20:4). All 
were obtained from Sigma Chemical Co. Limited (Sigma Grade, approxi- 
mately 99% pure). They were dissolved in ethanol and added to culture 
medium to give a standard concentration of 0.08 mg /ml, which 
corresponds to the normal level of C18:1 in human serum (Schrade et 
alp 1960). The ethanol concentration did not exceed 0.42% in the 
test culture medium and was also added at the same concentration to 









100 300 600 
Glucose concentration 
(mg /dl culture medium) 
Effect of increasing glucose concentration on the transformation 
response to PHA (0.63 111/m1) of cultured lymphocytes from eight 
normal subjects. Glucose concentrations of 300 and 600 mg /dl 
have a small but significant (p4.0.05) effect in depressing lympho- 
cyte transformation. Mean PHA response 
± 
S.E.M. is shown for each 
glucose concentration. 
From MacCuish (1976) 
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Itigmphocytes for culture were obtained from twelve healthy 
volunteers (laboratory personnel) and prepared as described in 
section 5/3. All determinations were performed in triplicate and 
the following cultures were prepared: control cultures in EBI only; 
control cultures with 0.42% ethanol; control cultures with PHA at 
0.63 )l1 /ml; control cultures with 0.42% ethanol and PHA 0.63 it /ml; 
and cultures containing each of the three FA studied (dissolved in 
ethanol) at a conéentration of 0.08 mg /ml. The cultures containing 
FA were allowed to interact with the cells for one hour in the dark 
at room temperature before being stimulated with PHA (0.63 }zl /ml) 
and thereafter incubated for 48 hours, with 3H- thymidine added after 
44 hours. Results in all cases were expressed as mean cpm x 103 
S.E.M. 
The results of this experiment are summarised in figure 5/6. 
The exact values from the various culture groups were as follows: 
Control cultures in E. : 0.29 0.02 
Control cultures in EHi't with ethanol : 0.27 0.03 
Control cultures with PHA : 7.7 ± 2.1 
Control cultures with PHA and ethanol : 8.3 
± 
2.2 
Cultures with oleic acid : 3.9 1 
Cultures with linoleic acid : 2.0 0.9 
Cultures with arachidonic acid : 0.3 0.01 
Statistical analysis confirmed a highly significant suppression 
of PHA -induced lymphocyte transformation in all cultures to which FA 
had been added (p <0.01 by Wilcoxon's test). Ethanol alone had no 
effect on transformation. The extént of suppression was related to 









Unstim. PHA PHA+ PHA+ PHA+ 
Oleic Linoleic Arachidonic 
C18 :1 C18:2 C20:4 
Effects of various fatty acids (in a concentration of 80 jig /ml culture) 
on PHA -induced transformation of lymphocytes from twelve normal 
subjects. Control cultures ( Unstim.) contain no PHA; ail other 
cultures contain PHA at 0.63 )11 /ml. All fatty acids induce highly 
significant (p.(0.01) depression of lymphocyte transformation, most 
marked with arachidonic acid. 
Results expressed as in Figure 5/5. 
From MacCuish (1976) 
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PUFA linoleic and arachidonic acid; transformation was completely 
suppressed in cultures containing the latter PUFA, and differed 
significantly (p <0.01) from all other cultures containing PHA. 
510 Discussion of results 
The results presented in this chapter confirm that lymphocyte 
transformation to blast cells by PHA, generally accepted as an 
in vitro test of cell- mediated immunologic response (Roitt et al, 
1969; Greaves et al, 1974) is normal in well controlled insulin - 
dependent diabetics when compared with matched normal controls. 
This agrees with the results of Ragab et al (1972), who found no 
differences in the PHA responses of lymphocytes from twenty -three 
diabetics and twenty -four controls. Contrary results (depression 
of PHA response) reported by Brody and Merlie (1970) were based on 
their observations in six elderly diabetics who had persistent 
glycosuria and marked hyperglycaemia (blood glucose 300 -514 mg /dl) 
and had not taken insulin for between twelve and twenty -four hours 
before the lymphocytes were prepared for study. Therefore it 
appears likely that these results reflected the metabolic disturbance 
of poorly controlled diabetes, rather than any inherent immunologic 
abnormality, and the present findings in poorly -controlled diabetic 
subjects agree with this hypothesis. 
Further support for the view that depressed PHA response in 
diabetics is due to metabolic abnormality is provided by the finding 
of normal numbers of circulating T and B lymphocytes in diabetics, 
irrespective of whether they were well or poorly controlled at the 
time of study. Since PHA is considered mainly to test the function 
of the T -cell population (Roitt et al, 1969; Greaves et alt 1974), 
it/ 
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it would be surprising to find a depression of PHA response in 
subjects with normal numbers of T cells, unless the serum itself 
contains factors inhibiting lymphocyte transformation. The presence 
of inhibitory factors is already recorded in diseases such as breast 
cancer (Whittaker et al, 1971), multiple sclerosis (Knowles et al, 
1968) and active syphilis (Levene et al, 1969); from the results 
obtained in the present studies, it appears that poorly -controlled 
insulin- dependent diabetics exhibit a similar phenomenon. 
What is the nature of the inhibitory factor(s) in diabetic 
serum? Clearly they are transient, and related to poor control, 
since lymphocyte transformation is normal in well controlled 
diabetics. Poorly controlled diabetes is characterised by hyper- 
glycaemia, hyperlipidaemia (especially by mobilisation of FFA in 
insulin- deficient patients) and (eventually) by ketoacidosis 
(Alberti and Hockaday, 1977; Dunn, 1982). It seems unlikely that 
metabolic acidosis per se is the major factor inhibiting lymphocyte 
transformation since many of the poorly controlled patients studied 
in the present series showed no significant disturbance of acid -base 
balance, and mobilisation of FFA must always precede the production 
of ketone bodies by the liver. On the other hand, the experiments 
described in sections 5/8 and 5/9 would suggest that hyperglycaemia 
and FFA are both potent inhibitors of lymphocyte transformation. 
Of these two influences, it appears that hyperglycaemia plays a 
lesser part and is probably only of importance when the blood glucose 
concentration exceeds 300 mg /dl. However FFA causes marked 
depression of lymphocyte transformation, the depressant effect being 
especially marked with polyunsaturated fatty acids. Thus it is 
tempting/ 
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tempting to speculate that the effects of high levels of blood 
glucose and FFA combine in the poorly controlled diabetic to produce 
a state of transient immunologic abnormality which may have practical 
clinical implications in rendering the patient more susceptible to 
infection. Infections - both viral and bacterial - are identified 
as the single most important factor in the majority of patients with 
diabetic ketoacidosis (MacCuish, 1977) and it is usually assumed 
that the infection has been responsible for the metabolic decompens- 
atior. The studies presented in this chapter might support an 
opposite view, i.e. that poorly controlled diabetes in itself induces 
a state of temporary immunodeficiency, at least of the cell- mediated 
limb of the immune system, which makes the patient peculiarly 
vulnerable to intercurrent infection. With regard to other body 
defence mechanisms in the same context, Bagdade (1976) has examined 
granulocyte function in diabetes and has concluded that normal chemo- 
tactic, phagocytic and intracellular microbicidal functions of poly - 
morph leucocytes are also largely dependent on good metabolic control. 
The corollary of all these observations would be that every effort 
should be made to attain and maintain good metabolic control in 
insulin -dependent diabetics, and thereby avoid the immunologic 
abnormalities which may lead to the development of clinically signifi- 
cant infections. 
Parts of this work have already been published: (MacCuish et al, 
1974c; MacCuish and Irvine, 1975; MacCuish, 1976). 
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CHAPTER SIX 
STUDIES OF THE PREVALENCE OF AUTOANTIBODIES TO NONPANCREATIC ANTIGENS 
IN DIABETIC AND NONDIABETIC POPULATIONS 
6/1 Introduction and purpose of studies 
It will be apparent from the General Introduction (section 1/4) 
that many studies of autoantibody prevalence in diabetic and non - 
diabetic populations have already been undertaken. However it was 
felt that some of the findings reported in these studies, and the 
hypotheses constructed therefrom, justified additional and critical 
evaluation. The investigations reported in this chapter were there- 
fore undertaken with the following specific objectives: 
a) To examine the differences (if any) in the prevalence of serum 
autoantibodies between a diabetic and nondiabetic population; and 
to relate the differences to the age, sex and antidiabetic therapy 
in the various diabetic subpopulations. 
b) To examine the disparate claims by Nerup and Binder (1973) and 
Whittingham et al (1971) that increasing duration of insulin- dependent 
diabetes was associated respectively with increasing or decreasing 
autoantibody prevalence. 
c) To ascertain whether a population of diabetics with evidence 
of the specific vascular lesions of the disease (i.e. diabetic mìro- 
angiopathy) showed a differing autoantibody prevalence from.a diabetic 
population with no evidence of such lesions. 
6/2 Selection of diabetic and nondiabetic populations for study 
A total of four hundred diabetics were studied, subdivided 
into the following groups: 
Insulin -dependent diabetics with microangiopathy 
This group comprised one hundred and fifty patients (half being 
women 
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women, half men) with clinical evidence of diabetic microangiopathy. 
In eighty -five there was evidence of retinopathy alone, the ocular 
lesions consisting of a background type of retinopathy with micro - 
aneurysms, blob haemorrhages and exudates; venous retinopathy, 
with or without associated haemorrhage; and primary or secondary 
proliferative retinopathy (neovascularisation). In many of these 
patients, especially the younger subjects, a mixed type of retino- 
pathy was present in which some or all of the above elements were 
combined. In several the retinopathy had been treated as appropriate 
with photocoagulation, laser -beam therapy or the use of the drug 
clofibrate (Atromid - S). None of the patients had clinical evidence 
of diabetic nephropathy and none had measurable proteinuria or an 
elevated blood urea. 
The remaining sixty -five patients in this group had more wide- 
spread clinical evidence of diabetic microangiopathy. All had 
clinical signs of oculorenal pathology: the ocular lesions were as 
described above while the renal lesions consisted of proteinuria, 
,nephrotic syndrome or progressive uraemia. In several cases the 
diagnosis of diabetic nephropathy had been histologically confirmed 
by renal biopsy. The ocular lesions tended to be especially severe 
in these patients with diffuse microangiopathy, and ten of the sixty - 
five had previously undergone pituitary ablation (Cullen et al, 1971) 
in an effort to arrest the progression of their retinopathy. Two 
patients were being treated by intermittent haemodialysis for end - 
stage renal failure due to diabetic nephropathy and several had 
evidence of autonomic neuropathy, manifest by abnormal vasomotor 
responses and gastrointestinal disturbance. 
The/ 
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The age and sex distribution of the patients in this group is 
shown in detail in tables 6/1 and 6/2. 
Insulin- d_ .endent diabetics without clinical microanio.ath 
This group again consisted of one hundred and fifty patients, 
matched exactly for age and sex with respect to the first group, 
and as closely as possible for duration of insulin- dependent diabetes. 
No patient in this group had clinical evidence of diabetic retino- 
pathy or nephropathy, none had measurable proteinuria and all had a 
normal blood urea. No renal biopsies had however been performed in 
this group. 
The age and sex distribution of the patients in this group is 
shown in detail in tables 6/1 and 6/2. 
Insulin -independent diabetics 
There were one hundred patients in this group; in forty -one 
their disorder was controlled by dietary restriction of carbohydrate 
alone while the remainder were controlled by diet plus an oral hypo- 
glycaemic agent (sulphonylurea or biguanide). No conscious effort 
was made to exclude patients with specific complications, and 
thirteen had evidence of a mild background diabetic retinopathy. 
However no patient had severe ocular or renal disease. 
The age and sex distribution of the patients in this subgroup 
is shown in detail in tables 6/1 and 6/2. 
The age of onset and the duration of clinical diabetes were 
noted for each patient. Care was also taken to exclude any diabetic 
with known coexisting autoimmune disease or endocrinopathy, or any 




Analysis of 400 diabetic patients studied, 
according to antidiabetic treatment required 
Treatment 
Age at time of study 
10-39 years 40-69 years 












Insulin / angiopathy+ 35 35 40 40 
Insulin/angiopathy- 35 35 40 40 
Totals 85 95 110 110 
Angiopathy+ = 
Angiopathy- _ 
patients with specific diabetic 
microvascular lesions 






Age and sex distribution of 
diabetic patients and control subjects 
Age by decades 
2nd 3rd 4th 5th 6th 7th 
Females 25 35 35 42 41 27 205 females /195 males 
Males 18 30 37 39 38 33 (Total 400) 
Totals 43 65 72 81 79 60 
Age and sex distribution of 
insulin -dependent diabetic patients and controls 
Age by decades 
2nd 3rd 4th 5th 6th 7th 
Females 21 28 21 24 29 27 150 females /150 males 
Males 20 29 21 34 25 21 (Total 300) 
Totals 41 57 42 58 54 48 
Age and sex distribution of 
insulin -independent diabetic patients and controls 
Age by decades 
2nd 3rd 4th 5th 6th 7th 
Females 1 5 19 13 10 7 105 females /95 males 
Males 1 3 11 10 15 5 (Total 100) 
Totals 2 30 23 25 12 
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There were a total of four hundred control subjects, matched 
for age and sex with the diabetics in all the above subgroups. 
Most of the controls were healthy volunteers, consisting of labor- 
atory or hospital personnel; many of the middle -aged controls 
were University servitors and were obtained with the kind assistance 
of Dr. E.W. Barnes. Hospital outpatients were used in several 
instances as controls for teenage and elderly diabetics, but none 
of the controls obtained from this or any other source were known 
to have endocrine or autoimmune disease. 
The age and sex distribution of the control subjects, which is 
identical to that of the diabetics, is shown in detail in table 6/2. 
6/3 Methods used for the detection of autoantibodies 
Serum samples were obtained from each patient and control, 
stored at -20 °C, and tested for the presence of the following anti- 
bodies: 
Antibody to thyroclobulin using the tanned -cell haemagglutination 
technique (Fulthorpe et alp 1961). The reagents were supplied in 
kit form (Wellcome Reagents Ltd.) and a detailed description of the 
technique used is given in Appendix I/3 of this thesis. The test 
was routinely performed in serum dilutions of 1:5, 1:25, 1:2500 and 
1:25000; a titre of greater than or equal to 1:25 was taken as 
significant. 
Antibody to thyroid cytoplasm using the indirect immunofluorescence 
(Coons) technique, a detailed description of which is given in Appendix 
I/2 of this thesis. The antigen for this test consisted of human 
thyroid gland, obtained at partial thyroidectomy for thyrotoxicosis. 
Small blocks of this tissue were snap -frozen, cut into thin (5 micron) 
sections/ 
179 
sections on a cryostat and used as tissue substrate. 
Antibody to gastric parietal -cell cytoplasm using the indirect 
immunofluorescence technique. The tissue substrate for this test 
consisted of human gastric mucosa, obtained from the body of the 
stomach at partial gastrectomy and prepared as above. 
Antibody to mitochondria using the indirect immunofluorescence 
technique. Rat kidney was used as the tissue substrate in this 
test, prepared as above. Staining of mitochondria in the renal 
tubules was particularly noted and sera giving positive reactions 
in this fashion were regarded as negative for thyroid -cell and 
gastric -cell antibodies, because of the nonspecific nature of 
mitochondrial antibodies. 
Antibodies to cell nuclei (ANF) using the indirect immunofluorescence 
technique and examining all three tissues above (thyroid, stomach, 
.kidney) for the presence or absence of nuclear staining. 
Each serum sample was tested with the three tissue substrates 
mounted together on the same slide, thus providing a check for 
tissue- specificity of any antibodies detected. 
In addition to these tests, the presence or absence of anti- 
bodies to adrenal cortex was established in sera from a proportion 
of the diabetics (one hundred and twenty -three insulin -dependent 
patients, fifty -seven insulin -independent patients) and their 
corresponding =diabetic controls. The technique used was again 
the indirect immunofluorescence test, the tissue substrate consisting 
of human adrenal gland which had been removed as soon as possible 
after death. 
The results of antibody determination in diabetics and controls 
were 
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were compared statistically by using the chi -squared test and 
employing Yates' correction for small samples where appropriate. 
6/4 Results of autoantibody studies 
6/4a Overall antibody prevalence in diabetics and controls 
Table 6/3 summarises the overall differences in antibody preval- 
ence between diabetics and controls. The prevalence of antibodies 
to thyroglobulin was marginally higher in male diabetics and in 
patients of either sex aged under forty years (p<0.05 in both 
subgroups). There were however no significant differences when 
female diabetics and diabetics of either sex aged forty years or 
over were compared with their corresponding controls, nor did the 
prevalence of thyroglobulin antibody in the whole diabetic group 
differ significantly from that in the control group. Likewise there 
were no significant differences in the prevalence of antibodies against 
cell nuclei or mitochondria between diabetics and controls (overall 
prevalence 1% for each antibody in both groups). 
In contrast there was a highly significant increase in the 
prevalence of antibodies to both thyroid cytoplasm and gastric 
parietal -cell cytoplasm in diabetics as compared to controls: the 
difference was highly significant when the overall groups were compared 
(1)4(0.001) for each antibody) and when subgroups of subjects according 
to sex and age were considered (p <0.001 - p <0.005 in all subgroups; 
table 6/3). 
As figure 6/1 shows, a rising prevalence of all three antibodies 
(thyroglobulin, thyroid cytoplasm, gastric parietal -cell cytoplasm) 
was observed with advancing age in diabetics and in controls. In the 




Autoantibody prevalence in controls and diabetics, 
according to sex and aie 
Group 
(Number in group) 
Female controls (205) 
Female diabetics (205) 
Male controls (195) 
Male diabetics (195) 
Controls aged 10-39 yrs (180) 
Diabetics aged 10 -39 yrs (180) 
Controls aged 40-69 yrs (220) 
Diabetics aged 40-69 yrs (220) 
All control subjects (400) 






Number* positive for antibody to: 

















l4( <0.05) 27(<0.001) 29(<0.001) 
21 26 25 
23(NS) 42( <0.005) 45( <o.005) 
30 34 32 5 5 
37 (NS) 69( <o.Dol) 74( <O.001) 6(Ns) 4(NS) 
. antibody to thyroglobulin 
antibody to thyroid cytoplasm 
antibody to gastric parietal -cell cytoplasm 
. antibody to cell nuclei 
. antibody to mitochondria 
*Figures in parentheses = statistical significance of the prevalence of the 
antibodies in subgroups of diabetics compared to that in matched controls. 
Statistical analysis by the chi -squared test. NS = not significant. 
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FIGURE 6/1 (OPPOSITE): 
Percentage prevalence of autoantibodies specific for thyro- 
globulin, thyroid cytoplasm and gastric parietal -cell 
cytoplasm in total diabetics (0------0) and controls (0- - - -i) 
according to age. The highly significant (p <0.001) differences 
in the prevalence of the latter two antibodies in diabetics are 
maintained with increasing age. 
Statistical analysis by the chi -squared test, using Yates' 
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diabetics and controls aged over sixty years. In the case of anti- 
bodies to thyroid cytoplasm and gastric parietal -cell cytoplasm, the 
differences in antibody prevalence between young diabetics and controls 
(aged less than forty years) were maintained more or less in parallel 
when the older age groups were considered. Indeed it is apparent from 
figure 6/1 that the prevalence of either antibody in young diabetics 
(aged under forty years) is already higher than the corresponding 
figures in elderly control subjects (aged over sixty years). 
Antibody to adrenal cortex was found in only two diabetics - an 
insulin- dependent male patient aged forty -two and a sixty -six year 
old female patient controlled by oral hypoglycaemics - and in none of 
one hundred and eighty matched controls. Statistical significance 
cannot be attached to these figures because of the small number of 
positive results. 
6/4b Antibo. . revalence in various diabetic sub, ou.s 
A more detailed breakdown of the distribution of thyrogastric 
antibodies in the sera of insulin -dependent and insulin- independent 
diabetics is given in table 6/4. In the case of thyroglobulin antibody, 
there was no significant difference in the prevalence of this antibody 
between the subgroups of young (under age 40) and older (age 40-69) 
diabetics, irrespective of their sex or antidiabetic therapy, and the 
matched controls. When the prevalence of this antibody in insulin - 
dependent and insulin -independent patients was directly compared, again 
there were no significant differences between these subgroups. 
In the case of antibodies to thyroid cytoplasm and gastric 
parietal -cell cytoplasm, it is apparent that the highly significant 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































accounted for by insulin- dependent patients of either sex, irrespective 
of age (p < 0.001 - 1)(0.005 in all subgroups). The differences in 
antibody prevalence between insulin -independent patients and controls 
were much less striking, only reaching weak statistical significance 
(p < 0.05) in three of the eight subgroups indicated in table 6/4. 
When the prevalence of thyroid -cell antibody in insulin- dependent and 
insulin -independent diabetics was directly compared, there was a 
significant increase in insulin- dependent females of any age (p<0.005) 
i 
but no significant differences between insulin -dependent and insulin- 
independent males. Similar significance was recorded for the differ- 
ing prevalence of gastric parietal -cell antibody in insulin- dependent 
and insulin-independent females, while the higher prevalence of this 
antibody in insulin- dependent males also reached weak statistical 
significance (p <0.05). 
6/4c Comparison of antibody prevalence in insulin- dependent diabetics 
with and without clinical microangiópathy 
The prevalence of thyrogastric antibodies in insulin- dependent 
diabetics with clinical microangiopathy is compared in table 6/5 with 
the figures in age- and sex - matched diabetics who had no clinical 
evidence of such lesions. No significant differences between the 
groups were apparent. 
Antibody prevalence as related to duration of insulin- dependent 
diabetics in these two groups is compared in table 6/6: again there 
were virtually no differences between patients with and without micro- 
angiopathy, although the prevalence of gastric parietal -cell antibody 
was marginally higher (p<0.05) in male patients with microangiopathy 
who had had the disorder for less than five years. However the number 




The distribution of .ositive tests for t o astric autoantibodies 
in insulin -dependent diabetics according to age and the .re 




Insulin -dependent diabetics* 
Angiopathy- Angiopathy+ 
f 
Aged 10-39 years: 
No. positive for antibody to: 
Thyroglobulin 8 6(NS) 
Thyroid cytoplasm 12 15(NS) 
Gastric parietal -cell cytoplasm 13 16(NS) 
Total no. of subjects 70 70 
Aged 40 -69 years: 
No. positive for antibody to: 
Thyroglobulin 10 13(NS) 
Thyroid cytoplasm 19 23(NS) 
Gastric parietal -cell cytoplasm 20 25(NS) 
Total no. of subjects 80 80 
Angiopathy+ _ 
Angiopathy- _ 
patients with clinical evidence of 
specific complications. 
patients with no clinical evidence of 
specific complications. 
(See text) 
*Figures in parentheses = statistical significance of the prevalence 
of antibodies in subgroups of diabetics with microangiopathy compared 
to that in age- and sex -matched patients without microangiopathy. 
Statistical analysis by the chi -squared test, using Yates' correction. 
NS = not significant. 
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TABLE 6/6 
The distribution of positive tests for thyrogastric autoantibodies 
in insulin -dependent diabetics accordin to duration of disease 
and the presence or absence of specific diabetic complications 
Group 
Insulin -dependent diabetics* 
Angiopathy- Angiopathy+ 
Duration of diabetes <5 years: 
No. positive for antibody to: 
Thyroglobulin 7 6(NS) 
Thyroid cytoplasm 16 12(NS) 
Gastric parietal -cell cytoplasm 15 16( 0.05) 
Total no. of subjects 73 45 
Duration of diabetes 5 -10 years: 
No. positive for antibody to: 
Thyroglobulin 8 6(NS) 
Thyroid cytoplasm 11 16(NS) 
Gastric parietal -cell cytoplasm 13 15(NS) 
Total no. of subjects 58 66 
Duration of diabetes >10 years: 
No. positive for antibody to: 
Thyroglobulin 3 7(NS) 
Thyroid cytoplasm 4 10(NS) 
Gastric parietal -cell cytoplasm 5 10(NS) 
Total no. of subjects 19 39 
Explanation as for table 6/5. 
*Figures in parentheses = statistical significance of the prevalence 
of antibodies in subgroups of diabetics with microangiopathy compared 
to that in the corresponding subgroups of patients without micro - 
angiopathy. 
Statistical analysis as for table 6/5. 
difference would not be sustained if a larger number of patients 
had been studied. 
If the data in table 6/6 is analysed vertically, i.e. with 
respect to lengthening duration of diabetes within each group, there 
is no suggestion of either an increase or decrease in antibody 
prevalence with increasing duration of clinical diabetes in patients 
with and without microangiopathy. 
6/5 Discussion of results 
The observed differences in antibody prevalence between the 
diabetic and nondiabetic populations in this study are in broad 
agreement with the findings reported by earlier investigators and 
summarised in the introduction to this thesis (section 1/4; tables 
1/5, 1/6). The overall prevalence of antibody to thyroglobulin is 
virtually identical in both groups, while there is a striking increase 
in the prevalence of antibodies to both thyroid cell cytoplasm and 
gastric parietal -cell cytoplasm in diabetic patients. A detailed 
breakdown of the distribution of these antibodies in diabetic sub- 
groups has shown clearly that thyrogastric antibodies occur far more 
commonly in insulin -dependent than insulin -independent patients and 
are especially common in women. The figures for insulin -independent 
diabetics are in contrast much closer to those for the control 
population. Antibodies which are tissue -specific rather than organ - 
specific (ANF or mitochondrial antibody) are found with equal frequency 
in diabetics and nondiabetics, and have no clinical significance out - 
with the context of connective -tissue disorders or biliary disease. 
Antibodies to adrenal cortex are found only rarely in diabetics but 




These findings are not novel but are incidental to the main 
purpose of the present study, which was designed with two specific 
objectives. The first - to examine antibody prevalence in relation 
to the duration of insulin- dependent diabetes - was prompted by the 
conclusions reached by the two groups of workers who had previously 
investigated this aspect of immunity in diabetes. Nerup and Binder 
(1973) studied autoantibodies in the sera of 132 diabetics and 128 
controls: in the subgroup of 44 patients who had been diabetic for 
more than ten years, they found a significant increase in thyrogastric 
antibody prevalence compared to the matched control subgroup. The 
increase was only weakly significant (p <0.05) but was taken as 
evidence that increasing duration of 'juvenile- onset' diabetes was 
associated with increasing autoantibody prevalence. However it is 
difficult to see how this conclusion could be sustained as the same 
authors proceeded to compare thyrogastric antibody prevalence 
directly in their subgroups of newly -diagnosed diabetics (duration 
less than one year) and longstanding diabetics (duration more than 
ten years) and found no differences between these groups. Furthermore, 
Nerup and Binder detected no differences in antibody prevalence between 
'juvenile- onset' (insulin- dependent) and 'maturity -onset' (insulin - 
independent) patients, which is in marked contrast to the findings in 
the much larger series of Ungar et al (1968) and Irvine et al (1970). 
Somewhat different results were reported by Whittingham et al (1971) 
in a series of 400 diabetics and matched controls: these authors 
described a significant decrease in thyrogastric antibody prevalence 
amongst/ 
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amongst ageing diabetics. The decrease was especially notable in 
insulin -dependent patients, predominantly women, of more than twenty 
years' standing, and Whittingham et al proffered the suggestion that 
the phenomenon was accounted for by the premature death of diabetics 
with positive thyrogastric antibodies. However no statistical 
values were offered in support of the decreasing antibody prevalence, 
which at best seemed only weakly significant. 
The present study has not confirmed the findings of Nerup and 
Binder or of Whittingham and her colleagues. On the contrary it 
was found that high prevalence of thyrogastric antibodies was 
invariably associated with insulin- dependent diabetes, and that the 
differences between diabetics and controls were quite independent of 
the age of the patients (figure 6/1; table 6/4) or the duration of 
insulin -dependent diabetes (table 6/6). The frequent possession of 
these antibodies seems to be a feature of insulin- dependent diabetes 
at the very onset of clinical disease, and any increase thereafter 
merely parallels the anticipated increase with advancing age which is 
seen in the normal population. 
The second objective was to examine any possible relationship 
between antibody status and the presence of significant microvascular 
disease in insulin- dependent diabetes. No previous study of this 
nature had been undertaken, and it was tempting to speculate that 
autoantibodies might have been found more commonly in patients with 
severe microangiopathy: the grossly abnormal basement membrane of 
affected diabetic blood vessels, coupled with ischaemic lesions in 
affected organs, might have allowed the passage into the circulation 
of material which would elicit a humoral antibody response. Again, 
if/ 
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if the findings of Whittingham et al had been sustained, the presence 
of autoantibodies might conceivably have been associated with parti- 
cularly severe microangiopathy, as a potent cause of premature death 
amongst longstanding diabetics. Neither speculation can be justified, 
however, as the results have clearly shown (tables 6/5, 6/6) that the 
presence or absence of significant (i.e. clinically detectable). 
diabetic microangiopathy is not associated with any particular increase 
or decrease in autoantibody prevalence, irrespective of the age of the 
patient or the duration of diabetes. 
In conclusion it can therefore be said that the studies presented 
in this chapter have provided further support for the belief that 
autoantibody formation is an integral part of the diathesis of insulin - 
dependent diabetes, and is independent of the age of onset, the duration 
of treatment or the specific complications of the disease. It is not 
possible to estimate how frequently the presence of antibodies in these 
patients is the precursor of overt autoimmune disease but the strong 
clinical associations of diabetes with thyroid, gastric and adrenal 
autoimmunity have already been commented upon. 




ENVIRONMENTAL AND GENETIC FACTORS IN THE POSSIBLE GENESIS 
OF AUTOIMMUNE DIABETES MELLITUS: 
SMART AND CONCLUSIONS 
7/1 Introduction 
It is believed that the studies contained in the preceding 
chapters, in which a variety of humoral and cellular autoimmune 
phenomena have been identified in certain cases of diabetes mellitus, 
lend credibility to the concept that diabetes may sometimes be a true 
organ- specific autoimmune disease. When this concept is considered, 
however, it is obligatory to examine two difficult questions. First, 
what kind of factor might trigger off an autoimmune process leading 
to endocrine pancreatic failure in a susceptible subject? Second, 
what peculiarity or defect in that subject's immune apparatus might 
make him or her susceptible to that stimulus? The answers to both 
questions are, naturally, obscure; nonetheless it is important to 
examine the available evidence which has suggested that viral infection 
may sometimes initiate the onset of diabetes in man and indicated that 
persons with a general susceptibility to autoimmune processes (including 
diabetes) may be identifiable by histocompatibility (HLA) studies. 
7/2 Viral infection and autoimmunity in diabetes mellitus 
The suggestion that viral infection might be aetiologically 
related to diabetes mellitus was apparently first offered by Harris 
(1899), based on his observation that an attack of mumps might be 
closely followed by the development of clinical diabetes. Since then 
it has been established both clinically and experimentally that viral 
infection can invade the pancreas of many animal species. The 
induction/ 
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induction of carbohydrate intolerance by viral inoculation of the 
experimental animal was first accomplished by Craighead and McLane 
(1968)/ who inoculated mice with the M variant of the encephalo- 
myocarditis (EMC) virus to produce a disease which clinically and 
pathologically resembled human, abrupt -onset diabetes with insulitis. 
Numerous subsequent investigators have since documented the ability 
of variants of the EMC virus, of group B Coxsackie viruses and of 
reovirus to induce a diabetes -like syndrome in rodents (Craighead 
and Steinke, 1971; Muntefering et al, 1971; Wellman et al, 1972; 
Coleman et al, 1973; Craighead, 1975; Notkins, 1977; Onodera et 
al, 1978; 'Mon et al, 1978; table 1/10). From these and other 
studies it has become clear that differing strains or variants of 
these viruses can cause either a diffuse pancreatitis or more 
specific lesions of the endocrine pancreas; thus the inoculation 
of the E variant of the EMC virus and Coxsackie B3 virus produce a 
generalised pancreatitis without specific insular damage or the 
development of diabetes, while the M variant of EMC virus, Coxsackie 
B4 virus and reovirus type 3 induce only a mild exocrine pancreatitis 
but a severe, rapidly -evolving insulitis which is invariable 
accompanied by diabetes. These latter, 'specific' insulitis- producing 
viruses seem to produce a typical series of pancreatic changes: 
within forty -eight hours of their inoculation, many islets show 
interstitial oedema and marginal or central necrosis of cells. On 
the third and fourth days, there is extensive and total necrosis of 
some islets, both alpha and beta cells being involved, and macro- 
phages begin to infiltrate between the islet cells at this time. 
Between the third and the fifteenth day, but most commonly after about 
a week, poorly- developed inflammatory infiltrates of the pancreas are 
seen 
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seen, and the islets are infiltrated by mononuclear round cells and 
a few polymorphs. Marked degeneration of the surviving beta cells 
is evident. The lesions are always patchy, many islets being initially 
normal on light microscopy, but latterly these ostensibly unharmed 
islets exhibit advancing beta cell degranulation. The extent of 
islet -cell damage seems to be partly dependent on the metabolic state 
of the animal at the time of inoculation; mice who have been pre- 
treated with steroids or rendered obese by gold -thi- glucose injection 
show particularly severe lesions (Craighead, 1966), suggesting that 
beta cells which are most active metabolically are also the most 
vulnerable to damage by viral invasion. Moreover, reference has 
already been made (chapter 1/6) to the fact that only certain strains 
of mice possess a genetic susceptibility to viral infection which 
results in the development of insulitis and diabetes, and that this 
susceptibility is associated with the possession by susceptible 
animals of certain immune response genes within the major (H -2) murine 
histocompatibility complex. 
In man, evidence to support a role of viral infection in the 
aetiology of diabetes has been confined to insulin -dependent (Type 1) 
diabetes, where the clinical onset of disease, with its abrupt symptoms, 
provides a convenient temporal point for the epidemiologist to relate 
to associated clinical or pathological phenomena. Indirect evidence 
to associate viral infections with the acute onset of IDDM includes 
data on seasonal variation of disease, and the association of common 
childhood viral infections with the subsequent onset of diabetes. 
The earliest epidemiological studies were those of Gamble and Taylor 
(1969) who first described an increased incidence of cases of IDII in 
Britain/ 
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Britain during the autumn and winter seasons. Several other large 
studies have subsequently confirmed these observations: for example, 
the estimated time of onset of IDDM in 2511 children living in four 
different American States followed a similar seasonal pattern (peaks 
in the late summer, early autumn, winter months) and a study of the 
onset of IDDM in 851 Australian children showed peaks of onset in 
autumn and winter months (MacMillan et al, 1977; Fleegler et al, 
1979). All these studies suffer from the common disadvantages of 
being,retrospective, depending on information from parental recall 
or clinical records and based on the assumption that there is a short 
interval between infection and onset of clinical diabetes. 
With regard to viral diseases which might be causally implicated 
in the induction of diabetes in man, the specific infections reported 
to be associated with the onset of IDDM include mumps, rubella, 
Coxsackie virus, infectious hepatitis, infectious mononucleosis and 
cytomegalovirus (Craighead, 1981). Most of these reports are based 
on observations of one or at most a few cases: the exception is the 
work of Gamble and colleagues, who correlated cases of IDDM in autumn 
and winter with the seasonal prevalence data for Coxsackie type B4 
viral infections. By retrospective serological testing, they were 
able to show that sera from IDD patients with clinical disease duration 
of less than three months contained significantly higher antibody 
titres to Coxsackie B4 than the sera of nondiabetic controls or IDDM 
with longstanding duration of disease (Gamble et al, 1969). These 
observations are interesting but require to be confirmed, preferably 
on a prospective basis, and it is curious that later studies by the 
same authors (Gamble et al, 1973) and others (Baum, 1974; Hierholzer 
anv 
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and Farris, 1974; Nelson et al, 1975; Dippe et al, 1975) apparently 
failed to show any association between Coxsackie (or other) viral 
infections and the development of IDDM in children and young persons. 
However, all these studies have suffered from the defect of assuming 
that IDDM must ensue within a reasonably short time after viral 
infection and it is quite possible that a long time interval can 
elapse betwen the initial viral insult and the ultimate destruction 
of sufficient beta cells to cause insulin deficiency. Indeed a 
lengthy time interval between infection and diabetes might be con- 
sidered to be more likely if the virus is exerting its effects by 
inducing an immunologic reaction to pancreatic islets, with a gradual 
destruction of beta cells, rather than causing a direct destructive 
intracellular infection of beta cells. Support for the hypothesis 
that a long interval may occur between the viral infection and the 
appearance of IDDM is given by the study of Sultz et al, who found an 
increased prevalence of new cases of IDDM in Erie County, New York, 
several years after the community -wide outbreak of mumps (Sultz et al, 
1975). Moreover, pancreatic cytoplasmic islet -cell antibodies have 
recently been detected in (nondiabetic) children following mumps 
infection (Helmke et al, 1980) and again this would argue that an 
immunologic process may be initiated by viral infection but may not 
lead to the rapid onset of overt IDDM. The studies which have 
indicated the value of cytoplasmic ICA as a 'marker' for the eventual 
appearance of IDDM have already been reviewed in chapter two, and it 
is worth re- emphasising that a long period of apparently normal 
carbohydrate metabolism may elapse between the detection of ICA and 
the onset of IDDM (Irvine, Gray and Steel, 1980; Gorsuch et al, 1981; 
Bottazzo/ 
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Botiazzo et al, 1981). 
The possible mechanisms whereby viral infection of the pancreas 
or other tissue could initiate immunopathological processes have 
been well reviewed by Freytag (1974). Virus invasion of the host is 
followed by two differing cell changes, according to the general 
properties of viruses: the virus either multiplies and matures in 
one cell and after cytolysis invades other cells, producing spreading 
infection, or there is a steady -state interaction in which the virus 
replicates in the host cells, leaving the host structurally intact but 
producing functional alterations within the infected cells. Either 
or both of these virally -mediated cell changes can lead to a wide 
variety of different immunological reactions which probably all have 
cytotoxic effects. In the specific context of autoimmunity, Freytag 
(1974) concludes that viral infection can give rise to: 
1. New antigenic sites in the protein of cells. 
2. Production of cell -specific antibodies and sensitised 
lymphocytes. 
3. A nonspecific acceleration of general immune responses. 
By such cellular changes, virus infection may trigger off an autonomous 
development of chronic inflammatory processes, i.e. autoimmune 
processes, even though the virus itself has already been overcome by 
the host. These mechanisms have provided at least the theoretical 
basis for a relationship between virus infection and human diabetes 
with insulitis, and this relationship has now been proven in man. 
Craighead (1974), examining histological material from infants dying 
with fully docomented Coxsackie B virus infections, found changes in 
the pancreas (fibrosis, interstitial pancreatitis, lymphocyte 
infiltration/ 
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infiltration of the islets of Langerhans) identical to those 
described by Gepts (1965) (chapter one) but did not record the 
presence of diabetes in these infected children. The extensive 
pathological study of Jenson et al (1980) examined pancreases from 
250 children with fatal infections caused by at least fourteen viruses. 
Lesions in the islets were found in four cases of Coxsackie B viral 
infection, twenty cases of cytomegalovirus and two cases each of 
varicella -zoster and congenital rubella. The cases of Coxsackie B 
infection showed beta cell destruction and acute or chronic inflam- 
matory infiltrates, similar to the observations of Craighead, while 
typical inclusion bodies were found in cases of cytomegalovirus and 
varicella -zoster (Jenson et al, 1980). 
Recently Yoon et al (1979) described the isolation of Coxsackie 
virus B4 from the pancreas of a previously healthy ten year old child 
(with a strong family history of IDDM) who was admitted in diabetic 
ketoacidosis and died of meningo -encephalitis after eight days in 
hospital. At autopsy the pancreas showed the classical changes of 
insulitis, while the virus isolated therefrom was injected into 
susceptible mice and induced diabetes with beta cell destruction 
(Yoon et al, 1979). At present this striking case has provided the 
most direct evidence for a viral aetiology of IDDM in an individual 
patient but Coxsackie B5 has been isolated from the faeces of an 
infant with viral infection who developed diabetes mellitus a few 
days later ( Champsaur et al, 1980) and a child who developed diabetes 
and died shortly after open -heart surgery was shown to have Coxsackie 
B4 antigens in her pancreatic islets (which showed insulitis) and 
high titres of B4 antibodies in her blood (Gladisch et al, 1976). 
Itl 
It is likely that further examples will be obtained by using modern 
methods of isolation and culture of viruses from human tissues. 
Clarification of a relationship between viral infection and the 
subsequent development of IDDM has been tantalisingly slow to emerge, 
despite the epidemiological and pathological studies conducted over 
the past thirteen years. Viral infections might play only a minor 
role in catalysing the genetic factors which lead to IDDM and studies 
(England and Roberts, 1981) which examine the cost effectiveness of 
antiviral immunisation to prevent IDDM are probably premature. Never- 
theless, it has been calculated that if only 15 per cent of IDDM is 
virally induced, and if a polyvalent vaccine was developed that was 
only 13 per cent effective, then vaccinating all children at the age 
of three years would be cost effective and would prevent over one 
hundred thousand cases of IDI in the U.S.A. within fifty years (England 
and Roberts, 1981). At present this kind of exercise is hypothetical, 
and must await a clearer definition of the role of viruses in IDI. 
Thus far, all that can be said is that on epidemiological and patho- 
logical grounds, virus infections are a plausible initiating cause of 
IDDM in persons who have a genetic susceptibility to the disease. 
Other environmental factors - for example, a widely used pesticide 
which is similar in structure to streptozotocin - may also be capable 
of initiating an immunologically - mediated destruction of the islet 
cells in susceptible individuals and has been implicated in the 
development of over two hundred cases of IDDM (Karam et al, 1979; see 
also chapter one, section 1/6); however, the importance of such 




7/3' Histocom.atibilit HLA anti en inm in diabetes mellitus 
If viral infection is indeed proven to be the stimulus (or one 
of several stimuli) to a series of autoimmune processes which result 
in diabetes mellitus, histocompatibility (HLA) antigen typing may 
equally prove to be a means of identifying those subjects whose 
defective immune apparatus renders them susceptible to these processes. 
The HLA chromosomal region is situated on the short arm of chromosome 
6 and represents approximately one thousandth of the total human 
genome. The genes coding for HLA antigens A, B, C, D and DR 
(D- related) occupy closely linked loci in this region, which also is 
the site for genes coding for C2 and C4 of the classical complement 
pathway and Bf of the alternative complement pathway (figure 7/1). 
The HLA system is polymorphic at each locus and there is linkage 
disequilibrium between the various loci. Linkage disequilibrium 
means that certain HLA specificities encoded by genes at the different 
linked loci occur much more frequently together on the same haplotype 
than would have been predicted on a statistical basis. For example, 
in Caucasian populations the HLA-B locus antigen B8 occurs together 
with the HLA-D locus antigen DW3 several times more frequently than 
expected. The same applies for Al and B8 or A3 and B7 in North 
European populations. 
The HLA alleles are expressed as cell surface proteins: 
HLA-A, -B and -C antigens are present on virtually all nucleated cells 
in the body and are characterised on peripheral blood lymphocytes by 
using a wide range of antisera in a complement- dependent microlympho- 
cytotoxicity test. Chemically, A, B and C antigens are two -chain 












The HLA system on chromosome 6 (short arm). The major histo- 
compatibility loci (HLA -A, -C, -B, -D and -DR) are shown in 
black. Other loci are coding for factors C2 and C4 of the 
classical complement pathway and for Bf of the alternative 
complement pathway. Approximate distances betwen the different 
loci are given in centimorgans, 0 represents the centromere. 
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and -DR antigens are much more restricted in expression and are 
found predominantly on B lymphoctes and macrophages. The former 
are detected by mixed lymphocyte culture techniques (MLC) and the 
latter by classical serological methods on separated B lymphocytes 
or by double colour immunofluorescence. Chemically, D and DR 
antigens also consist of two non -covalently bound glycosylated peptide 
chains; in passing, it can be noted that the (non enzymatic) glyco- 
sylation of these chains will be increased in poorly controlled, 
hyperglycaemic diabetics and may have fascinating implications for 
the genesis of microvascular complications in diabetes. 
The earliest study of HLA typing in diabetes was that of 
Finkelstein et al (1972), who examined a series of forty -four insulin - 
dependent patients and found no significant alteration in antigen 
frequency from that in the nondiabetic population. However this 
study is invalid as the patient population was not only small but 
racially heterogeneous (Caucasian, Mexican and Negro), and any 
alterations in antigen frequency would thus have been obscured. In 
contrast Singal and Blajchman (1973) studying an all- Caucasian popula- 
tion, found a significantly higher frequency (thirty -six per cent) of 
the antigen B15 in insulin- dependent diabetics when compared with 
non -insulin -dependent patients and controls (prevalence nine and ten 
per cent respectively). The latter study was extended in Denmark 
by Nerup et al (1974b) who reported a significantly higher frequency 
of antigen B15 and B8 in a series of one hundred and forty -six 
Caucasian diabetics, and correlated the presence of these antigens 
with the age of onset of diabetes, the weight of the patient and the 
type of antidiabetic therapy. Antigen B15 was found in both juvenile 
anda 
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and middle aged patients, but usually in association with IDDM, 
while B8 was found almost exclusively in juvenile- onset, non -obese 
IDI. Almost simultaneously a similar positive association between 
IDDM (Type 1 diabetes) and B8 /B15 was established in the U.K. diabetic 
population (Cudworth and Woodrow, 1975, 1976). Over the next few 
years, these results were confirmed and extended in multiple population 
studies: as work proceeded on HLA typing, it has emerged that DW3 -DR3 
and DW4 -DR4 represent the strongest and therefore the primary assoc- 
iations with IDDM (Christy et al, 1979; Cudworth et al, 1979). All 
the available data now indicates that the associations with HLA-B, -C 
and -A antigens and complement factors are secondary and due to linkage 
disequilibrium within the HLA system (Cudworth and Wolf, 1982). The 
prime importance of DW3, DR3 and DM in IDDM has now been demonstrated 
in populations of Japanese (Sakurami, 1982), black American (Rodey et 
al, 1979) and Mexican- American IDDM (Zeidler et al, 1982): HLA B8 
occurs rarely in all these populations and other HLA locus alleles are 
found in linkage disequilibrium with the D and DR alleles. In the 
U.K. between 80 and 95% of Caucasian IDDM populations are now found to 
possess DR3 or DR4, the relative risks associated with these factors 
being 7.39 and 9.25 respectively, while possession of both DR3 and 
DM confers a relative risk of IDDM of 14.26 (Cudworth and Wolf, 1982). 
(The term 'relative risk' is applied to the association between HLA 
and a particular disease to indicate how much more frequently the 
disease in question occurs in carriers of a particular antigen as 
compared with those lacking this antigen: relative risk denotes the 
strength but not the statistical significance of HLA and disease 
associations). To date (end of 1982) eighty -three population studies 
have/ 
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have demonstrated an increased relative risk from the development 
of ID]11 associated with HLA -B8, B15, B18, CW3, DW3, DW4, DR3 and DR4 
in Caucasians and DW3, DR3 and DR4 in the Japanese, black American 
and Mexican- American populations (Albin and Rifkin, 1982; see also 
Christy et al, 1979 and Cudworth, 1981). By contrast, one remark- 
able observation found in most (Caucasian) population studies is the 
extremely low frequency in IDBM of HLA -DR2 and B7, which are in 
linkage disequilibrium, and it has been postulated that these alleles 
may exert a 'protective' effect against the development of IDIOM 
(Ludwig et al, 1977; Christy et al, 1979; Cudworth, 1978). The 
same types of studies have confirmed beyond question that there is no 
association between NIDDM (Type 2 diabetes) and HLA factors. 
Family studies of IDDM in Caucasian populations have amply con- 
firmed the above findings and, by HLA typing both parents and all 
children in a family, have provided the opportunity to initiate genetic 
counselling by estimating relative risks in HLA- identical or haplo- 
identical siblings of an IDDM proband (Gorsuch et al, 1981; Cudworth 
and Wolf, 1982): for example, it can be demonstrated that an HLA- 
identical sibling has a 90 -times increased risk and a haplo -identical 
sibling a 37 -times increased risk of developing IDDM by the age of 
16 years. 
All the extensive population and family studies of HLA in IDDM, 
paying due regard to the patterns of linkage disequilibrium within 
HLA, have strongly suggested that genetic heterogeneity occurs within 
IDIBII. It is now possible to define two separate axes of HLA factors, 
each axis being associated with susceptibility to developing IDDM, 
and a single axis of HLA factors which confers protection from IDII 
(Cudworth/ 
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(Cudworth et al, 1978, 1980). The first susceptibility axis (or S1) 
is defined by the primary associations of DW3 -DR3 and the secondary 
associations with B8, B18 and Al. The S2 axis is constructed in the 
same fashion, DW4 and DR4 representing the primary, and B15, B40, CW3 
and A2 the secondary associations. By contrast, DW2 and DR2 represent 
the primary and B7 and A3 the secondary associations which comprise 
the HLA anis (the R axis) of significant resistance to the risk of 
developing diabetes. Indeed, the risk of developing diabetes is 
virtually zero in DW2 -DR2 subjects (Nerup et al, 1980). The most 
up to date (1982) information for each axis is presented in figure 
7/2, which takes into account the recent 'splitting' of HLA -B15 into 
two subgroups (BW62, BW63) and the subdivision of HLA -B40 into BW60 
and BW61 (Cudworth and Wolf, 1982) . 
What biological significance is there in these very striking 
associations between IDDM and the possession of certain HLA antigens, 
or indeed the 'protection' from IDDM apparently associated with other 
HLA antigens? The principle explanations to connect a disease of 
unknown cause (such as IDDM) with a genetic marker (such as HLA type) 
are ethnic stratifications, causation or association. The first 
explanation has already been negated by the population studies referred 
to above, which found the same HLA antigens associated with IDDM in 
distinctly different ethnic groups. Causation would imply HLA DR3 /DR4 
are directly involved in the initial pathogenesis of diabetes: it is 
certainly possible that these antigens could act as receptors for 
viruses or hormones, or that their presence on the membrane of the 
beta cells is necessary to activate the immune recognition system, 




DW DR BF C2 C4 B C A 
DW3 - DR3 
F I -C - A3 - BO - B I8 CW5 A 25 AW30 
S -C - AO - BI - B8 CW7 Al 
S -B -AO- B4 -BW62 
DW4 - DR4 < A4 
S -C <AO > B2 -BW60 CW3 A2 
DW2 - DR2 B7 A3 
The HLA system in relation to insulin- dependent (Type 1) diabetes 
mellitus. Two axes of HLA factors are associated with susceptibility 
and one with resistance to the development of IDDM. The first 
susceptibility axis 01) is primarily associated with DW3 -DR3 and the 
second susceptibility axis (S2) with DW4 -DR4. All the other factors 
of the Ai CI B1 C4, C2 and Bf loci are secondarily increased because 
of linkage disequilibrium within the HLA complex. The axis of 
resistance (R) is primarily associated with DW2 -DR2 with secondary 
increases in B7 and A3. 
All the above associations are only valid for Caucasian populations. 
*B15 is now subdivided into BW62 and BW63 
*B40 is now subdivided into BW60 and BW61 
Modified from Cudworth and Wolf (1982) 
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'assóciation' theory implies that HLA alleles are linked to one or 
more alleles responsible for the predisposition to develop IDIM: 
for example, that immune response genes might exist within the HLA 
system and be in linkage disequilibrium with the genes of the DR 
locus (McDevitt and Bodmer, 1974). The existence of such immune 
response (Ir) genes is established in the mouse, in which animal they 
are linked to the genes for the major murine histocompatibility 
system (the H -2 complex) (Moller, 1978); by analogy it can be 
postulated that a similar condition exists in man, and that Ir genes 
associated with the DR locus alleles confer a genetically controlled 
immune response which leads to the state of IDDM in susceptible 
individuals or protection from IDDM in resistant individuals. The 
modern evidence which has formulated the concept of genetic hetero- 
geneity within IDDM would favour the existence of two separate Ir 
genes in strong linkage disequilibrium with the S1 and S2 HLA axes, 
probably with the DR3 and DR¢ alleles (figure 7/2) and a third Ir 
gene or genes, in linkage disequilibrium with DR2, conferring protec- 
tion against development of IDI. As yet, there is no way to 
identify immune response genes in man, so the hypothesis must still 
be sub judice. However, it is intriguing to speculate that HLA 
antigens act as markers for immune response genes in analogous fashion 
to the presence of islet -cell antibodies as markers for the develop- 
ment of IDDM. Thus the possession of an HLA susceptibility axis 
confers a high risk of IDDM; the appearance of ICA in an individual 
implies that the process of immunologically -- mediated beta cell 
destruction has already started and that IDDM may ultimately ensue. 
This is certainly the kind of inference that can be drawn from the 
various 
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various studies reviewed in chapter two, where the presence of both 
'markers' was demonstrated in subjects who developed IDDM over vary- 
ing (sometimes lengthy) periods of time. The mode of action of 
these postulated immune response genes remains speculative. Possibly 
they control the immune response to environmental factors capable of 
initiating damage to the pancreatic islet beta cell membrane, e.g. 
viruses, but evidence for this will not be obtained until the Ir 
genes in man are'identified and characterised. 
is there heterogeneity of immune response within IDDM? The 
concept of two separate HLA-DR associated susceptibility genes might 
lead one to expect that there may be separate clinical associations 
between DR3 and DM with immunological or clinical aspects of the 
disease. The strong clinical associations between insulin -dependent 
diabetes and organ- specific autoimmunity have already been reviewed 
in chapter one, and it will be recalled from chapter two that HLA -B8 
has a significant positive association with idiopathic Addison's 
disease, Grave's disease, primary hypothyroidism and Hashimoto 
thyroiditis. It is difficult to believe that the association of 
HLA-B8 with so many different autoimmune diseases is coincidental. 
The evidence which indicates that HLA-B8 is associated with persistence 
of islet -cell antibodies in insulin- dependent diabetics has been 
discussed earlier (chapter two); many of these patients examined by 
Irvine et al (1977a) and Cudworth et al (1980) had coexistent overt 
autoimmune disease, while both these studies identified a similar 
group of B8- positive diabetics with polyendocrine antibodies (thyroid, 
gastric, adrenal) rather than overt disease. The clear inference to 
be drawn from all these associations is that gene(s) in the HLA 
chromosomal/ 
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chromosomal region in linkage disequilibrium with HLA-B8 may confer 
peculiar susceptibility to organ- specific autoimmunity, including an 
autoimmune form of diabetes. In other words, the HLA susceptibility 
axis for insulin- dependent diabetes which includes HLA -B8 is the axis 
which permits the development of autoimmune diabetes. Logically, one 
would expect an equally striking association between HLA DR3 and auto - 
immunity to be found in these diabetics; as noted in chapter two, 
studies of combined HLA -B and -DR typing in diabetics are sparse but 
one rcent and striking observation was the finding by Cudworth and 
Wolf (1982) that seventeen of eighteen patients with coexistent 
insulin- dependent diabetes and Grave's disease were HLA -DR3 and -B8 
positive. Naturally there was a striking female preponderance in 
these patients, many of whom have persistent islet -cell or other organ- 
specific autoantibodies. By analogy with other autoimmune diseases, 
it can be anticipated that a patient population of true autoimmune 
diabetics should contain an excess of females. 
By contrast, alleles of the second HLA axis of susceptibility to 
insulin- dependent diabetes do not seem to confer any strong association 
with autoimmunity. HLA -B15 (now subdivided into BW62 and BW63) which 
is in linkage disequilibrium with DR4, is associated with different 
immunological responses in diabetes, including increased titres of 
antibodies to exogenous insulin injections (Bertrams et al, 1976; 
Ludwigsson et al, 1977; Schernthaner et al, 1977; Irvine et al, 
1978b) and perhaps with increased titres of antibodies to Coxsackie B4 
virus (Cudworth et al, 1977). Much work needs to be done to further 
define the concept of immune heterogeneity in IDDM, and to examine 
non -Caucasian/ 
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non -Caucasian populations of IDDM (in which B8 and BW62 /BW63 are 
rare) for relationships between HLA and autoimmune or other immune 
phenomena. Some preliminary studies of this nature have been under- 
taken in Japan where the prevalence of IDDM is much lower than the 
West (West, 1978). HLA -DW3, -DR3 and -DR4 are associated with IDDM 
in Japanese, but HLA-B8 is virtually absent in this ethnic group. 
It was found that IDDM Japanese patients had a much lower prevalence 
of cytoplasmic ICA (146 within one year following diagnosis) than 
their equivalents in a Caucasian population, and that ICA did not 
persist beyond four years following diagnosis (Irvine, 1980). Clearly 
it will be important to extend these observations to other ethnic 
groups in which HLA-B8 is rare, and to see whether a presumably weak 
autoimmune component is associated with a lower prevalence of IDDM in 
such populations. 
7/4 Summary and conclusions 
In conclusion, it is appropriate to recall the criteria originally 
proposed for ' autoimmune diabetes mellitus' in the Introduction to this 
thesis (table 1/3); and it is now possible to state that an impressive 
weight of direct and indirect evidence suggests that autoimmune 
mechanisms have an important role in the aetiology of some cases of 
insulin- dependent diabetes mellitus in man. 
With regard to the indirect evidence, insulin- dependent diabetes 
is commonly associated with overt or subclinical autoimmune disease and 
may appear as part of a polyendocrine autoimmune syndrome. Organ - 
specific autoantibodies are frequently found in sera from insulin - 
dependent diabetics, directed especially against antigens in the 
thyroid or stomach, and are present to excess in the relatives of these 
patients/ 
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patients. The high prevalence of thyrogastric antibodies in insulin - 
dependent diabetes is independent of the age of onset of clinical disease, 
duration of treatment or the presence of specific diabetic complications. 
All these facts suggest that autoantibody production is an integral part 
of the diathesis of insulin- dependent diabetes. Insulin- dependent 
diabetics often possess the same HLA factors that are found in patients 
with thyroid or adrenal autoimmune disease, especially HLA -B8, and 
these HLA factors are probably linked with immune response genes which 
permit the full expression of an autoimmune response. 
With regard to the direct evidence, insulitis seems to be a 
relatively common finding in the pancreas of newly diagnosed insulin - 
dependent diabetics and has inevitably been compared with the very 
similar round -cell infiltrates found in organ -specific autoimmune disease 
affecting the adrenal, thyroid and stomach. The autoimmune analogy is 
further strengthened by the findings in human diabetes of cell- mediated 
immunity to porcine, bovine and human pancreatic antigens (chapters 
three and four) and islet -cell autoantibodies (chapter two). The 
presence of islet -cell antibodies has been documented in individuals 
with normal or mildly -impaired carbohydrate tolerance who have sub- 
sequently progressed to develop typical ketosis -prone insulin- dependent 
diabetes. All these studies lend strong credibility to the concept of 
a true autoimmune form of diabetes mellitus, which has now been shown 
to fulfil the classical criteria for the disease (close relationship 
with other autoimmune diseases, lymphocytic infiltration of the end - 
organ, circulating humoral antibody directed against the end -organ, 
circulating lymphocytes sensitised against the end -organ). For an 
external or environmental factor to initiate the autoimmune process 
in 
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in susceptible individuals, one may turn to the epidemiological 
studies suggesting an association between insulin- dependent diabetes 
and viral infections, especially mumps and Coxsackie, and the patho- 
logical evidence,which has demonstrated Coxsackie virus as a cause 
of insulitis or even of insulin- dependent diabetes in a few cases. 
At the end of 1974, shortly after the first descriptions of 
pancreatic cytoplasmic islet -cell antibody, it was possible for the 
author to review the concept of autoimmune diabetes mellitus in 
The Lancet and to summarise thus: 'it may not be too fanciful to 
propose a unifying hypothesis whereby young subjects, who have 
inherited a particular complex of immune -response genes by virtue of 
their HLA type, respond to (say) a viral infection by initiating an 
irreversible and relentless series of autoimmune processes which 
culminate in destruction of the endocrine pancreas and the develop- 
ment of clinical diabetes mellitus' (MacCuish, 1974). With hindsight, 
it can be said that the basic hypothesis may be valid but is an over- 
simplification. We now appreciate that insulin- dependent diabetes 
differs from the classical autoimmune diseases in several important 
respects. First, there is no recognised association between any 
common viral infection and the subsequent development of classical 
or organ- specific autoimmune disease. Second, the age distribution of 
IDDM is distinctly different from the classical autoimmune diseases, 
the majority of cases occurring in young persons and the minority in 
the elderly. Third, islet -cell antibody is never found in some 
patients (say 15 to 20%), is a transient phenomenon in many others 
and persists in only a minority of patients (with coexistent auto - 
immune disease). Fourth, cell- mediated antipancreatic autoimmunity, 
albeit/ 
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albeit in an assay system using unseparated leucocytes and tumour - 
derived antigen, can only be detected in about 50% of patients with 
IDDM at or shortly after the diagnosis of clinical disease. Fifth, 
there is an association of IDOM with HLA- DW4 -DR4 which is not found 
with the classical autoimmune diseases. All these facts clearly 
imply that genetic and immunological heterogeneity is a feature of 
insulin- dependent diabetes and that autoimmunity may be the dominant 
factor in only one subgroup of patients. 
Appreciation of these factors has led to a difficulty in 
incorporating all this new knowledge of aetiological factors within 
a framework which not only allows a better classification of insulin - 
dependent diabetes but also takes account of the need fór any 
classification to be both comprehensive and flexible with regard to 
the relative importance of HLA, autoimmunity, viruses, etc. in 
individual cases. The earlier classification of the WHO Expert 
Committee on diabetes mellitus (1965), which subdivided patients by 
age of onset into 'juvenile -onset diabetes' (insulin -dependent) and 
'maturity -onset diabetes' (insulin -independent) was clearly inappropriate 
and has been subjected to rigorous criticism by workers who were 
intimately involved with many of the studies referred to in this thesis. 
Cudworth (1976) first proposed removal of classification by age and 
called juvenile -onset or insulin -dependent diabetes 'Type l' to dis- 
tinguish it from 'Type 2' or maturity -onset (insulin- independent) 
diabetes. Bottazzo and Doniach (1976) used this numbering system to 
classify subtypes of insulin -dependent diabetes as 'Type la' (possibly 
due to viral infection) and 'Type lb' (possibly due to autoimmunity). 
The 
215 
The'same workers subsequently refined and amplified the features of 
this classification as further information was forthcoming from HLA 
and immunological studies (Cudworth et al, 1980; Cudworth and Wolf, 
1982), but retained the same numerical system. Irvine (1977) proposed 
a subdivision of Type 1 diabetes into three categories according to 
whether the main factor was a genetically determined diathesis towards 
islet -cell autoimmunity (Type la), towards islet cell damage by 
appropriate viral infection or other agent in the absence of islet - 
cell autoimmunity (Type lc), or a combination of the two diatheses 
(Type lb). Irvine's classification also took into account the know- 
ledge that ICA- positive diabetics could pass through a clinical phase 
of milder diabetes, controlled by oral hypoglycaemic drugs, but sub- 
sequently progressing to insulin -dependent diabetes, by classing such 
patients as Type 1 diabetics. The views of all these authorities were 
later considered at an international workshop set up by the National 
Diabetes Data Group (NDDG) of the National Institutes of Health, U.S.A., 
to develop a nomenclature and classification system for diabetes 
mellitus (NDDG, 1979). In essence, the NDDG favoured the grouping of 
all insulin- dependent patients into Type 1 diabetics (IDDM), without 
further numerical subdivision, but recognised the association of 
environmental and HLA factors and abnormal immune responses, including 
autoimmune reactions with this type of diabetes. A simplified version 
of this classification scheme was subsequently adopted by the second 
report of the WHO Expert Committee on Diabetes Mellitus (1980) and is 
now coming into general use (table 1/4). Further analysis of the 
merits of the various classifications proposed for Type 1 diabetes is 
beyond the scope of this thesis but the author would submit that it 
is/ 
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is important for any classification to recognise that the different 
aetiologic factors in Type 1 diabetes (genetic susceptibility, viral 
infections, immunological response, etc.) are likely to exert a 
spectrum of influence in individual cases rather than being confined 
to discrete subtypes. Thus in some cases a major autoimmune and 
minor environmental influence may interact, in others the environ- 
mental factor (say severe viral infection) may predominate, and so 
forth. Moreover, the influence of these factors which initiate beta 
cell damage may long predate the onset of clinical diabetes, far less 
the need for exogenous insulin injections. All these considerations 
will always make it difficult to judge the relative importance of 
different aetiologic factors in the genesis of Type 1 diabetes but it 
seems safe to suggest that autoimmune responses alone, or viral 
infection alone, will only induce diabetes in a minority of patients. 
Finally, any practical applications of the studies described and 
reviewed in this thesis remain to be discussed. It appears to the 
author that these fall into two categories. For the present, the 
,demonstration that poorly -controlled diabetes impairs immunologic 
function should encourage clinicians to achieve the best possible 
metabolic control for patients under their care; this can be aided 
by modern methods of home blood glucose monitoring and measurements 
of glycosylated proteins in diabetes. Second, the demonstration that 
islet -cell antibody is a marker for eventual insulin- dependent diabetes 
is an important observation that would have immediate clinical 
application if a standardised, reproducible antibody assay was developed 
for general hospital laboratory usage. For the future, the recogni- 
tion that a relatively slow immune- mediated destruction of the beta 
cell 
ell is taking place before the onset of insulin -dependent diabetes, 
r that viral infection may long predate the disease, offers oppor- 
unity for immune intervention at the time before beta cell damage is 
rreversible. In the present state of knowledge, current immuno- 
uppressive techniques could not be applied with safety to such 
ndividuals, but further characterisation of the pancreatic islet - 
ell antigen- antibody system might permit a rational form of immuno- 
herapy to be devised and exhibited before irreversible damage is done 
o the pancreas. The record of the past gives every reason to hope 
hat the next ten years will be marked by major advances in our under - 
tanding of the genesis of insulin- dependent diabetes mellitus and 
pso facto the appropriate means of its prevention. 
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APPENDIX I 
LABORATORY METHODS AND TECHNIQUES 
(Where not fully described in the relevant chapters) 
I/1 Buffers and reagents, etc. 
I /la Sterile phosphate buffered saline 
To one litre of distilled water, add the following chemicals (all 
obtained from British Drug Houses Ltd., 'Analar' grade): 
Potassium dihydrogen orthophosphate - 0.34 g 
Dipotassium hydrogen orthophosphate - 1.21 g 
Sodium chloride - 8.0 g 
Sterilise the solution by autoclaving at 115 °C for ten mins. 
I /lb Ficoll / Triosil preparation 
Used for the separation of human lymphocytes from whole blood by 
density centrifugation. 
Materials 
Ficoll powder (obtained from Pharmacia AB or Sigma Ltd). 
Triosil '75' - 75% solution (obtained from Glaxo Ltd). 
Method 
Dissolve 9.557 g Ficoll in 80 ml distilled water. 
Add 20 ml (i ampoule) Triosil. 
Add water until specific gravity of solution is 1.076 -1.078 at room 
temperature. 
Sterilise by autoclaving at 115 °C for ten minutes. 
Store in dark, in coldroom or refrigerator. Do not freeze. 
Bring to room temperature before use. 
I /lc Eagle's 
I /lc Eagles Basal Medium (Ern) 
Used for the in vitro cultivation of human cells, with serum added 



















mg /litre Vitamins mg/litre 
21.0 aneurine 1.0 
12.0 choline 1.0 
9.5 folic acid 1.0 
52.0 inositol 2.0 
52.0 nicotinamide 1.0 
33.0 pant othenat e 1.0 
48.0 pyridoxal 1.0 
8.0 d- biotin 1.0 
18.0 riboflavin 0.1 
47.0 
mg /litre Miscellaneous mg /litre 
6800 glucose 1000 
400 1- glutamine 292 
200 phenol red 10 
200 NaHCO3 1100 
150 
EBM is conveniently obtained from Wellcome Reagents Ltd. (Catalogue 
TC30) as a sterile working solution with added antibiotics (penicillin 
2 x 105 units /litre, streptomycin 1 x 105 }tg ¡litre. 
I/2 Indirect immunofluorescence technique for antibody detection. 
This technique, which was first introduced by Coons et alp 
employs/ 
employs an antibody labelled with a fluorescent dye to locate the 
complementary antigen in microscopic preparations. The site of the 
antigen:antibody interaction is localised by fluorescence microscopy 
(e.g. thesis, figure 5/1). In this way fluorescein -labelled class 
specific antibodies to human IgG, IgM and IgA are used to demonstrate 
the presence and define the class of human immunoglobulin synthesised 
within cells or fixed on to cell surfaces. 
In the studies described in this thesis, the indirect immuno- 
fluorescence technique has been used to identify circulating auto- 
antibodies against thyroid cell cytoplasm, gastric parietal -cell 
cytoplasm, adrenal cortex, pancreatic islet -cell, cell nuclei (ANF) 
and mitochondria. 
Method 
1. Snap- frozen blocks of the required tissue substrate (thyroid, 
kidney, etc.) are cut into thin (approx. 5 micron) sections in a 
cryostat at -20 °C. The sections are transferred onto clean glass 
slides (76 x 25 mm, thickness 0.8 -1.0 mm) and allowed to air -dry at 
room temperature. 
2. ' The sera for testing are removed from storage in a deep -freeze 
and thawed in a water bath at a temperature of 34 -37 °C. This temper- 
ature range allows rapid thawing and does least damage to the immuno- 
globulins. 
3. The prepared slides are placed in Shandon trays, moistened with 
a small amount of veronal buffer. 
4. Each test serum sample is mixed by gently inverting two or three 
times. A generous aliquot of each sample is applied to the appropriate 
slide using a platinum loop. The loop is flamed to sterilise between 
each/ 
each serum sample. 
5. When all the test sera have been applied to the appropriate 
sections, the slides are allowed to incubate for thirty minutes. 
6. At the end of this time, the sections are thoroughly washed 
by dipping the slides in veronal buffer (pH 7.2) in a Coplin jar; 
thereafter the slides are placed in a washing bath containing the 
same buffer and washed for twenty minutes. 
7. The slides are then transferred to a fresh bath of veronal 
buffer for a further fifteen -minute wash. 
8. Each slide is then removed separately from the washing bath 
and dried, leaving only the section in a pool of veronal buffer. 
9. Using the plantinum loop, one drop of the required antihuman 
Ig- fluorescein conjugate is applied to each slide, in sufficient 
quantity to cover the entire section. The fluorescent- labelled 
antibodies are all obtained from Wellcome Reagents Ltd., and the 
following classes are available: anti -human Igo (Reference MF 03); 
anti -human Igñi (Reference MF 04); anti -human IgA (Reference MF 05). 
A polyvalent conjugate (anti -human IgG, IgM, IgA) is also available 
(Reference MF 01). Many circulating autoantibodies are of IgG 
class (e.g. thyroid /gastric microsomal, pancreatic islet -cell). 
10. The sections are allowed to incubate with the labelled antibody, 
in Shandon trays, for twenty minutes. 
11. At the end of this time, the sections are washed as before by 
dipping the slides in a Coplin jar of veronal buffer before being 
washed for twenty minutes in the same buffer. 
12. The slides are then transferred to a fresh bath of veronal 
buffer for a further fifteen -- minute wash. 
13/ 
13. The slides are finally removed from the washing bath, dried as 
before (i.e. without damaging the section), and the sections are 
mounted using 10% glycerol and 22 x 22 mm Chance No 0 coverslìps. 
14. The prepared slides are left to air -dry. Thereafter they are 
examined with a u.v. microscope for evidence of fluorescence. 
I/3 Tanned cell ha,emagglutination test for thyroglobulin antibody 
This test is used for the quantitative measurement of auto- 
antibodies to human thyroglobulin. Thyroglobulin is extracted from 
human thyroid by classical salt precipitation techniques and coupled 
to sheep red cells: if these coated cells are incubated in the 
presence of antibody -containing serum they are agglutinated, yielding 
an even carpet of cells at the bottom of a tube or perspex cup. Lack 
of agglutination (i.e. with antibody - negative serum) is indicated by 
the cells settling into a tight button. 
Longterm stability of the tanned coated cells used in the test 
is achieved by formalisation of the final suspension. As a proportion 
of human sera contain heterophile antibodies capable of agglutinating 
sheep cells, control tanned sera (uncoated with thyroglobulin) are 
also used to test each serum. 
Reagent s 
1. Thyroglobulin Haemagglutination Test Kit (Wellcome Reagents Ltd., 
Catalogue No. AD 02). Contains 35 ml 1$ suspension of formalised? 
tanned sheep red blood cells coated with human thyroglobulin in a 
borate buffer? and an identical quantity of a suspension of uncoated 
tanned red cells. 
'2. .Normal saline (0.85ó solution). 
3/ 
3. A positive control human serum (containing thyroglobulin anti- 
body in a titre of at least 1:2500) and a negative control human 
serum. 
Apparatus 
1. Test tubes (3" xi" pyrex) and metal test -tube rack. 
2. Oxford or Eppendorf 100 microlitre pipette with disposable 
plastic tips. 
3. Graduated pipette (10 ml) for addition of saline to wells, and 
1 ml gi.aduated pipette. 
4. Agglutination trays (WHO perspex plates). 
Method 
1. Pipette 0.1 ml of each serum sample (including the positive 
control of known titre) into a pyrex test tube. 
2. To each test tube add 0.4 ml control cells from the Wellcome 
kit. 
3. Mix well, allow to stand an the bench for 15 minutes, then centri- 
fuge for 10 minutes at 2000 rpm. The supernatant after centrifugation 
(i.e. a 1:5 dilution of serum free from sheep cell agglutinins) is used 
for the test. 
4. Into each row of the WHO plate (which contains 8 rows of wells, 
10 wells per row) pipette 0.1 ml volumes of the following serum 
dilutions: 
1/5; 1/25; 1/250; 1/25000; 1/250000; 1/2500000; and 1/5 
(for the control well). 
5. Add 0.1 ml of thyroglobulin sensitised (coated) cells to each of 
the first seven wells and 0.1 ml control (uncoated) cells to cup eight. 
6. Mix cells and sera by very gentle shaking, cover with a glass 
plate/ 
plate and allow to stand undisturbed at room temperature for at 
least six hours (preferably overnight) before reading. 
Results 
The thyroglobulin titre in a test serum is the highest dilution 
at which all the cells form a diffuse carpet over the bottom of the 
well. A negative test appears as a small circle, or compact button 
of cells, at all dilutions. 
The control well (well eight) must always give a clear -cut 
negative result. If this well shows agglutination, the test serum 
must be reabsorbed and then retested. 
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Using an indirect immunofíuorescence 
Summary technique, circulating antibodies to 
;ncreatic islet cells were found in the sera of.S.patients 
eth insulin -dependent diabetes mellitus and coexist - 
ct autoimmunity. All these patients had at least 
ae major overt autoimmune disease, and all had a 
piety of organ- specific antibodies in the serum_ In 
,th case the islet -cell antibody was of IgG class. 
these findings provide further direct evidence to 
apport the hypothesis of an autoimmune form of 
5betes mellitus. 
Introduction 
CONSIDERABLE interest has lately been expressed in 
x possibility that autoimmunity may have some 
tiological role in a proportion of cases of juvenile- 
tat diabetes mellitus: Indirect evidence to support 
WI a hypothesis has been provided by observation 
tthe clinical association between diabetes and other 
Stases of established or putative autoimmune 
i. 
ology (pernicious anæmia,t = thyrotoxicosis,a` 
Shimoto thyroiditis,'4 primary hypothyroidism," 
opathic Addison's disease," idiopathic hypopara- 
rtoidism,' 10 and myasthenia gravis tt).. Similarly, 
eological studies have confirmed an excess preva- 
xe of humoral organ- specific autoantibodies in dia- 
dies when compared with age and sex matched non- 
Attic populations- -e.g., circulating antibodies to 
roid and gastric parietal cytoplasm are found two 
Vfour times more frequently in diabetics than non - 
lbetjcs,2u.0 the prevalence of antibodies to intrinsic 
aor is increased at least fourfold in diabetics over 
it in matched control populations,t2 and the preva- 
ce of adrenal antibodies, which are rare in the 
rice of idiopathic Addison's disease, has been esti- 
ed to be over thirty times higher in diabetic than 
iabetic populations.'" In all cases the excess 
body prevalence is mainly associated with female 
;;insulin dependency, and juvenile -onset diabetes. 
Bore direct evidence in support of an autoimmune 
bthesis has been obtained from in -vitro studies of 
cellular immunity in diabetes; antipancreatic cellular 
hypersensitivity has been demonstrated by the leuco- 
cyte-migration technique in approximately 30 % of 
diabetics -mainly recently diagnosed insulin- depen- 
dent patients 1547-and blastogenic transformation of 
lymphocytes from untreated or newly-diagnosed dia-. 
betics has been induced by prolonged culture of these 
cells in the presence of insulin or insulin -B -chain 
antigens .0 These and other in -vitro studies indicate 
the existence in diabetics of lymphocyte subpopula- 
tions, presumably T lymphocytes, sensitised against 
antigens of the endocrine pancreas or its secretions. 
Direct evidence comes from the pathological finding 
of " insulitis " ( lymphocytic infiltration of the islets 
of Langerhans) in the pancreas in untreated young 
diabetics who died shortly after the onset of their 
disease,'" although this lesion is not accompanied by 
the plasma -cell infiltration and lymphoid -follicle for- 
mation that is regarded as typical of the accepted 
organ -specific autoimmune diseases 
One major difficulty in applying the autoimmune 
hypothesis to diabetes mellitus has been the failure 
- to find humoral autoantibodies, directed against the 
endocrine pancreas, in sera of diabetics. Early investi- 
gators, using hæmagglutination, gel diffusion, and pre - 
cipitin techniques,21.22 claimed to find antipancreatic 
antibodies in the sera of many of the diabetics they 
tested, as well as in other forms of chronic pancreatic 
disease. However, these results were not confirmed," 
and were probably artefacts. We have previously 
searched with an immunofluorescent technique for 
such an antibody in sera from several hundred dia- 
betics, of all clinical types, without success,2.24 and 
others 2S28 have had a similar experience. However, 
we can now describe the detection of circulating anti- 
bodies against the islets of Langerhans in sera from a 
number of patients in whom insulin -dependent dia- 
betes coexisted with idiopathic Addison's disease and 
other autoimmune disorders 
Patients and Methods 
Patients 
Sera from the following groups of patients and controls 
were tested for islet -cell antibodies: 
(A) 20 juvenile -onset insulin- dependent diabetics with co-. 
existent Addison's disease. All had circulating adrenal anti- 
bodies and all but 2 were women. Apart from adrenal failure, 
9 had one or more additional autoimmune disease (thyrotoxi 
coals, Hashimoto thyroiditis, primary hypothyroidism, perni- 
cious anatnia, and premature ovarian failure), accompanied by 
the appropriate circulating antibodies. 
(B) 20 juvenile -onset insulin -dependent diabetics with dr- 
7896 cc 
1530 
culating thyroid and /or gastric parietal cytoplasmic antibodies, 
but no evidence of overt autnimmune disease_ These patients 
were matched as closely as possible for age, sex, and duration 
of diabetes with the patients in group A. 
(C) 25 juvenile -onset insulin -dependent diabetics with no 
organ -specific antibodies in the serum. 
(D) 40 non-diabetic controls with no organ -specific anti- 
bodies in the serum. 
Detection of Islet -cell Antibodies 
Fresh human pancreas was used as the tissue substrate 
for these experiments. The tissue was snap frozen im- 
mediately after removal, stored in small blocks at -40° C, 
and cut as required into thin (5-7 pro.) sections on _a 
cryostat. All tests were performed on air -dried, unfixed 
sections. Islet -cell antibodies were detected by the indirect 
immunofluorescence technique, using antihuman IgG 
fluorescein- isothiocyanate (F.T.c.) conjugate (Wellcome) at 
a 1/14 dilution. All sera were initially tested undiluted, 
but those giving positive results were subsequently retested 
in serial dilutions to establish the antibody titres. Positive 
sera were further tested with anti-IgA and anti -IgM con- 
jugates to ascertain the immunoglobulin class of the 
antibodies. Experiments were also undertaken to confirm 
that the fluorescence observed with anti-IgG conjugate 
could be abolished by pretreatment of the pancreatic 
sections with unlabelled anti -human IgG. 
Other Auromltibody Studies 
Using techniques previously described,2 all sera were 
tested for antibodies to thyroglobulin, thyroid cytoplasm, 
gastric parietal cytoplasm, cell nuclei, and mitochondria 
In addition sera from patients in group A with premature 
ovarian failure were examined 22 for antibodies reactive 
with extra- adrenal steroid -producing cells (ovary, testis, 
and placenta), and those with pernicious an mia were 
examined for intrinsic- factor antibodies? 
Results 
Islet -cell Antibodies 
Cytoplasmic immunofluorescence of the pancreatic 
islets was detected in 5 of the 105 sera tested, all from 
patients in group A (table L). In each case the fluores- 
cence seemed to involve the islet cells diffusely, being 
present in a and S cells in addition to ß cells. 
Immunofluorescence was detected using undiluted 
serum only in 1 case, the antibody titre ranging from 
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TABLE I- ISLET -CFI t ANTIBODIES DETEl.1 iJ BY L', a uNOFLUOR- 
ESCENCE IN DIABETIC PATIENTS 
Group Patients tested 
Islet -cell antibody 
Positive Negative 
A Diabetic with Addison's disease 5 15 
B Diabetic with thyrogastric antibodies o 20 
C Diabetic with negative autoanti- 
bodies .. .. o 25 
D Non-diabetic with negative auto- 
antibodies .. . . o 40 
Total .. 5 100 
1/4 to 1/128 in the other 4 sera (table u). Some 
variation in the intensity of fluorescence within indi- 
vidual islet cells was observed with the two strongest 
sera, but in all cases the islets stood out brightly from 
surrounding exocrine tissue. In each serum the anti- 
body was shown to be of IgG class, immunofluores- 
cence being negative with anti -IgA and anti -IgM 
conjugates, and it was also possible to abolish the 
fluorescence by pretreatment of the pancreatic sections 
with unlabelled anti -IgG. With negative sera the 
pattern of fluorescence was entirely different; the 
islets either merged with exocrine tissue or were only 
distinguished with difficulty, and any fluorescence ob- 
served was either an orange -pink autofluorescence or 
occasional faint cytoplasmic fluorescence_ sporadically 
distributed in both endocrine and exocrine tissue. 
Other Autoimmune Lesions in Patients with Islet -cell 
Antibodies 
The clinical and serological findings in the 5 cases 
with islet -cell antibodies are presented in table II. As 
stated, all were diabetics with idiopathic Addison's 
disease and 4 had additional overt autoimmune disease 
or diseases. The 3 patients with premature ovarian 
failure had a multiplicity of steroid -cell antibodies 
reacting with different antigens in ovary, placenta, 
and testis, typical of the serological findings in this 
polyendocrine syndrome? 
Discussion 
We have detected an antibody to pancreatic islet 














(tine) T.4 G.P.C. 
I.r. 
(titre) A.N.A. 
MiID Ovary PLaeeata Testis 
44 F Thyrotoxicosis, 22 128 4 _ - - i - - - + + -I- 
diabetes mellitus, 30 
Addison's disease, 36 
amenorrhoea 36 
43 F Amenorrha-a, 28 64 8 250 + T 94 - - + + + 
. pernicious an>mia, 33 u /rl. 
primary hypothyroidism, 40 
Addison's disease_, 40 
diabetes mellitus 43 
33 F Hashimoto thyroiditis, 29 8 16 25,000 + T - - - N.T. N.T. N.T. 
Addison's disease, 29 
diabetes mellitus 31 
32 F Diabetes mellitus, 26 4 8 - - - - - - N.T. N.T. N.T. 
Addison's disease 31 
45 F Oligomenorrhoa, 30 Undiluted + - + - + - 
primary hypothyroidism, 31 saurñ 
diabetes mellitus, 44 only 
Addison's disease 45 
Thg = antibodies to thyroglobulin. T.C_ =antibodies to thyroid cell G.P.C. = antibodies to gastric parietal cell. 1-F..--antibodies to intrinsic factor. 
A.N.A. =antibodies to cell nuclei. Mito =antibodies to mitochondria. -I- =antibody present, titre not determined. -= antibody not present. 
N.T. =serum not tested for antibody. 
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cell by immunofluorescence in 5 out of 20 insulin- 
dependent diabetics with coexistent Addison's disease 
whose sera we have studied so far. Earlier attempts, 
including our own,'-24 -26 may have failed because sera 
from diabetics with overt autoimmune disease of other 
organs were deliberately excluded while sera from 
patients with maturity -onset diabetes, in which an 
autoimmune mtiology is unlikely, were included. Our 
findings suggest that islet -cell antibody cannot be 
found in diabetics whose serum contains no other 
antibodies or even in those who merely possess 
circulating thyrogastric or other antibodies, but is 
confined to patients with one or more major overt 
autoimmune diseases, in addition to diabetes mellitus. 
We have not yet examined sera from insulin- 
independent diabetics with autoimmune disease for 
the presence of islet -cell antibody, and it is important 
to consider whether the presence of such antibodies 
is related to previous insulin therapy. This seems 
most unlikely since the antibody was not detected in 
insulin- dependent patients who did not have overt 
autoimmune disease, and the pattern of islet -cell 
fluorescence with positive sera was completely differ- 
ent from that previously reported 29 (but not subse- 
quently confirmed) for insulin antibodies. 
Further studies are needed to confirm the organ- 
specificity of islet -cell antibody and to characterise the 
nature and location of the antigen(s) against which it 
is directed. It is too early to speculate on a role for 
such antibodies in the mtiology of diabetes, although it 
is tempting to postulate that their -. presence may be 
associated with the insulitis seen in some cases of 
juvenile -onset diabetes. An accurate estimate of the 
frequency of islet -cell antibody will not be possible 
until larger numbers of sera from diabetics with auto - 
immune disease, and indeed from non -diabetics with 
autoimmune disease, have been tested. However, it 
1I seems reasonable to conclude that islet -cell antibodies 
'I are uncommon in diabetics, that they probably occur 
only in patients with overt autoimmunity, but that 
their existence may provide further direct evidence to 
strengthen the concept of " autoimmune diabetes 
mellitus ". 
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Addendum 
G. F. Bottazzo, A. Florin- Christensen, and D. 
Doniach (Lancet, 1974, ii, 1279) have lately reponed 
the detection of antibodies to pancreatic islet cells in 
the sera of 13 patients with multiendocrine deficiencies 
associated with organ- specific immunity. 10 were 
diabetic. 
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Autoimmune Diabetes Mellitus 
HORMONE- PRODUCING tissue seems peculiarly vul- 
;cable to assault by autoimmune disease mech- 
¡sms, and it is understandable that an mtiological 
* for autoimmunity should be sought in an 
docrinopathy as common as diabetes mellitus. 
e evidence suggesting an autoimmune basis for 
main types of diabetes has been marshalled from 
eral sources. Firstly, there are the clinical obser- 
'ons that diabetes coexists with overt autoimmunity 
often than can be accounted forjby chance. 
yrogastric autoimmune diseases such as pernicious 
x,12 thyrotoxicosis,3 Hashimoto thyroiditis,4 
Ind primary hypothyroidism 5,8 are all said to be 
xountered with increased frequency in diabetics 
indeed in their first- degree relatives.2 The most 
essive example is idiopathic Addison's disease 
oimmune adrenalitis), in which the prevalence of 
diabetes is around 14% 7 -i.e., about six times 
er than in background population. Diabetes may 
t with multiple autoimmune disorders, notably 
combination of adrenalitis and thyroiditis 
'dt's syndrome 5), and may appear in the rare 
'al endocrinopathies.8 
These clinical observations are complemented 
largely confirmed by work on circulating organ - 
cáfic humoral autoantibodies. Most investigators 
zrd a twofold to fourfold increase in the prevalence 
thyrogastric cytoplasmic antibodies in diabetic 
1,2,9 intrinsic -factor antibody occurs with similar 
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frequency,1'2 and adrenal antibody may be thirty 
times more common in diabetic than in nondiabetic 
populations? As with overt autoimmune diseases, 
excess antibody prevalence is particularly associated 
with insulin- dependent juvenile -onset diabetes, pre- 
dominantly in women, and sera from the first- degree 
relatives of these diabetics show a similar antibody 
excess.10 Further genetic evidence to link diabetes 
with autoimmunity has been derived from studies 
ofhistocompatibility -antigen (HL -A) typing: HL -AB 
is so frequent in juvenile -onset insulin- taking dia- 
betics that it has been proposed as a genetic marker 
for the disease,11 and the same antigen has been 
detected with similar frequency in thyrotoxicosis 12 
and idiopathic Addison's disease.13 Complexes like 
HL -A carry not only the genes controlling 
serologically detectable antigens but also immune, 
response (Ir) genes which control the development 
of cell -mediated immunity to certain antigens, and 
it is intriguing to speculate that the Ir genes associated 
with HL -A8 are those which permit the full expres- 
sion of an autoimmune response, irrespective of the 
stimulus which elicits this response. 
Direct evidence for the autoimmune hypothesis 
comes mainly from work on pancreatic abnormalities 
and on cell -mediated immunity in diabetes. Lympho- 
cytic infiltration of the islets of Langerhans in the 
pancreases of young diabetics was first recognised 
by SCHMIDT in 1902,14 but this lesion, termed 
insulitis by vox MEYENBURG,15 was thought to be 
extremely rare until it was detected by GEPTS 16 in 15 
of 22 patients who died of acute diabetes. The 
pancreases examined by GEPTS were all removed 
from patients aged under thirty who had died less 
than six months after the onset of diabetic symptoms 
and . who were mostly untreated before death. 
Insulitis in this selected group has come to be 
regarded as a common lesion, although its exact fre- 
quency is a matter of conjecture 11 and the advent of 
insulin treatment makes it unlikely that any modern 
pathologist will now see enough material to arrive 
at an accurate figure. - What does seem certain is 
that insulitis is a transient lesion that has never been 
found in juvenile diabetics who died more than a year 
after the onset of symptoms.18"17 The temptation 
to compare insulitis with the end -organ changes 
( adrenalitis, thyroiditis) in accepted autoimmune 
disease is strong, and the belief that this lesion may 
also have an immune basis is supported by experi- 
10. Nissley, S. P., Drash, A. L., Blizzard, R. M., Sperling, M., Childs, 
B. Diabetes, 1973, 22, 63. 
11. Nerup, J., Platz, P., Andersen, O. 0., Christy, M., Lyngsec, J., 
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mental data: RENOLD et al.18 induced a true auto- 
immune insulitis by injecting cattle with homologous 
insulin, and a particularly striking model of experi- 
mental autoimmune diabetes has lately been described 
by NEIZtrn et al.19 who found that injection of homo- 
logous endocrine pancreas suspensions in rodents 
was followed by the appearance of insulitis, anti - 
pancreatic ' cellular hypersensitivity, and carbo- 
hydrate, intolerance. There are, however, equally 
powerful epidemiological 20 and experimental 21 
grounds for believing that insulitis in human diabetes 
may be due to viral infection of the endocrine 
pancreas, possibly with group -B Coxsackie or other 
common viruses; conceivably the real solution to the 
question of what causes insulitis is that the immuno- 
logical and viral hypotheses are not mutually exclu- 
sive, and that virus infection in man can serve as 
the mediator to trigger a series of immunological 
reactions which result in insulitis. 
Investigations of lymphocyte function provide the 
fourth support for the hypothesis of autoimmune 
diabetes. The absolute numbers of circulating T and 
B lymphocytes in diabetics are normal,22 but a 
proportion of these cells (presumably T cells) can 
be shown in vitro to be sensitised against antigens 
derived from the substance or the hormones of the 
endocrine pancreas. The leucocyte- migration test 
(L.M.T.) was first used by NERUP et al.23 to detect 
antipancreatic cellular hypersensitivity in human 
diabetes, the antigen -being an extract of porcine 
pancreas, and the results were confirmed by the 
same 24 and other 25 investigators using antigens of 
bovine and human pancreas, respectively. These 
three investigations indicate that antipancreatic 
cellular hypersensitivity (to an antigen which is 
organ- specific but species- non -specific) can be 
displayed in between 20% and 30% of diabetics, 
almost all of whom have the juvenile -onset insulin- 
dependent type of disease. The phenomenon is 
present in both treated and untreated diabetics and 
is thus not due to exogenous -insulin therapy. The 
corollary to the studies with the L.M.T., which used 
particulate antigens, is provided by the demonstra- 
tion 26 that soluble antigen (insulin or insulin -B- 
chain) can induce blastogenesis of cultured small 
lymphocytes from young untreated and newly 
diagnosed patients. But despite these findings there 
18. Renold, A. E., Soeldner, J. S., Steinke, J. Ciba Foundation Calla- 
. quiunt (edited by M. P. Cameron and M. O'Connor); vol. 15, p. 12. 
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22. MacCuish, A. C., Urbaniak, S. J., Campbell, C. J., Duncan, L. J. P., 
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is still .a natural reluctance to accept the entity 
of autoimmune diabetes in the absence of any evid- 
ence of B -cell sensitisation -i.e., the presence in 
diabetic serum of a humoral autoantibody directed 
against the endocrine pancreas. Previous extensive 
searches for such an immunoglobulin had proved 
quite fruitless 2,27,28 and it was assumed not to exist; 
now, however, comes evidence from London zs 
and Edinburgh (p. 1529) that antipancreatic 
antibody can indeed be found in diabetes- provided 
one looks in the right place, as it were.' The combined 
results of BorrAzzo et al.29 and of MACCuisH and his 
co-workers this week indicate that this newest antibody 
is very similar to its counterparts in autoimmune 
disease; it is detectable by immunofluorescence; it 
is an immunoglobulin of IgG class; it fixes comple- 
ment; and it probably shares the other properties 
common to the thyrogastric autoimmune systems, 
The antibody can be found in patients who have never 
received insulin and is directed against all cell -types 
in the islets of Langerhans, the exocrine pancreas 
being uninvolved. Thus far, islet -cell antibody has 
been detected only in association with overt auto- 
immunity, almost exclusively in insulin- dependent 
patients in whom diabetes coexists with single or 
polyglandular autoimmune disease. The simple 
explanation for the previous failure to detect 
this antibody is that the earlier searchers examined 
sera from unelected diabetics or deliberately ex- 
cluded diabetics with overt autoimmunity.2,27,28 
It will now be necessary to characterise the precise 
properties of islet -cell antibody, to determine the 
nature of the antigens against which it is directed, 
and to estimate its prevalence in the diabetic popula- 
tion. - However, . its discovery has two immediate 
implications: firstly, it lends strong credence to the 
concept of a true autoimmune form of diabetes 
mellitus, which now fulfils most of the classic 
criteria (close relationship with other autoimmune 
diseases, lymphocytic infiltration of the end -organ, 
circulating lymphocytes sensitised to the end -organ, 
circulating humoral antibody directed _ against the 
end- organ). Secondly, islet -cell antibody may prove 
a convenient rapid marker for identifying autoimmune 
diabetes, the patients thus identified being subse- 
quently examined by other immunological tech - 
niques. The factors which initiate autoimmune 
diabetes remain as obscure as ever, but, having 
regard to all the available evidence, it may not too be 
fanciful to propose a unifying hypothesis whereby 
young subjects, who have inherited a particular 
complex of immune- response genes by virtue of their 
HL -A type, respond to (say) a viral infection by 
initiating an irreversible and relentless series of 
autoimmune processes which culminate in d struc- 
tion of the endocrine pancreas and the development 
of clinical diabetes mellitus. 
4 
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Cell -mediated Immunity to Human Pancreas 
in Diabetes ellitus 
A. C. MacCuish, M.R.C.P., Jennifer Jordan, A.I.M.L.T., 
C. J. Campbell, M.R.C.P., L. J. P. Duncan, F.R.C.P., and W. J. Irvine, F.R.C.P., 
Edinburgh, Scotland 
SUMMARY 
Cellular hypersensitivity to an extract of human pancreas, using 
the leucocyte migration test (LMT), was found in twenty -nine of 
101 diabetic and eight of fifty normal control subjects. However, the 
difference in response between diabetics and controls was confined 
to young insulin -dependent patients, there being no distinction be- 
tween normal subjects and older diabetics treated by diet or oral 
hypoglycemic agents. The use of rat liver mitochondria and bovine 
insulin as antigens in the LMT did not induce inhibition of leuco- 
cyte migration in diabetics or controls. DIABETES 23:693 -97, Au- 
gust, 1974. 
Immune phenomena in diabetes mellitus have re- 
cently been studied by in vitro tests of cell- mediated 
immunologic function to detect an antigen- sensitized 
population of lymphocytes. Thus Federlin et al.1,2 
showed that lymphocytes from diabetics allergic to 
insulin were transformed to blast cells when exposed 
to purified bovine insulin antigen. Other inves- 
tigators, using the leucocyte migration test (LMT),3 
have suggested that autoimmune mechanisms may be 
present in diabetics by demonstrating migration in- 
hibition of diabetic leucocytes when exposed to an- 
tigens derived from duct -ligated porcine pancreas" 
and fetal calf pancreas.'° Attempts to inhibit migra- 
tion by using insulin alone as antigen have so far been 
unsuccessful.'° Migration inhibition in diabetics has 
also been reported using human and rat liver 
mitochondria;7 these antigens can, however, only be 
considered as general nonspecific "markers" of au- 
From the Departments of Endocrinology and Diabetes, Royal 
Infirmary; Immunology Laboratories, Forrest Road; Department 
ofTherapeutics, University of Edinburgh, Edinburgh. 
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toimmune disease since inhibition of leucocyte migra- 
tion to liver mitochondria is commonly present in pa- 
tients with Hashimoto's thyroiditis'° and pernicious 
anemia'10 as well as in primary biliary cirrhosis.' 
The present study extends these observations by (1) 
assessing the effect of an antigen derived from human 
pancreas on leucocyte migration in diabetics and con- 
trols and (2) comparing the results with those ob- 
tained using rat liver mitochondria and bovine insulin 
as antigens. 
PATIENTS AND METHODS 
Patients. One hundred and one diabetic and fifty -six 
control subjects were studied and were classified as 
follows: 
Young diabetics. These were thirty -one insulin - 
dependent diabetics: eighteen women and thirteen 
men aged eighteen to forty -two years (mean 28.5) and 
insulin treated for between one and nineteen years 
(mean 7.4). 
Young controls. These were twenty -seven healthy 
nondiabetic volunteers who were selected to allow 
statistical comparisons with the young diabetics. Fif- 
teen were women and twelve men aged eighteen to 
forty -two years (mean 28.6). 
Older diabetics on oral hypoglycemic agents (OHA). 
There were thirty -four diabetics diagnosed at age forty 
years or more who were controlled by dietary restric- 
tion plus a sulfonylurea. Twenty were women and 
fourteen men aged forty -five to seventy years (mean 
59.7). 
Older diet - treated diabetics. These thirty -six patients 
were controlled by simple carbohydrate restriction 
only; twenty -one were women and fifteen men aged 
forty -six to sixty -nine years (mean 60.5). 
AUGUST, 1974 693 
CELL -MEDIATED IMMUNITY TO HUMAN PANCREAS IN DIABETES MELLITUS 
Older controls. Twenty -three healthy nondiabetic 
volunteers were studied, selected by sex (thirteen 
women and ten men) and age (range forty -eight to 
sixty -nine, mean 57.4 years), to allow valid statistical 
comparison with the previous two groups. 
Positive reactors. This small group, included to 
check the potency of the mitochondrial preparation, 
consisted of one patient with primary biliary cirrhosis 
and five with Hashimoto's thyroiditis, known to show 
inhibition of leucocyte migration when previously 
tested.' 
All the diabetics regularly attended the Diabetic 
Department as outpatients and when blood was taken 
for study, were well controlled and free of infection. 
Control subjects were healthy volunteers, with the 
exception of the positive reactors. 
Antigens 
Human pancreas was obtained immediately after 
death from a previously healthy young man who sus- 
tained fatal head injuries in an automobile accident 
and whose kidneys were used for transplant. The fresh 
pancreas was cut into small pieces, homogenized in 
sterile phosphate buffered saline, filtered through fine 
gauze and then centrifuged at 700 g for twenty min- 
utes. The supernatant was used as antigen, its protein 
content being adjusted to 10 mg. /ml. and stored at 
-20° C. in small aliquots. When required these were 
thawed and further diluted with tissue culture fluid 
consisting of Eagle's Basal Medium (EBM, Wellcome) 
supplemented with 10 per cent fetal calf serum. Pilot 
experiments showed the highest nontoxic concentra- 
tion of antigen to be 200 pg. /ml., which was used for 
all experiments. 
Mitochondrial preparations were obtained from the 
livers of young Wistar rats by the differential cen- 
trifugation technic of Nerup and Bendixen.41 This 
mitochondrial antigen was used at a concentration of 
200 µg ./ml. culture medium. 
Highly purified bovine insulin was obtained from the 
Lilly Research Laboratories (lot no. 615- D63 -5) in 
crystalline form and diluted in culture medium to 
give a working concentration of 116 pg./ml. 
Leucocyte migration test (LMT) 
The LMT was performed as described previously 
from this laboratory,''10 the method used being that 
of Bendixen and Soborg3 with minor modifications. 
The theoretical basis of the test depends on the fact 
that lymphocytes from a sensitized individual, on con- 
tact with specific antigen, produce a soluble factor(s) 
which modifies cell migration. In the absence of an- 
tigen, cell migration is unaffected. Fifty milliliters of 
venous blood were collected from patients and con- 
694 
trois, heparinized (preservative -free heparin 10 
units /ml.) and allowed to sediment at 37° C. from one 
to two hours. The leucocyte -rich plasma was removed, 
centrifuged at 150 g for ten minutes and the cell 
pellet washed three times in EBM. Contaminating red 
cells were lysed with ammonium chloride (0.83 per 
cent) for five minutes and the leucocyte pellet washed 
a further three times with EBM. The washed cells 
were then resuspended in EBM with 10 per cent fetal 
calf serum. Capillary tubes (25 µl.) were filled with 
the cell suspension, sealed at one end and centrifuged 
at 150 g for five minutes. The tubes were cut 1 mm. 
below the cell -fluid interface and the cell pellet 
positioned, with a dab of silicone grease, in a leuco- 
cyte migration chamber (Sterilin Ltd.). One series of 
at least three chambers was filled with culture 
medium alone and a second series with culture 
medium plus antigen. The chambers were sealed with 
glass coverslips and incubated on a flat surface at 37° 
C. for twenty -four hours. The fanlike pattern of mi- 
gration was then projected (Projectina microscope) 
and the area measured by planimetry. The effect of 
antigen on cell migration (the "migration index ") was 
expressed as a percentage of migration without anti- 
gen using the formula: 
Migration index = 
Mean migration with antigen x 100% 
Mean migration without antigen 
A figure of less than 80 per cent was taken to indicate 
significant inhibition of migration and above 120 per 
cent, significant stimulation; this range is identical to 
that adopted by other investigators4,7 and represents 
two standard deviations above and below the mean 
migration index shown by normal subjects to antigens 
in this and previous studies.s,Io 
Photograph: inhibition of leucocyte migration in the presence 
of pancreatic antigen. On She left, leucocytes 
have migrated normally from the capillary tube 
into culture medium; on the right, migration has 
been inhibited by the addition of pancreatic an- 
tigen to the culture medium. 

































































A. C. MACCUISH, M.R.C.P., AND ASSOCIATES 
HUMAN PANCREATIC ANTIGEN - 200 lug /ml 
130-1 
All diabetics and normal controls were tested with 
human pancreatic antigen (figures 1 and 2). Seventeen 
of the thirty -one young diabetics showed inhibition as 
compared with only four of the twenty -seven young 
controls; the mean migration index for the former 
(77.7 ± 2.3 S.E.M.) was significantly lower than in 
the latter (88.3 ± 2.1). In contrast only six older 
diabetics on OHA and six of those on diet alone 
showed migration inhibition compared with two of 
the corresponding controls; the respective mean mi- 
gration indices were 93.4 i- 2.8, 91.5 ± 2.4 and 
94.4 ± 2.5 and do not differ significantly. The young 
insulin- dependent diabetics differed significantly 
from all other groups, both individually and collec- 
tively (p < 0.01 by the Wilcoxon test) but there were 
otherwise no significant differences (table 1). 
The results of tests using rat liver mitochondrial 
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FIG. 1. Leucocyte migration tests with human pancreatic antigen 
in young controls and insulin -dependent diabetics. Inhibi- 
tion of migration is shown by seventeen (55 per cent) 







































FIG. 2. Leucocyte migration tests with human pancreatic antigen 
in older controls and insulin- independent diabetics. Inhi- 
bition of migration is shown by six (17 per cent) each of 
diabetics on OHA and diet respectively, compared with 
two (9 per cent) controls. 
indices ± S.E.M. for young diabetics, normal con- 
trols and older diabetics were 88.5 ± 3.2, 92.7 ± 2.3 
and 91.9 ± 2.3, respectively, these groups not differ- 
ing significantly. In contrast all patients with 
Hashimoto's thyroiditis or primary biliary cirrhosis, 
included as positive reactors, showed marked migra- 
tion inhibition (mean 69.5 ± 2.4), confirming the 
potency of the mitochondrial antigen; this group dif- 
fered significantly from all other groups, both collec- 
tively and individually (p < 0.01 by Wilcoxon's test, 
table 2). 
Bovine insulin was used as antigen to test leucocyte 
TABLE 1 
Leucocyte migration tests in diabetics and controls 
Human pancreatic antigen -200 pg. /mll. 
Groups compared 
Young diabetics -all other groups 
Young controls-older controls 
Young controls -older diabetics 
(Diet & OHA) 
Older controls -older diabetics 
(Diet & OHA) 
Difference between groups 
p < 0.01 sig 
p > 0.10 NS 
p > 0.10 NS 
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FIG. 3. Leucocyte migration tests with rat liver mitochondrial an- 
tigen in insulin- dependent and independent diabetics, 
normal controls and "positive reactors" (see text). Only the 
group of positive reactors shows significant inhibition of 
migration. 
migration in all the young insulin- treated diabetics 
and corresponding controls; none showed migration 
inhibition to insulin at a concentration of 116 pg./ml. 
culture medium (equivalent to 3.2 i.u. /ml. culture 
medium). Above this level a toxic effect was observed. 
The mean migration was virtually identical in diabe- 
tics and controls (94.8 ± 4.1 and 93.9 ± 3.7, respec- 
tively). 
DISCUSSION 
Nerup et al.4 first described inhibition of leucocyte 
migration to a pancreatic antigen in fifteen of 
twenty -two diabetics, all but four of whom were 
insulin- dependent, and most were under forty -five 
years of age. The antigen used was derived from 
pooled porcine pancreas in which atrophy of exocrine 
TABLE 2 
Leucocyte migration tests in diabetics and controls 
Rat liver mitochondrial antigen -200 pg./ml. 
Groups compared 
Young diabetics- controls 
Young diabetics -older diabetics 
(Diet & OHA) 
Older diabetics -controls 
(Diet & OHA) 
Positive reactors -all other groups. 




p > 0.10 NS 
p > 0.10 NS 
p > 0.10 NS 
p < 0.01 sig 
tissue had been induced by prolonged ligation of the 
pancreatic duct. The same investigators5'6 later used 
an antigen of homogenated fetal calf pancreas to dem- 
onstrate migration inhibition in thirty -one (28 per 
cent) of 112 diabetics. Inhibition was shown in both 
juvenile- and maturity -onset diabetics, occurring as 
often in insulin- dependent as in noninsulin- dependent 
patients; however, the phenomenon was most com- 
monly found in young recently diagnosed diabetics, 
irrespective of therapy. The present studies using 
human pancreas have demonstrated migration inhibi- 
tion in a comparable number of diabetics (29 per cent 
of 101 patients) and confirm that cell- mediated im- 
munity as judged by the LMT is found most often in 
insulin- dependent patients with juvenile -onset dia- 
betes. As yet we have not tested a sufficient number of 
young insulin- dependent patients, or newly diagnosed 
untreated diabetics, to draw any further conclusions. 
Nerup et al. did not find inhibition of migration in 
any type of diabetic by using porcine or bovine insulin 
antigens, -6 and this has been our experience using 
bovine insulin. It would seem that the results of the 
present and previous studies indicate the existence in 
diabetes of a state of cell- mediated immunity to an 
antigen which is present in the pancreas, species - 
nonspecific (demonstrable with porcine, bovine and 
human pancreas), and different from insulin. The 
phenomenon is found almost exclusively in juvenile - 
onset diabetics. 
In diabetics the position regarding migration inhi- 
bition to antigens from other organs is more con- 
troversial. Richens et al.7 showed inhibition in 
twenty -six of thirty -five young insulin- dependent 
diabetics and in four of twelve elderly insulin - 
independent diabetics tested with an antigen consis- 
ting of liver mitochondria from young Sprague - 
Dawley rats; subsequent studies by the same inves- 
tigators have suggested that the antigenic component 
is localized to the inner mitochondrial membrane.12 
Richens et al. also described migration inhibition in a 
small number of insulin- dependent diabetics tested 
with human liver mitochondria but found no inhibi- 
tion to antigens of mitochondria from rat kidney and 
adrenal.? On the other hand Nerup et al.4-ó used 
antigens of porcine kidney, porcine liver, fetal calf 
liver and thymus in their series of diabetics and did 
not demonstrate migration inhibition to any of these 
antigens. Our own results, using rat liver mitochon- 
dria of proven potency, are in agreement with the 
latter investigators. The reason for the differences be- 
tween the various studies are not clear but may in part 
reflect different methods of antigen preparation: 
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Richens et al. used the method of Zamecnik and 
Keller13 and employed as antigen the fraction ob- 
tained by ultracentrifugation at 5,000 g, ' while the 
earliest study of Nerup et al.4 used a different method 
of antigen preparations i and employed as antigen the 
fraction obtained by centrifugation at 104,000 g, 
which has a high content of microsomes. 
Further studies are required to clarify this problem 
and also to attempt to define which component of 
pancreatic tissue acts as antigen toward the lympho- 
cyte population in patients with diabetes mellitus. 
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Cell-mediated Immunity in Diabetes Mellitus 
Lymphocyte Transformation by Insulin and Insulin Fragments 
in Insulin -treated and Newly - diagnosed Diabetics 
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SUMMARY 
Using a radioisotope labeling technic, the ability of bovine and 
porcine insulin antigens to induce lymphocyte transformation was 
tested with cells from the peripheral blood of thirty nondiabetic 
controls, fifty established insulin- dependent diabetics with no evi- 
dence of insulin allergy, and ten newly diagnosed diabetics (five 
untreated, five insulin- treated for less than three weeks). Lympho- 
cytes from twenty -six (42 per cent) of the diabetics showed signifi- 
cant blastogenesis to bovine or porcine insulin, as compared with 
two (7 per cent) of controls; the phenomenon was shown by both 
established and newly diagnosed patients including four who had 
never received insulin. The results indicate that cellular hypersen- 
sitivity to insulin, as judged by an in vitro test, is relatively common 
in insulin- treated diabetics without in vivo evidence of allergy, and 
suggest that hypersensitivity may also be present in untreated diabet- 
ics. 
Lymphocytes from twenty -one of the twenty -six diabetics who 
responded to intact insulin were further tested using bovine and 
porcine insulin A chain and bovine B chain as antigens. The A chain 
of either insulin induced significant blastogenesis in only one diabetic 
but bovine B chain induced significant blastogenesis in fourteen 
(67 per cent) of the patients tested. These results suggest that B chain 
is the major antigenic site determining cellular hypersensitivity to 
insulin. DIABETES 24:36 -43, January, 1975. 
Cell- mediated immune mechanisms in human 
diabetes mellitus have recently been studied by in 
vitro tests. The leucocyte migration test' has demon- 
strated migration inhibition of diabetic leucocytes 
cultured in the presence of antigens derived from 
porcine,' fetal calf' or human pancreas.' The 
phenomenon was most common in recently - 
diagnosed, juvenile -onset diabetics and was indepen- 
dent of antidiabetic treatment, being found in pa- 
tients who were insulin- dependent, insulin - 
independent or untreated at the time of study. " -4 The 
same investigators did not find migration inhibition 
From the Departments of Endocrinology and Diabetes, Royal 
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ment of Therapeutics, University of Edinburgh, Edinburgh, Scot- 
land. 
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of diabetic leucocytes by antigens derived from liver, 
kidney, thymus or adrenal, nor did purified insulin 
inhibit migration; it has therefore been suggested that 
the results indicated the presence in young diabetics of 
a state of cellular immunity to species -nonspecific 
antigen(s), pancreatic in origin but different from in- 
sulin. The organ -specificity of the antigen must, how- 
ever, remain in doubt at present in view of reports" 
that liver mitochondria can inhibit migration of 
leucocytes in diabetes as well as in other diseases -9 of 
established autoimmune etiology. 
Mitogen- or antigen- induced transformation of 
lymphocytes to blast cells'" are alternative in vitro 
tests of cellular immune function. The mitogen 
phytohemagglutinin (PHA) is considered to stimulate 
mainly T lymphocytes1 t 11 and has been used to de- 
monstrate that transformation responses are normal in 
well controlled diabetics1' -14 and depressed in poorly 
controlled diabetics.13.14 In contrast there is little in- 
formation concerning antigen- induced lymphocyte 
transformation in diabetes, but various 
investigators15 -17 have shown that bovine insulin can 
induce blastogenesis in lymphocytes from diabetics 
with both immediate (urticarial) and delayed (cutane- 
ous) insulin allergy. 
In the present investigation we have used bovine 
and porcine insulin as antigens to detect sensitized 
lymphocyte populations in treated diabetics without 
in vivo evidence of insulin allergy, and in untreated 
diabetics; in addition, isolated fragments (A and B 
TABLE 1 
Composition of Lilly bovine and porcine insulins used as antigens 
Content* Bovine Insulin Porcine Insulin 
Proinsulin 0.06 0.15 
Glucagon 0.007 0.002 
Zinc 0.80 0.70 
Monodesamido insulin 13.0 7.0 
"Arginine" insulins 1.0 2.0 
Potency (U /mg.) 25.4 25.4 
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chain) of the insulins from both species have been used 
in an attempt to localize the immunogenic portion of 
the insulin molecule. 
PATIENTS AND METHODS 
Patients. Sixty diabetics were studied. Forty -two 
were women and eighteen were men, from sixteen to 
seventy -one years of age (mean 42.1). Fifty were estab- 
lished diabetics and have been insulin- treated between 
six months and twenty -four years. Ten were newly 
diagnosed diabetics, five of whom had been insulin - 
treated for three weeks or less and five of whom were 
untreated at the time of study. All were attending an 
outpatient clinic and in all (except for the newly - 
diagnosed) the disorder was well controlled as judged 
by the following criteria: steady weight and insulin 
dosage; absence of thirst or polyuria; no heavy 
glycosuria; no ketonuria; mid -morning blood glucose 
less than 250 mg. per 100 ml. All were taking insulin 
of bovine origin, prepared either as soluble (Regular) 
insulin or in a sustained -release form (Protamine -Zinc 
or IZS Lente insulin). None had evidence of im- 
TABLE 2 
Ability of varying concentrations of bovine insulin to induce transformation 
(judged by 3H- thymidine uptake) of cultured lymphocytes from a diabetic with 
insulin allergy. No significant increase of blastogenesis is obtained by adding 
more than 10 µg insulin per culture. 
Control* Cultures plus Bovine Insulin Antigen* 
Cultures 
50 Ag/ml. 500 µg/ml. 1,000 µg/ml. 5,000 Ag/rni. 
1 Ag /culture 10 µg /culture 20 Ag/culture 100 µg/culture 
i 
First il 
Assay 1,080. 8,720 12,480 13,640 10,390 
Second 
Assay 1,769 9,550 14,570 14,210 12,620 
*All results as cpm 
mediate or delayed -type insulin allergy. 
The control group comprised thirty healthy non - 
diabetic volunteers. For statistical purposes it was 
selected to be comparable in terms of sex (twenty 
women, ten men) and age (range fifteen to seventy- 
two years, mean 40.8 years) with the diabetic group. 
Most controls were laboratory or hospital personnel; a 
few were hospital outpatients who were not known to 
TABLE 3 
Ability of bovine insulin, porcine insulin and PHA to induce transformation (judged by 3H- thymidine uptake) 
of cultured lymphocytes from thirty normal subjects. Results expressed both as counts per minute (cpm) 
and transformation index (T.I. -see text). All figures are means of triplicate cultures. 




15 /m 939 546 0.58. 
72/f 1,318 806 0.61 
29/f 704 501 0.71 
19 /m 1,188 893 0.75 
34/f 1,026 784 0.76 
34/f 823 669 0.80 
66/f 975 792 0.81 
32/f 1,133 941 0.83 
53/m 1,572 1,322 0.85 
24/f 759 654 0.86 
58/f 1,033 914 0.88 
36/m 1,007 899 0.89 
26/f 659 589 0.90 
68/f 1,583 1,521 0.96 
32/m 1,292 1,250 0.97 
48/f 875 860 0.98 
41/f 958 940 0.98 
28/f 1,106 1,104 1.00 
36/f 1,136 1,178 1.04 
18 /m 848 891 1.05 
69/m 710 750 1.05 
54/f 1,285 1,363 1.06 
26/f 955 1,042 1.09 
46/f 797 880 1.10 
48 /f 923 1,017 1.10 
45/m 1,714 1,910 1.11 
32/f 1,073 1,222 1.14 
57/m 1,809 2,583 1.43 
36/m 1,465 2,109 1.44 













































































































































CELL -MEDIATED IMMUNITY IN DIABETES MELLITUS 
TABLE 4 
Ability Of bovine insulin, porcine insulin and PHA to induce transformation (judged by 3H- thymidine uptake) of cultured lymphocytes 
from fifty established insulin- dependent diabetics. Results as in table 3. 
Study Age /Sex Control 
Number cpm cpm 
Bovine Insulin Porcine Insulin Maximal PHA 
T.I. cpm T.I. Response (cpm) 
1 27/m 964 705 
2 50 /f 1,541 1,123 
3 42/f 1,495 1,146 
4 40/f 809 728 
5 31 /m 1,475 1,388 
6 62/f 878 .843 
7 65/f 1,096 1,071 
8 40 /f 1,167 1,172 
9 59/f 1,122 1,120 
10 66/f 994 1,001 
11 45/m 1,226 1,270 
12 38 /f 915 959 
13 42/m 1,518 1,597 
14 25/f 728 760 
15 48/f 1306 1,427 
16 46/f 811 900 
17 55/f 963 1,079 
18 20 /f 870 979 
19 37/f 931 1,051 
20 69/m 1,071 1210 
21 23/f 1,000 1,140 
22 46/m 939 1,067 
23 41/f 1043 1,210 
24 45/f 720 848 
25 21 /f 923 1,155 
26 70 /f 1,320 1,690 
27 25/f 1,448 1,853 
28 62/m 962 1,228 
29 14 /f 634 818 
30 27/f 859 1,112 
31 22/m 951 1,109 
32 67/f 869 1,169 
33 57/m 1,446 1,952 
34 52/f 1,094 1,557 
35 46/m 832 1,192 
36 42/f 1,391 2,130 
37 30 /f 989 1,533 
38 41/f 943 1,525 
39 37/f 885 1,430 
40 48/f 1,000 1,659 
41 61/f 1,832 3,077 
42 . 54/f 1,016 1,802 
43 59/f 1,547 2,769 
44 52/f 843 1,512 
45 61/m 1,042 1,963 
46 62/f 897 1,790 
47 26/f 734 1,508 
48 71/f 1,458 3,164 
49 38/m 864 2,449 
50 39/f 1,046 3,797 
have endocrine or immunological disease. 
Antigens. Bovine and porcine insulins of known po- 
tency and composition (table 1) were obtained from 
the Lilly Research Laboratories. Bovine insulin A 
chain and B chain (aminoethylated), and porcine insu- 
lin A chain (S- sulfonate) were obtained from the same 
source. All preparations were in crystalline powder 
form. On the day of use they were dissolved in a 
38 
0.73 1,039 1.08 35,900 
0.73 1,326 0.86 17,500 
0.85 1,053 0.80 22,400 
0,90 802 0.98 18,700 
0.94 1,400 0.95 26,400 
0.96 805 0.92 24,100 
0.98 956 0.87 30,700 
1.00 1,006 0.86 17,600 
1.00 1,327 1.10 20,400 
1.01 1,351 1.36 18,500 
1.04 1,164 0.95 26,400 
1.05 1,049 1.15 25,000 
1.05 2,173 1.43 13,900 
1.05 881 1.21 17,400 
1.09 1,259 0.96 7,800 
1.11 853 1.05 41,800 
1.12 1,014 1.05 21,400 
1.13 1,357 1.56 33,300 
1.13 863 0.93 27,600 
1.13 1,089 1.02 10,600 
1.14 1,320 1.32 19,300 
1.14 1,221 1.30 27,400 
1.16 1,079 1.03 12,700 
1.18 794 1.10 15,500 
1.25 1,609 '1.74 50,600 
1.28 1,990 1.51 20,400 
1.28 1,445 1.00 26,600 
1.28 1,062 1.11 38,200 
1.29 799 1.26 8,500 
1.30 1,120 1.30 11,900 
1.31 1,561 1.83 21,100 
1.34 927 1.07 21,200 
1.35 2,053 1.42 39,500 
1.42 1,503 1.37 14,000 
1.43 1,278 1.53 10,300 
1.53 2,465 1.77 18,200 
1.55 1,553 1.57 35,900 
1.62 1,719 1.82 19,200 
1.62 1,686 1.90 27,900 
1.66 1,809 1.81 26,700 
1.68 2,994 1.63 18,900 
1.77 1,641 1.61 20,500 
1.79 2,614 1.69 14,100 
1.79 2,366 2.80 17,600 
1.88 1,777 1.71 26,000 
1.99 1,282 1.42 47,100 
2.06 1,454 1.98 21,300 
2.17 3,762 2.58 41,000 
2.83 2,049 2.38 13,900 
3.63 4,707 4.50 34,500 
mixture of 10 per cent sterile phosphate buffered 
saline /80 per cent Eagle's Basal Medium /10 per cent 
fetal calf serum. 
The optimal concentration of insulin for use in our 
investigations was determined by measuring the blas- 
togenic effect of insulin on lymphocytes from a diabet- 
ic with known insulin allergy; the patient was a 
twenty- two -year -old man who had a daily insulin re- 
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TABLE 5 
Ability of bovine insulin, porcine insulin and PHA to induce transformation (judged by °H- thymidine uptake) of cultured lymphocytes 
from ten newly diagnosed diabetics. Results as in table 3. 
Study 
Number 








51 58 /f 1,505 1,472 0.98 1,430 0.95 17,700 
52 37/m 841 832 0.99 699 0.83 7,800 
53 19 /m 1,043 1,029 0.99 1,343 _1.29 19,400 
54 42/m 891 972 1.09 881 0.99 9,900 
55 18 /m 619 680 1.10 930 1.50 13,800 
56 19/f 1,473 2,458 1.67 2,591 1.76 38,000 
57 23/f 757 1,498 1.98 1,520 2.00 25,400 
58 30 /m 802 1,626 2.03 1,729 2.16 16,500 
59 16/m 1,138 2,675 2.35 2,281 2.00 25,400 
60 19 /f 1,307 5,313 4.07 5,925 4.53 16,600 
quirement in excess of 200 units in addition to 
cutaneous reactions to bovine insulin injections, and 
who therefore showed evidence of both humoral and 
cell- mediated insulin hypersensitivity. Lymphocytes 
were obtained from this patient on two separate occa- 
sions, prepared and cultured as described below, and 
exposed to varying concentrations of bovine insulin 
antigen. The results (table 2) show that maximal blas- 
togenesis was stimulated with insulin at a concentra- 
tion of 500 µg /ml. (10 mg /culture), no significant in- 
crease in lymphocyte 3H- thymidine uptake being in- 
duced by higher concentrations of insulin. Thus on 
the basis of this preliminary dose - response analysis, all 
experiments were performed with solutions contain- 
ing 500 pg /ml. intact insulin or insulin fragment. 
Sample Collection and Lymphocyte Culture. Fifteen mil- 
liliters venous blood was removed from each patient and 
control at mid -morning and anticoagulated with 
preservative -free heparin. Lymphocytes were prepared 
from whole blood by the methods (density centrifuga- 
tion, repeated washing in EBM) described in previous 
studies14.18 from this laboratory, and suspended in 
EBM with 10 per cent fetal calf serum at a concentra- 
tion of 1 X 106 cells per milliliter. 
TABLE 6 
Effects of bovine and porcine insulin on PHA - induced transformation of 
lymphocytes from five normal subjects. Neither insulin 
has a significant effect on the °H- thymidine uptake of 
PHA- stimulated lymphocytes. 
Maximal °H- thymidine Uptake (cpm) 
A portion of the lymphocytes from each subject was 
cultured in the presence of the mitogen phytohemag- 
glutinin (PHA) to provide a convenient assessment of 








Age /Sex With PHA PHA +B.I.* PHA +P.I.* 
36/m 32,000 35,000 31,000 FIG. 1. 
19 /m 25,000 24,000 22,000 
32/m 9,000 8,000 9,000 
26/f 28,000 26,000 26,000 
36/m 14,000 16,000 14,000 
*B.I.- Bovirte insulin 10 µg /culture 
P.I.- Porcine insulin 10 µg /culture 
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LYMPHOCYTE TRANSFORMATION- BOVINE INSULIN ANTIGEN 
Lymphocyte transformation in controls and diabetics in- 
duced by bovine insulin antigen. The mean transforma- 
tion index - S.E.M. is shown to the right of the individual 
results for each group. Dotted lines (- - - -) indicate the 
normal range (mean ± 2 S.D.) of transformation indices in 
control subjects. Significant transformation (index >1.45) 
is shown by fifteen established and five newly diagnosed 
diabetics as compared to one control. Both diabetic groups 
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LYMPHOCYTE TRANSFORMATION-PORCINE INSULIN ANTIGEN 
FIG. 2. Lymphocyte transformation in controls and diabetics in- 
duced by porcine insulin antigen. Symbols as in figure 1. 
Significant transformation is shown by twenty established 
and six newly diagnosed diabetics as compared to two 
controls. Both diabetic groups differ significantly (p 
<0.01) from the control group. 
tion. The lymphocyte transformation response to 
PHA was measured by an extensively investigated 
micromethod,19 which utilizes the cellular uptake of 
radioactive DNA precursor (3H- thymidine) as the 
index of lymphocyte stimulation and has been used in 
our previous study14 of PHA responses in diabetes 
mellitus. This micromethod enables a mitogen dose - 
response curve to be constructed for lymphocytes from 
each subject by using PHA at concentrations of 0.32, 
0.63 and 1.25µl per milliliter culture. The radioac- 
tivity of stimulated cells was determined by an au- 
tomatic beta counter (Nuclear Enterprises NE8312) 
and results are expressed as counts per minute (cpm). 
The remaining lymphocytes from each patient and 
control were cultured in the presence of insulin an- 
tigen. The technic used was modified from the PHA 
micromethodl9 and is briefly summarized as follows: 
aliquots of 2 X 105 lymphocytes were pipetted into 
the wells of plastic tissue culture plates (Cooke Mic- 
rotiter). All experiments were performed in triplicate 
and consisted of a control row of cultures without 
antigen, and rows to which 20 µl of the required an- 
tigen solution (i.e. 10 µg insulin or insulin fragment) 
was added. The plates were gassed with a 95 per cent 
air /5 per cent CO2 atmosphere and incubated at 
37 °C. in sealed, humidified containers. After five days 
the cultures were labeled with 3H- thymidine (specific 
activity 5 Ci/mmol, dose 0.4 per culture) and 
terminated sixteen hours later by harvesting the cells 
onto glassfibre filter discs and preparing them" for 
scintillation counting. The prepared samples were 
counted in an automatic beta counter. 
Results were obtained as counts per minute (cpm); 
the effect of antigen in stimulating blastogenesis (the 
`transformation index') was expressed by the formula: 
_ cpm of cultures with antigen 
Transformation Index 
cpm of cultures without antigen 
The normal range of transformation indices using 
intact insulin antigens was obtained from the mean 
transformation index ±2 standard deviations of the 
results given by both insulins in the control group 
(i.e. 60 experiments). The range in normals by this 
method was found to be 0.57 -1.45 (mean 1.01 ± 
0.44), and a transformation index above 1.45 was 
thus taken to indicate significant antigenic stimula- 
tion of blastogenesis. Several cultures from controls 
and diabetics were examined by light microscopy to 
confirm that the uptake of radioactive label was paral- 
leled by morphological blast transformation. 
All diabetics and controls were tested with intact 
bovine and porcine insulin antigens. Lymphocytes 
from those patients who showed significant transfor- 
mation were further tested with bovine A and B chain 
and porcine A chain. 
RESULTS 
Mitogenic effects of PHA. The maximal PHA response 
of diabetics and controls (i.e. the highest lymphocyte 
incorporation of 3H- thymidine label induced by one 
of the three concentrations of PHA used) is shown in 
tables 3 -5. The mean maximal PHA response in the 
thirty controls was 23.1 ± 4.3 (expressed as cpm X 
103 ± S.E.M.) while the corresponding figure in the 
sixty diabetics was 22.5 ± 4.7. The two groups do 
not differ significantly in PHA responsiveness and the 
results confirm our earlier observation14 that 
mitogen- induced lymphocyte transformation is nor- 
mal in diabetes mellitus, except at times of severe 
metabolic decompensation. 
The maximal PHA response of five control subjects 
was further measured in lymphocyte cultures to which 
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TABLE 7 
Ability of bovine insulin A chain, porcine insulin A chain and bovine B chain to induce transformation (judged by 3H- thymidine uptake) 
of cultured lymphocytes from twenty -one diabetics who showed significant transformation to intact insulin molecule. 





Bovine A Chain 
cpm T.I. 
Porcine A Chain 
cpm T.I. 
Bovine B Chain 
cpm T.I. 
49 970 942 0.97 739 0.76 680 0.70 
47 1,004 1,104 1.10 1,670 1.69 944 0.94 
38 1,150 1,220 1.06 781 0.68 1,380 1.20 
*58 902 939 1.04 747 0.83 1,136 1.26 
41 1,623 1,445 0.89 2,173 1.34 
45 1,684 1,161 0.69 2,339 1.39 
36 1,092 963 0.88 1,527 1.40 
40 870 938 1.08 523 0.60 1,313 1.51 
*60 1,422 1,466 1.03 2,415 1.70 
44 759 639 0.84 834 1.10 1,364 1.80 
43 1,670 1,385 0.83 3,173 1.90 
*57 518 682 1.10 1,171 1.90 
42 925 1,833 1.98 906 0.98 1,880 2.03 
*59 1,062 1,010 0.95 1,094 1.03 2,123 2.10 
26 1,566 1,598 1.02 1,690 1.08 3,445 2.20 
*56 1,241 1,450 1.17 6,452 5.20 
39 950 1,020 1.07 5,605 5.90 
37 860 1,039 1.20 6,192 7.20 
48 1,287 1,364 1.06 1,094 0.85 11,866 8.70 
25 705 750 1.05 6,201 8.80 
46 964 972 1.01 630 0.66 9,350 9.70 
*Newly diagnosed patient 
1011!g bovine or porcine insulin had been added. The 
results (table 6) indicate that neither bovine nor por- 
cine insulin have an appreciable effect on 
8H-thymidine uptake in the presence of PHA when 
added to forty- eight -hour cultures in the stated con- 
centrations. 
Antigenic effects of intact insulins. The effects of 
bovine and porcine insulin antigens in inducing blas- 
togenes is of lymphocytes from controls and diabetics 
are presented in tables 3 -5 (as absolute cpm) and in 
figures 1 and 2. Only one normal subject showed 
significant transformation using bovine insulin an- 
tigen; in contrast fifteen established and five newly 
diagnosed diabetics (three untreated, two insulin - 
treated for less than three weeks) showed significant 
transformation, their indices ranging from 1.53 to 
4.07 (figure 1). The groups of both established and 
newly diagnosed diabetics differed significantly from 
the control group (p <0.01 by Wilcoxon's test). 
Experiments using porcine insulin as antigen (fig- 
ure 2) gave a virtually identical pattern. Two control 
subjects showed significant transformation, as corn - 
pared with twenty established and six newly diag- 
nosed diabetics (four untreated, two treated for less 
than three weeks). Both diabetic groups again differed 
significantly (p<0.01) from the controls. Almost all 
the diabétics who showed transformation to porcine 
insulin also showed transformation to bovine insulin 
JANUARY, 1975 
(tables 4 and 5). 
Antigenic effects of A and B chains. Lymphocytes were 
available for study from twenty -one of the twenty -six 
diabetics who showed significant transformation to 
intact insulin molecule. The effects of bovine A chain, 
porcine A chain and bovine B chain on these lympho- 
cytes are shown in table 7 and figure 3. The A chain of 
either insulin was almost without effect, inducing 
significant blastogenesis in only one diabetic; in con- 
trast the B chain of bovine insulin induced significant 
lymphocyte transformation in fourteen (67 per cent) of 
the twenty -one patients tested. In some diabetics the 
isolated B chain appeared to be more potent in 
stimulating blastogenesis than intact insulin 
molecule, the transformation index being greater than 
4.0 in six patients. Statistical analysis confirmed that 
the effects of B chain on lymphocyte transformation 
differed significantly (p<G.01) from those of the A 
chain of either insulin. 
DISCUSSION 
Under the stated culture conditions, intact insulin 
(bovine and porcine) was observed to induce transfor- 
mation of lymphocytes in vitro from one -third of the 
diabetics tested. In this context, insulin may be re- 
garded as showing cellular antigenic activity analo- 
gous to the effects of PPD on lymphocytes from 
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LYMPHOCYTE TRANSFORMATION WITH INSULIN FRAGMENTS 
FIG. 3. Lymphocyte transfo motion induced by bovine and porcine 
A chain and bovine B chain in twenty -one diabetics who 
responded to intact insulin. Symbols as in figure 1. Closed 
circles (e)-established diabetics; open circles (o) -newly 
diagnosed diabetics. Significant transformation to either 
A chain is shown by only one diabetic, as compared to 
fourteen (67 per cent) who respond to B chain. The effects 
of B chain differ significantly (p <0.01) from those of the 
A chain of either insulin. 
lymphocytes from patients with pernicious anemia21 
and thyroglobulin on lymphocytes from patients with 
Hashimoto thyroiditis.22 The blastogenic effect of in- 
sulin is perhaps not surprising in the group of estab- 
lished diabetics that we tested: all had been insulin - 
treated for months or years, virtually al123 would be 
expected to have humoral antibodies to injected insu- 
lin, and it is reasonable to suppose that some have 
developed cellular immunity in the form of an 
insulin- sensitized lymphocyte subpopulation. Similar 
findings were reported by Halpern et al.15 and Feder - 
lin et al.16,17 in diabetics with insulin allergy, both of 
immediate (urticarial) and delayed (cutaneous) type; 
our own experience suggests that the phenomenon is 
42 
not uncommon in diabetics who have no clinical signs 
of allergy. In these patients the in vitro test of lym- 
phocyte function may be the most sensitive measure- 
ment of an insulin hypersensitivity which is not of 
clinical significance. 
More interesting is the finding of insulin- induced 
lymphocyte transformation in six of ten newly diag- 
nosed patients, four of whom had never been given 
insulin and two of whom had been insulin- treated for 
less than three weeks. Further studies are needed to 
confirm these observations in larger numbers of un- 
treated diabetics but the present results at least sug- 
gest that a proportion of such patients have an 
insulin- sensitized lymphocyte population before ex- 
ogenous insulin has been given and before23 humoral 
insulin antibodies have developed. Nondiabetics do 
not show this cell population and its existence may 
reflect a state of cell- mediated autoimmunity, to insu- 
lin or insulin precursor, in early diabetes. 
The virtually identical findings with bovine and 
porcine insulin prompted us to examine their compo- 
nent chains for antigenicity, and the results show a 
clear -cut difference between the effects of the two 
major chains. On the one hand, neither bovine nor 
porcine A chain induced significant lymphocyte trans- 
formation, and as the structure of human insulin A 
chain is identical to that of porcine insulin24 it may be 
presumed that human A chain is also without blas- 
togenic effect. On the other hand, bovine insulin B 
chain (which is identical to that of porcine insulin and 
differs24 from the amino -acid sequence of human B 
chain only at position 30) had a striking effect in 
inducing blastogenesis of lymphocytes from two 
thirds of those patients who responded to intact. insu- 
lin. The results thus suggest that B chain is the major 
antigenic site producing cellular hypersensitivity to 
insulin. Support for this hypothesis is given by the in 
vivo animal experiments of Clark and Munoz, who 
injected guinea pigs with bovine insulin, A and B 
chain in Freund's adjuvant: Cutaneous hypersensitiv- 
ity was readily elicited by intact insulin and B chain, 
but A chain had no significant effect.25 
The role of insulin B chain in cell-mediated im- 
munity to insulin may be contrasted with the humoral 
response to insulin, where various studies26.27 have 
suggested that the A chain is the major determinant of 
antibody production. It seems that differing antigenic 
activity, whether cellular or humoral, may reside at 
differing sites on the insulin molecule, such activity 
being perhaps governed partly by genetically deter- 
mined configuration of antibody binding sites28 and 
partly by the relationship between the structure of 
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antibody and the amino -acid sequence against which 
it is directed. Finally, the apparent lack of antigenic - 
ity of A chain in our experiments might be explained 
by the physical changes undergone by this peptide 
during the splitting of insulin: Isolated A chain is 
`stretched' by comparison with its configuration in the 
intact insulin molecule,29 and the intra chain disul- 
fide bridge between six and eleven is broken with 
the formation of cysteic acid residues" which could 
prevent antigen- antibody reaction at this site. 
Further studies should attempt to delineate more 
clearly the cellular antigenic portion of insulin and to 
indicate whether related proteins or precursors (e.g. 
proinsulin, C- peptide) have similar properties in early 
diabetes. 
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SUMMARY 
A quantitative in vitro method for phytohaemagglutinin (PHA) induced lympho- 
cyte transformation is described. This method has the following advantages. 
Cultures require as few as 105 lymphocytes and are performed in microtrays, 
over a short incubation period (48 hr). 
A short pulse time of 4 hr with [3H]thymidine is utilized. This enables high levels 
of [3H]thymidine to be maintained throughout the labelling period, ensures maxi- 
mum incorporation of thymidine into cellular DNA, and diminishes cellular 
damage by internal irradiation. 
The extraction process has been simplified by using a communal washing pro- 
cedure after drying the cultures on glass -fibre filter discs. The procedure is both 
quicker and more reproducible (coefficient of variation 6 %) than extraction and 
drying on filtration manifolds (coefficient of variation 23 %). 
The effect of adjusting variables such as the number of cells, incubation time, 
concentration of [3H]thymidine, concentration of PHA, specific activity of [3H]- 
thymidine and duration of [3H]thymidine pulse has been studied in order to ap- 
proach optimal labelling conditions for the assay system. 
The reproducibility of the method has been investigated by repeated testing of 
normal individuals on a day -to -day basis and over extended periods. The mean 
coefficient of variation for samples repeated daily and over longer time intervals 
(weeks or months between samples) was 15 %. 
INTRODUCTION 
The transformation of cultured small lymphocytes by the mitogen phytohaemagglutinin 
PHA) is now extensively employed as a general assessment of cell- mediated immune func- 
ion in a variety of clinical states (Oppenheim, Blaese & Waldmann, 1970; Gatti, Garrioch 
Good, 1970; Trubowitz, Masek & Del Rosario, 1966; Lischner, Punnet & DiGeorge, 
Correspondence: Dr W. J. Penhale, Immunology Laboratories, 2 Forrest Road, Edinburgh. 
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1967; Hosking, Fitzgerald & Simons, 1971). The most frequently used method of quanti- 
fying the response to PHA is by measuring the rate of DNA synthesis, using the incor- 
poration of a labelled precursor such as [3H]thymidine. 
This procedure, as generally applied in the investigation of clinical disease, has suffered 
from a number of disadvantages. 
(1) Often there has been inadequate definition of the dose -response relationship of PHA 
with comparisons between groups limited to a single PHA dose. 
(2) The majority of assay systems described have used 106 or more lymphocytes per 
culture, thus requiring substantial volumes of blood. 
(3) A lengthy culture period, often of 72 hr, has been adopted. 
(4) The extraction methods employed are frequently elaborate and time -consuming, 
involving repeated washing of cells either by centrifugation or filtration. 
(5) The culture conditions are often not optimal for maximum incorporation of label, 
thus reducing sensitivity and discrimination of the assay. 
These factors have probably contributed to the conflicting reports from different workers 
of the responsiveness of lymphocytes to PHA in immunological deficiency (Gotoff, 1968) 
and certain forms of neoplasia (Han & Takita, 1972; Paty & Bone, 1973) as well as in other 
clinical states. 
We describe here an in vitro lymphocyte transformation method which attempts to over- 
come these difficulties; cell numbers per culture have been reduced, the DNA extraction 
method is simple and highly reproducible, the conditions of culture have been adjusted to 
ensure optimal labelling of DNA, and a complete dose -response profile has been 
established. 
MATERIALS AND METHODS 
Materials 
Phytohaemagglutinin (PHA). Bacto PHA -P (Difco Laboratories) of the same batch 
(number 575219) was used throughout. It was reconstituted as recommended by the manu- 
facturers with distilled water, stored in 0.10 ml aliquots at - 20 °C and used immediately 
once thawed. 
Eagle's basal medium (EBM). This 'contained antibiotics and was buffered with 0.1 
bicarbonate (TC30, Wellcome Reagents Ltd). 
Foetal calf serum. CS06, Wellcome Reagents Ltd. 
Tritiated thymidine. [3H]Thymidine was obtained from the Radiochemical Centre, Amer - 
sham. Two specific activities were used: 5 Ci /mmole (Code TRA 120); and 15 Ci /mmole 
(Code TRK 120). 
Scintillation fluid. NE233, Nuclear Enterprises Ltd. 
Glassfzbre filter discs. Whatman GF /C, diameter 2.5 cm, marked with typeface. 
Ficoll. Sigma Chemical Company. 
Triosil 440. Nyegaard & Co., Norway. 
Collection of blood samples and separation of lymphocytes 
Venous blood (10 -20 ml /subject) was obtained from a panel of healthy laboratory per- 
sonnel with preservative -free heparin as anticoagulant (Evans Medical, 100 units /ml blood). 
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fractionated by density gradient centrifugation (Perper, Zee & Mickelson, 1968). The 
lymphocyte layer was removed, the cells washed three times in EBM and finally resuspended 
in EBM supplemented with 10% foetal calf serum. Cell suspensions were counted and 
adjusted to the required concentration; all suspensions contained more than 95% lympho- 
cytes with a viability greater than 98% when tested by the Trypan Blue dye exclusion 
method. 
General procedure for lymphocyte culture 
Stock PHA was diluted in EBM, with 10% foetal calf serum, to the appropriate con- 
centration for each particular experiment. Aliquots of 20 pl of diluted mitogen were pipetted 
into the wells of Cooke Microtitre plastic culture plates (M29ART, Flow Laboratories), 
and 200 µl of lymphocyte suspension (containing 0.2 x 106 cells) added to each well. All 
determinations were performed in triplicate and included control cultures without PHA. 
The plates were incubated in a humidified 5% CO2: 95% air atmosphere for 44 hr; [3H]- 
thymidine was then added and incubation continued for a further 4 hr. 
Variations in culture conditions in individual experiments 
In experiment 1, the response of 0.2 x 106 cells per culture to a range of six concentra- 
tions of PHA (from 0.16 to 5.0 c1 /ml culture) was investigated. Each culture received 0.4 
µCi of [3H]thymidine (5 Ci /mmole) and the incorporation of label was measured after 4 hr. 
In experiment 2, the effect of incubation time was investigated using 0.2 x 106 lympho- 
cytes per culture and PHA at a concentration of 1.25 pl /ml. Cultures were incubated for 
periods ranging from 4 to 144 hr, followed in each case by a 4 -hr pulse with 0.4pCi of [3H]- 
thymidine (5 Ci /mmole). 
In experiment 3, the optimum concentration of thymidine per culture was investigated. 
Cell numbers and PHA concentration were as for experiment 2 and a constant incubation 
time of 44 hr was used. [3H]thymidine was then added in final concentrations varying 
from 2 x 10 -4mM to 16 x 10 -4mM and incubation continued for a further 4 hr. 
In experiment 4, the effect of increasing specific activity of [3H]thymidine was investi- 
gated. Culture conditions were as for experiment 3 but a constant concentration of [3H]- 
thymidine (32 x 10 -4mM) was used, and the specific activity varied from 10 -0.16 Ci/ 
mmole. 
In experiment 5, the length of time over which the rate of incorporation of label remained 
maximal was investigated by both continuous and short -term pulsing. Culture conditions 
were as for experiment 3 but each culture received a constant dose of 0.4 pCi of [3H]- 
!Ihymidine, of specific activity 5 Ci /mmole and the duration of thymidine pulse was varied 
from 4 to 24 hr. Subsequent experiments, using lymphocytes from the same pool of normal 
ionors and identical culture conditions, compared the effects of both hourly and con - 
inuous pulsing, with a constant dose of 0.8 pCi of [3H]thymidine per culture over a period 
of 4 hr. 
In experiment 6, the concentration of cell suspensions was varied from 1 x 105 /ml to 
lx 106/m1 (i.e. 0.2 x 105 -0.6 x 106 cells /culture). All cultures were stimulated with PHA 
tt 1.25 pl /ml, incubated for 44 hr and labelled with 0.4 ICi of [3H]thymidine for a further 
I hr. 
In experiment 7, where several aspects of reproducibility were examined, the following 
;vulture conditions were used: 1 x 106 cells /ml (2 x 105 /culture); PHA at concentrations of 
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0.32, 0.63 and 1.25 pl /ml culture; [3H]thymidine of specific activity 5 Ci /mmole at a con- 
centration of 4 µCi /culture; incubation time of 44 hr; [3H]thymidine pulse of 4 hr. 
General procedure for culture extraction 
At the end of the culture period, the cells in each well were resuspended by gentle pipet - 
ting and transferred to numbered glass -fibre filter discs which had previously been placed on 
a pin board. The discs were then dried either on the bench with the aid of a fan (for approxi- 
mately 1 hr) or by placing the pin board in an incubator or hot -air oven (for approximately 
20 min). Dried discs were collected together in a large flask and subjected to a series of 
communal rinses using successively 5% trichloracetic acid, phosphate- buffered saline 
(pH 7.2) and absolute methanol, each rinse lasting for 5 min. The discs were then redried in 
an oven on sheets of absorbent paper, placed in glass counting vials containing 5 ml of 
scintillation fluid and finally counted for 60 sec in an automatic beta counter (Packard 
Tricarb 2425). Results are expressed as counts per minute (cpm), the counting efficiency 
being constant. 
Vials and scintillation fluid were re- usable by simply removing the filter disc. Before re- 
use the vials were screened by counting for 10 sec and any giving a background of greater 
than 100 cpm were rejected. 
Variations in culture extraction procedure 
In experiment 7, the reproducibility of the method described above, that is the `dry and 
communal rinse' procedure, was compared with the more commonly used method of har- 
vesting and extraction on a filtration manifold: after culture in micro plates under standard 
conditions, cells were bulked together and aliquots distributed on a series of filter discs, 
which were then washed either on a filtration manifold or by the `communal rinse' method. 
RESULTS 
(1) Dose response to PHA 
Fig. 1 shows the mean response of lymphocytes from eight subjects to a range of six 
concentrations of PHA. A good level of [3H]thymidine incorporation was consistently 
achieved at all doses, the peak responsg'lying between 0.32 and 1.25 pl of PHA per ml culture. 
Fig. 1 also illustrates the enhanced uptake of label obtained when the optimal concentration 
of thymidine is used (vide infra). Maximal levels of incorporation again occurred at PHA 
doses between 0.32 and 1.25 yl /ml culture; at higher doses the toxic effect of PHA was 
again evident and the uptake of label was less. 
(2) Effect of incubation time on [3H]thymidine incorporation 
Lymphocytes from five subjects were used. Fig. 2 shows that under the stated conditions, 
the highest incorporation of label was achieved with a total culture period of 48 hr, was 
slightly lower after 72 hr and thereafter declined rapidly with increasing length of culture. 
Thus, the period arbitrarily chosen for convenience, i.e. 48 hr, is that which also yields the 
highest observed incorporation. 
(3) Relationship between thymidine concentration and incorporation of [3H]thymidine 
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cells was found to occur in linear fashion until the concentration of thymidine reached 
8 x 10 -4 mM (4 µCi /ml) (Fig. 3). Further increase in thymidine concentration thereafter 
did not lead to a corresponding increase in incorporation of label, indicating that the satu- 
rating level of isotope (i.e. the concentration at which the influence of endogenous thymidine 
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FIG. 1. Mean lymphocyte responses in eight subjects to a range of PHA doses. (o) Mean 
s.e.m. of response at a sub -optimal concentration of thymidine (4 x 104 mM). () Mean ± s.e.m. 
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FIG. 2. Effect of length of culture on the level of [3H]thymidine incorporation of PHA- stimu- 
lated lymphocytes from five subjects. Each point represents the mean ± s.e.m. of five experiments. 
( 8 x 10 -4 mM under the stated conditions. In unstimulated cultures, the amount of 
idiation increased steadily throughout the range of thymidine concentration, reflecting the 
icreasing background level of radiation. 
Effect of increasing the specific activity of [3H]thymidine 
This experiment used lymphocytes from six donors and enabled the toxic effects of [3H] 
i 
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thymidine label caused by internal radiation to be investigated. Fig. 4 demonstrates that 
a linear incorporation of label was obtained throughout the range of specific activities 
used, suggesting that even at the higher levels of radiation DNA synthesis was not adversely 
affected. However, when the actual incorporation at each specific activity was compared 
with that predicted by calculation from the incorporation at the lowest specific activity 
10° 
10' 
5xIO2 20 40 0 16.0 
Thymidine concentration (x10 -4mm) 
FIG. 3. The relationship between thymidine concentration and incorporation of label in 
lymphocytes from five subjects. () Mean± s.e.m. of five experiments using PHA -stimulated 
cells. (o) Mean +s.e.m. of identical cultures of unstimulated cells. 
016 0-32 0.63 1.25 25 
Specific activity (Ci /mmole) 
FIG. 4. Relationship of specific activity of [3H]thymidine and incorporation of label in lym- 
phocytes from six subjects. () Mean +s.e.m. of the observed cpm at each specific activity. 
(o) Value expected at each specific activity by calculation from the cpm observed at a specific 
activity of 0.16 Ci /mmole (where irradiation damage is minimal). The hatched area shows the 
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(where toxic effects could be assumed to be negligible) it was clear that a progressive decline 
in incorporation from the calculated level was taking place. Since the concentration of 
thymidine was at saturating levels throughout the range of specific activities this loss could 
be attributed to the effect of internal irradiation due to the increase of specific activity 
alone. Thus it is evident that the use of higher specific activities of isotope, whilst increasing 
the cpm, also incurs the penalty of a progressive burden of damage due to internal irra- 
diation. Since the effect was noted even at the lowest specific activities ( -'300 mCi /mmole) 
it is not possible to avoid some radiation damage if adequate cpm are to be obtained. 
Throughout this study 5 Ci /mmole has been arbitrarily selected for all experiments as it 
yielded a suitable number of counts. However, from this particular experiment, it is evident 
that for routine use a lower specific activity would be more appropriate which, although 
giving a lower incorporation of label, will more accurately reflect the response to PHA. 
60 
0 I I I 
0 4 a 12 /i 24 
Length of [3H] Thymidine pulse (hr) 
FIG. 5. Effect of pulse time with [3H]thymidine and the level of incorporation of label by PHA - 
stimulated lymphocytes from five subjects. Each point represents the mean ± s.e.m. of five 
experiments. 
(5) Effect of length of [3H]thymidine pulse 
These experiments examined the period over which saturation conditions with thymi- 
ne were maintained. The effect of the length of a continuous pulse was investigated 
mg lymphocytes from five donors and shows (Fig. 5) that even with a thymidine 
ncentration of 4 x 10 -4 mM, a constant rate of uptake of label was maintained over 
2 hr. This suggests that adequate levels of thymidine were available to provide saturating 
onditions throughout this period, thus minimizing the dilutional effects from endogenous 
hymidine. In a further series of experiments, using lymphocytes from the same pool of 
althy donors but a higher concentration of thymidine, the accumulated uptake achieved 
y separate hourly pulses over the selected 4 -hr labelling period was compared with a con - 
nuous pulse over the same period. Fig. 6 shows that the incorporation level of the con- 
nuously pulsed cultures was identical with the level reached by accumulating the individual 
ourly pulses, again showing that an adequate saturating or flooding level was maintained 
y a single continuous pulse throughout the 4 -hr period. 
(. 
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(6) [3H]thymidine incorporation at different lymphocyte concentrations 
Using lymphocytes from twelve donors, a linear incorporation of [3H]thymidine was 
found over the range 0.1 x 106 -0.5 x 106 cells /ml (0.2 x 105 -1.0 x 105 cells /culture) 













FIG. 6. Effect of exposure time to [3H]thymidine on the rate of incorporation of label by PHA - 
stimulated lymphocytes from five subjects. The columns show the mean± s.e.m. of the hourly 
incorporations, [3H]thymidine being added at hourly intervals from 44 to 48 hr. (9--0) 
mean± s.e.m. of continuously pulsed cultures using the same lymphocytes, [3H]thymidine being 
added at 44 hr and incubation continuing until 48 hr. (o - - o) Cumulative incorporation 
based on the summation of the hourly incorporations. 
105 
103 I I I I 
GI 02 05 I.0 20 30 
Lymphocyte concentration (x106 /m1 ) 
FIG. 7. Influence of lymphocyte concentration on the incorporation of label. Each point 
represents the mean response+ s.e.m. of lymphocytes from twelve donors. 
culture) (Fig. 7). Thereafter no further increase in uptake occurred, indicating that an upper 
limit of 1 x 106 cells /ml (2.0 x 105 cells /culture) can be used in this system with optimal 



















Jay -to -day 








A rapid micro -method for lymphocyte transformation 163 
(7) Reproducibility of the method 
Several aspects of the reproducibility of the method have been examined. In Fig. 8 the 
variation between individual counts in each triplicate set of a series of a hundred con- 
secutive determinations is expressed as the percentage coefficient of variation. In 93% of the 
triplicate series this was less than 15 %, with the mode between 5 and 10 %, indicating that 
the reproducibility of both culture and extraction procedures was within acceptable limits 











0 5 10 5 20 25 30 
Coefficient of variation (%) 
FIG. 8. Percentage coefficients of variation within each triplicate set of a series of 100 con- 
secutive samples. 
The reproducibility of the extraction procedure alone was then compared with that of the 
extensively used method of manifold filtration. The effects of variation due to culture were 
eliminated by bulking all the cells after [3H]thymidine labelling and transferring equal 
aliquots to the filters. Whilst comparable mean cpm were obtained, the coefficient of vari- 
ation was considerably greater with filtration than with the `communal rinse' procedure 
(Table 1). 







counted (x 103) (%) 
`Communal 
rinse' 
20 69.0 ± 0.91 6 
Filtration 20 59.9 ±3.09 23 
Finally, the variability observed in repeated samples obtained from a number of healthy 
)ersons and patients with organ -specific autoimmune diseases was investigated. In Table 2, 
lay -to -day variations are presented for a group of five normal subjects at one dose of PHA 
125 pl /m1) showing the degree of variability to be expected in healthy individuals when 
luctuations due to factors such as infection are minimized by frequent sampling. Even under 
L* 
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TABLE 2. Repeated daily PHA response in normal subjects 
Age 
Mean cpm (x 103) Coefficient of 
variation 
Subject (years) Day 1 Day 2 Day 3 (%) 
Male 31 16.2 15.8 19.1 10.6 
Male 29 15.5 14.8 9.5 24.7 
Male 34 22.6 33.5 18.3 31.5 
Male 32 38.3 21.7 28.6 28.0 
Male 26 24.7 21.2 25.9 10.0 
TABLE 3. PHA responses over an extended period in normal and autoimmune 
subjects 
Subject Age /sex Date 
PHA (µl /ml) 
No PHA 0.3 0.6 F2 
Normal 30 /M 23.7.73 0.4 10.5* 25.5 26.1 
20.8.73 0.6 10.9 14.1 14.6 
11.9.73 0.5 8.2 10.5 142 
15.10.73 0.6 11.1 15.0 16.4 
4.11.73 0.4 10.5 15.1 17.1 
Normal 28/M 23.7.73 02 15.7 20.9 13.3 
16.10.73 0.4 13.1 20.4 18.7 
4.11.73 0.5 14-2 22-7 16.4 
Normal 27/M 24.7.73 0.2 16.0 22.8 25.1 
20.8.73 0.7 22.1 19.8 21.3 
15.10.73 0.6 18.5 20.4 24.6 
Normal 31 /M 25.7.73 0.3 21.6 27.4 24.4 
4.11.73 0.6 15.6 242 19.9 
Normal 32/M 6.8.73 0.5 13.9 14.8 15.2 
4.11.73 ; 0.6 14-1 16.6 20.0 
Normal 29/M 2.8.73 0.3 18.3 22.0 26.6 
12.9.73 0.6 3.4 5.4 5.7 
Normal 26/F 2.8.73 0.4 144 26.0 24.5 
12.9.73 0.5 13-0 21.6 12.0 
Normal 24/F 8.10.73 0.3 10.5 16.3 15.8 
31.10.73 0-2 12.9 15.6 14.9 
Normal 37/F 4.9.73 0.4 10.0 12.5 16.7 
31.10.73 0.3 102 12.0 18.4 
Pernicious 63/F 14.8.73 0.6 8.0 9-0 1F9 
anaemia 4.9.73 0.9 6.5 7.6 1F7 
Pernicious 74/F 14.8.73 0.5 3.7 6.9 9.1 
anaemia 4.9.73 0.7 32 6.8 13.3 
Addison's 46/M 21.8.73 0.3 2.6 6.3 4.4 
disease 14.9.73 0.6 2.6 6.3 4.7 
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A rapid micro -method for lymphocyte transformation 165 
these circumstances it is evident that the coefficient of variation may be as high as 30% 
between samples from'the same subject. The results of repeated sampling of normal subjects 
and patients with autoimmune disease, over a much wider period of time, are shown in 
Table 3. On those samples tested more than twice, a mean coefficient of variation of 15% 
was found over the range of three PHA doses. However, in some individuals, the variation 
was again in the region of 30 %. 
Although precise age- and sex -matched controls are not presented here with which to 
compare autoimmune patients, it can be seen that in these patients the counts are con- 
siderably lower than in the normal subjects. This discrepancy cannot be accounted for by 
the inherent variability between samples. A depression of PHA transformation has been 
found to be a regular feature of certain forms of organ- specific autoimmunity and is 
currently under further investigation in this laboratory (MacCuish et al., to be published). 
DISCUSSION 
Doubts have recently been expressed concerning the selectivity of PHA for human thymus - 
derived T lymphocytes, as evidence has been presented showing that in man some B lympho- 
cytes are also stimulated to transform (Phillips & Roitt, 1973). However, the test has proved 
of value in resealing immunological deviations in a number of clinical states, and its use in 
this context is likely to continue; it may, perhaps, come to be regarded as a convenient means 
of assessing the functional level of the recirculating pool of lymphocytes in general, rather 
than the T -cell element specifically. 
Fitzgerald (1971) has shown that in certain immunodeficiency states the dose of PHA 
which gives the most sensitive discrimination between normal and abnormal response is not 
necessarily that producing the maximum response. It is probable that the same effect holds 
for other clinical disorders and it is therefore desirable to use a range of doses of PHA with 
each lymphocyte sample rather than a single dose. The value of a rapid micro -method 
requiring small numbers of cells in this context is obvious. Most previous clinical studies of 
lymphocyte transformation with PHA have employed cell concentrations of 106 or more 
per culture. Under the conditions we describe it has been found not only more expedient to 
use fewer cells but also necessary, since 106 /ml was found to be the upper limit of linearity 
when the relationship between lymphocyte numbers and [3H]thymidine uptake was investi- 
pted. This finding is in agreement with the conclusions of others including Yamamura 
1973). Using the micro -method as described, and a standard concentration of 0.5 x 106 
:ells per ml (1 x 105 cells /culture), it is possible to investigate the full dose -response profile 
o PHA, with all samples in triplicate, using a total of 2 x 106 lymphocytes. This number 
an readily be obtained from 5 ml of peripheral blood. 
Earlier studies have also used longer culture periods, usually of 72 hr. Under the present 
:onditions we have found that there is nothing to be gained by culturing for this duration 
Rice a higher incorporation of label is attained using the shorter, more convenient time of 
8 hr. 
A recent investigation of thymidine kinetics in human lymphocyte transformation 
ïample & Chretien, 1971) has emphasized the need to obtain optimal labelling conditions; 
its is necessary to achieve maximum efficiency of labelling. Furthermore, DNA synthesis 
y different cell populations can only be compared correctly if the same intracellular activity 
f labelled precursor is reached in each population. These conditions can only be achieved 
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if the culture is saturated, or flooded, with thymidine throughout the labelling period. It is 
therefore important to determine the optimal conditions for a particular method, as has 
been done in the present study, before it is applied to routine use. 
When determining optimal labelling conditions it is also necessary to ensure that intra- 
nuclear disintegrations resulting from the incorporation of labelled precursor do not cause 
unacceptable radiation damage to the cells. Drew & Painter (1962) have shown that the 
extent of cellular damage is a product of the specific activity of the label and the duration 
of exposure. In the present study we have found evidence that even at the lower specific 
activities there is an appreciable effect due to internal radiation, and this becomes pro- 
gressively more severe with increasing specific activity. This effect does not seem to have 
been taken into account in many clinical studies where isotope of high specific activity is 
frequently used (up to 30 Ci /mmole in some studies) and may be combined with relatively 
long labelling periods (up to 3 days). Since it appears that some cell damage due to this 
effect is unavoidable it is necessary to compromise and use the lowest specific activity con- 
ducive with adequate cpm over the shortest possible pulse time. For routine use it is there- 
fore suggested that the specific activity of the isotope should not be greater than 2 Ci /mmole 
and the pulse time no longer than 4 hr. 
The extraction of DNA by drying and `communal rinsing' has been found to have a 
number of advantages over more extensively used methods. 
(1) It requires less time for the extraction of a given number of cultures than methods 
based either on centrifugation or filtration. 
(2) It is more sparing of reagents. 
(3) No specialized or expensive equipment is necessary. 
(4) Both counting vials and scintillant can be re -used. 
(5) It has proved to be more reproducible in our hands than either centrifugation or 
filtration procedures. 
In conclusion, we recommend the following conditions for the PHA transformation test. 
0.5 x 106 lymphocytes /m1 (105 /culture) are cultured in EBM with 10% foetal calf serum 
for 44 hr in the presence of PHA at concentrations of 0.32, 0.63 and 1.25 pi /ml culture. 
Thereafter [3H]thymidine of specific activity 2 Ci /mmole is added at a final concentration 
of 8 x 10 -4 mm, and the cultures incubated for a further 4 hr before termination. Studies 
of the effect using culture media other than EBM have not been undertaken. 
The use of a dose -response curve to PHA, rather than a single concentration, may 
facilitate the identification of patients with abnormalities of cell- mediated immunological 
function. This response curve requires to be recalibrated for each batch of PHA. 
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SUMMARY 
The lymphocyte transformation response to the mitogen 
phytohemagglutinin (PHA) was determined in forty well controlled 
insulin- dependent diabetics, forty matched normal subjects and 
fourteen poorly controlled insulin -dependent diabetics. There was 
no significant difference in the PHA responses of normal subjects 
and well controlled diabetics, but poorly controlled diabetics 
showed a marked depression of lymphocyte transformation. 
Peripheral blood T and B lymphocyte subpopulations were also 
measured in fifteen normal subjects, fifteen well controlled diabe- 
tics and ten poorly controlled diabetics. The results showed no 
significant difference between normal and diabetic subjects, 
whether well or poorly controlled. 
The depressed PHA response in poorly controlled diabetics 
would seem to reflect inadequately corrected metabolic distur- 
bance rather than an inherent, genetically determined im- 
munologic abnormality. DIABETES 23:708 -12, August, 1974. 
Recent studies have examined the role of cell - 
mediated immune mechanisms in diabetes mellitus. 
For example, the leucocyte migration test (LMT)1 has 
reportedly shown cellular hypersensitivity in diabetics 
against both nonspecific antigens (human and rat liver 
mitochondria') and an antigen derived from the mi- 
crosomal fraction of the islets of Langerhans (porcine 
pancreatic antigens). In the latter study a positive 
;;correlation was found between the LMT response and 
delayed -type skin hypersensitivity to the antigen.3 
From the Departments of Endocrinology and Diabetes, Royal 
Infirmary, Immunology Laboratories, Forrest Road, and Depart- 
ment of Therapeutics, University of Edinburgh, Edinburgh, Scot- 
!' land. 
Accepted for publication April 24, 1974. 
Other investigators have used the lymphocyte 
transformation response to the mitogen phytohemag- 
glutinin (PHA)4 as an in vitro test of cell- mediated 
immune function: some record the PHA response to 
be impaired with diabetic lymphocytes,' suggesting 
immunologic abnormality, while others report it to be 
normal.' To re- examine these results we have meas- 
ured the lymphocyte transformation response to PHA 
in well controlled and poorly controlled insulin - 
dependent diabetics and in normal subjects; in addi- 
tion erythrocyte rosette 7 -9 and in indirect immuno- 
fluorescence 7,9 technics have been used to compare 
the numbers of circulating T and B lymphocytes in 
peripheral blood from these three groups. 
PATIENTS AND METHODS 
Patients 
PHA responses were studied in forty well con- 
trolled diabetic and forty normal subjects who were 
carefully matched for age and sex. The diabetic sub- 
jects (twenty -two women, eighteen men; mean age 
42.4 years) were insulin- dependent, attended an out 
patient clinic, and were free from infection on the day 
of study. The control subjects were healthy volun- 
teers, mainly laboratory personnel or hospital outpa- 
tients not known to have endocrine disease or im- 
munologic abnormality. 
PHA responses were also studied in a group of four- 
teen poorly controlled insulin- dependent diabetics. 
These patients had been brought to an outpatient 
clinic for routine or emergency review and their disor- 
der was judged to be poorly controlled by the follow- 
ing criteria: midmorning blood glucose exceeding 350 
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mg. /100 ml.; recent increase in insulin requirements; 
the presence of heavy glycosuria and /or ketonuria. 
Some were subsequently admitted to the hospital for 
correction of their metabolic abnormalities but none 
had received antibiotics-or drugs other than insulin at 
the time of study. Their clinical details are presented 
in table 1. 
T and B cell subpopulations were measured in fif- 
teen of each of the well controlled diabetic and normal 
subjects and in ten of the poorly controlled diabetic 
subjects. 
Collection of blood samples and separation of lymphocytes 
Venous blood was withdrawn at midmorning and 
was anticoagulated with preservative -free heparin 
(Weddell Pharmaceuticals or Evans Medical). A por- 
tion of each sample was used for measurement of total 
and differential white blood cell counts. Lymphocytes 
were separated from the remainder by density cen- 
trifugation on a Ficoll -Triosil gradient10 and washed 
three times in Eagles' Basal Medium (EBM, Well- 
come Reagents Ltd.). The cells were then resuspended 
in EBM with 10 per cent fetal calf serum (Wellcome), 
counted and the concentration adjusted to 1 x 106 
cells per milliliter. All cell suspensions contained 
more than 95 per cent lymphocytes with a viability 
greater than 98 per cent on trypan blue exclusion. 
Lymphocytes from the same sample were used for the 
PHA test and for T and B cell estimations. 
Lymphocyte culture with PHA 
Stock PHA (PHA -P, Difco) was diluted in EBM 
TABLE 1 
Clinical details of the fourteen poorly controlled diabetic patients in 







(mg. per cent) 
Cause of poor control 
24/F 10.b 358 Depressive illness 
37/F 0.3 355 Recent diagnosis. 
Establishing control 
48/F 5.2 450 Urinary tract infection 
60 /F 16.0 355 Emotional stress 
61 /F 11.0 352 Upper respiratory tract 
infection 
66/F 5.0 440 Foot infection 
68/F 0.05 385 New diagnosis. Establishing 
control 
69/F 7.1 650 Congestive cardiac failure 
17 /F 6.9 510 Ketoacidosis, cause unknown 
19 /M 10.0 365 Skin sepsis, chest infection 
28 /M 13.0 408 Alcoholic, drinking bout 
'45/M 6.0 400 Acute bronchitis 
46/M 9.0 360 Dental infection 
60 /M 3.7 800 Bronchopneumonia 
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with 10 per cent fetal calf serum to give three solu- 
tions containing respectively 0.32, 0.63 and 1.25.1. 
PHA per milliliter. Aliquots of 20p I. ofeach solution 
were pipetted into the wells of Cooke Microtiter trays 
(Flow Laboratories) and 2 x 105 cells added to each 
well. All determinations were performed in triplicate 
and included control cultures without PHA. The mi- 
crotrays were gassed with an air -5 per cent CO2 mix- 
ture and incubated at 37° C. in sealed containers. 
3H- thymidine of specific activity 5 Ci. /mmol 
(Radiochemical Centre, Amersham) was diluted with 
sterile saline to give a working concentration of 2 
iCi. /100 µl. Twenty microliters of this solution (i.e. 
0.4 pCi.3H- thymidine) was added to each culture 
after forty -four hours' incubation. The cultures were 
regassed and reincubated for four hours. The contents 
of the wells were then pipetted on to fiberglass filter 
papers (Whatman GF /C) which were air -dried, 
washed successively with cold 5 per cent trichloracetic 
acid, phosphate buffered saline and absolute 
methanol, and finally placed in Packard glass count- 
ing vials. Five milliliters of scintillation fluid 
(NE233, Nuclear Enterprises Ltd.) was added to each 
vial and the samples counted for sixty seconds in an 
automatic beta counter (Packard 2425), the results 
being expressed as counts per minute (cpm). 
Identification of T lymphocytes by sheep erythrocyte rosettes 
The technic used' to identify E- rosettes was derived 
from that of Jondal et al. 8 and incorporated the mod- 
ifications of Stjernsward et a1.3 
Identification of B lymphocytes 
Two technics were used: a rosette technic" using 
sheep red cells coated with antibody and complement 
(EAC rosettes), and indirect immunofluorescence,''8 
whereby the cells are distinguished by surface im- 
munoglobulin marker. 
RESULTS 
Lymphocyte transformation with PHA 
The dose -response curves of lymphocytes from well 
controlled diabetic and normal subjects are shown in 
figure 1. The mean transformation responses in the 
diabetics to the three doses of PHA employed were 
17.0 ± 4.3, 20.8 ± 4.2 and 21.4 ± 4.3, respectively 
(expressed as cpm x 103 ± S.E.M.). The correspond- 
ing values in the controls were 15.3 ± 4.3, 19.7 ± 
3.9 and 21.8 ± 3.9. Both curves are virtually identi- 
cal and the lymphocyte transformation response to 
PHA is not abnormal in well controlled diabetics. 
The dose -response curve of lymphocytes from the 
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FIG. 1. Mean lymphocyte transformation responses in forty well 
controlled insulin- dependent diabetic ( ) and forty 
age- and sex -matched normal subjects ( ) at three con- 
centrations of PHA. The two dose -response curves do not 
differ significantly. S.E.M.'s are omitted for clarity but are 
given in the text. 
figure 2 with the curve obtained from fourteen of the 
well controlled diabetics, matched as closely as possi- 
ble for age, sex and duration of diabetes. The mean 
transformation responses in poorly controlled diabe- 
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FIG. 2. Lymphocyte transformation responses (mean ± S.E.M.) in 
fourteen poorly controlled insulin- dependent diabetics 
( -) and fourteen well controlled insulin- dependent 
diabetics ( - - --), who were matched for age, sex and dura- 
tion of diabetes. The mean response in the poorly control- 
led diabetics is significantly lower (p < 0.001) at all con- 
centrations of PHA. 
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± 1.4 and 8.2 ± 0.6, respectively. The correspond- 
ing values in well controlled diabetics were 16.5 ± 
2.0, 20.2 ± 1.9 and 21.3 ± 2.0. These results show 
a statistically significant reduction of PHA response in 
poorly controlled insulin- dependent diabetics at all 
three concentrations of PHA (p<0.001 by the Stu- 
dent t test). 
Populations of T and B lymphocytes in peripheral blood 
Tables 2, 3 and 4 list the total lymphocyte counts 
and the numbers of circulating T and B cells, expres- 
sed both as absolutes and percentages of total lympho- 
cyte counts, in samples taken respectively from fifteen 
well controlled diabetics, fifteen normal subjects and 
ten poorly controlled diabetics. The results show no 
significant difference in the mean number and percen- 
tage of T cells (assessed by E- rosettes) or B cells (asses- 
sed by EAC rosettes or immunofluorescence technics). 
Circulating lymphocyte subpopulations are therefore 
normal in diabetics when obtained at times of 'good' 
and `poor' metabolic control. 
DISCUSSION 
The above results confirm that lymphocyte trans- 
formation to blast cells by PHA, generally accepted as 
an in vitro test of cell- mediated immunologic 
response,1112 is normal in well controlled insulin - 
dependent diabetics when compared with matched 
normal controls. This agrees with the results of Ragab 
et al.6 who found no differences in the PHA responses 
of lymphocytes from twenty -three diabetics and 
twenty -four controls. Contrary results (depression of 
PHA response) reported by Brody and Merlie5 were 
based on the observations in six elderly diabetics who 
had persistent glycosuria and marked hyperglycemia 
(blood glucose 300 to 514 mg. per 100 ml.), and had 
not taken insulin between twelve and twenty -four 
hours before the lymphocytes were obtained for study. 
It therefore appears likely that these results reflect the 
metabolic disturbance in poorly controlled diabetes, 
rather than any inherent immunologic abnormality, 
and the present findings in poorly controlled diabetic 
subjects agree with this hypothesis. 
Further support for the view that depressed PHA 
response in diabetics is due to metabolic abnormality 
is provided by the finding of normal numbers of cir- 
culating T and B lymphocytes in diabetics, irrespec- 
tive of whether they were well or poorly controlled at 
the time of study. Since PHA response is considered 
mainly to test the function of the T -cell population,11 
it would be surprising to find a depression of PHA 
response in subjects with normal numbers of T cells; 
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TABLE 2 
Total lymphocyte counts and subpopulations of T and B lymphocytes in peripheral blood from fifteen well controlled insulin- dependent diabetic 
patients. (E) = T lymphocytes identified by sheep erythrocyte rosettes. (EAC) = B lymphocytes identified by erythrocyte- antibody -complement 
rosettes. (IF) = B lymphocytes identified by indirect immunofluorescence. 
Age /Sex Total T -cells T -cells B -cells B -cells B -cells B -cells 
Lymphocyte (E) (E) (EAC) (EAC) (IF) (IF) 
count/mm3 number per cent number per cent number per cent 
22/F 1,403 878 62.6 449 32.0 
28/F 2,350 1,465 62.3 357 15.2 
35/F 1,566 1,038 66.3 188 12.0 227 14.5 
55/F 2,560 1,318 51.5 294 11.5 
56/F 2,211 1,282 58.0 104 4.7 736 33.3 
59/F 1,320 854 64.7 121 9.2 300 22.7 
62/F 671 374 55.8 203 30.3 221 33.0 
62/F 1,360 743 54.6 299 22.0 
68/F 2,132 1,552 72.8 544 25.5 452 21.2 
17 /M 2,464 1,627 65.9 315 12.8 490 19.9 
19 /M 3,250 1,570 48.3 504 15.5 523 16.1 
36/M 1,975 1,284 65.0 375 19.0 257 13.0 
42/M 1,682 1,182 70.3 579 34.4 
63/M 1,440 935 64.9 2,321 16.1 
Mean 1,879 1,153 62.0 338 19.5- 375 20.4 
±S.E.M. 165 91 1.79 56 3.29 42 1.98 
except perhaps in diseases such as breast cancer,I3 
multiple sclerosis,14 or active syphilisis where the 
serum itself may contain factors inhibiting lympho- 
cyte transformation, and in subjects treated with the 
drug co- trimoxazole. t6 The possibility of finding in- 
hibitory factors in the sera of poorly controlled diabe- 
tics is presently being investigated and preliminary 
results suggest that hyperglycemia per se may contri- 
bute to depressed lymphocyte transformation in these 
patients. Finally, it should be noted that the demon- 
stration of a normal PHA response and T -cell popula- 
tion in well controlled insulin- dependent diabetics 
does not exclude the possibility that smáller numbers 
of circulating lymphocytes in such patients may show 
transformation when exposed to a specific antigen, 
perhaps derived from pancreatic islet tissue. 
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TABLE 3 
Total lymphocyte counts and subpopulations of T and B lymphocytes in peripheral blood from fifteen normal subjects. 
Abbreviations as for table 2. 
Age /Sex Total T -cells T -cells B -cells B -cells B -cells B -cells 
Lymphocyte (E) (E) (EAC) (EAC) (IF) (IF) 
count/mm3 number per cent number per cent number per cent 
27/F 1,333 857 64.3 216 16.2 
27/F 710 474 66.8 192 27.0 90 12.7 
38/F 1,976 1,320 66.8 174 8.8 326 16.5 
47/F 1,606 896 55.8 527 32.8 390 24.3 
55/F 1,817 950 52.3 136 7.5 
57/F 770 506 65.7 218 28.3 123 16.0 
57/F 2,667 1,560 58.5 494 18.5 416 15.6 
64/F 2,184 1,223 56.0 109 5.0 618 28.3 
69/F 2,054 1,516 73.8 496 24.1 251 12.2 
18 /M 3,000 2,223 74.1 1,125 37.5 690 23.0 
25/M 700 513 73.3 86 12.3 123 17.5 
35/M 2,379 1,421 59.3 43 1.8 816 34.3 
42/M 1,974 1,137 58.4 516 26.5 405 20.8 
66/M 1,672 1,167 69.8 274 16.4 
Mean 1,855 1,194 64.4 323 19.4 415 20.5 







































PHYTOHEMAGGLUTININ TRANSFORMATION AND CIRCULATING LYMPHOCYTE SUBPOPULATIONS 
TABLE 4 
Total lymphocyte counts and subpopulations of T and B lymphocytes 
in peripheral blood from ten poorly controlled insulin- dependent diabe- 
tic patients. Abbreviations as for table 2. 















24/F 1,035 735 71.0 207 20.0 
37/F 2,700 2,173 80.5 259 9.6 
60 /F 1,936 1,073 55.4 407 21.0 
61/F 2,430 1,638 67.4 676 27.8 
66/F 2,436 1,571 64.5 470 19.3 
68 /F 1,850 1,166 63.0 487 26.3 
19 /M 600 303 50.5 102 17.0 
28 /M 1,472 883 60.0 202 13.7 
45/M 1,971 1,242 63.0 242 12.3 
46/M 1,950 1,225 62.8 558 28.6 
Mean 1,838 1,201 63.8 361 19.5 
± S.E.M. 145 109 1.59 38 3.25 
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Autoimmunological Aspects of Diabetes 
Mellitus 
A. C. MACCUISH 
W. J. IRVINE 
Until recently, diabetes mellitus has been a disease surprisingly neglected by 
clinical immunologists but this situation is now being remedied and the past 
five years in particular have seen an increasing volume of research effort 
directed to this common endocrinopathy. In this chapter, the current state 
of knowledge in the following aspects of autoimmunity as related to diabetes 
mellitus is reviewed: 
1. The clinical associations between diabetes and other diseases in which 
autoimmunity is postulated or established as a major aetiological factor. 
2. The serological associations of diabetes with other autoimmune diseases, 
i.e., studies on the prevalence of serum antibodies to non -pancreatic 
antigens in diabetics. 
3. Studies of serum antibodies to pancreas and pancreatic hormones in 
diabetes. 
4. Studies of cell- mediated autoimmune mechanisms in diabetes. 
5. Studies of histocompatibility (HL -A) antigen typing in diabetes. 
6. Pathological changes in the pancreas of early or untreated diabetes. 
7. Viral infection in relation to the onset of diabetes. 
8. Immunological abnormalities in relation to the microvascular complica- 
tions of diabetes. 
The studies reviewed here are mainly concerned with human diabetes 
mellitus; the most important animal models in which experimental diabetes 
has been induced by immune mechanisms are also briefly considered. 
CLINICAL ASSOCIATIONS BETWEEN DIABETES 
AND AUTOIMMUNE DISORDERS 
Some of the earliest and most compelling indirect evidence for abnormal 
immune mechanisms in diabetes has been provided by the clinical observation 
of an association between diabetes and other disorders of putative or estab- 
lished autoimmune aetiology. Coexisting diabetes and adrenal insufficiency 
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in a single patient was first recorded in the mid -nineteenth century (Ogle, 
1866) and numerous subsequent studies have reinforced the view that the 
two disorders -one common, one rare -are linked more intimately than can 
be accounted for by chance (Balfour and Sprague, 1949; Faber and Gronbaek, 
1956; Beaven et al, 1959; Solomon et al, 1965; Irvine and Barnes, 1972; 
Nerup, 1974). From these and other studies the prevalence of diabetes in 
Addison's disease has been reported as between seven and twenty -three per cent, 
with an approximate average of eighteen per cent (Irvine and Barnes, 1974), 
thus representing at least a six -fold excess over the estimated prevalence (one to 
three per cent) of diabetes in the overall population of Britain or the United 
States (Marks, Krall and White, 1971). Fewer investigators have attempted 
to estimate the prevalence of Addison's disease in diabetes but Kozak (1971) 
recorded a figure of 0.023 per cent among newly -diagnosed cases of diabetes 
at the Joslin Clinic and Nerup (1974) reported a very similar figure (0.028 
per cent) when he examined the prevalence of Addison's disease in a popula- 
tion of fifty thousand Danish diabetics. The prevalence of Addison's disease 
in the general population has been estimated at between 0.0039 per cent 
(Stuart -Mason et al, 1968) and 0.0060 per cent (Nerup, 1974b); thus the 
excess prevalence of Addison's disease in diabetics appears to be in the order 
of five -fold over the general population. 
The development of more sophisticated diagnostic aids, in particular the 
ability to detect organ- specific humoral antibodies (Anderson et al, 1957; 
Blizzard and Kyle, 1963), has confirmed that diabetes is usually associated 
with idiopathic (autoimmune) adrenalitis rather than tuberculous adrenal 
destruction, and this is borne out by pathological studies. One extensive 
review of the literature noted idiopathic adrenal atrophy in seventy -four 
per cent, and tuberculous adrenal involvement in only twenty -two per cent 
of those patients with dual disease who came to autopsy, and a similar 
pattern of adrenal pathology was demonstrated in diabetics with combined 
thyroid and adrenal dysfunction (Solomon et al, 1965). It has also become 
clear that autoimmune adrenal disease is associated with the juvenile -onset 
(insulin- dependent) rather than the maturity -onset (insulin- independent) 
type of diabetes, that adrenal failure precedes pancreatic failure and vice 
versa in approximately equal numbers, and that both diseases make a 
simultaneous clinical appearance in the minority of cases (Irvine and Barnes, 
1974; see also Chapter 8). 
The association between diabetes and pernicious anaemia was first reported 
in 1910 (Parkinson, 1910) and since then has been described by several 
investigators (Arapkis et al, 1963; Ungar et al, 1968; Irvine et al, 1970; 
Munichoodappa and Kozak, 1970). The prevalence of diabetes in patients 
with pernicious anaemia is said to be seven per cent (Ungar, Whittingham 
and Francis, 1967), again well in excess of the figure for the general population, 
and conversely the prevalence of pernicious anaemia in selected diabetic 
populations has been variously estimated as 0.39 per cent (Chanarin, 1964), 
four per cent (Ungar et al, 1968) and five per cent (Irvine et al, 1970). The 
lower figures probably underestimate the true position as pernicious anaemia 
is often of latent form in diabetics and associated with intrinsic -factor anti- 
bodies (frequently suggested as the `marker' of latent or frank pernicious 
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anaemia) in only fifty to sixty per cent of cases (Ardeman and Chanarin, 
1963; Irvine, 1965). An accurate estimate of prevalence is therefore only 
achieved when the clinician is prepared to screen all diabetics at risk (mainly 
middle -aged to elderly females, irrespective of antidiabetic treatment) not 
only for intrinsic- factor antibodies but also for an adequate serum vitamin 
B12 level (Ungar, Whittingham and Francis, 1967). 
Multiple reports have suggested an association between diabetes and 
thyroid disorders. The diseases in question comprise thyrotoxicosis, usually 
in juvenile diabetics (Hayles et al, 1959; Perlman, 1961), chronic or Hashi- 
moto thyroiditis in both children and middle -aged patients (Landing et al, 
1963; Masi et al, 1965; Crome, Erdohezi and Rivers, 1967), and primary 
hypothyroidism (Solomon et al, 1965; Hecht and Gerschberg, 1968; 
Andreani, 1974). Both pernicious anaemia and thyroid disorders occur with 
significant frequency (three and nine per cent respectively) in the first -degree 
relatives of diabetic patients (Irvine et al, 1970). 
Finally, an association of diabetes with myasthenia gravis has also been 
recently documented (Osserman, 1969). 
SERUM ANTIBODIES TO NON -PANCREATIC ANTIGENS 
IN DIABETES MELLITUS 
The clinical associations of diabetes with autoimmune diseases are impressive 
but perhaps even more striking is the high prevalence of certain organ- specific 
autoantibodies in diabetic serum. Numerous serological studies have been 
performed in diabetics, directed in particular to the detection of thyroid or 
gastric autoantibodies, and the results of some of the more extensive in- 
vestigations are presented in Table 1. These studies have been performed in 
young and elderly as well as in unselected (random) populations. Patients 
with overt thyroid or gastric disease have been excluded, and in most 
instances the results have been compared with those from large non -diabetic 
populations of comparable age and sex distribution. The overall prevalence 
of various autoantibodies in diabetics can therefore be calculated with fair 
accuracy from the pooled data of the major series (Table 2) and more detailed 
information is given in the following explanatory notes: 
Thyroglobulin autoantibodies 
Most investigators agree that the prevalence of antibodies to thyroglobulin in 
diabetes (measured by the tanned cell haemagglutination technique) is 
marginally but hardly significantly increased over that in the non -diabetic 
population. In both groups the overall prevalence seems to lie between seven 
and ten per cent (Tables 1 and 2), and major deviations from this relatively 
narrow range are found only in restricted population strata: for example, the 
high figures recorded by Maret and Berthaux (1965) in diabetics and controls 
were obtained from groups whose members were almost exclusively female 
and all aged over seventy years. Only one study (Simkins, 1968) has described 
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a major difference between diabetics and controls (prevalence ten and four 
per cent respectively) and the results obtained by this investigator may be 
partly explicable by the racial differences between the groups; Simkins 
examined mixed Caucasian /Negro populations but half the diabetic and only 
twenty -nine per cent of the control group were negroes. 
Table 1. Prevalence of autoantibodies in sera from diabetic and non -diabetic 
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84 (21) 8 (2) 
65 (11) - 
- - - 5( <l) 
32 (10) 
17 (4) 
90 (9) 170 (16) 
56 (6) 68 (8) 
176 (17) - 11 (1) 
53 (6) - 9 (1) 
13 (3) 
1 ( <I) 
22 (9) 15 (6) 
20 (6) 4 (1) 
56 (14) 84 (21) 
34 (9) 40 (10) 
Diabetic (133) 13 (10) 27 (20) 21 (16) 
Controls (128) 10 (8) 4 (3) 7 (5) 
Diabetics (250) 23 (9) 43 (17) 45 (18) 





88 (22) - 
110 (27) - 
3 (2) 3 (2) 
0 (0) 0 (0) 
3 (1) - 
2 (1) - 
°All subjects aged under 16 years. 
°All subjects aged over 70 years. 
`No distinction between antibodies to thyroglobulin and thyroid cytoplasm. 
T/G = antibody to thyroglobulin. 
T/C = antibody to thyroid cytoplasm. 
PCA = antibody to gastric parietal cytoplasm. 
IF = antibody to gastric intrinsic factor. 
ANF = antinuclear antibody. 
ADR = antibody to adrenal cortex. 
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Table 2. Overall prevalence of autoantibodies in sera from diabetic and 
non -diabetic populations, calculated from the pooled data in Table 1 
Subjects 
(No. studies) 
Number (per cent) positive for: 
T/G T/C PCA IF ANF ADR 
Diabetic (1901) 191 (10) - 
Controls (1848) 134 (7) - 
Diabetic (2203) - 363 (16) 
Controls (2044) - 136 (7) - 
Diabetic (2572) - - 445 (17) 
Controls (2755) - - 202 (7) 
Diabetic (1180) - - - 29 (2) 
Controls (2296) - - - 6 (<1) - 
Diabetic (1837) - - - - 105 (6) 
Controls (1649) - - - - 121 (7) 
Diabetic (385) - - 3 (1) 
Controls (468) - - 0 (0) 
Abbreviations as Table 1. 
Autoantibodies to thyroid and gastric parietal cytoplasm 
Antibodies to thyroid or gastric parietal cell (detected initially by complement 
fixation, latterly by the Coombs indirect immunofluorescence technique) are 
conveniently considered jointly as their distribution is very similar in diabetic 
populations and indeed they may coexist in the same patient. Most investiga- 
tors (Table 1; Figure 1) record a two- to fourfold increase in diabetics over 
the expected prevalence of either antibody in the general population, but in 
selected groups, for example in juveniles, the difference may be even greater 
(Pettit, Landing and Guest, 1961). 
The combined effects of age, sex and antidiabetic therapy on antibody 
prevalence have been carefully analysed in several studies and allow the 
following conclusions to be drawn: 
1. Thyrogastric antibodies are found most commonly in young female, 
insulin- dependent diabetics. 
2. The prevalence of thyrogastric antibodies in older diabetics (i.e., above 
age forty) is much closer to that in control populations. Again the excess 
is mainly associated with female sex and insulin dependency. 
3. The joint occurrence of thyroid and gastric antibodies is almost exclusive 
to diabetics. 
4. A high titre of thyroid cell antibodies in ostensibly euthyroid diabetic 
children may be associated with chronic (Hashimoto) thyroiditis. 
The marked difference in antibody prevalence between insulin- dependent 
and insulin- independent patients is probably accounted for by differing 
modes of inheritance for juvenile -onset and maturity -onset diabetes. The 
genetics of diabetes are complex and the modern view favours a multi - 
factorial hypothesis, involving the additive effects of several genes (Falconer, 
1967). By this hypothesis overt diabetes results from an amalgam of genetic 
and environmental factors, the former being strongest in juvenile -onset and 
the latter in adult -onset diabetes. In this context it is interesting to note that 
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evidence for genetic heterogeneity in diabetes has been sought, and found, 
by serological study of the relatives of juvenile diabetics: a significantly higher 
frequency of thyroid and gastric antibody titres was found among parents 
and siblings of juvenile diabetics with positive titres than among relatives of 
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Figure 1. The percentage incidence of autoantibodies specific for thyroglobulin, thyroid 
cytoplasm and gastric parietal -cell cytoplasm in a series of 1032 diabetics and of 871 controls 
according to sex and age in decades. Reproduced from Irvine et al (1970) by courtesy of 
the Editor of The Lancet. 
The few studies which have related antibody prevalence to duration of 
diabetes are of particular interest. Some workers have described increasing 
prevalence of thyrogastric antibodies with lengthening duration of disease, 
but this relationship only appears to be valid for insulin- taking patients, 
aged under thirty years, who have been diabetic for more than ten years 
(Nerup and Binder, 1973). Conversely the most extensive published series 
found no clearcut relationship between antibody prevalence and duration 
of disease (Irvine et al, 1970). Whittingham et al (1971) applied a sophisticated 
computer programme to carefully- matched populations and detected an 
actual decrease in thyrogastric antibody prevalence with increasing duration 
of insulin- dependent diabetes, the decrease being especially marked in 
diabetics of more than twenty years' standing. These authors offered the 
explanation that their findings reflected an unexpectedly high death rate 
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among longstanding diabetics with thyrogastric antibodies, and further 
demonstrated that antibody prevalence in long -term insulin- dependent 
diabetics aged under forty is equal to that in the non -diabetic population 
aged over sixty. Serologically, therefore, there is some evidence that the long- 
term insulin- dependent diabetic population, especially female, has aged 
prematurely by at least twenty years, but how this phenomenon may con- 
tribute to an excess mortality amongst these patients is not yet clear. Apart 
from degenerative disease of the large blood vessels, there is no other con- 
vincing biological evidence of premature aging in diabetes mellitus. 
The appearance of serious and so- called specific diabetic complications 
(renal, retinal, neuropathic, etc.) is of course notoriously associated with 
insulin- dependent diabetes of at least ten years' duration, and it is to be 
hoped that future serological studies will explore the relationships between 
duration and therapy of diabetes, antibody status and appearance of micro - 
angiopathy. At present it may be reasonable to accept that the presence of 
thyrogastric antibodies in young insulin- dependent patients might identify a 
particular risk factor for early death, and to keep such patients under close 
surveillance for the development not only of overt thyrogastric disease but 
also of specific diabetic vascular lesions. 
Autoantibodies to gastric intrinsic factor 
Antibodies to intrinsic factor (IF), detected by a radioimmunoassay method 
using coated charcoal, are found much less commonly than parietal -cell 
antibodies in diabetes. Nonetheless their presence is of especial importance 
because of the strong association, mentioned earlier, with underlying per- 
nicious anaemia. Thus Ungar et al (1968) found IF antibody in eight of 400 
diabetics studied, three of whom had latent pernicious anaemia, while Irvine 
et al (1970) found IF antibody in 13 of 380 patients studied, latent pernicious 
anaemia being present in six of the nine patients who underwent additional 
investigations. The apparently low prevalence of IF antibody in the overall 
diabetic population (Table 2) appears in correct perspective when it is 
appreciated that all investigators who have searched for this antibody 
are unanimous in indicating that IF antibodies are found only in middle -aged 
to elderly diabetics, almost exclusively female and predominantly insulin - 
dependent. In these selected population strata it has been estimated that the 
prevalence of IF antibody is between four and five per cent (Ungar et al, 
1968; Irvine et al, 1970) and half the patients thus identified will have latent 
pernicious anaemia. These figures represent an increase of at least four -fold 
over the expected prevalence of IF antibody in matched non -diabetic popu- 
lations and are sufficiently impressive to reinforce the value of screening for 
IF antibody in the diabetic population at particular risk. 
Autoantibodies to adrenocortical cells 
Few investigators have examined diabetic populations for adrenal antibodies 
(Table 1). However, it is worth noting that this antibody, which is detectable 
in more than fifty per cent of patients with idiopathic Addison's disease and 
is extremely rare outside that context, was found by Nerup and Binder 
(1973) in three insulin- dependent diabetics with no overt evidence of adrenal 
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failure. The strong clinical associations of diabetes with Addison's disease 
have already been commented upon and cell- mediated immunity against 
adrenal antigen has also been demonstrated in diabetics (Nerup and Bendixen, 
1969). 
Other autoantibodies and antigens in diabetes 
The prevalence of antibodies which are tissue -specific rather than organ - 
specific, for example mitochondrial antibody and antinuclear factor (AN F), 
does not appear to be increased in diabetic populations (Table 2). Likewise 
the prevalence of lymphocytotoxic antibodies is not different in diabetics, 
whether insulin- dependent or insulin- independent, from that in the normal 
population (Singal and Blachman, 1973). 
SERUM ANTIBODIES TO PANCREAS AND 
PANCREATIC HORMONES IN DIABETES MELLITUS 
In contrast to the striking and widely- documented prevalence of organ - 
specific antibodies to other tissues, intensive efforts to demonstrate anti - 
pancreatic or anti -insulin antibodies in diabetes have until recently been 
largely unrewarding. Early investigators, using haemagglutination, gel - 
diffusion and precipitin techniques claimed to find antipancreatic antibodies 
in the sera of a high proportion of the diabetics that they tested, as well as in 
other forms of chronic pancreatic disease (Murray and Thal, 1960; 
Fonkalsrud and Longmire, 1961). These results were not confirmed sub- 
sequently and were probably due to methodological artefacts (Villavicencio, 
Thurnau and Goetz, 1965). Efforts to detect antipancreatic antibody by the 
immunofluorescence technique proved equally fruitless (Irvine et al, 1970; 
Nerup and Binder, 1973; Doniach, 1974a) and it was assumed that such an 
immunoglobulin did not exist. Very recently, however, two independent 
studies have confirmed the existence of an antibody directed against the 
endocrine pancreas in diabetic sera (Bottazzo, Florin- Christensen and 
Doniach, 1974; MacCuish et al, 1974a), and the combined results of these 
studies allow the following conclusions to be drawn: 
1. Islet -cell antibody is only detectable in patients with overt autoimmunity 
and is found almost exclusively in insulin- dependent diabetics in whom 
diabetes coexists with single or polyglandular autoimmune disease (Table 
3). In this selected group of diabetics, the antibody has thus far been found 
in approximately thirty per cent of sera tested. The simple explanation for 
the previous failure to detect islet -cell antibody is that the earlier searches 
examined sera from unselected patients (e.g., insulin- independent diabetics) 
or deliberately excluded diabetics with overt autoimmunity. 
2. Islet -cell antibody is demonstrable in unfixed pancreatic sections by 
immunofluorescence, is an immunoglobulin of IgG class and fixes comple- 
ment. It is thus very similar to its established counterparts in autoimmune 
disease. Fluorescence is abolished by pretreatment of the pancreatic tissue 
substrate with alcohols, gluteraldehyde and formaldehyde but is unaffected 
by acetone fixation. These fixative reactions support the belief that the 
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Figure 2. Pancreatic .islet -cell antibody in diabetes mellitus. Cryostat section of human 
pancreas treated with serum of a diabetic patient, followed by anti -human IgG -FITC 
conjugate, showing cytoplasmic fluorescence over the islet of Langerhans. Fluorescence is 
apparent in all cell types in the islet. 
In the light of present knowledge and techniques, the presence of insulin 
antibodies should not be accepted unless the serum under study can be 
proved to contain immunoglobulins, which bind isotope -labelled insulin, by 
a specific and sensitive method (gel filtration, paper chromatography or 
dextran- coated charcoal). It is therefore of particular interest to record that 
by using these elegant techniques, eight cases from Japan (Ohneda et al, 
1974) and one from Norway (Falling and Norman, 1972) have been reported 
of patients who by all reasonable criteria had never taken exogenous insulin 
and whose serum nonetheless contained insulin- binding (auto)antibodies. 
The term `insulin autoimmune syndrome' has been applied to describe the 
salient clinical and biochemical abnormalities (Hirata et al, 1972); most 
patients have been studied in considerable detail and have the following 
features in common: 
1. No history of immunisation with insulin. 
2. Presentation with post -prandial hypoglycaemic attacks. Demonstration 
of carbohydrate intolerance (diabetic type) on glucose loading, followed 
by reactive hypoglycaemia. No fasting hyper- or hypoglycaemia. 
3. High titre of insulin- binding antibodies in plasma, the antibodies binding 
mammalian insulins with ease but having the strongest affinity for human 
and porcine insulin. 
4. Characterisation of the insulin- binding antibody as IgG immunoglobulin 
of K type (in contrast to injected insulins, which evoke a heterogeneous 
response of IgG, IgM and IgA antibodies of both K and L type). 
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pancreatic islet antigen- antibody system will share the other properties 
common to the thyrogastric autoimmune systems (Doniach, 1974b), and 
indicate that the antigen is likely to be microsomal, i.e., comprised of mem- 
brane lipoproteins from subcellular fractions of smooth endoplasmic 
reticulum. Absorption and subcellular fractionation studies will however 
be necessary to characterise the antigen. 
Table 3. Prevalence of autoantibodies (IgG class) against pancreatic islet cells, 
in sera from diabetics and non -diabetics 
Subjects tested 
Islet -cell antibody 
Positive Negative 
Diabetic with co- existent autoimmune disease 15 35 
Non -diabetic with clinical autoimmune disease 3 81 
Diabetic with positive thyrogastric autoantibodies 0 20 
Diabetic with negative autoantibodies 0 64 
Non -diabetic with negative autoantibodies 0 58 
Total 18 258 
Autoantibodies (IgG class) against pancreatic islet cells, detected by indirect immuno- 
fluorescence. 
Combined results of Bottazo, Florin -Christensen and Doniach (1974) and MacCuish et al 
(1974a). 
3. Islet -cell antibody produces a uniform cytoplasmic immunofluorescence 
affecting all cell types (a, ß and S) in the islets of Langerhans (Figure 2). 
The exocrine pancreas is unaffected. 
The detection of islet -cell antibody in diabetics has two immediate implica- 
tions : first, it adds strong credence to the concept of an autoimmune form of 
diabetes, especially when considered in conjunction with the evidence, 
discussed below, of T -cell sensitisation to pancreatic antigens in diabetes; 
secondly, the antibody may prove a convenient rapid `marker' for the auto - 
immune form of diabetes, the patients thus identified being examined for 
other evidence of autoimmunity by sophisticated immunological techniques 
and possibly also for histocompatibility type. It will be particularly important 
to undertake studies of cell- mediated immune function in diabetics who are 
shown to possess this humoral antibody. 
The situation with respect to anti -insulin antibodies in diabetes is broadly 
similar. A few workers apparently demonstrated such antibodies, in untreated 
diabetics, by the complement consumption test (Pay, Jezkova and Skrha, 
1963; Chetty and Watson, 1965), the precipitin test (Penchev, Andreev and 
Ditzov, 1968), or the histoimmunologic technique (Mancini et al, 1965). 
These procedures are however disputed (Van de Wiel and Van de Wiel- 
Dorfmyer, 1964; Chao, Karam and Grodsky, 1965) and do not seem specific 
for insulin antibodies. In contrast Berson and Yalow never observed insulin - 
binding antibodies in thousands of samples from untreated diabetics, and 
conversely could readily detect them in the serum of virtually every patient 
on insulin therapy (Berson et al, 1956; Berson and Yalow, 1965). 
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1971), and the application of such techniques to the study of human disease, 
have presented some of the most promising opportunities for demonstrating 
immunological abnormality in diabetes mellitus. Thus far three main areas 
of cell- mediated immunity in diabetes have been explored and the results 
obtained are outlined below. 
General cellular immune response and circulating lymphocyte subpopulations 
RESPONSE TO NONSPECIFIC MITOGENS. The mitogen phytohaemagglutinin (PHA) 
induces transformation of cultured small lymphocytes to blast cells (Nowell, 
1960). Under appropriate conditions, sixty to seventy per cent of lymphocytes 
are transformed in vitro by PHA and the majority of these cells will be T 
lymphocytes (Roitt et al, 1969), although some B lymphocytes are also 
stimulated to transform (Phillips and Roitt, 1974). PHA testing is therefore 
extensively employed as a general assessment of cell- mediated immune 
function in a variety of clinical states and may be regarded as a convenient 
means of judging the functional level of the recirculating pool of lymphocytes. 
Conflicting results have been reported by the investigators who initially 
performed PHA testing in diabetes. Brody and Merlie (1970) found marked 
depression of blast transformation in diabetes, comparable to that in patients 
with chronic lymphatic leukaemia, while Ragab, Hazlett and Cowan (1972) 
found no difference in the PHA responses of lymphocytes from diabetics and 
healthy controls. However, it seems clear that these opposing views can be 
reconciled by relating the PHA response in diabetics to the adequacy of 
metabolic control when the cells were removed for testing: the report of 
Brody and Merlie was based on observations in six elderly patients who had 
persistent glycosuria and hyperglycaemia (blood glucose 300 to 514 mg %) 
and had not taken insulin for between twelve and twenty -four hours before 
the lymphocytes were removed for study. In contrast the normal results 
reported by Ragab et al were obtained from twenty -three healthy diabetic 
outpatients. In our own experience (MacCuish et al, 1974b) using a sensitive 
micromethod assay system (Penhale et al, 1974), we have found no difference 
in the PHA responses of a large number of well -controlled diabetics when 
compared with a matched healthy population (Figure 3). Conversely we have 
demonstrated profound depression of lymphocyte transformation in poorly 
controlled patients (Figure 4). Thus it is reasonable to regard a depressed 
PHA response as one reflection of inadequately corrected metabolic dis- 
turbance in poorly controlled diabetes rather than inherent genetically 
determined immunological abnormality in this disease. 
T AND B LYMPHOCYTE SUBPOPULATIONS. Further support for the view that 
general cellular immune status is normal in well -controlled diabetes has been 
provided by the demonstration that circulating lymphocyte subpopulations 
of T and B cells are normal in diabetics, irrespective of the patient's metabolic 
control and therefore of the PHA response (MacCuish et al, 1974b). These 
findings again point to functional rather than structural lymphocyte abnor- 
mality in poorly controlled diabetes, and our own investigations in these 
patients suggest that both hyperglycaemia and elevated levels of plasma free 
fatty acids make important contributions to depressing lymphocyte blasto- 
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5. Hyperinsulinism. 
6. Hypertrophy of the islets of Langerhans (in those patients who underwent 
laparotomy). 
The apparently paradoxical response to glucose loading found in the 
insulin autoimmune syndrome, which in some respects resembles the carbo- 
hydrate intolerance of early diabetes, may be explicable on the following 
basis: insulin secreted in response to glucose is avidly bound by the circulating 
antibodies (causing hyperglycaemia); blood glucose remains high when the 
binding capacity is saturated and insulin production continues unchecked 
from the maximally -stimulated beta cells (causing hypoglycaemia). Small 
amounts of free insulin, in equilibrium with the large bound fraction, prevent 
the development of ketoacidosis or fasting hyperglycaemia. The remarkable 
homogeneity of the antibody identified (IgG in all cases) suggests a mono- 
clonal production. 
It is likely that awareness will now lead to further cases of this interesting 
syndrome being identified. However, the relevance of these findings to the 
pathophysiology of human diabetes is uncertain; at present it must be 
concluded that such cases are rare in clinical presentation, that insulin 
autoantibodies are exceptional, and that the majority of untreated juvenile - 
onset diabetics do not possess such antibodies. It is probable that there is at 
best a tenuous connection between the insulin autoimmune syndrome and 
the immune phenomena described in `classical' diabetes mellitus. 
Antibodies to glucagon, the other major hormone secretion of the islets 
of Langerhans, have also been recently described in insulin- taking diabetics 
(Stahl et al, 1972; Cresco et al, 1974). Their appearance is readily explicable 
on the basis of immunisation by the small quantities of glucagon with which 
commercial insulins are contaminated. There is no suggestion that they exist 
in the untreated diabetic. Similar considerations apply to to proinsulin anti- 
bodies. 
Finally, the postulate that diabetes may result from the production of an 
immunologically or biologically abnormal insulin, by an inflamed and failing 
pancreas, remains unproven. Studies in diabetics have shown no evidence 
of structural abnormality of pancreatic insulin (Kimmel and Pollock, 1967), 
the secretion of the precursor proinsulin into the circulation is unimpaired 
(Goldsmith, Yalow and Berson, 1969), and the conversion of proinsulin to 
insulin seems to proceed normally (Rubenstein and Steiner, 1971). However, 
it has been calculated on theoretical grounds that at least thirty variants of 
proinsulin could exist in the human population (Steiner, 1972). There is some 
evidence that plasma insulin in juvenile diabetics is less active biologically 
than immunologically (Roy, Shapcott and O'Brien, 1968) and it would be 
well to keep an open mind to the possibility that abnormalities of insulin 
biosynthesis or structure may eventually be demonstrated in diabetes. 
STUDIES OF CELL -MEDIATED AUTOIMMUNE 
MECHANISMS IN DIABETES MELLITUS 
The major components of the cellular limb of the immune system are sum- 
marised elsewhere in this volume (page 289). The recent development of 
sensitive in vitro techniques to investigate cellular immune responses (Bloom, 
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in diabetes, especially as the other known defects in diabetic defence mech- 
anisms (abnormal chemotaxis and phagocytosis) are probably independent 
of the metabolic state (Baciu, Derenenco and Vitebski, 1967; Hill et al, 1974). 
Finally, it is worth noting that the demonstration of a normal PHA response 
and T -cell population in well -controlled diabetes has not excluded the 
possibility that smaller numbers of circulating lymphocytes in such patients 
may show recognition when exposed to a specific antigen, derived from 





















Time BG HCO3 
Ohrs 650 <5 
12hrs 270 14 
24hrs 124 21 
48hrs 58 24.5 
72hrs 110 23.5 
BG - blood glucose (mg%) 
Ohrs HCO3 - plasma bicarbonate (mEq /l) 
I 
1.25 
Figure 5. Lymphocyte transformation responses to three concentrations of PHA in an 
insulin- dependent diabetic during recovery from ketoacidosis. Transformation response is 
grossly depressed in severe metabolic decompensation but returns to normal within 72 
hours following correction of the ketoacidosis. 
Migration inhibition studies in diabetes mellitus 
The leucocyte migration technique (LMT), as developed by Bendixen and 
Soborg (1969) for studies of immune phenomena in human disease, has been 
used by several investigators to provide evidence of cellular (delayed type) 
hypersensitivity to specific antigens in diabetes mellitus. The theoretical basis 
of the test depends on the ability of lymphocytes from a sensitised individual, 
on contact with specific antigen, to produce a soluble factor(s) which modifies 
the normal migration of white blood cells in culture medium (Figure 6). 
The first successful demonstration of antipancreatic cellular hypersensitivity 
in diabetes by this technique was accomplished by Nerup et al (1971), who 
prepared an antigen of very high islet -cell content from porcine pancreas in 
which atrophy of exocrine tissue had been induced by surgical ligation of the 
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Diabetics 
Matched 
- -- controls 
PHA CONCENTRATION (NI /mt) 
447 
Figure 3. Mean lymphocyte transformation responses in 40 well controlled insulin- dependent 
diabetic and 40 age and sex -matched normal subjects at three concentrations of PHA. The 
two dose -response curves do not differ significantly. Reproduced from MacCuish et al 
(19746) by courtesy of the Editor of Diabetes. 
genic response. Indeed, the PHA response returns steadily to normal as the 
metabolic abnormalities are corrected (Figure 5). It is interesting to speculate 
that acquired defects of cell- mediated immunity in diabetic metabolic 
decompensation may in part be the cause, rather than effect, of the infections 
which are so frequent in such patients (Campbell et al, 1974), and on these 









0 0.32 0.63 1.125 
PHA concentration -cul /ml 
Figure 4. Lymphocyte transformation responses (mean ± s.e.m.) in 14 poorly controlled 
insulin- dependent diabetics ( ) and 14 well controlled insulin -dependent diabetics 
(- - - -) who were matched for age, sex and duration of diabetes. The mean response in the 
poorly controlled diabetics is significantly lower (P < 0.01) at all concentrations of PHA. 
Reproduced from MacCuish et al (1974b) by courtesy of the Editor of Diabetes. 
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found in diabetics who have never received insulin injections, and in whom the 
question of prior sensitisation by exogenous antigen does not therefore arise, 
while no correlation has been found between the presence of insulin anti- 
bodies and a positive LMT in treated patients (Nerup et al, 197I, 1973a). Thus 
it seems fair to regard the studies cited above as a demonstration of a true 
autoimmune phenomenon in diabetes. The failure of insulin itself to act as 
antigen in the LMT may merely reflect the technical limitations of this 
particular test, which yields satisfactory results with particulate but rarely 
with soluble antigens; alternatively the active antigen may be an insulin 
precursor (proinsulin, C- peptide) or some other pancreatic protein or 
cellular constituent. 
The position regarding migration inhibition with antigens from other 
organs is more controversial and centres round the question as to whether 
liver mitochondria are also capable of inhibiting leucocyte migration in 


































on OHA on diet 
n =35 n =36 
Figure 7. Leucocyte migration test with human pancreas extract in 101 diabetics and 50 
controls. Data from MacCuish et al (1974c). 
A = 27 healthy young controls (mean age 28.6 years). 
B = 31 juvenile -onset diabetics treated with insulin (mean age 28.5 years). 
C = 23 healthy older controls (mean age 57.4 years). 
D = 35 maturity -onset diabetics on oral hypoglycaemics (mean age 59.7 years). 
E = 36 maturity -onset diabetics on diet alone (mean age 60.5 years). 
Wilcoxon's tests 
B-A P < 0.01 
B-C P < 0.01 
B-D P < 0.01 
B-EP < 0.01 
A-C P > 0.10 
A-DP> 0.10 
A-E P > 0.10 
C-D P > 0.10 
C-E P > 0.10 
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pancreatic duct for eight weeks before the organ was removed. This antigen 
induced inhibition of leucocyte migration in peripheral -blood buffy coat 
samples from fifteen of twenty -two diabetics, all but four of whom were 
insulin- dependent and most aged under forty -five years. Intracutaneous 
injection of the same preparation into six diabetics with positive in vitro 
reactions induced typical delayed -type hypersensitivity in four, thus 
strengthening the validity of the results as an indication of in vivo cell - 
mediated immunity. These findings have subsequently been extended and 
confirmed by the same workers, using an antigen of homogenated fetal calf 
pancreas (Nerup et al, 1973a, 1974b) and by ourselves, using an antigen of 
homogenated human pancreas (MacCuish et al, 1974c; Figure 7). The lower 
proportion of positive results in these later studies is attributable in part to 
the low islet -cell content of pancreatic homogenates and in part to the 
inclusion of patients with insulin- independent types of diabetes. 
Figure 6. Inhibition of leucocyte migration in the presence of pancreatic antigen. On the left, 
leucocytes have migrated normally from the capillary tube into culture medium; on the 
right, migration has been inhibited by the addition of pancreatic antigen to the culture 
medium. Reproduced from MacCuish et al (1974e) by courtesy of the Editor of Diabetes. 
The results of migration inhibition studies using pancreatic and other 
antigens in diabetes are summarised in Table 4. With respect to specific anti- 
gens, it now seems possible to state that considering the diabetic population 
as a whole, approximately thirty per cent of patients show evidence by the 
LMT of a state of cell- mediated immunity to an antigen which is present in 
the pancreas, is species- non -specific (demonstrable with porcine, bovine, 
human and rat pancreas), and is possibly different from insulin. The phen- 
omenon is found in both juvenile -onset and maturity -onset diabetics, 
occurring in insulin- independent as well as insulin- dependent patients; it is, 
however, much more commonly found in young, recently diagnosed diabetics 
(irrespective of therapy) than in any other type of patient. It is of particular 
importance to note that antigen- induced migration inhibition has been 
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diabetes. Richens et al (1973) described striking migration inhibition of 
leucocytes from both young and elderly diabetics to mitochondrial antigens 
prepared from human and rat liver, and in a subsequent study (Richens et al, 
1974) suggested that the antigenic component was localised to the inner 
mitochondrial membrane. This reactivity to liver mitochondria can of course 
be considered as a general nonspecific `marker' of autoimmune disease, since 
inhibition of leucocyte migration is commonly induced by this antigen in 
patients with Hashimoto thyroiditis (Calder et al, 1972), pernicious anaemia 
(Goldstone et al, 1973) and primary biliary cirrhosis (Brostoff, 1970). Thus 
the findings of Richens et al, if confirmed, would provide further evidence 
for aligning diabetes mellitus with this group of diseases. However, it will 
be seen from Table 4 that the results obtained by Richens et al are as yet 
unconfirmed by other investigators using antigens prepared either from liver 
or from other mitochondrial -rich tissues (adrenal, kidney). The reasons for 
the differences between the various studies are not yet clear but in part may 
reflect differing methods of antigen preparation; until this question is resolved, 
it is not possible to make any definitive statement regarding the in vitro 
effects of mitochondrial antigens on diabetic leucocytes. 
Studies of lymphocyte transformation in response to insulin antigens 
The transformation of cultured small lymphocytes (presumably T cells) to 
lymphoblasts in the presence of antigen is another widely used in vitro test 
of cellular immune function. As with studies using a mitogen such as PHA, 
the effect of antigen is assessed by direct examination of cultured cell 
morphology using the light microscope or, more conveniently, by pulsing 
the cultures with a radioactive DNA precursor (e.g., 3H- thymidine) which 
will be incorporated into the nuclei of transforming cells : the extent of 
blastogenesis can subsequently be measured by beta counting of the extracted 
nucleoprotein. In the context of autoimmune disease, the transformation 
technique has been used to demonstrate the presence of lymphocyte sub - 
populations sensitised to intrinsic factor in patients with pernicious anaemia 
(Tai and McGuigan, 1969) and to thyroglobulin in patients with Hashimoto 
thyroiditis (Ehrenfeld, Klein and Benezra, 1971). Human diabetes mellitus 
would seem to be a suitable model for the transformation technique in an 
attempt to demonstrate the existence of lymphocyte subpopulations which 
`recognise' components or secretions of the endocrine pancreas. At present, 
however, there is little information concerning antigen- induced lymphocyte 
transformation in this disease although various investigators (Halpern, Ky 
and Amache, 1967; Federlin, Kreigbaum and Flad, 1968; Federlin, 1971) 
have shown that bovine insulin can induce blastogenesis in lymphocytes 
from diabetics with both immediate (urticarial) and delayed type (cutaneous) 
insulin allergy. 
We have recently studied the effects of adding purified insulins and insulin 
chains to cultured lymphocytes from newly -diagnosed diabetics and insulin - 
taking patients without evidence of allergy (MacCuish et al, 1975). The 
extent of blastogenesis in these cultures was assessed both by morphological 
examination and by 3H- thymidine uptake. The results of some of these 
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3. Two- thirds of the patients whose cells had responded to intact insulin, 
also showed significant transformation when the lymphocytes were 
cultured in the presence of isolated bovine insulin B chain (Figure 9). 
In contrast there was virtually no blastogenic response when the cells 
were cultured in the presence of isolated bovine or porcine insulin A chain. 
The blastogenic effect of intact insulin is perhaps not surprising in the 
group of established diabetics that were tested: all had been insulin- treated 
for months or years, virtually all would be expected to have humoral anti- 
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LYMPHOCYTE TRANSFORMATION WITH INSULIN FRAGMENTS 
Figure 9. Lymphocyte transformation induced by bovine and porcine A chain and bovine 
B chain in 21 diabetics who responded to intact insulin. Symbols as in Figure 8. Closed 
circles = established diabetics; open circles = newly diagnosed diabetics. Significant 
transformation to either A chain is shown by only one diabetic, as compared to 14 (67 
per cent) who respond to B chain. The effects of B chain differ significantly (P < 0.01) 
from those of the A chain of either insulin. Reproduced from MacCuish et al (1975) 
by courtesy of the Editor of Diabetes. 
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1. Lymphocytes from a considerable proportion (approximately twenty -five 
per cent) of insulin- taking diabetics, who have no clinical sign of insulin 
allergy, undergo significant blastogenesis when cultured in the presence 
of insulin (Figure 8). Cells from diabetics which respond in this fashion to 
bovine insulin, which all the patients were receiving, will also respond in 
an identical fashion to porcine insulin. 
2. Lymphocytes from five out of ten newly diagnosed diabetics also under- 
went significant transformation when exposed to bovine and porcine 
insulin (Figure 8). Two of these five patients had been insulin -treated for 
less than three weeks, while three had never received insulin or other 

















LYMPHOCYTE TRANSFORMATION- BOVINE INSULIN ANTIGEN 
Figure 8. Lymphocyte transformation in controls and diabetics induced by bovine insulin 
antigen. The mean transformation index ± s.e.m. is shown to the right of the individual 
results for each group. Dotted lines indicate the normal range (mean ± 2 s.d.) of trans- 
formation indices in control subjects. Significant transformation (index > 1.45) is shown 
by 15 established and 5 newly diagnosed diabetics as compared to one control. Both diabetic 
groups differ significantly (P < 0.01) from the control group. Reproduced from MacCuish 
et al (1975) by courtesy of the Editor of Diabetes. 
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comparable to that demonstrated in autoimmune thyroid disease (Calder 
et al, 1973a and b). Again, however, diabetes is a suitable disease model for 
the application of these techniques and it may be anticipated that they will 
soon be applied in this field. 
HISTOCOMPATIBILITY (HL -A) ANTIGEN TYPING IN 
DIABETES MELLITUS 
There is disagreement regarding the results of histocompatibility (HL -A) 
antigen typing in diabetics. Finkelstein, Zeller and Walford (1972) found no 
significant alteration in HL -A antigens in forty -four insulin- dependent 
patients but the validity of this study is dubious as the patient population 
was racially heterogeneous (Caucasian, Mexican and Negro) and any 
alterations in antigen frequency might thus have been obscured. In contrast, 
Singal and Blachman (1973), studying an all- Caucasian population, found a 
significantly higher frequency (thirty -six per cent) of the antigen W15 in 
insulin- dependent diabetics when compared with insulin -independent 
patients and controls (prevalence ten and nine per cent, respectively). The 
latter study has recently been confirmed and extended by Nerup et al (1974b) 
who reported a significantly higher frequency of the antigens W15 and HL -A8 
in a series of 146 Caucasian diabetics, and correlated the presence of these 
antigens with the age of onset of diabetes, the weight of the patient and the 
type of antidiabetic therapy: antigen W15 was found in both juvenile and 
maturity -onset patients, but usually in association with insulin- dependent 
diabetes, while HL -A8 was found almost exclusively in juvenile- onset, non - 
obese, insulin- dependent diabetics. Almost two- thirds of the subjects studied 
by Nerup et al possessed one or both of these antigens, which can be regarded 
as genetic markers for insulin- dependent diabetes, and the authors have 
estimated that subjects who are HL-A8/W15 positive have a two to three -fold 
higher risk of developing insulin- dependent diabetes than individuals lacking 
these antigens. These findings are of considerable interest in the context of 
autoimmunity as an increased frequency of antigen HL -A8 has already been 
detected in patients with thyrotoxicosis (Grumet et al, 1973) and idiopathic 
Addison's disease (Platz et al, 1974). Histocompatibility complexes like 
HL -A carry not only the genes controlling serologically detectable antigens 
but also immune response (Ir) genes which control the development of 
cell- mediated immunity to certain antigens; in the search for a common 
denominator for the development of endocrine autoimmunity, it is intriguing 
to speculate that the Ir genes associated with HL -A8 are those which permit 
the full expression of an autoimmune response, irrespective of the stimulus 
which elicits this response. 
PATHOLOGY OF THE PANCREAS IN DIABETES MELLITUS 
A number of pathological studies over the past decade have described the 
morphological findings in the pancreata of various clinical types of diabetes 
mellitus; the major conclusions are summarised in Table 5. The appearance 
of the pancreas in acute juvenile -onset patients is naturally of especial 
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that some have developed cellular immunity in the form of an insulin - 
sensitised lymphocyte subpopulation. Many mammalian cells have receptors 
for insulin and this has also been shown to be true for human lymphocytes 
(Gavin et al, 1973). The phenomenon appears to be relatively common in 
diabetics who have no clinical sign of insulin allergy, and may be regarded 
as a sensitive in vitro measurement of an insulin hypersensitivity that is not 
of clinical significance. 
More interesting is the finding of insulin- induced lymphocyte transforma- 
tion in a small number of newly- diagnosed patients who were either untreated 
or insulin- treated for a very brief period. Further studies will be required to 
confirm these observations in larger numbers of untreated diabetics but the 
initial results at least allow the tentative suggestion to be made that a propor- 
tion of such patients have an insulin- sensitised lymphocyte population before 
exogenous insulin has been given and before humoral insulin antibodies have 
developed. Thus the existence of this cell population may reflect a state of 
cell- mediated autoimmunity, to insulin or insulin precursor, in early diabetes, 
and may be the analogue to the population detected in these patients by the 
LMT. 
Two conclusions are possible from the studies of lymphocyte transforma- 
tion induced by isolated insulin chains (Figure 6). In the first place, the 
striking blastogenic effect of isolated B chain (which is metabolically inert) 
strongly implies that the blastogenesis induced by intact insulin molecule is 
a true immunological effect, rather than some metabolic effect brought about 
by a hormonal action of insulin on the insulin receptors of lymphocytes. 
Secondly, the clearcut difference between the effects of the two major poly - 
peptide chains (A chain being inactive, B chain highly active) might suggest 
that the B chain is the major antigenic site determining cellular hypersen- 
sitivity to insulin. The role of B chain in this context may be contrasted with 
the humoral response to exogenous insulin, where various studies suggest 
that the A chain is the major determinant of antibody production (Berson 
and Yalow, 1959; Wilson, Dixon and Wardlaw, 1962). Thus it is possible 
that differing antigenic activity, whether cellular or humoral, resides at 
different sites on the insulin molecule, although the factors governing the 
expression of such activity remain obscure. However, it must also be remem- 
bered that an apparent lack of cellular antigenicity of A chain might be 
explained by the physical changes undergone by this peptide during the 
splitting of insulin; isolated A chain is `stretched' by comparison with its 
configuration in the intact insulin molecule and the intra -chain disulphide 
bridge between 6 and 11 is broken, with the formation of cysteic acid residues 
which could prevent antigen- antibody interaction at this site. It is to be 
hoped that further studies of antigen- induced lymphocyte transformation 
may delineate more clearly the cellular antigenic portion of insulin and may 
indicate whether related proteins or precursors (e.g., proinsulin, C- peptide) 
have similar properties in early diabetes. 
Other tests of cell- mediated immunity in diabetes mellitus 
As yet there is no published information on lymphocyte cytotoxicity or on 
lymphocyte- dependent antibody- mediated (K -cell) cytotoxicity in diabetics 
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relevance to the aetiology of diabetes mellitus, and in this connection the 
finding of `insulitis' has excited particular speculation. The term `insulitis' 
was first coined by von Meyenburg (1940) to describe the inflammatory 
lesions in the islets of Langerhans of some diabetics, although such lesions 
had in fact been described by the early investigators of diabetic pathology at 
the beginning of this century, well before the era of insulin treatment (Schmidt, 
1902; Heiberg, 1911). The lesions of insulitis may be heavy, involving the 
majority of the islets, or light, involving only scattered islets. Affected islets 
are usually of the atrophic type and infiltrated with lymphocytes, commonly 
round their periphery but sometimes throughout the islet. Large mono- 
nuclear cells, sometimes polymorphs and very rarely eosinophils may also 
be present in the infiltrate, but plasma cells have never been observed. The 
most common appearance seems to be of a `halo' of lymphocytes just outside 
the capsule of the islet, extending a little way into the periphery of the 
endocrine tissue and probably cuffing capillaries in the islet stroma (Warren, 
LeCompte and Legg, 1966); more diffuse lymphocytic infiltration, over- 
running the whole islet, is less commonly encountered (Gepts, 1965). The 
lesion in juvenile diabetes is quite distinct from the insulitis which occurs in 
some infants of diabetic mothers ; the latter condition is characterised by an 
infiltrate which is predominantly of polymorphs, includes many eosinophils, 
and is without effect on pancreatic insulin production. 
For many years insulitis was considered to be a very rare phenomenon, 
confined to a few cases of diabetes of recent onset in children (Warren and 
Root, 1925; LeCompte, 1958). It has been only briefly mentioned, or not at 
all, in many textbooks on pathology or diabetes and many pathologists have 
never seen a case (LeCompte and Legg, 1972). The finding by Gepts (1965) 
of insulitis in fifteen out of twenty -two young diabetics, i.e., more than two - 
thirds of the pancreata that he examined, was therefore in direct contrast to 
this classical opinion and several reasons can be advanced which suggest 
that the rarity of this lesion is more apparent than real. First, comparatively 
few pathologists now have the opportunity to examine by modern techniques 
the pancreas of juvenile -onset diabetes shortly after the onset of disease, 
and this is of course a direct result of the advent of insulin therapy. Secondly, 
it has never been detected in young diabetics who have died more than 
twelve months after the onset of disease, by which time the changes in the 
pancreas are so extensive (Table 5) as to obscure any subtle cellular infiltrate. 
Thirdly, it has never (with one exception) been described in maturity -onset 
diabetes, the exception being the cases detected by LeCompte and Legg (1972), 
who found insulitis in two elderly diabetics with brittle, atypical maturity - 
onset diabetes that required insulin treatment in each case shortly before 
death. Fourthly, insulitis may in any case be a transient phenomenon which 
is present only for months or even weeks during the development of clinical 
diabetes. Finally, the lesion may be so slight as to be easily overlooked, 
affecting only a few islets and perhaps detectable only with the electron 
microscope. Against all these plausible arguments must however be set the 
recent findings of Doniach and Morgan (1973) who were unable to find 
any insulitis in the pancreata of nine juvenile -onset patients who died within 
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heterologous anti -insulin serum) and active immunisation procedures (i.e., 
injection of homologous or heterologous insulin) have been successful in 
producing insulitis in a variety of species, and in the context of autoimmunity 
the models described by Renold and his colleagues and by Nerup et al (1973b) 
are of particular interest. These investigators have shown that the injection 
of homologous insulin in cattle or sheep, or a suspension of homologous 
endocrine pancreas in rodents can be followed by pathological changes in the 
pancreatic islets which strongly resembles the lesions of insulitis found by 
Gepts (1965) in human diabetes. Insulitis in these experimental animals does 
not always lead to the development of overt diabetes mellitus but is accom- 
panied by the production of humoral anti -insulin antibodies (Renold, 
Soeldner and Steinke, 1964) or of antipancreatic cell- mediated hypersensi- 
tivity (Nerup et al, 1973b). The findings have obvious implications for the 
hypothesis of autoimmune diabetes in man, although it has not yet been 
possible in any animal model to fully characterise the antigen(s) responsible 
for the development of the insulitis lesion and the appearance of sensitised 
lymphocyte subpopulations. 
VIRAL INFECTION AND AUTOIMMUNITY IN 
DIABETES A'IELLITUS 
The suggestion that viral infection might be aetiologically related to diabetes 
mellitus was apparently first offered by Gundersen (1927), based on his 
observation that an attack of mumps might be closely followed by the 
development of clinical diabetes. Since then it has been established both 
clinically and experimentally that viral infection can invade the pancreas of 
many animal species. The induction of carbohydrate intolerance by viral 
inoculation of the experimental animal was first accomplished by Craighead 
and McLane (1968), who inoculated mice with the M variant of the en- 
cephalomyocarditis (EMC) virus to produce a disease which clinically and 
pathologically resembled human, abrupt -onset diabetes with insulitis. 
Numerous subsequent investigators have since documented the ability of 
variants of the EMC virus and of group B Coxsackie viruses to induce a 
diabetes -like syndrome in rodents (Craighead and Steinke, 1971; Muntefering, 
Schmidt and Korber, 1971; Wellman et al, 1972; Coleman, Gamble and 
Taylor, 1973). From these and other studies it has become clear that differing 
strains or variants of these viruses can cause either a diffuse pancreatitis or 
more specific lesions of the endocrine pancreas. Thus the inoculation of the 
E variant of EMC virus and Coxsackie B3 virus induces a generalised pan - 
creatitis without specific insular damage or the development of diabetes, 
while the M variant of EMC virus and Coxsackie B4 virus produces only a 
mild exocrine pancreatitis but a severe, rapidly -evolving insulitis which is 
invariably accompanied by diabetes. These latter `specific' insulitis -producing 
viruses seem to produce a typical series of pancreatic changes: within forty - 
eight hours of their inoculation many islets show interstitial oedema and 
marginal or central necrosis of cells. On the third and fourth days, there is 
extensive and total necrosis of some islets, both a and ß cells being involved, 
and macrophages begin to infiltrate between the islet -cells at this time. 
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might therefore be summarised as indicating that insulitis is not a particularly 
rare lesion, but nor is it as common as the findings of Gepts would suggest, 
and overall it probably occurs at some time in something under half the 
cases of juvenile diabetes mellitus. 
The production of insulitis in experimental models 
Several theories have been advanced as to the cause of insulitis (and per se 
as to the possible cause of onset of diabetes). Early workers suggested that the 
lesion might represent destruction of the islet cells either by over -stimulation 
or by some unidentified cytotoxic agent (von Meyenburg, 1940). Both 
explanations seem unlikely as no other similar lesions have ever been observed 
in other endocrine glands submitted to overstimulation, nor do they appear 
in the islets of alloxan- induced diabetes. The two present theories which have 
received the strongest support from clinical and experimental studies are the 
viral and immunological hypotheses respectively. Epidemiological and other 
evidence for viral infection as a cause of insulitis and diabetes is considered 
below. With respect to the immunological hypothesis, the various animal 
models in which insulitis has been induced by immune mechanisms are 
summarised in Table 6. It will be seen that both passive (i.e. injection, of 
Table 6. Summary of the pathological findings in various animal species following 











Species Reference Findings 
Injection of 
homologous 





pancreas (in CFA) 
Rat Lacy and Wright (1965) 
Mouse Logothetopoulos and 
Bell (1968) 
Mouse Freytag (1972) 
Cattle Renold, Soeldner and 
Steinke (1964) 
LeCompte et al (1966) 
Sheep Federlin, Renold 
and Pfeiffer (1968) 
Rabbit Toreson et al (1964) 
Grodsky et al (1966) 
Lee et al (1969) 
Kloppel, Altenahr and 
Freytag (1972) 
Cattle Renold, Soeldner and 
Steinke (1964) 
LeCompte et al (1966) 
Sheep Federlin, Renold 
and Pfeiffer (1968) 
Rat Nerup et al (1973a) 
Andersen et al (1974) 
Diffuse exocrine pancreatitis, 
acute transient insulitis (mainly 
eosinophils), carbohydrate 
intolerance 
Chronic insulitis (mainly 
monocytes) 
Chronic insulitis (mononuclear), 
fibrosis of some islets, 
exocrine pancreas normal, 
humoral anti -insulin antibody 
production, diabetes in a few 
animals 
Identical to experiments using 
heterologous insulin 
insulitis (mononuclear), ß-cell 
degeneration, exocrine pancreas 
normal, antipancreatic cellular 
hypersensitivity (by the LMT), 
transient diabetic state 
CFA = Complete Freund's adjuvant. 
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host. These mechanisms would provide at least the theoretical basis for a 
relationship between virus infection and human diabetes with insulitis, 
although this relationship still remains to be proved. On the one hand it is 
encouraging to note that Craighead (1974), examining histological material 
from infants dying with fully- documented Coxsackie B virus infections, has 
found changes in the pancreata (fibrosis, interstitial pancreatitis, lymphocytic 
infiltration of the islets of Langerhans) identical to those described by Gepts 
(1965) in his cases of juvenile diabetes with insulitis. On the other hand, it 
is salutary to record that to the date of this review, no published work has 
yet described the culture of any virus from the blood, pancreatic tissue or 
excreta of a newly- diagnosed diabetic patient. 
IMMUNOLOGICAL ABNORMALITIES IN RELATION TO 
THE COMPLICATIONS OF DIABETES MELLITUS 
Microangiography is the most serious specific complication of longstanding 
diabetes mellitus and the general features of this lesion (basement membrane 
thickening, deposition of certain plasma proteins, hyalinisation and loss of 
function in small blood vessels) are such as to arouse speculation that they 
may be due to abnormal immunological reactions. It should be said at the 
outset that at present there is no evidence of any kind to suggest that micro - 
angiopathy is related to autoimmune disease mechanisms in diabetes, and 
research in this area remains a major future endeavour. However, the 
remarkable failure of pathologists to recognise a specific diabetic micro - 
angiopathy prior to the insulin era (Kimmelstiel and Wilson, 1936) and the 
detection of insulin antibodies in virtually all insulin -treated diabetics, 
prompted Berson et al (1956) to suggest that the vascular lesion in diabetes 
was the result of insulin therapy and was caused by deposition of insulin - 
antibody complexes on the basement membrane of the renal and other 
microvessels. 
There is a certain amount of experimental evidence to support this immune 
complex hypothesis: renal tissue from diabetics shows fine granular deposits 
on the basement membrane, resembling those found in post -streptococcal 
and membranous glomerulonephritis (Bloodworth, 1968), while the glomeruli 
in diabetic nephropathy have insulin- binding capacity and also contain 
immunologically -detectable insulin (Berns et al, 1962). The latter features 
are also seen in the vessels of the diabetic eye (Coleman et al, 1962). The 
blood of some diabetics is said to contain insulin antigen- antibody complexes 
(Jayarao et al, 1974) and perhaps even more interesting is the recent observa- 
tion that insulin and human IgG can react in vitro under mild reducing 
conditions to produce a complex that has high potency for complement 
fixation (Cantrell, Stroud and Pruitt, 1972). The latter mechanism would be 
considered an immunologic `bypass' since specific antibody to insulin is 
not required. 
On the other hand, the evidence against some form of immunity to insulin 
as the basis for diabetic angiopathy is rather more convincing (Editorial, 
1972). Immunohistopathological studies have revealed that the basement 
membrane in diabetic glomerulosclerosis contains not only insulin, IgG, 
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Between the third and the fifteenth day, but most commonly after about a 
week, poorly developed inflammatory infiltrates of the pancreas are seen, 
and the islets are infiltrated by mononuclear round cells and a few poly - 
morphs. Marked degeneration of the surviving ß cells is evident. The lesions 
are always patchy, many islets being initially normal on light microscopy, 
but latterly these ostensibly unharmed islets exhibit advancing 0-cell degranu- 
lation. The extent of islet -cell damage seems to be partly dependent on the 
metabolic state of the animal at the time of inoculation; mice who have been 
pretreated with steroids or rendered obese by gold -thio- glucose injection 
show particularly severe lesions (Craighead, 1966), suggesting that ß cells 
which are most active metabolically are also the most vulnerable to damage 
by viral invasion. 
Viral diseases which are known to invade the pancreas have recently been 
summarised by Steinke and Taylor (1974); in man, these include infection 
with the mumps, rubella and infectious mononucleosis viruses as well as the 
group B Coxsackie viruses. A possible clinical significance for these observa- 
tions in relation to the development of human diabetes was proposed by 
Gamble and Taylor (1969), who initially described an increased incidence of 
cases of diabetes in the autumn and winter seasons, and subsequently 
correlated these cases with the seasonal prevalence data for Coxsackie type 
B4 virus infections. By retrospective serological testing they were able to 
show that the sera of insulin- dependent diabetics of less than three months' 
duration contained a significantly higher antibody titre to Coxsackie B4 
than the sera of non -diabetic normal controls or longstanding diabetic 
patients (Gamble et al, 1969). These observations are interesting but require 
confirmation, preferably on a prospective basis, and it is curious that later 
studies by the same authors (Gamble, Taylor and Cumming, 1973) and 
others (Baum, Aynsley -Green and MacCallum, 1974) have apparently failed 
to show any association between viral infection and the development of 
diabetes in children under the age of twelve years. 
The possible mechanisms whereby viral infection of the pancreas or other 
tissue could initiate immunopathological processes have been well reviewed 
by Freytag (1974). Virus invasion of the host is followed by two differing 
cell changes according to the general properties of viruses: the virus either 
multiplies and matures in one cell and after cytolysis invades other cells, 
producing spreading infection, or there is a steady -state interaction in which 
the virus replicates in the host cells, leaving the host structurally intact but 
producing functional alterations within the infected cells. Either or both of 
these virally- mediated cell changes can lead to a wide variety of different 
immunological reactions which probably all have cytotoxic effects. In the 
specific context of autoimmunity, Freytag (1974) concludes that viral 
infections can give rise to: 
1. New antigenic sites in the protein of cells. 
2. The production of cell- specific antibodies and sensitised lymphocytes. 
3. A nonspecific acceleration of general immune responses. 
By such cellular changes, virus infection may trigger off an autonomous 
development of progressive chronic inflammatory processes, i.e., autoimmune 
processes, even though the virus itself has already been overcome by the 
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in organ- specific autoimmune disease (adrenal, thyroid, stomach) and the 
autoimmune analogy is considerably strengthened by the recent findings, 
described in this chapter, of sensitised lymphocyte populations and circulating 
islet -cell antibodies in human diabetes. It is, however, unlikely that auto - 
immunity could be the sole cause of the insulitis lesion as islet -cell antibodies 
seem to be a rare finding in diabetes, except in patients with coexistent overt 
autoimmune disease, and insulitis itself is not accompanied by the plasma - 
cell infiltration and lymphoid -follicle formation that are regarded as classical 
findings in the `accepted' organ- specific autoimmune diseases. Infection with 
group B Coxsackie or similar viruses has also been postulated as a cause of 
insulitis and it is important to remember that the autoimmune and the viral 
hypotheses are not mutually exclusive, i.e., that an autoimmune process 
might well be triggered off by viral infection. It is tempting to speculate that 
the nature and duration of the immune response to viral infection is primarily 
determined by the immune response gene(s) of the infected patient, which in 
turn is probably dependent on HL -A type. One might then construct a 
unifying hypothesis whereby young subjects, having inherited a particular 
type of immune response gene by virtue of their HL -A type, respond to 
(say) a viral infection by initiating an irreversible and relentless series of 
autoimmune processes which culminate in destruction of the endocrine 
pancreas and the development of clinical diabetes (Editorial, 1974). 
The studies reviewed in this chapter lend strong credibility to the concept 
of a true autoimmune form of diabetes mellitus, which has now been shown 
to fulfil most of the classical criteria (close relationship with other auto - 
immune diseases, lymphocytic infiltration of the end -organ, circulating 
humoral antibody directed against the end -organ, circulating lymphocytes 
sensitised against the end -organ). It is not yet possible to suggest what 
proportion of patients with diabetes have developed their disorder on the 
basis of autoimmunity but the available evidence indicates that this syndrome 
will be found most frequently in young insulin- dependent diabetics, pre- 
dominantly of female sex, who possess a variable pattern of circulating 
autoantibodies, a specific pattern of HL -A complexes and may also have 
clinical or laboratory evidence of recent viral infection. It may be anticipated 
that future studies of autoimmune diabetes will explore the interrelationships 
between these various factors, examine immune mechanisms in such patients 
by a variety of sophisticated techniques, and examine the possibility (as yet 
without foundation) that autoimmunity may have some significance for the 
development of diabetic microangiopathy. 
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